2013N168152_09 CONFIDENTIA L
ViiV Healthcare and The GlaxoSmithKline group of companies 200056
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: A Phase IIb Stud y Evaluating a Long -Acting Intramuscular 
Regimen of [COMPANY_004]1265744 plus TMC278 For theMaintenance of 
Virologic Suppression Following an Induction of Virolog ic 
Suppression on an Oral regimen of [COMPANY_004]1265744 plus 
Abacavir/Lamivudine in HIV -1 Infected, Antiretroviral Therap y-
Naive Adult Subjects
Compound Number: [COMPANY_004]1265744
Development Phase: IIB
Effective Date: 16-NOV-2017
Protocol Amendment Number:  07
Authors:  
Copy right [ADDRESS_419185] -08 Amendment No.:01 
Updated protocol summary , clarified study  drug naming conventions, updated T&E 
tables, clarified stud y drug descriptions, clarified IDMC, clarified health outcomes 
timings and questionnaires, additional miscellaneous changes
2013N168152_01 [ADDRESS_419186] -11 Amendment No.:[ADDRESS_419187] -16 Amendment No.:[ADDRESS_419188] -28 Amendment No.:01
Republ ished to clarify  revision chronology ; corrected Section 6.3 treatment 
administration
2013N168152_04 2014 -JAN-23 Amendment No.: 02
Primary modifications:  Study  design adapted to consolidate the Induction Period into a 
single 20 Week arm and for the addit ion of an every  8 week IM regimen into the 
Maintenance Period.  Increased sample size to 265 subjects.  Primary  endpoint changed 
from Week 24 to Week 32.  Dose rationale updated.
2013N168152_05 2014 -JUN-13 Amendment No.: 03:  
Primary  modifications:  Epz icom / Kivexa added as Investigational Product beginning at 
Day 1 of the Maintenance Period; clarification that alternative background therapy  (if 
positive for HLA -B*5701) is not counted as the protocol permitted switch for NRTI; 
clarification regarding pr ovision of alternative NRTI  therapy ; change in visit window for 
subjects on the oral dosing arm; excursion temperatures added for Epzicom / Kivexa and 
Edurant; text added for Epzicom / Kivexa overdose; deleted option for subject informed 
consent b y legal r epresentative; Time and Events Table clarifications. Additional 
clarifications and ty pographical corrections throughout.
2013N168152_06 2015 -APR -22 Amendment No. 4
Primary  modifications:  Addition of a [ADDRESS_419189] dose pharmacokinetic samples and 
ECG at Week 32 and Week 48 for subjects receiving intramuscular [COMPANY_004]744 L A and  2018N380094_00
2013N168152_09 CONFIDENTIA L
ViiV Healthcare and The GlaxoSmithKline group of companies 200056
3TMC278 L A.  Addition of LAI116482 Week 96 data.  Addition of maladministration of 
injection risk.  Additional clarifications for injection site reaction collection.  Clarified 
visit windows.
2013N168152_07 2016 -JUN-21 Amendment No. 5
Primary  modifications:  Allowed subjects to remain on their randomized IM regimens 
during the extension period (rather than switching to a single selected IM regimen as 
originall y planned).  Allowed subjec ts randomized to the oral arm to switch to one of the 
optimized Q8W/Q4W regimens (using proposed phase 3 dosing schedules, see Section 
5.1.6 ), based on subject preference.  Added Dose Rationale for optimized IM dosing 
based off new modelling.  New explorat ory objective sand endpoints added for 
evaluation of maintenance and optimized Q8W/Q4W regimens at Week [ADDRESS_419190] updated Extension Period I M dosing schedule.  Added Extension Period PK 
assessments for subjects switching to the optimized I M regimens.  Added new study  
‘Extension Switch Population’ for the ‘Week 128 anal ysis’.  Added IDMC monitoring of 
number of PDVFs for subjects switching from oral treatment to optimized IM regimens.  
Added Week 128 Extension Switch Analy sis and a Week 152 Anal ysis
2013N168152_08 2017 -AUG-14 Amendment No. 6 (United 
States Specific 
Amendment)
This [LOCATION_002] specific amendment has been developed to assess the amount of peak 
drug concentrations (both cabotegravir [CAB] and rilpi[INVESTIGATOR_12979] [RPV] long acting 
injectables [L AI]) that enters the Central Nervous Sy stem and more specifically , the 
cerebr ospi[INVESTIGATOR_872] (CSF) after subjects receive an injection of the LAI CAB and RPV in 
the LATTE -2 study . This amendment will also characterize the plasma concentration of 
CAB/RPV L AI obtained at the same time point as the CSF anal ysis and will also assess 
the relationship between the peak concentration of CAB/RPV in the CSF with the amount 
of HIVRNA in the CSF using a sensitive HIVRNA assay  called single copy  assay   
2013N168152_09 2017 -NOV-16 Amendment No. 7
This amendment is to update a planned interim anal ysis from Week 152 to Week 160. 2018N380094_00
 2018N380094_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2013N168152_09 CONFIDENTIA L
200056
5SPONSOR INFORMA TION PAGE
Clinical Study Identifier: 200056
This study  is sponsored by  [CONTACT_103673].  Gla xoSmithKline is responsible for
implementing and managing all aspects of this study .
Sponsor Legal Registered Address:
ViiV Healthcare
[ADDRESS_419191]
Middlesex, TW8 9GS
[LOCATION_006]
Telephone:   
Sponsor Contact [CONTACT_339228] 
P.O. [ZIP_CODE]
Research Triangle Park, NC [ZIP_CODE]
-3398, [LOCATION_003]
Telephone: 
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline affiliate
compan y (or designee). Where applicable, the details of the S
ponsor and contact [CONTACT_23957].
Sponsor Medical Monitor Contact [CONTACT_7171] : 
 MD, MPH
ViiV Healthcare
Research Triangle Park
Five Moore Drive, Rese arch Triangle Park, NC [ZIP_CODE] ([LOCATION_003])
Mobile: 
Office Telephone: 
Fax: 
e-mail:  2018N380094_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2013N168152_09 CONFIDENTIA L
200056
6Sponsor Serious Adverse Events (SAE) Contact [CONTACT_7171]:
 MD, MPH
ViiV Healthcare
Researc h Triangle Park
Five Moore Drive, Research Triangle Park, NC [ZIP_CODE] ([LOCATION_003])
Mobile: 
Office Telephone: 
Fax: 
e-mail: 
Regulatory Agency Identifying Number(s):
US IND 109,[ADDRESS_419192]-000783-[ADDRESS_419193] to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:
[CONTACT_132026]:
Investigator Phone Number:
Investigator Signature [CONTACT_1782] 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419194] of Study Terms ..................................................................................... 27
1.3. Cabotegravir ([COMPANY_004]1265744) –Oral (CAB) ................................................. 28
1.4. Cabotegravir –Long Acting Injectable (CAB LA) ......................................... 28
1.5. Rilpi[INVESTIGATOR_12979] –Oral (RPV) ............................................................................... 29
1.6. Rilpi[INVESTIGATOR_12979] –Long Acting Injectable (RPV LA) ............................................. 29
1.7. Study LAI116482 ........................................................................................ 30
1.8. 200056 ....................................................................................................... 32
1.9. Study Rationale .......................................................................................... 34
1.10. Dose Rationale ........................................................................................... 37
1.10.1. CAB ............................................................................................. 37
1.10.2. CAB LA ........................................................................................ 37
1.10.3. RPV ............................................................................................. 46
1.10.4. RPV LA ........................................................................................ 47
1.11. Benefit: Risk Assessment ........................................................................... 54
1.11.1. Risk Assessment ......................................................................... 55
[IP_ADDRESS]. CAB and CAB LA ....................................................... 55
[IP_ADDRESS]. RPV and RPV LA ....................................................... 58
[IP_ADDRESS]. Abacavir/Lamivudine (ABC/3TC) ................................ 60
[IP_ADDRESS]. Study Procedures ....................................................... 61
[IP_ADDRESS]. Risk of Treatment Failure ........................................... 61
1.11.2. Other Clinically Relevant Information ........................................... 61
1.11.3. Benefit Assessment ..................................................................... 62
1.11.4. Overall Benefit: Risk Conclusion .................................................. 62
2.OBJECTIVES AND ENDPO INTS ........................................................................... 63
3.INVESTIGATIONAL PLAN ..................................................................................... 65
3.1. Study Design Schematic ............................................................................. 65
3.2. Study Design .............................................................................................. 66
3.2.1. Screening Period ......................................................................... 66
3.2.2. Induction Period ........................................................................... 67
3.2.3. Eligibility for the Maintenance Period ........................................... 67
3.2.4. Maintenance Period ..................................................................... 68
3.2.5. Extension Period .......................................................................... 70
[IP_ADDRESS]. Entering from the CAB LA + RPV LA Arm .................. 70
[IP_ADDRESS]. Eligibility for the Extension Period for Subjects 
Enterin g From the CAB 30 mg + ABC/3TC Arm ......... 70
[IP_ADDRESS]. Entering from the CAB 30 mg + ABC/3TC Arm .......... 71
3.2.6. Long -term Follow -Up Period –IM Regimens only ........................ [ADDRESS_419195] SELECTION AN DWITHDRAW AL CRITERIA ....................................... 77
4.1. Number of Subjects .................................................................................... 77
4.2. Inclusion Criteria ......................................................................................... 77
4.3. Exclusion Criteria ........................................................................................ 79
4.4. Additional Eligibility Cri teria......................................................................... 81
4.5. Withdrawal Criteria ..................................................................................... 81
4.5.1. Subjects Receiving CAB LA and / or RPV LA .............................. 84
4.6. Virologic Failure .......................................................................................... 84
4.6.1. Definition of Virologic Failure ....................................................... 84
4.6.2. Managing Virologic Failure .......................................................... 85
[IP_ADDRESS]. Suspected Virologic Failure ........................................ 85
[IP_ADDRESS]. Confirmed Virologic Failure ........................................ [ADDRESS_419196] and Other Study Treatment .................................... 86
5.1.1. Cabotegravir ([COMPANY_004]1265744) –Tablet (CAB) ............................... 86
5.1.2. Rilpi[INVESTIGATOR_12979] -Tablet (RPV) ............................................................. 87
5.1.3. Epzicom / Kivexa ......................................................................... 87
5.1.4. Cabotegravir ([COMPANY_004]1265744) –Injectable Suspension 
(CAB LA) ..................................................................................... 87
5.1.5. Rilpi[INVESTIGATOR_12979] –Injectable Suspension (RPV LA) ............................... 87
5.1.6. Dosage and Administration .......................................................... 88
5.1.7. Dosing Considerations for CAB LA + RPV LA .............................. [ADDRESS_419197] Accountability ................................................................................ 91
5.5. Treatment Compliance................................................................................ 91
5.6. Protocol Permitted Substitutions ................................................................ .92
5.6.1. Oral Bridging ................................................................................ 92
5.7. Interruption of Study Treatment and Visit/Dosing W indows ......................... 93
5.7.1. Oral Dosing Including Long Term Follow Up ................................ 93
5.7.2. IM Dosing .................................................................................... 93
5.8. Discontinuation of Study Treatment ............................................................ 94
5.8.1. Discontinuation of ABC/3TC ........................................................ 94
5.8.2. Discontinuation of CAB LA or RPV LA ......................................... 94
5.9. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014] .................................... 95
5.9.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 95
5.9.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 95
[IP_ADDRESS]. Concurrent with CAB and/or RPV ............................... 96
[IP_ADDRESS]. Concurrent with RPV .................................................. 96
[IP_ADDRESS]. Concurrent with either CAB LA or RPV LA ................. 96
5.10. Treatment after the End of the Study .......................................................... 97
5.10.1. Long -Term Follow -Up Period ....................................................... 97
5.11. Treatment of Study Treatment Overdose .................................................... 97
6.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 98
6.1. Time and Events Table –Induction Period .................................................. 98
6.2. Time and Events Table –Maintenance Period for IM Regimen (CAB 
LA+RPV LA Q8 W).................................................................................... 101 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
106.3. Time and Events Table –Maintenance Period for IM Regimen (CAB 
LA+RPV LA Q4 W).................................................................................... 104
6.4. Time and Events Table –Maintenance Period for Oral Regimen 
(CAB 30 mg+ABC/3TC) ............................................................................ 107
6.5. Time and Events Table –Extension Period for IM Regimen (CAB 
LA + RPV LA -Q8W).................................................................................. 111
6.6. Time and Events Table –Extension Period for IM Regimen (CAB 
LA + RPV LA -Q4W)................................................................................ 114
6.7. Time and Events Table –Long -Term Follow Up Period ............................ 117
6.8. Critical Screen ing and Baseline Assessments .......................................... 118
6.8.1. Screening .................................................................................. 118
6.8.2. Baseline ..................................................................................... 119
6.9. Efficacy ..................................................................................................... 119
6.9.1. Plasma HIV -1 RNA .................................................................... 119
6.9.2. Lymphocyte Subsets, CD4+ and CD8+ ..................................... 119
6.9.3. HIV Associated Conditions ........................................................ 120
6.10. Safety ....................................................................................................... 120
6.10.1. Clinical evaluations .................................................................... 120
6.10.2. Laboratory Assessments ........................................................... 121
6.10.3. Liver Chemistry Stoppi[INVESTIGATOR_339140] ........................ 122
[IP_ADDRESS]. Liver Chemistry Stoppi[INVESTIGATOR_2121] ............................. 122
[IP_ADDRESS]. Liver Chemistry Stoppi[INVESTIGATOR_2121], Subject 
Management ............................................................ 123
[IP_ADDRESS]. Liver Chemistry Stoppi[INVESTIGATOR_2121] -
Rechallenge ............................................................. 124
6.10.4. Adverse Events .......................................................................... 126
[IP_ADDRESS]. Definition o f an AE .................................................... 126
[IP_ADDRESS]. Definition of an SAE ................................................. 127
6.10.5. Laboratory and Other Safety Assessment Abnormalities 
Reported as AEs and SAEs ....................................................... 128
6.10.6. Specific Toxicities / Adverse Event Management ....................... 128
[IP_ADDRESS]. Treatment Interruption Due to an Adverse 
Event ........................................................................ 128
[IP_ADDRESS]. Grade 1 or Grade 2 Toxicity/Adverse Event ............. 129
[IP_ADDRESS]. Grade 3 T oxicity/Adverse Event ............................... 129
[IP_ADDRESS]. Grade 4 Toxicity/Adverse Event ............................... 130
[IP_ADDRESS]. Diarrhea ................................................................... 131
[IP_ADDRESS]. Hypertriglyceridemia/ Hypercholesterolemia ............. 131
[IP_ADDRESS]. Creatine Phosphokinase (CPK) Elevation ................ 132
[IP_ADDRESS]. Lipase Elevations and Pancreatitis ........................... 132
[IP_ADDRESS]. Decline in Renal Function ......................................... 132
[IP_ADDRESS] .Proteinuria ................................................................ 133
[IP_ADDRESS]. QTc Prolongation ..................................................... 134
[IP_ADDRESS]. Injection Site Reactions (ISRs) ................................ .134
[IP_ADDRESS]. Allergic Reaction ...................................................... 134
6.10.6 .14. Abacavir Hypersensitivity Reaction (ABC HSR) ........ 135
[IP_ADDRESS].1. Essential Patient Information ................ 135
[IP_ADDRESS].2. Reporting of Hypersensitivity 
Reactions ............................................. 136
[IP_ADDRESS] 5.Rash W ithout ABC HSR Symptoms ......................... 136
[IP_ADDRESS]. Seizures ................................................................... 137
6.10.7. Cardiovascular Events ............................................................... 138 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
116.10.8. Death Events ............................................................................. 138
6.10.9. Disease -Related Events and/or Disease- Related 
Outcomes Not Qualifying as SAEs ............................................. 138
6.10.10. Monitoring Suicidal Ideation and Behavior ................................ .139
6.10.11. Pregnancy ................................................................................. 140
[IP_ADDRESS]. Pregnancy Testing .................................................... 140
[IP_ADDRESS]. Time Period for Collecting Pregnancy 
Information ............................................................... 140
[IP_ADDRESS]. Action to be Taken if Pregnancy Occurs ................... 140
6.10.12. Time Period and Freq uency of Detecting AEs and SAEs ........... 141
6.10.13. Method of Detecting AEs and SAEs ........................................... 141
6.10.14. Prompt Reporting of Serious Adverse Events and Other 
Events to [COMPANY_004] ........................................................................... 142
[IP_ADDRESS]. Regulatory Reporting Requirements for SAEs .......... 143
6.11. Pharmacokinetics ..................................................................................... 143
6.11.1. PK Sample Collection ................................................................ 144
6.11.2. Rationale of PK Sampling Strategy ............................................ 146
6.11.3. Bioanalysis of CAB and RPV ..................................................... 146
6.12. Viral Genotypi[INVESTIGATOR_103623] ............................................................ 147
6.12.1. HIV-1 pol Viral Genotypi[INVESTIGATOR_103623] ............................. 147
6.12. 2.HIV-1 Exploratory Analysis ........................................................ 147
6.13. Pharmacogenetic Research ...................................................................... 147
6.14. Health Outcomes ...................................................................................... 148
7.DATA MANAGEMENT ......................................................................................... 149
8.DATA ANALYSIS A ND STATISTICAL CONSI DERATIONS ................................ .149
8.1. Hypotheses ............................................................................................... 149
8.2. Study Design Considerations .................................................................... 149
8.2.1. Sample Size Assumptions ......................................................... 149
8.2.2. Sample Size Sensitivity .............................................................. 151
8.2.3. Sample Size Re- estimation ........................................................ 152
8.3. Data Analysis Considerations ................................................................... 152
8.3.1. Analysis Populations .................................................................. 152
[IP_ADDRESS]. Intent -to-Treat Exposed Population (ITT -E).............. 152
[IP_ADDRESS]. Intent -to-Treat Maintenance Exposed 
Population (ITT- ME)................................................. 153
[IP_ADDRESS]. Per Protocol Maintenance Exposed Population 
(PP-ME)................................................................... 153
[IP_ADDRESS]. PK Population ........................................................... 153
[IP_ADDRESS]. Safety Population ..................................................... 153
[IP_ADDRESS]. Extension Switch Population .................................... 153
8.3.2. Analysis Data Sets ..................................................................... 153
8.3.3. Treatment Comparisons ............................................................ 154
[IP_ADDRESS]. Primary Comparisons of Interest .............................. 154
[IP_ADDRESS]. Other Comparisons of Interest .................................. 154
8.3.4. Planned Analysis ....................................................................... 154
[IP_ADDRESS]. IDMC Interim Analyses ............................................. 155
[IP_ADDRESS]. Futility Interim Monitoring .......................................... 155
[IP_ADDRESS]. Day 1 Interim Analysis .............................................. 158
[IP_ADDRESS]. Week 32 Primary Ana lysis........................................ 158
[IP_ADDRESS]. Week 48 Analysis ..................................................... 158 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
[IP_ADDRESS]. Week 96 Analysis ..................................................... 158
[IP_ADDRESS]. Week 128 Extension Switch Analysis ....................... 158
[IP_ADDRESS]. Week 160 Analysis ................................................... 158
8.3.5. Key Elements of Analysis Plan .................................................. 159
[IP_ADDRESS]. Efficacy Analyses ..................................................... 159
[IP_ADDRESS]. Safety Analyses ........................................................ 160
[IP_ADDRESS]. Treatment Com pliance ............................................. 161
[IP_ADDRESS]. Health Outcomes Analyses ...................................... 161
[IP_ADDRESS]. Pharmacokinetic Analyses ........................................ 161
[IP_ADDRESS]. Pharmacokinetic/Pharmacodynamic Analyses ......... 162
[IP_ADDRESS]. Viral Genotypi[INVESTIGATOR_007]/Phenotypi[INVESTIGATOR_339141] ................... 162
[IP_ADDRESS]. Pharmacogenetic Analyses ...................................... [ADDRESS_419198] CONSID ERATIONS ............................................................. 162
9.1. Posting of Information on Publ icly Available Clinical Trial Registers .......... 162
9.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ...................................................................................... 162
9.3. Quality Control (Study Monitoring) ............................................................ 163
9.4. Quality Assurance ..................................................................................... 163
9.5. Study and Site Closure ............................................................................. 164
9.6. Records Retention .................................................................................... 164
9.7. Provision of Study Results to Investigators, Posting of Informatio n 
on Publicly Available Clinical Trials Registers and Publication .................. 165
9.8. Independent Data Monitoring Committee (IDMC) ..................................... 165
10.REFERENCES ..................................................................................................... 166
11.APPENDICES ...................................................................................................... 169
11.1. Appendix 1: CDC Classification System for HIV -1 Infections (1993) ......... 169
11.2. Appendix 2: Division of AIDS Table for Grading the Severity of Adult 
and Pediatric Adverse Events ................................................................... 172
11.3. Appendix 3: Pharmacogenetic Research .................................................. 191
11.4. Appendix 4: Liver Safety Drug Restart or Rechallenge Guidelines ............ 196
11.5. Appendix 5: Country Specific Requirements ............................................. 203
11.6. Appendix 6: Changes to the Protocol ........................................................ [ADDRESS_419199] OF A BBREVIATIONS
 Dosing interval, time between consecutive doses
3TC Lamivudine, EPI[INVESTIGATOR_227302] R
ABC Abacavir, ZIAGEN
AE Adverse Event
AIDS Acquired immuno deficiency  syndrome
ALT Alanine Aminotransferase
ART Antiretroviral Therap y
AST Aspartate Aminotransferase
AUC Area Under the Curve
AUC(0 -) Area under the plasma drug concentration-time curve from predose to the 
end of the dosing interval at stead y state
BMI Body Mass Index
BP Blood Pressure
BUN Blood urea nitrogen
C Concentration at the end of a dosing interval
c/mL Copi[INVESTIGATOR_014]/millilitre
CAB Cabotegravir , Oral
CAB LA Cabotegravir , Long Acting Injectable
CDC Centers for Disease Control and Preven tion
CI Confidence Interval
Cmax Maximum plasma drug concentration
CPK Creatine Phosphokinase
CV Coefficient of variation
DAIDS Division of Acquired Immunodeficiency  Syndrome
ECG Electrocardiograph
eCRF Electronic case report form
eC-SSRS Electroni c Columbia Suicidality  Severity  Rating Scale
EFV Efavirenz
FC Fold Change
FDA Food and Drug Administration
FDC Fixed dose combination
FTC Emtricitibine
GCP Good Clinical Practices
GI Gastrointestinal
[COMPANY_004] GlaxoSmithKline
HAART Highl y Active Antiret roviral Therap y
HbsAg Hepatitis B Virus surface Antigen
HBV Hepatitis B Virus
HCV Hepatitis C Virus
HDPE High Density  Polyethylene
HIV-1 Human Immunodeficiency  Virus Ty pe 1
HIVMQ HIV medication questionnaire
HIVTSQ HIV treatment satisfaction questio nnaire
HIVTSQc HIV Treatment Satisfaction Questionnaire change version 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
14HIVTSQs HIV Treatment Satisfaction Questionnaire status version
HSR Hypersensitivity reactions
IAS International AIDS Society
IB Investigator’s Brochure
IC90 90% Inhibitory  Concen tration
ICH International Conference on Harmonization
IDMC Independent Data Monitoring Committee
IEC Institutional Ethics Committee
IM Intramuscular
INI Integrase Inhibitor
INR International Normalized Ratio
IP Investigational Product, both formulat ions of cabotegravir and rilpi[INVESTIGATOR_339142] -to-Treat
ITT-ME Intent -to-Treat Maintenance Exposed
IUD Intrauterine Device
IV Intravenous
LA Long acting
LLOD Lower limit of detection
LSLV Last Subject Last Visit
mg Milligram
mL Milliliter
MSDF Missing, Switch or Discontinuation = Failure
MSDS Material Safet y Data Sheet 
ng Nanogram
NNRTI Non-nucleoside reverse transcriptase inhibitor
NRTI Nucleoside reverse transcriptase inhibitor
OC Observed case
PD Pharmacod ynamic
PDVF Protocol Defined Virologic Failure
PGx Pharmacogenetics
PI [INVESTIGATOR_339143]
Q4W Every  4 Weeks
Q8W Every  8 Weeks
QT C Corrected QT interval
RAP Reporting anal ysis plan
RBC Red blood cell
RNA Ribonucleic acid 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
15RPV Rilpi[INVESTIGATOR_12979], Edurant , oral formulation of TMC27 8
RPV LA Rilpi[INVESTIGATOR_12979] , Long Acting Injectable
RT Reverse transcriptase
SAE Serious adverse event
SPM Study  Procedure Manual
SVF Suspected Virologic Failure
t1/[ADDRESS_419200] Upper limit of normal
US [LOCATION_002]
VSL C ViiV Safety and Labeling Committee
WBC White blood cells
WD Withdrawal
Trademark Information
Trademarks of ViiV Healthcare Trademarks not owned by 
[CONTACT_339229] (raltegravir)
Monogram Biosciences
PhenoSense
Truvada 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
16PROTOCOL SUMMA RY
Stud y Terms
For the ease of the reader, the following terms will be useful to understand:
Cabotegravir ([COMPANY_004]1265744) – the ViiV compound under study .  When written 
as shown, this refers to either the oral or long acting formulation.
oCAB – the oral formulation of cabotegravir ; 
oCAB LA –the long acting injectable formulation of cabotegravir ; LA stands 
for “long acting”;
Rilpi[INVESTIGATOR_12979] –the Janssen / partner compound under study .  When written as 
shown, this refers to either the oral or long acting formulation.
oRPV –rilpi[INVESTIGATOR_339144] , also known as Edurant;
oRPV LA - the long acting injectab le formulation of rilpi[INVESTIGATOR_12979] ; LAstands for 
“long acting”;
Induction – the induction of virologic suppression of Human Immunodeficiency  
Virus Ty pe 1 (HIV-1)infection in anti -retroviral naive subjects prior to the 
initiation of the CAB LA + RPV LA regimen.  This period will be represented in 
text, schema and Time and Events as negative weeks.  The length of induction is 
[ADDRESS_419201] day  of the Induction Period (i.e. this is not Day  1). 
Maintenance – the maintenance of virologic suppres sion of HIV -1 infection; the 
length of maintenance being evaluated is [ADDRESS_419202] day  of the 
Maintenance Period.  
Dosing Regimen - Two intramuscular (IM)dosing regimens are being evaluated:  
every  4 weeks (Q4W) and every  8 weeks (Q8W). One oral dosing is being 
evaluated (oral).
Extension –extending study  treatment past the key  study  analy sis points; length 
of extension being evaluated is until investigational product (IP) is either locally 
approved and commercially  available, a subject no longer derives clinical 
benefit, a subject meets a protocol -defined reason for discontinuation or until 
development of IP is terminated.
Long -Term Follow -Up –follow up period for subjects receiving at least one dose 
of CAB LA and/or RPV LA who have di scontinued treatment or have been 
withdrawn; length of follow up being evaluated is 52 weeks. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
17IP = Investigational product; both formulations of CAB and RPV .  Epi[INVESTIGATOR_339145] / 
Kivexa (ABC/3TC) will also be considered IP beginning at Day  [ADDRESS_419203] an intramuscular dosing regimen of CAB 
LA plus RPV LA based on a comparison of the Week 32 antiviral activity, tolerability , 
and safet y of thetwo IM dosing regimens , relative to CAB 30mgplus a bacavir 
(ABC )/lamivudine (3TC) orally  once daily.
Stud y Schematic
Induction Period
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
18Maintenance and Extension Period
Notable Inclusion Criteria
Male or female subjects at least 18 y ears old that are HIV -1 positive (HIV -1 
ribonucleic acid ( RNA )1000 copi[INVESTIGATOR_014]/millilitre [c/mL ])
Women of childbearing potential may  be enrolled if they  agree to use adequate 
contraception for the life of the study  and at least 52 weeks after withdrawal from 
an IM regimen.
CD4+ cell count 200 cells/mm3(or higher as loc al guidelines dictate).
Antiretroviral t herap y (ART )naive (no more than 10 day s of prior therapy  with 
any antiretroviral agent following a diagnosis of HIV -1 infection.  Any  previous 
exposure to an HIV integrase inhibitor or non -nucleoside reverse transcr iptase
inhibitor will be exclusionary ).
Notable Exclusion Criteria
Any evidence of primary resistance based on the presence of an y major 
resistance -associated mutation (International AIDS Society [IAS]-[LOCATION_003], 2013 )in 
the Screening result or, if known, any  historical resistance test result.
Subjects with known moderate to severe hepatic impairment.   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
19History  of ongoing or clinically  relevant hepatitis within the previous 6 months, 
including chronic hepatitis B virus (HBV) i nfection ( Hepatitis B Virus Surface
Antigen [HBsAg ]positive). As ymptomatic individuals with chronic hepatitis C 
virus (HCV) infection will not be excluded, however Investigators must carefull y 
assess if therap y specific for HCV infection is required; subj ects who are 
anticipated to require such therap y must be excluded.
History  of liver cirrhosis with or without hepatitis viral co -infection.
Current or anticipated need for chronic anti -coagulation.
Any verified Grade 4 laboratory  abnormality .
Any acute lab oratory  abnormality  at Screening, which, in the opi[INVESTIGATOR_684], would preclude the subject’s participation in the study  of an 
investigational compound.
Subject has estimated creatinine clearance <50 mL/min via Cockcroft -Gault 
method.
Alanine a minotransferase (ALT) 5 times upper limit of normal ( ULN ).  Subjects 
with AL T > 2xUL N but <5xUL N may  participate in the study , if in the opi[INVESTIGATOR_339146] ([COMPANY_004] )medical monitor the lab 
abnormality  will not interfere with the study  procedures or compromise subject 
safet y.
ALT 3xULN and bilirubin 1.5xUL N (with >35% direct bilirubin).
Subjects who are HLA -B*5701 positive and unable to use an alternative 
nucleoside reverse transcriptase inhibitor ( NRTI )backbone (subjects who ar e 
HLA -B*5701positive may be enrolled if they  use an alternative NRTI backbone 
that does not contain abacavir ).
Any clinically  significant finding on screening or Baseline electrocardiograph 
(ECG).
Tattoo or other dermatologic condition over gluteus region.
Need for chronic anticoagulants.
Stud y Design
Study  [ADDRESS_419204] of a Screening Period, Induction Period, Maintenance Period, 
Extension Period and a Long- term Follow -up Period (withdrawn IM dosing regimen
subjects only ). 
Induction Period
Following the 28 -day Screening Period, eligible subjects will be enrolled into the study  
and begi n a 20-week Induction Period utilizing an oral regimen of CAB 30 mg once dail y 
plus ABC/3TC 600/[ADDRESS_419205] day  on study  and will be seen every  4 weeks 
for study  treatment dispensing and safet y and e fficacy  assessments.  
At Week (-4) the treatment regimen is modified to add RPV [ADDRESS_419206] demonstrated tolerability  to the Induction Period regimen and with an 
undetectable HIV -1 RNA (<50 c/mL) at the Week ( -4) visit are eligible to enter the 
Maintenance Period. A single repeat to determine eligibility  may  be allowed ONLY after 
consultation with the medical monitor.  Subjects with HIV- 1 RNA 400c/mL at 
Week (-4) are not eligible to enter the Maintenance Period ,will not be allowed a repeat to 
determine eligibility and will therefore be withdrawn from the study . 
Maintenance Period
At Day  1, the Maintenance Period begins.  Eligible subjects will be r andomized 2:2:1 to 
receive an IM regimen of CAB LA 400 mg + RPV LA 600 mg every  4 weeks for 96 
weeks, an IM regimen of CAB LA 600 mg + RPV LA 900 mg every  8 weeks for 96 
weeks, or to continue on the oral Induction Period regimen of CAB 30 mg + ABC/3TC 
once daily for 96 weeks (or 100 weeks if continuing on to the Extension Period).  Subject 
randomization will be stratified by  [CONTACT_1766]’ HIV
-1 RNA prior to Week (-8)(<50 c/mL, 
yes or no).
On the first day  of the Maintenance Period (Day  1), subjects will receive their last dose of 
the Induction regimen ( CAB 30 mg+ABC/3TC+RPV 25mg) in the clinic andinitiate 
either IM injections or be dispensed the oral regimen depending on the randomization 
arm.  Add-on RPV treatment will be discontinued for all subjects after Day 1.  
Dosing for each arm is as follows (all injections are single injections per drug unless 
otherwise noted):
IM injections every  8 weeks (Q8W)
Day 1 only  –CAB LA 800 mg (loading dose delivered as two 400 mg IM 
injections) + RPV LA 900 mg IM
Week 4 o nly -CAB LA 600 mg IM (second loading dose, no RPV LA )
Week 8 - CAB LA 600 mg IM + RPV LA 900 mg IM every  8 weeks for 96 
weeks
IM injections every  4 weeks (Q4W)
Day 1 only  -CAB LA 800 mg (loading dose delivered as two 400 mg IM 
injections) + RPV LA 600 m g IM
Week 4 - CAB LA 400 mg IM + RPV LA 600 mg IM every  4 weeks for 96 
weeks
Oral Control Arm 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
21CAB 30 mg + ABC/3TC once dail y for 96 weeks (or 100weeks if going on to the 
Extension period)
It is important to note that keepi[INVESTIGATOR_85883]’s dosing / visi t schedule is a very  
important component to the study .  IM dosing is expected to occur during the week in 
which the subject’s projected visit falls (as according to the Day  1 visit).  A (+ or - ) 7-day
window , from the projected visit date, is allowable for IM dosing but not preferred.  At 
one-week post dose visits (Week 1, Week 25, and Week 41), there is no defined visit 
window, rather visits should occur approximately  [ADDRESS_419207] injection.
Visits for subjects on the oral dosing arm are expected t o occur as projected according to 
the Baseline visit.  There is a (+ or -) 3-dayvisit window, from the projected visit date.  
However, the number of tablets dispensed should be considered when scheduling the next 
visit.   Visits in L ong Term Follow Up are to occur as projected from the last injection 
with a (+ or -) 3-dayvisit window, from the projected visit date .
All subjects are seen ap proximately  every  4 weeks for safety , efficacy  and PK 
assessments through Week 32.  After Week 32, subjects will contin ue to be seen as per 
the Time and Events Schedule (see Section 6) for dosing, safet y, efficacy and PK 
assessments through Week 96 (or Week 100 for the oral arm if continuing on to the 
Extension Period).
Some visits that are not aligned with dosing will be conducted b y telephone interview.  
This allows for safety  assessments to be conducted at all visits, but limits clinic visits for 
non-dosing visits.
See the Time and Events Schedule Section 6.2and Section 6.3for more information.   See 
Section [IP_ADDRESS] for additional information regarding special requirements from Week [ADDRESS_419208] demonstrated tolerability  to the irMaintenance Period regimen and 
with an undetectable HIV- 1 RNA (<50 c/mL) at the Week 96 visit are eligible to enter 
the Extension Period. A single re peat to determine eligibility  may  be allowed ONLY
after consultation with the medical monitor.  Subjects with HIV- 1 RNA 400c/mL  at 
Week 96are not eligible to enter the Extension Period, will not be allowed a repeat to 
determine eligibility and will ther efore be withdrawn from the stud y.
Extension Period
Both IMdosing regimen (Q8W and Q4W) will continue to be evaluated in the Extension 
period.
Entering from the CAB LA + RPV LA Arm s
All subjects who successfully  complete 96weeks of CAB LA + RPV LA treatm ent in the 
Maintenance Period as described in Section [IP_ADDRESS] , will continue with their current IM 
dosing regimen of CAB LA and RPV LA in the Extension Period until: 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
22study  treatment is locally approved and commercially  availab le, 
the subject no longer derives clinical benefit, 
the subject meets a protocol- defined reason for discontinuation  
until development of either CAB LA or RPV LA is terminated.  
Subjects will remain on their current regimen after Week 96 and will cont inue to receive 
their Maintenance Period IM dosing regimen for the remainder of study  participation.  
Safety  and efficacy  assessments will be conducted every  16 weeks. Dosing visits will 
occur according to the selected dosing regimen.   See the Time and Eve nts Schedule 
Section 6.5and Section 6.6formore information .  
Entering from the CAB 30 mg+ ABC/3TC Arm
All subjects who successfully  complete 96 weeks of CAB 30mg+ ABC/3TC trea tment 
in the Maintenance Period will have the option to continue study  participation by  
[CONTACT_339230] (either Q8W or Q4W) of 
CAB LA + RPV LA in the Extension Period .  Subjects not choosing to switch to an 
optim ized long acting regimen will complete their study  participation at Week 96.
Subjects who choose to continue on to the Extension Period will be assessed for 
eligibility  to begin the irselected CAB LA + RPV LA regimen.  Subjects will continue on 
their Maint enance regimen ( CAB 30 mg+ ABC/3TC) while eligibility  is being 
confirmed.  RPV will not be added to their Maintenance regimen prior to the switch to 
optimized I M dosing .  Subjects were given RPV during the last 4 weeks of the I nduction 
Period to evaluate safet y and tolerability  before being randomized to continue in the 
Maintenance Period and thus further evaluation is not necessary .  
Participants with a Week 96 HIV- 1 RNA <50 c/mL, will continue their oral regimen 
(CAB 30 mg+ ABC/ 3TC)until Week 100.  I norder to qualify  to receive CAB LA + 
RPV L A injections at Week [ADDRESS_419209] be
undetectable (<50 c/mL; a single repeat HIV -[ADDRESS_419210] may  be allowed prior to Week 
100following consultation with the Medical Monito r).  
If the Optimized Q4W IM D osing Regimen is Selected by [CONTACT_339231] 100, participants will return to the clinic, take the last dose of their oral 
regimen (CAB 30 mg+ ABC/3TC ), and receive the first CAB LA (600 mg) + RPV LA 
(900 mg) injec tions (within 2 hours of the final oral dose of CAB + ABC/3TC ).  The 
second and third injections ( CAB LA 400 mg + RPV L A 600 mg) will be administered at 
Week [ADDRESS_419211] injections occur within the 
window of Week 107 to Week 108, but no later than Week 108.  Subsequent injections 
(CAB LA 400 mg + RPV L A 600 mg) will occur every  4 weeks thereafter, from the 
projected visit date, with a (+ or -) 7 day  dosing window being allowed ( but not 
preferred ).  Following the Week [ADDRESS_419212] dose of their oral (CAB 
30mg+ ABC/3TC ), and receive the first CAB LA (600 mg)+ RPV LA (900 mg) 
injections (within 2 hours of the final oral dose of CAB + ABC/3TC ).  The second 
loading injections will be administered at Week 104(CAB LA 600mg + RPV L A 
900mg,with subsequent injections ( CAB LA 600mg + RPV L A 900mg)occurring 
every  [ADDRESS_419213] case management.  Afte r Week 112, a dosing window ( 7 day s) for injections is 
allowed, but not preferred.
Subjects will continue study  treatment until CAB LA and RPV LA are either locall y 
approved and commercially  available, the subject no long er derives clinical benefit, the 
subject meets a protocol -defined reason for discontinuation or until development of either 
CAB LA or RPV LA is terminated. 
Safety  and efficacy  assessments will be conducted as per the Time and Events Schedule
(See the Time and Events Schedule Section 6.5and Section 6.6for more information. )
Subjects not eligible to enter the Extension Period will end their study  participation and 
will complete the W ithdrawal Visit.   Sites may  be reimbursed for up to a one month 
supply  of antiretroviral medication to facilitate transition to non -study  ART for subjects 
that do not qualify  for the Extension Period.
Long -term Follow -Up Period IM Regimens
Any subject who receives at least a single dose of CAB LA and/or RPV LA and 
discontinues the CAB LA + RPV LA regimen for an y reason must remain on suppressive 
Highl y Active Antiretroviral Treatment (HAART) for at least [ADDRESS_419214] dose 
of CAB LA and/or RPV LA in order to prevent selective pressure on HIV and the 
potential for selection of resistant mutants.  This period is considered stud y participation 
and subjects will be followed on study  during this time.
In the Long -Term Follow -Up Period, subjects will receive oral HAART and be followed 
for [ADDRESS_419215] dose of CAB LA and/or RPV LA. In order to assure that 
subjects have access to HAART during the Long- Term Follow -Up Period, [COMPANY_004] may
supply  HAART regionally or reimbursement will be provided during this period. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419216] has ongoing adverse events ( AEs)or lab abnormalities at 
the last on- study  visit.
Key Study  Assessments
HIV-1 RNA and CD4 +cell counts
Laboratory  assessments including hematology , blood chemistry , urinal ysis and 
fasting glucose, lipi[INVESTIGATOR_339147]
PK assessments including 2-hour post dose samples at Day  1, Week s 32,48, 100 
and 128.
Monitoring and rec ording of all AEs and serious adverse events ( SAEs )
Physical exams and vitals
Past medical history , family  history , social history , medication history .  Targeted 
history  on cardiovascular risk (smoking history , family  and personal history)
HIV-associated c onditions
Exercise habits utilizing a subject diary
Electrocardiograms
Assessment of Injection Site Reactions (I SRs) clinically  and utilizing a subject 
diary
Columbia Suicide Severity  Rating Scale (eC- SSRS)
Health Outcomes questionnaires for treatment sati sfaction and medication 
adherence
Definition of Virologic Failure
Non-response as indicated by  a less than a 1.0 log 10copi[INVESTIGATOR_014]/mL  decrease in plasma 
HIV-1 RNA after 4 weeks of starting the Induction Period, which is subsequently  
confirmed, unless the plasma HIV-1 RNA is < 400 c/mL .
Rebound as indi cated b y two consecutive plasma HIV-1 RNA levels 200c/mL  
after prior suppression to < 200 c/mL .  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
25Rebound as indicated b y two consecutive plasma HIV -1 RNA that are 
> 0.5 log 10c/mL  increase in plasma HIV- [ADDRESS_419217] HIV -1 RNA value is  200 c/mL.
Permitted Treatment Substitutions
Subjects who are HLA -B*5701 positive at the Screening visit are allowed to enter the 
study  on an approved dual-NRTI backbone that does not contain abacavir (e.g. 
tenofovir/emtricitibine [ TDF/FTC ]).  This regimen may be supplied regionally by [CONTACT_339232].
Switch of background NRTI  therapy  to an alternative approved NRTI therapy  for toxicity  
or tolerability  management is all owed once during the study .  Switches of a background 
NRTI  for any  other reason are not permitted in the study . 
In exceptional circumstances, the medical monitor may  authorize the use of CAB and/or 
RPV (oral regimen) as a short -term “bridging” strategy  for subjects who have begun 
CAB LA + RPV LA.  This strategy  would only  be employ ed to address an y potential gap 
in CAB LA + RPV LA dosing as a result of scheduling conflicts which would prevent 
planned dosing.
Independent Data Monitoring Committee
An Indepen dent Data Monitoring Committee (IDMC) will evaluate the efficacy , 
tolerability , and safet y of CAB and RPV before all eligible subjects have transitioned 
from the Induction Period to the Maintenance Period. This IDMC review may  be 
conducted after approximat ely [ADDRESS_419218] reached Week 8 of the Maintenance 
Period, depending on IDMC agreement . In addition, futility  guidance is included to 
monitor the performance of alltreatment arms when 50% of subjects have completed 
Week 24 of the Maintenance Period inorder to prevent subjects from continuing on a 
dosing regimen if existing data indic ates that subjects are at unacceptable risk of 
inadequate maintenance of virologic suppression .
As subjects enter the Maintenance Period of the study , if the number of pro tocol defined 
virologic failures meets or exceeds the pre -specified thresholds specified in the IDMC 
Charter, this will be considered strong evidence of an inadequate response and will 
trigger a comprehensive data review b y the IDMC.  Similar thresholds wi ll be used b y the 
IDMC to monitor the number of protocol defined virologic failures for subjects switching 
from oral CAB 30 mg +ABC/3TC to an optimized I M dosing regimen during the 
Extension Period.  The IDMC charter will contain details of this continual monitoring of 
the protocol defined virologic failure rates, the specifics around what will trigger a data 
review, and the safety  summaries and efficacy  analy ses that will be provided should a 
data review be required.
If one of the IM dosing regimens ( Q8W or Q4W ) is discontinued as a result of an IDMC 
review or an y subsequent anal ysis (as detailed in the IDMC Charter), those subjects who 
have not met an y clinical management criteria for discontinuation and who were 
randomized to the discontinued IM dosing re gimen, or selected a discontinued optimized  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419219] has 
completed the Week 32 study  visit and the database has been cleaned and released for 
analysis.  The results of this analy sis will be used to characterize safety , tolerability  and 
durability  of antiviral response of both IM dosing regimens of CAB LA + RPV LA and 
to select a regimen for further development . 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
271. INTRODUCTION
1.1. Background
It is estimated that 34 million people are currently  living with HIV/ a cquired 
immunodeficiency  syndrome (AIDS)and that the wo rldwide epi[INVESTIGATOR_339148] a rate of 2.5 million new infections and cause 1.7 million deaths per y ear [UNAI DS, 
2012]. While advances in the development of new antiretroviral therapi[INVESTIGATOR_014] (ART) provide 
extensi ve insights into the management of HIV -infected individuals, chronic HIV 
infection in adults continues to be characterized by [CONTACT_339233], increasing transmission of resistant virus and issues associated with long term 
toxicity of ART. The current paradigm in the treatment of HIV involves life -long 
therap y with multiple antiretrovirals. This dependency  on medical therap y requires that 
we continue to improve on the durability , tolerability  and convenience of all antiretroviral 
classes. There is an enduring need to develop new agents with improved safety  and 
resistance profiles and convenient dosing for both antiretroviral treatment -naïve and 
treatment -experienced patients.
1.2. List of Study  Terms
For the ease of the reader, the fol lowing terms will be useful to understand:
Cabotegravir ([COMPANY_004]1265744) –the ViiV compound under study .  When written 
as shown, this refers to either the oral or long acting formulation.
oCAB – the oral formulation of cabotegravir ;
oCAB LA –the long acting i njectable formulation of cabotegravir ; LA
stands for “long acting”;
Rilpi[INVESTIGATOR_12979] (TMC278) –the Janssen / partner compound under study.  When 
written as shown, this refers to either the oral or long acting formulation.
oRPV–rilpi[INVESTIGATOR_339149] , also known as 
Edurant ;
oRPV LA -the long acting injectable formulation of rilpi[INVESTIGATOR_12979] ;LAstands 
for “long acting”;
Induction – the induction of virologic suppression of Human Immunodeficiency  
Virus Ty pe 1 (HIV-1)infection in anti -retroviral naive subjects prior to the 
initiation of the CAB LA + RPV LA regimen.  This period will be represented in 
text, schema and Time and Events as negative weeks.  The length of induction is 
[ADDRESS_419220] day  of the Induction Period ( i.e. this is not Day  
1).
Maintenance – the maintenance of virologic suppression of HIV- 1 infection; the 
length of maintenance being evaluated is [ADDRESS_419221] day  of the 
Maintenance Period.    2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
28Dosing Regimen - Two i ntramuscular (IM) dosing regimens are being 
evaluated:  every  4 weeks (Q4W) and every  8 weeks (Q8W).  One oral dosing is 
being evaluated (oral).
Extension –extending study  treatment past the key  study  analy sis points; length 
of extension being evaluated is until investigational p roduct (IP) is either locally  
approved and commercially  available, a subject no longer derives clinical 
benefit, a subject meets a protocol -defined reason for discontinuation or until 
development of IP is terminated.
Long -Term Follow -Up –follow up period for subjects receiving at least one 
dose of CAB LA and/or RPV LA who have discontinued treatment or have been 
withdrawn; length of follow up being evaluated is 52 weeks.
IP = Investigational product; both formulations of CAB and RPV .Epzicom / 
Kivexa will also be considered IP beginning at Day 1 of the Maintenance 
Period.
1.3. Cabotegravir ([COMPANY_004]1265744) –Oral (CAB)
CAB is an integrase inhibitor with potent in vitro andin vivo inhibition of HIV -1. CAB
shows low nanomolar activity  against a broad range of HIV-1 s trains, including clinical 
isolates with documented raltegravir resistance. Human pharmacokinetics (PK) data with 
the oral formulation support once dail y dosing without the use of a pharmacokinetic 
enhancer. Potent short -term antiviral activity  of once d aily dosing of CAB was 
demonstrated during 10 -day monotherapy  in integrase -naïve HIV -1 infected subjects. 
Mean reductions from Baseline on Day  11 plasma HIV -1 ribonucleic acid ( RNA )were 
2.14 and 2.55 log 10copi[INVESTIGATOR_014]/millilitre (c/mL )at the CAB doses of 5 m g and 30 mg once 
daily , respectively [GlaxoSmithKline Document Number RM2009/[ZIP_CODE]/00 and 
GlaxoSmithKline Document Number RM2008/[ZIP_CODE]/00]. 
Data from the non -clinical tox icology  evaluations conducted to date with 
CAB have not 
identified an y progression -limiting toxicity . CAB has been administered in earl y phase 
clinical studies at doses between [ADDRESS_419222] frequent 
adverse events ( AEs)(>3subjects) observed during CAB dosing were headache (13.9%), 
nausea (4.3%), and dizziness (3.8%) [ Lou, 2013].  
Through Phase I and Phase IIa studies conducted to date, there have been no CAB related 
Grade 2 -4 AEs or serious serious adverse events ( SAEs )reported. No CAB laboratory  
trends have been identified.  An ongoing Phase IIb study  of CAB , LAI116482 is 
described below ( see Section 1.7).
1.4. Cabotegravir –Long A cting Injectable (CAB LA )
CAB LA, a long acting injectable formulation of cabotegravir , has been dosed in [ADDRESS_419223] received single or repeat dos es of CAB LA at doses 
between 100 to 800 mg , either intramuscularly  (IM) or subcutaneousl y (SC) and either 
alone or in combination with RPV LA (stud y LAI114433 [single dose LA, n=58], study   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
29LAI115428 [repeat dose LA, n=40], and study  LAI116815 [single dose LA, n=38]). The
adverse event (AE) profile has been similar to those of CAB (oral) .  To date, no studies in 
HIV-[ADDRESS_419224] been conducted with CAB LA.  
CAB LAhas been generally well- tolerated as either an IM or SC dose .  Intramuscular 
injection site reactions (ISRs) have been predominantly  mild or Grade 1 (85%), self-
limited, and have not led to study  discontinuation in any  subject to date. Erythema, 
nodules, induration, and warmth at the injection site were most commonl yreported in 
healthy subjects.  Painless nodules were more common following SC injections than I M 
injections.   No treatment emergent serious AEs have been reported in any  of the healthy  
volunteer studies involving CAB LA.  [LAI115428 GlaxoSmithKline Document Number 
2011N112455_03 and GlaxoSmithKline Document Number RM2010/[ZIP_CODE]/04 : 
LAI114433]. 
All of the above characteristics make cabotegraivir an attractive compound for continued 
HIV drug development.
1.5. Rilpi[INVESTIGATOR_12979] –Oral (RPV)
RPV, the oral formulation of rilpi[INVESTIGATOR_12979] (Edurant ), is a diary lpyrimidine derivative anda 
potent non -nucleoside reverse transcriptase inhibitor (NNRTI) with in vitro activity  
against wild ty pe HIV -[ADDRESS_419225] NNRT I-resistant mutants.  RPV is currently approved 
as a 25 mg oral tablet formulation in multiple countries such as the [LOCATION_002] ( US), 
EUandCanada for use in antiretroviral (ARV) treatment- naïve patients as per the 
approved label in each country  / regi on. Review and approval in other countries is 
ongoing. RPV combines once dail y dosing with potent antiviral activity and a good 
tolerability /safety  profile. The approval of RPV is based on Week 96 safet y and efficacy 
analyses from 2 randomized, double bl ind, active controlled Phase III trials in ART 
treatment -naive subjects .
The Phase III trials (TMC278 -C209 [ Molina , 2011] and TMC278 -C215 [ Cohen , 2011]) 
compared RPV to efavirenz (EFV) each with a ba ckground regimen of 2 NRTI s, in 
antiretroviral -naïve HIV -1 infected subjects with HIV -1 RNA  5000 c/mL and no 
NNRTI resistance. Both trials were identical in design, with the exception of the 
background regimen. The Week 48 efficacy  outcome for the pool ed data from TMC278-
C209 and TMC278 -C215 (N=1368) showed that the proportion of subjects with HI V-1
RNA < 50 c/mL was 83% for RPV based regimen compared to 80% for the EFV based 
regimen (Snapshot algorithm) . The overall virologic failure rate was 13% for the RPV 
compared to 9% for EFV. The proportion of patients who discontinued study  due to an 
adverse event or death was 2% for RPV and 7% for EFV [ Cohen, 2012]. 
1.6. Rilpi[INVESTIGATOR_12979] –Long Acting Injectable (RPV LA)
Rilpi[INVESTIGATOR_339150] a long acting injectable ( RPV LA) with PK that could 
support IM dosing every  4or 8weeks . Results from 3 completed Phase I trials 
(TMC278 -TiDP15 -C146 [C146] and TMC278- TiDP15 -C158 [C158]) have provided an 
understanding of the safety  and tolerabil ity after parenteral RPV LA dosing, as well as its 
pharmacokinetic characteristics. Seventy  subjects have received RPV LA injectable  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419226] been 
completed with RPV LA.
The results o f study  C146 demonstrated that RPV LA was generall y well tolerated at all 
doses (200, 400, or 600 mg) and with all injection routes (IM and SC). Overall, there 
were no RPV LA signs of sy stemic intolerance. The incidence of ISRs was dependent on 
the ty pe of administration and dose volume: better tolerability  was observed for doses of 
[ADDRESS_419227] to laboratory  parameters, vital signs, and electrocardiograph (ECGs).
In C158 ( N=20), RPV LA injectable suspension in the current formulation after single 
IM injection of 300 mg or of 600 mg, or after multiple dosing regimens of 3 successive 
IM doses was generall y safe and well tolerated. Successive monthl y IM administration 
(1200, 600, and 600 mg) of RPV LA was also well tolerated with few AEs and I SRs. No 
deaths or SAEs related to the trial medication were reported.  The most frequently  
reported AEs were headache (4 subjects [23.5%]) and mild injection site reactions (5 
subjects [ 29.4%]). There were no clinically  relevant effects on laboratory  parameters, 
ECGs, and vital signs (TMC278 [ Rilpi[INVESTIGATOR_12979], oral and parenteral] Integrated 
Investigator’s Brochure , 201 3).
In LA I115428, RPV LA was administer ed as successive monthly  IM injections as 
1200/900 mg or 1200/[ADDRESS_419228] discontinued due to an ISR, and n o 
treatment emergent se rious AEs were reported [GlaxoSmithKline Document Number 
2011N112455_03].
1.7. Stud y LAI116482
LAI116482 is an ongoing Phase IIb dose -ranging study  (CAB 10 mg, 30 mg, 60 mg) 
evaluating the utility  of a two- drug, two- class combination ( CAB + RPV) when both are 
given as a once dail y oral regimen following induction of virologic suppression using 
CAB plus 2 investigator selected NRTIs. Eligible subjects enter Maintenance at Week 24 
where they  begin the CAB + RPV regimen .  
To date, the study has enrolled 244 subjects, 181 of whom received one of three oral dose 
regimens of CAB (10 mg, 30 mg or 60 mg) plus 2 NRTI s. A planned Week 96 (24 weeks 
on Induction and 72 weeks on two -drug Maintenance) analysis is complete and 
demonstrated similar antiviral activity  across the three dosing arms of CAB in 
combination with RPV , which compared favorably to the control regimen of 
EFV 600mg once daily  plus 2 NRTI s.  
Rates of protocol defined virologic failure (PDVF) through Week 96 were low across all 
study  arms . Three subjects receiving CAB (one at each dose) and three subjects 
receiving EFV were characterized as PDVFs during Induction.  During Maintenance, 
three subjects receiving CAB (10 mg, n=2; and 30 mg, n=1) and two subjects rec eiving 
EFV were characterized as PDVF.    2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
31During Maintenance, t reatment emergent integrase inhibitor (INI)(Q148R) and NNRTI 
(E138Q) resistance mutations were identified in one subject on CAB (10 mg) .The 
subject experienced suspected virologic failure (S VF) at Week 48, which was 
subsequently confirmed.  There was no change in RPV susceptibility, and a 3.[ADDRESS_419229] on CAB (10 mg) developed treatment emergent NNRTI resistance 
(K101K/E and E138E/A ).  The subject experienced virologic failure at Week 72 which 
was subsequentl y confirmed.  There was no change to CAB susceptibility , and a 4.6 fold 
change in susceptibility  to RPV . There was n o treatment-emergent integrase resistance.
By [CONTACT_10585] 16 or at time of I P discontinuation if before Week 16, 63% of subjects were 
treated with Truvada (tenofovir/emtricitibine, TDF/FTC) as their background dual NRTI 
and 3 7% of the subjects were treated with EPZICOM/KIVEXA™ (abacavir/lamivudine, 
ABC/3TC).  Similar virologic response rates (HIV -1 RNA < 50 c/mL) through 24 weeks 
were seen in subjects taking CAB + ABC/3TC (87%) and in subjects taking CAB + 
TDF/FTC (8 6%). 
Following induction therapy, CAB + RPV (86%) maintained virologic suppression at a 
rate similar to EFV + NRTI s(83%) through [ADDRESS_419230] occurred on study  day 343.  
The majority  of AEs were Grade 1 (29%) or Grade 2 (49%) severit y.  Seven subjects on 
CAB versus nine on EFV withdrew due to an AE, one receiving 10 mg (ECG abnormal 
and palpi[INVESTIGATOR_26593]), two receiving 30 mg (panic attack , Burkitt’s ly mphoma ) and four 
receiving 60 mg (hepatitis, transaminases increased, anxiety disorder and musculoskeletal 
pain).  The majorit y of CAB related AEs were Grade 1 and few of those AEs led to 
withdrawal through Week 96(n=4 [2%] ).  There have been no CAB drug related SAEs to 
date.  
Two of the subjects that withdrew due to AE met liver stoppi[INVESTIGATOR_339151] (ALT) >10x upper limit of normal ( ULN )at approximately  Week 4 and 
Week 8 a fter initiating study  drug.  Both had pre -existing steatohepatitis and were dosed 
with CAB 60 mg + ABC/3TC.  Both subjects remained as ymptomatic, had normal serum 
bilirubin levels and had resolution of the ALT values after drug discontinuation.  These 2 
subjects accounted for the only  Grade 3 -4 ALT abnormalities in this study  to date.  
Overall, the rates of an y graded ALT or aspartate a minotransferase (AST )abnormality   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
32were similar between CAB and EFV dosed subjects through Week 96 : ALT:  20% and 
21% respec tively ; AST:  2 5% and 21% respectively .
These data from LAI116482 support the conduct of study  200056 by  [CONTACT_339234] a HAART regimen to induce 
virologic suppression.  In addition, this data co nfirmed antiviral activity  of CAB + RPV 
as a two- drug oral Maintenance regimen and provide s proof of principle for CAB LA + 
RPV LA as a maintenance regimen.  
Based upon the results through Week 96of the LAI116482 study [Margolis, 2015] , and 
in accordance with the pre -specified dose selection criteria at Week 48 , a 30 mg oral dose 
of CAB has been selected to be used in combination with ABC/3TC for induction of 
virologic suppression in study  200056.
All ongoing subjects in the LAI116482 study  have entered the Open Label Extension 
phase to continue to receive the two drug regimen of CAB 30 mg + RPV [ADDRESS_419231] evaluation of the virologic efficacy  of 
the oral tw o drug regimen of CAB and RPV , prior to initiating the long acting injectable 
regimen.  These data will be made available to Investigators.
1.8. 200056
The 200056 study  (LATTE -2) evaluated a 20 week induction of HIV -1 RNA suppression 
with a three drug oral antiretroviral regimen consisting of CAB + ABC / 3TC Fixed Dose 
Combination (FDC) followed b y randomization to a two -drug regimen consisting of 
intramuscular (IM) long -acting (LA) CAB LA + RPV L A compared t o continuation of 
oral CAB + ABC / 3TC for the maintenance of HIV -1 RNA suppression.  A total of 309 
participants were enrolled and treated.
During the Induction Period there was a rapid and sustained decline in HIV -1 RNA, with 
91% of participants (282/309 ) achieving HIV -1 RNA <50 c/mL through 20 weeks of 
therap y.  There was a single participant ( with known compliance issues) with confirmed 
virologic failure during the Induction Period.  Virologic testing revealed no treatment 
emergent phenot ypic or genot ypic resistance in this participant.
The primary  endpoint for 200056 was the Week 32 proportion of participants with HI V-1 
RNA <50 c/mL (Snapshot, I ntent -to-Treat Maintenance Exposed population [I TT-ME]). 
Following virologic suppression on three drug oral t herap y in the Induction Period, 
286participants qualified to enter randomization at the Day  1 visit, and were 
subsequently  randomized 2:2:1 onto every  4 week intramuscular (IM) injections with 
CAB LA + RPV LA (Q4W), every  8 week IM injections with CAB LA + RPV L A 
(Q8W) or continuation of oral CAB + NRTIs, respectivel y.  At the time of randomization 
at Day  1, participants entering one of the IM arms discontinued all oral ART. Through 
32 weeks of two -drug maintenance therap y, 95% (Q8W) and 94% (Q4W) of part icipants 
on injectable dosing were virologic successes, compared to 91% of participants 
continuing three drug oral CAB + NRTIs, meeting pre- specified criteria for comparability  
between the dosing arms. Through 32 weeks of Maintenance therap y, there was one  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
33participant each on Q8W and oral dosing with confirmed virologic failure (CVF), without 
any evolution of viral resistance. The CVF on Q8W dosing occurred following an 
aberrant RPV injection, without measurable plasma RPV concentrations [ADDRESS_419232] 
dosing.  
Week 48 data was a secondary  endpoint for 200056, and permitted the evaluation of the 
two-drug long- acting combinations’ ability  to maintain the virologic suppression 
demonstrated at Week 32.  At Week 48, 92% (Q8W) and 91% (Q4W) of participants 
recei ving injectable dosing had a sustained virologic response (HIV-1 RNA <50 c/mL) 
compared to 89% of participants continuing oral CAB + 2 NRTIs.  Although the 
proportion of participants with virologic success was similar for Q8W and Q4W dosing, 
the reason for Snapshot failure was different between the arms.  There were more 
Snapshot failures for virologic reasons on the Q8W arm (n=8, 7%) than in the Q4W arm 
(n=1, <1%), and more participants with no virologic data (discontinued due to AE or 
other reasons) on th e Q4W arm (n=9, 8%) compared to the Q8W arm (n=1, <1%).  
Between Week 32 and Week 48, one additional participant (Q8W) had confirmed 
virologic failure.  This participant had a Baseline HIV -1 RNA of 444,489 c/mL .  At 
Week 48, the participant was a suspecte d virologic failure with HIV -1 RNA = 463 c/mL.  
Upon retest, ten day s later, the virologic failure was confirmed with HIV -1 RNA of 
205c/mL .  At the time of CVF, this participant had treatment emergent NNRTI  
resistance K103N, E138G, and K238T, with high le vel phenot ypic resistance to 
delaviridine (>MAX), efavirenz (48 fold change [FC]), nevirapi[INVESTIGATOR_050] (>Max), and 
rilpi[INVESTIGATOR_12979] (3.34 FC). The fold change to etravirine (1.91) was below the lower cutoff.
Week 48 integrase genotype had the treatment emergent integrase resistance mutation 
Q148R, with accompan ying resistance to raltegravir (29 FC), elvitegravir (138 FC), and 
cabotegravir (6.06 FC). The Week 48 sample was not resistant to dolutegravir (1.38 FC).
Overall ,AEs and clinical chemistries were similar to th ose observed in prior studies with 
CAB, without discernible trends between Q8W, Q4W, and oral. Injections were well 
tolerated with two participants discontinuing due to injection tolerability  through 48 
weeks (both on Q8W dosing). The vast majorit y of in jection site reactions were due to 
pain/discomfort with nearly  all injection site reactions classified as mild (82%) or 
moderate (17%), with <1% of reactions classified as severe. There was no discernible 
tolerability  difference between Q4W (2 mL) dosing and Q8W (3 mL  dosing).  The most 
common non -ISR AEs during the Maintenance Phase were nasophary ngitis (24%), 
headache (16%), and diarrhea (13%) on IM arms and nasophary ngitis (30%), headache 
(11%), and diarrhea (5%) on oral CAB.  Through Week 48, SAEs duri ng the 
Maintenance Period occurred in 7% of participants randomized to CAB LA + RPV L A 
and 5% of participants randomized to remain on oral treatment, none were drug related.  
Based on the data from the Week [ADDRESS_419233] in 
evaluating the potential of Q8W dosing, subjects entering the Extension Period from the 
oral CAB 30 mg + ABC/3TC arm in this study  will be given the option to switch t o either 
an optimized Q8W or Q4W regimen.  Subjects originall y randomized to the IM regimen 
and entering the extension phase will remain on their randomized regimen.   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
341.9. Stud y Rationale
While advances in the development of new anti -retroviral therapi[INVESTIGATOR_014] (ART) provide 
extensive insights into the management of HIV -infected individuals, chronic HIV 
infection in adults continues to be characterized by [CONTACT_339233], increasing transmission of resistant virus and issues associated with th e long -term 
toxicity  of ART. The current paradigm in the treatment of HIV involves life -long 
therap y with multiple antiretrovirals. There is an enduring need to develop new agents 
with improved safet y and resistance profiles with convenient dosing for bo th 
antiretroviral treatment- naive and treatment -experienced patients. 
Various approaches to simplify  a patient's antiretroviral therap y (ART) regimen, after 
achieving virologic suppression, have been studied. Previous studies have evaluated 
switches to r itonavir -boosted PI  [INVESTIGATOR_339152] 
[Bierman , 2009 and Arribas , 2012]. While the data from these studies have shown both 
long-term non -inferiority and inferiorit y to continual Highl y Active Antiretroviral 
Therap y (HAART), they suggest that simplifying from a three drug dual class regimen to 
a single boosted protease inhibitor may  be a safe and effective option for the majority  of 
subject s studied who have effectivel y maintained virologic suppression. 
This clinical trial, 200056, will evaluate a different simplification approach (see 
Section 3.1for study  schematic).  In this study , subjects wi ll induce HIV -1 RNA 
suppression with a three drug antiretroviral regimen consisting of CAB + ABC/3TC FDC 
and then switch to a two -drug two -class regimen consisting of CAB LA + RPV LA for 
the maintenance of HIV -[ADDRESS_419234] an intramuscular dosing regimen of CAB
LA plus RPV LA based on a comparison of the Week 32 antiviral activity, tolerability , 
and safet y of two IM dosing regimens, relative to CAB 30mg plus ABC/3TC orally  once 
daily , in HIV -1 infecte d antiretroviral- naïve subjects.  
This study  consists of three parts: an Induction Period, Maintenance Period and 
Extension Period.  There is also a L ong-Term Follow Up Period for subjects who 
withdraw and have received at least one dose of CAB LA and / o r RPV LA. 
Induction Period
The objective of the Induction Period is to induce virologic suppression prior to the 
initiation of the CAB LA + RPV LA regimen.  In addition, the I nduction Period will 
evaluate the safet y, tolerability  and efficacy  of CAB in combination with ABC/3TC in 
HIV-1-infected, ART -naive adults. The Induction Period consists of an evaluation of 
CAB 30 mg once daily  plus ABC/3TC through 20 weeks .  Virologic suppression in the 
LAI116482 study was rapid, with 83% of CAB 30 mg treated subjec ts achieving an HIV -
1 RNA <50 c/mL by [CONTACT_10585] [ADDRESS_419235] 12 weeks prior to randomization into the 
Maintenance Period.  A review of the virology  data from LAI1164 82 suggests that few 
subjects required greater than 16 weeks of therap y to achieve virologic suppression  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
35(HIV -1 RNA <50 c/mL), including subjects who entered the study  with HIV -1 
RNA >100,000 c/mL.  
Unless subjects meet a study  withdrawal criterion, their regimen will be modified during 
Induction at Week ( -4) by  [CONTACT_339235] 25 mg orally  once dail y.  RPV is being added 
to the ART regimen for all subjects at Week (-4) to establish safet y and tolerability of 
RPV in individual subjects prior to initiating tr eatment with CAB LA + RPV LA during 
the Maintenance Period.  Subjects who do not or cannot tolerate CAB or RPV during this 
period should not enter the Maintenance Period.  At the majority  of time points, the 
incidence of (treatment related) AEs in the Phas e III RPV studies were comparable 
between the RPV and control group and highest during the first [ADDRESS_419236] rash events was 10.5 days.  No grade 4 rash events were 
reported.  In addition, this RPV add on will serve as a pharmacokinetic lead in, achieving 
steady  state levels of RPV, prior to the administration of RPV LA [ Rashbaum , 2011a and 
Rashbaum ,2011b].
The selection of CAB 30 mg + ABC/3TC as an induction regimen is validated by  [CONTACT_339236]116482.  I n addition, utilizing the same regimen, across all 
subjects, during the Induction Period will minimize the variability  of responses between 
subjects, study  comple xity, and the impact of differential response rates during the 
Induction Period which could impact the interpretation of Maintenance Period results.
Maintenance Period
All subjects with an undetectable HIV -1 RNA (<50 c/mL ) at the Week ( -4) visit are 
eligible to enter the Maintenance Period. 
The objective of the Maintenance Period of this study  is to assess the ability  of a two -
drug regimen of CAB LA and RPV LA to maintain virologic suppression for 96 weeks 
with the primary  endpoint occurring after 32 weeks .  Two injectable IM dosing regimens 
(Q8W and Q4W) and one oral control dosing regimen will be evaluated.   
Subjects eligible to enter the Maintenance Period will be randomiz ed 2:2:1 at Day  1 to 
one of the dosing regimens described below:
CAB LA 600 mg + RPVLA 900 mg IM every  8 Weeks (Q8W)
+ Loading Dose of CAB 800 mg at Day  1
+ Loading Dose of CAB 600 mg at Week 4
CAB LA 400 mg + RPV LA 600 mg IM every  4 Weeks (Q4W)
+ Loading Dose of CAB 800 mg at Day  1
CAB 30 mg + ABC/3TC once dail y
Randomization will be stratified b y HIV -1 RNA <50 c/mL  before Week (- 8)(yes or no). 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
36Subjects on either IM regimen will discontinue the I nduction regimen (including the add-
on of RPV) after a final dose in the clinic on Day  1.  Subjects on the oral regimen will 
discontinue the add-on of RPV after a final dose in the clinic on Day  1.  
While both drugs, CAB LA and RPV LA, have been studied with both SC and IM 
administration, the I M administration is being progressed into study  [ADDRESS_419237] 
accommodate the required injection vo lumes of both drugs and to ensure good 
tolerability .  
The selection of CAB 30 mg + ABC/3TC as an oral comparator regimen in this study , 
will allow for a direct comparison of subjects who either i) continue their existing 
regimen or ii) simplify  their regimen to one of the IM regimens .  The chosen comparator 
will also allow for a direct comparison of oral daily  pi[INVESTIGATOR_339153]. Q4W and Q8W IM 
administration, as it relates to efficacy , tolerability, safet y, and acceptability.  
Normalizing the comparator popul ations by  [CONTACT_339237] 1 will also serve to strengthen this comparison.
Long -term maintenance of HIV virologic suppression will be assessed.  
Extension Period
The Extension Period of this study  will allow for a collection of longer term efficacy  and 
safet y and tolerability data from subjects receiving CAB LA and RPV LA.  Both of the 
current IM dosing regimens, Q8W and Q4W , will be taken into the Extension Period of 
the study  based on similar efficacy  results across each arm ( see Section 1.8).
Unless subjects meet a study  withdrawal criterion, subjects on the oral regimen may  elect 
to continue on the Extension Period by [CONTACT_339238] + RPV LA (either Q8W or Q4W) . 
Long -Term Follow -UpPeriod
Subjects who have received at least one dose of CAB LA and/or RPV LA are anticipated 
to be at high risk for development of virologic resistance if ART is interrupted. The time 
period during which subjects m ay be at greatest risk for developi[INVESTIGATOR_339154]. This time period will vary  
by [CONTACT_339239], inhibitory  
concentration and half -life.  Plasma concentrations of both drugs may  be measurable for 
approximately  [ADDRESS_419238] a single dose of CAB LA and/or RPV LA 
and who discontinue the CAB LA + RPV LA regimen for an y reason must remain on 
suppressive HAART for at least [ADDRESS_419239] dose of CAB LA and/or RPV LA 
in order to prevent selective pressure on HIV and the potential for selection of resistant 
mutants.  I n this study , this will be accomplished through the Long -Term Follow -Up 
Period.  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
371.10. Dose Rationale
1.10.1. CAB
CAB 10 mg, 30 mg and 60 mg oral once dail y achieved similar efficacy at Week 24 of 
Induction when coadministered with 2 NRTIs and a t Week 48 of Maintenance (24 weeks 
on Maintenance) when coadministered with RPV 25 mg once dail y (Table 1).  Rates of 
virologic suppression through Week 48 (Maintenance) on the two drug regimen remained 
similar to that attained th rough Week 24 (Induction) on three -drug ART.  
The oral dosing period intended for induction of virologic suppression also serves as a 
lead-in period required to confirm tolerability  in each subject prior to initiating the 
prolonged exposure following CAB LA injection, which has been observed to be up to 52 
weeks following a single injection in some subjects [ GlaxoSmithKline Document 
Number RM2010/[ZIP_CODE]/04 : LAI114433].   Although all doses provided similar induction 
and maintenance of viral suppression, CAB 30 mg once dail y was selected as the oral 
dose to be used in combination with ABC/3TC for induction of virologic suppression in 
this study .  CAB 30mg achieves higher plasma exposures than the 10 mg oral dose, 
providing higher toxicity coverage prior to initiating IM dosing .  
Based upon the results through Week 48of the LAI116482 study , and in accordance with 
the pre -specified dose selection criteria at Week 24 , a 30 mg oral dose of CAB has been 
selected to be used in combination with ABC/3TC for induction of virologic suppression 
in this study .
1.10.2. CAB LA
CAB 10 mg, 30 mg and 60 mg orally  once dail y achieved similar efficacy at Week 24 of 
Induction when coadministered with 2 NRTIs and at Week 48 of Maintenance (24 wee ks 
on Maintenance) when coadministered with RPV 25 mg once daily ( Table 1).  Rates of 
virologic suppression through Week 48 (Maintenance) on the two drug regimen remained 
similar to that attained through Week 24 (Induction) on thr ee-drug ART .  The similar 
efficacy  in all three treatment arms in L AI116482 suggests that maintaining target 
concentration at the end of a dosing interval (C) following IM administration of CAB 
LA with RPV LAat approximately  the level of the 10 mg oral d ose (geometric mean 
1.35 g/mL , 8.1- fold above PA -90% inhibitory  concentration [IC90]) should also 
maintain suppression of HIV infection .  Once safety  and tolerability  are confirmed with 
oral dosing, maintaining target C following IM administration of CAB LA with RPV
LA at approximately  the level of the 10 mg oral dose (geometric mean 1.35 g/mL , 8.1-
fold above PA -IC90) should be sufficient to maintain suppression of HIV infection.  
Maintaining a target at approximately  the level of the [ADDRESS_419240] been established
during Induction.  
Using population pharmacokinetic (PK) modelling and simulations, CAB Cvalues for 
several IM dosing regimens were calculated and two regi mens were selected based upon:
ability  to reach target concentration earl y in treatment, 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
38ability  to maintain mean C above that obtained with oral CAB 10mg once daily  
during treatment ( CAB trough concentrations  1.35g/mL), and
minimizing the total numbe r of injections per visit .
Table 1 Proportion of Subjects with Plasma HIV -1 RNA <50 c/mL at Key  
Visits -Snapshot (MSDF) A nalysis (ITT- E Population)
Visit[COMPANY_004]744
10 mg
N=60
n (%)[COMPANY_004]744
30 mg
N=60
n (%)[COMPANY_004]744
60 mg
N=61
n (%)[COMPANY_004] 744 
Subtotal
N=181
n (%)EFV 
600 mg
N=62
n (%)
Week 16 –Induction 54 (90) 50 (83) 53 (87) 157 (87) 46 (74)
Week 24 –Induction 52 (87) 51 (85) 53 (87) 156 (86) 46 (74)
Week 48 -Maintenance 48 (80) 48 (80) 53 (87) 149 (82) 44 (71)
CAB LA–Maintenanc e Period
Q8W
Subjects randomized to CAB LA Q8W will receive a CAB 800mg IM Loading Dose on 
Day 1 (within 2 hours of final oral dosing), a [ADDRESS_419241] 800 mg IM loading dose and second 600 mg IM loading dose were selected so 
that  80% of subjects will be above 1.35 g/mL throughout treatment.  Mean (90% 
confidence interval [CI ]) simulated CAB Cvalues versus time across doses for CAB LA 
Q8W are presented graphically  in Figure 1. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
39Figure 1 Simulated Mean (90% CI) CABTrough Concentrations versus Time 
for CABLA Q8W
AtWeek 56 (approximately  one y ear of dosing ), CAB LA Q8W is predicted to achieve 
CAB trough concentrations  1.35g/mL (target) in 84% of subjects. Although the lower 
bound of the 90% CI falls below 1.35 g/mL, C for all subjects remains above 4 PA-
IC90(0.166 g/mL).  At Week 56, geometric mean CAB Cfor CAB LA Q8W is 
predicted to be 2.02g/mL , 1.5-fold above target and 12.2-foldabove PA -IC90(Table 2).   
Aone week delay  in dosing at steady  state the Q8W regimen is predicted to result in a 
geometric mean C that is 9% lower than for dosing that is administered on schedule 
while remaining a bove the 1.35 g/mL target associated with the 10mg oral dose .  
Q4W Subjects randomized to the Q4W dosing arm will first receive CAB 800mg IM as 
a loading dose on Day  1 (within 2 hours of final oral dosing) and then, starting at Week 4, 
will receive CAB 400 mg IM Q4W. 
The 800 mg loading dose was selected so that 80% of subjects will be above
1.35 µg/mL throughout treatment, including the end of the first dosing interval.  Mean 
(90% CI) simulated CAB Cvalues versus time across Q4W doses for CAB LA are 
presented graphicall y inFigure 2. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
40Figure 2 Simulated Mean (90% CI) [COMPANY_004]744 Trough Concentrations versus 
Time for CABLA Q4W
AtWeek 56 (approximately  one y ear of dosing ), CAB LA Q4W is predicted to achie ve 
CAB trough concentrations  1.35g/mL (target) in 99.6% of subjects.  Geometric mean 
CAB Cfor CAB LA Q4W at Week 56 is predicted to be 3.35 g/mL , 2.5- fold above 
target, 20.2- fold above the PA -IC90(0.166 g/mL), and similar to the observed mean C 
after 16 weeks of this regimen in healthy  subjects ( Table 2).
A one week delay  in dosing at steady  state for the Q4W regimen is predicted to result in a 
geometric mean C that is 8% lower than for dosing that is administered on sch edule 
while remaining above the 1.35 g/mL target associated with the 10 mg oral dose. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
41Table 2 Summary  of Cabotegravir PK Parameters following oral 
administration i n HIV infected subjects, CABLA administration in 
healthy  subjects, a nd follo wing Simulations
Route
Study
PopulationCAB RegimenCAB PK Parameter
C  or C0
(g/mL)aCmax
(g/mL)bAUC(0 -)
(gh/mL)cIQ
(C0:IC 90
ratio)d
Oral
LAI116482
HIV10 mg orally every day1.35
[45%]2.77
[33%]45.7
[32%]8.13
30 mg orally every day4.20
[40%]7.49
[28%]134
[32%]25.3
60 mg orally every day7.93
[39%]13.1
[44%]195
[48%]47.8
IM
LAI115428 
HVs800 mg IM LD
400 mg IM Q4W x33.22
[28%]4.37
[33%]2362
[27%]19.4
IM 
PopPK 
simulation
HIVLA Regimen #1 (200056):
800mg IM LD
400mg IM Q4W from W43.35
[35%]ND ND 20.2
IM
PopPK 
simulation
HIVLA Regimen #2 (200056):
800mg IM LD 1
600mg IM LD 2 (Week 4)
600mg IM Q8W from W82.02
[52%]ND ND 12.2
Data presented as Geometric mean [CVb %], HIV = HIV infected subjects, HV = Healthy Vol unteers, ND=Not 
determined, LD = Loading Dose
a. C0:  n=57 (10 mg orally), 53 (30 mg orally), 55 (60 mg orally), 9 (800 mg/400 mg IM), 
b. Cmax:  n=14 (10 mg orally), 12 (30 mg orally), 11 (60 mg orally), 9 (800 mg/400 mg IM)
c. AUC(0 -):  n=14 (10 mg orally), 12 ( 30 mg orally), 11 (60 mg orally), 9 (800 mg/400 mg IM)
d. PA-IC90determined in vitro 0.166 g/mL.
CAB LA – Extension Period
CAB concentrations following administration of CAB LA Q8W and Q4W during the 
Maintenance Period of LATTE -2 were lower than predicted by [CONTACT_339240] .Observed data for both CAB LA regimens in 
LATTE- 2 are presented in Figure 3.  The CAB LA population PK model has been 
updated to include data from Phase 2a/b studies, spe cificall y Study 201120 (CAB LA 
PrEP) and Study  200056.  The current model has increased from 93 subjects to 416 
subjects receiving CAB LA single or repeat IM injections. The rationales for the new
CAB LA IM dosing regimens are described below . 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
42Figure 3 Observed Mean (SD) Concentration -Time Data follo wing CA B LA  
Q8W and Q4W and Cfollo wing 30 mg PO QD through Week 48 
(200056, LA TTE-2)
Week0 0 1 4 8 12 16 20 24 25 28 3232 36 40 41 44 48 48Plasma CAB ( g/mL)
0.1110
800mg IM LD, 600mg IM W 4, W 8 and Q8W
800mg IM LD, 400mg IM Q4W
30mg PO QD
PA-IC90 (0.166 g/mL)
10mg PO QD C  (LATTE, 1.35 g/mL)
Both predose and 2h post injection concentrations are shown at Time Zero, Week 32, and Week 48.
Extension Phase Rationale for CAB LA Q8W
After the Maintenance Period oral regimen, the first and second CAB LA 600 mg IM 
dose at study  visit Week 100(1stinjection day ) and Week 104(2ndinjection) of the 
Extension Period of this study  was selected so that 50% of subjects are anticipated to be 
above 1.35 g/mL, the geometric mean C following oral CAB 10 mg once daily , 
throughout treatment which was shown to be efficacious in the LATTE study .  The lower 
bound of the 90% prediction interval is approximate ly 0.166 g/mL, indicating that 95% 
of subjects on this regimen should remain above the PA -IC90throughout dosing ( Figure 
4). 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
43Figure 4 Simulated* Median (90% Prediction Interval [PI]) CA B Plasma 
Concentrations versus Time for the Optimized CAB LA  Q8W
Regimen (600 mg IM Day  1, Week 4, Q8W thereafter )^
*Note: current simulations based on interim plasma concentration dataset
^Study Time and Events include a 4 week oral lead in.  Therefore, Day 1 = date of fi rst injections (Week 100study 
visit); Week 4 = second injections (Week 104study visit)
Model based predicted stead y-state CAB concentrations were consistent with observed 
data in this study , where CAB LA [ADDRESS_419242] dose of 600 mg IM at Week 8 prior to initiating Q8W.  
The mean CAB plasma concentration at Week 32 was 1.53 g/mL ( Figure 3). 
At steady  state, a one week delay  in dosing of the Q8W regimen is predicted to result in a 
median stead y state C that is 15% lower than for dosing that is administered on 
schedule, with 92% remaining above thePA-IC90(Figure 5). 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419243] of 1 -week Delay in Dosi ng at Steady State (Week 44) on 
Simulated *Median (90% PI) CA BPlasma Concentrations versus 
Time for the Optimized CAB LA  600 mg IM Q8W regimen ( Day 1, 
Week 4, and Q8W thereafter^ )
*Note: current simulations based on interim plasma concentration dataset
^Study Time and Events include a 4 week oral lead in.  Therefore, Day 1 = date of first injections (Week 100study 
visit); Week 4 = second injections (Week 104study visit)
Extension Phase Dose Rationale for CAB LA Q4W
The simulation of the predicted medi an (90% prediction interval [PI ]) CAB 
concentration -time profile based on the population PK model is shown in Figure 6.  The 
lower bound of the PI [INVESTIGATOR_339155] 4x PA-IC90throughout dosing.  
At steady  state, 9 8% of the population is predicted to achieve trough concentrations 
above 4x PA -IC90, and 88% is predicted to achieve trough concentrations above the 
geometric mean trough following the 10 mg oral dose in LATTE of 1.35 g/mL (8x PA -
IC90).   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
45Figure 6 Simulated* Median (90% Prediction Interval [PI]) CA B Plasma 
Concentrations versus Time for the Optimized CAB LA  Q4W 
Regimen (600 mg IM Day 1, then 400 mg IM Q4W thereafter^)
* Note: current simulations based on interim plasma concentrat ion dataset
^Study Time and Events include a 4 week oral le ad in.  Therefore, Day 1 = day of first injections (Week 100study visit); 
Week 4 = second injections (Week 104study visit)
Medium dashed line at 1.35 g/mL corre sponds to the geometric mean Ctrou gh concentration following oral CAB 10 
mg once daily  (LATTE) and is equivalent to 8x PA -IC90
Dotted line at 0.664 g/mL corresponds to 4x PA -IC90
Long dashed line at 0.166 g/mL corresponds to the PA -IC90.
At steady  state, a one week delay  in dosing o fthe Q4W regimen results in approximately  
15% reduction in median CAB trough. With this delay , 95% are predicted to remain 
above 4x PA -IC90, and79% are predicted to remain above the 10 mg oral target ( Figure 
7).  Simulations inc luding delay s greater than one week have been explored (not shown), 
with <70% of subjects remaining above the [ADDRESS_419244] of 1 -week Delay in Dosing at Steady  State (Week 4 0 delay ed 
to Week 41 ) on Simulated* Median (90% PI) CA B Plasma 
Concentrations versus Time for the Optimized CAB LA  Q4W regimen  
(600 mg IM Day  1, then 400 mg IM Q4W thereafter^)
* Note: current simulations based on interim plasma concentration dataset
^Study Time and Events include a 4 week oral lead in.  Therefore, Day 1 = day of first injections (Week 100study visit); 
Week 4 = second injections (Week 104study visit)
Medium dashed line at 1.35 g/mL corresponds to the ge ometric mean C following oral CAB 10 mg once daily  
(LATTE) and is equivalent to 8x PA -IC90
Dotted line at 0.664 g/mL corresponds to 4x PA -IC90
Long dashed line at 0.166 g/mL corresponds to the PA -IC90.
1.10.3. RPV
All subjects will receive 4 weeks of RPV 25 mg once daily, co-administered with 
CAB +ABC/3TC, from Week ( -4) through Day  [ADDRESS_419245] 
prior to possible IM dosing with RPV LA. Data from study  LAI116182 
[GlaxoSmithKline Document Number 2012N134026_02:  L AI116482 ] have 
demonstrated that there is no clinically  relevant drug -drug interaction following repeat 
oral administration of CAB with RPV. With this oral RPV add- on, subjects will also 
have stead y
-state RPV plasma concentrations prior to starting CAB LA dosing during the 
Maintenance Period . 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
471.10.4. RPV LA
During the Maintenance Period, subjects will receive either IM injections of CAB LA 
600mg every  4 weeks (Q4W) or RPV LA 900 mg every 8 weeks (Q8W) . The selection 
of the RPV LA dosing regimens is based on achieving RPV plasma concentrations in the 
range of those observed with oral RPV 25 mg once dail yin HIV -infected patients (mean 
(SD) C trough of 80 (36) ng/mL  in pooled Phase III studies (RPV + 2 NRTI s);and 77 (34) 
ng/mL in the Mainte nance Phase of LAI116482 (RPV + CAB ), as well as constructing a 
regimen that is most practical for patients, i.e. b y reducing the number of dosing/clinic 
visits while maintaining an acceptable injection volume.
Figure 8and Figure 9 show the model -predicted RPV plasma concentrations over a 
dosing interval at stead y-state with th erespective Q4W and Q8W RPV LA dosing 
regimens. The graph sshow the mean profile (red curve) with the 90% prediction interval 
(shaded area). Also indicate d are the mean C trough for oral RPV 25 mg once daily in HIV-
infected patients (Phase III, 80ng/mL ) and the protein- binding adjusted IC 90for RPV 
(12ng/mL), as well as a scatter of the individual C trough values (plotted both at the 
beginning and at the end of the RPV LA dosing interval) in HIV-infected patients (Phase 
III).
For the simulations, a pharmacokinetic model was used based on all available data from 
studies with the current RPV LA formulation (TMC278- C158, SSAT040, L AI115428) 
and the population PK model of RPV. With this model, the RPV LA dosing regimen (i.e., 
4 weeks RPV 25 mg every day  followed by  [CONTACT_339241]  4weeks of RPV LA 600 
mg) was simulated for [ADDRESS_419246] between 
day 168 (i.e. after injection 5) and day  336 (i.e., after injection 11) was determined, and 
from these median values, the mean across subjects was calculated [GlaxoSmithKline 
Document Number 2011N112455_03: L AI115428]. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
48Figure 8 Model -Predicted Mean (90% prediction interval) RPV Plasma 
Concentration -Time Profile at steady -state after Q4W IM injections of 
RPV LA 600 mg (immediately  following 4 weeks oral RPV 25 mg 
once daily )
Red line represents the predicted mean steady state C trough concentration.
Blue dotted line represents mean C trough for oral RPV 25 mg once daily; 
Green dotted line represents protein -binding adjusted IC 90for RPV; 
Black open circles represent individual C troughvalues with oral RPV 25 mg once daily  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
49Figure 9 Model -Predicted Mean (90% prediction interval) RPV Plasma 
Concentration -Time Profile at steady -state after Q8W IM injections of 
RPV LA 900 mg (immediately  following 4 weeks oral RPV 25 mg 
once daily )
Red line represents the predicted mean steady state C trough concentration.
Blue dotted line represents mean C trough for or al RPV 25 mg once daily; 
Green dotted line represents protein -binding adjusted IC 90for RPV; 
Black open cir cles represent individual C trough values with or al RPV 25 mg once daily
RPV LA – Maintenance Period
Q8W
For the Q8W RPV LA dosing regimen, the mean steady- state C trough is predicted to be 
around 65 ng/mL , as of the 1stinjection. Though this is below the mean RPV C trough with 
oral RPV 25 mg once daily , the range of model -predicted C trough is similar to the range of 
Ctrough with oral RPV 25 mg once daily in the RPV Phase III studies ( Figure 9) and i n 
LAI116482 (Maintenance) . The RPV plasma concentrations are also higher during the 
larger part of the RPV LA dosing interval. Furthermore, all patients are virologically  
suppressed before switching to the RPV LA regimen. In LA I116482, there were 58/160 
HIV-infected patients with a RP V C trough (based on population PK modeling) below 65 
ng/mL .  These 5 8patients all maintained virologic suppression.
Q4W
The mean stead y-state C trough with th e Q4W RPV LA dosing re gimen is predicted to be 
around 115 ng/mL .This is above the mean RPV C trough(80 ng/mL ) and the mean C avg
(100 ng/mL) for RPV 25 mg once dail y (Phase III) .Furthermore, the mean RPV plasma 
concentrations are already above the mean C trough for RPV as of the 1stinjection with 
RPV LA 600 mg. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
50RPV LA – Extension Period
Similar to C AB, RPV concentrations following RPV L A in LATTE -2 were lower than 
predicted by [CONTACT_339242].  Observed data for 
both RPV LA regimens in L ATTE -2 are presented in Figure 10.  The RPV L A 
popu lation PK model has been updated to include data from LATTE-2.
Figure 10 Observed Mean (SD) Concentration -Time Data follo wing RPV LA  
Q8W and Q4W through Week 48 and Day 1 Cfollowing RPV 25 mg 
PO QD (LA TTE-2)
Week0 0 1 4 8 12 16 20 24 25 28 32 32 36 40 41 44 4848Plasma RPV (ng/mL)
101001000
900m g IM Q8W
600m g IM Q4W
25mg PO QD
PA-IC90 (12ng/mL)
25mg PO QD  (LATTE, 70ng/mL)
Extension Phase Rat ionale for RPV LA Q8W
The new optimized RPV LA Q8W regimen for this study  was selected based on safet y 
and efficacy  data from this study , 200056 (LATTE -2) and supported b y modelling and 
simulation of pharmacokinetic and response data obtained following adm inistration RPV 
LA administration in healthy  subjects (Phase 1 studies C158 and LAI115428 
[GlaxoSmithKline Document Number 2011N112455_03] ) and in HIV -infected subjects 
(Phase 2 study  LATTE -2), the majority  of the data coming from 200056 (LATTE- 2). 
The predicted median (90% PI) stead y-state Cfor the optimized RPV L A Q8W regimen 
is 54 ng/mL  (25– 109 ng/mL ) (Figure 11).  With this regimen, 100% of subjects remain 
above the RPV PA- IC90during the whole dose interval at steady -state.  These data are 
similar to the observed Week 32 median stead y-state C which was also 54 ng/mL and 
the mean C was 58 ng/mL  (Figure 10).  With the 2ndRPV L A dose at Week 104, the 
anticipated median RPV Cat Week 104is 42 ng/mL  (versus 30 ng/mL  observed prior to  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
51second injection at Week 8 in L ATTE -2), with >98% of subjects above the RPV PA-
IC90.
Figure 11 Simulated *Median (90% PI) RPV Plasma Concentrations versus 
Time Profile for the Optimized RPV LA Q8W regimen (900 mg IM Day  
1, Week 4, and Q8W thereafter^)
* Note: current simulations based on interim plasma concentration dataset
^Study Time and Events include a 4 week oral lead in.  Therefore, Day 1 = da te of first injections (Week 100study 
visit); Week 4 = second injections (Week 104study visit)
At steady -state, a one week delay  in dosing for the Q8W regimen is predicted to result in 
a median stead y-state C that is approximately  13% lower (47 ng/mL) t han for dosing 
that is administered on schedule, with >99% of subjects still remaining above the RPV 
PA-IC90(Figure 12).  This supports allowance of some flexibility  in the dosing regimen 
in this study , similar to what is currentl y practiced in this study . 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
52Figure 12 Simulated * Median ( 90% PI) RPV Plasma Concentrations versus 
Time Profile for Optimized RPV LA  Q8W dosing regimen, impact of 
1-week visit windo w (injection at Week 45 instead of Week 44)^
* Note: current simulations based on interim plasma concentration dataset
^Study Time and Events include a 4 week oral lead in.  Therefore, Day 1 = date of first injections (Week 100study 
visit); Week 4 = second injections (Week 104study visi t)
Extension Phase Rationale for RPV LA Q4W
The optimized RPV L A Q4W regimen for this study  was selected based on L ATTE -2 
safet y and efficacy data as described above and supported b y modeling and simulation of 
pharmacokinetic data obtained following admini stration of RPV L A in healthy  
participants (Phase 1 studies C158 and LAI115428 [GlaxoSmithKline Document Number 
2011N112455_03]) and in HIV -infected participants (Phase 2 study  LATTE -2), with the 
majority  of the data coming from 200056 (LATTE -2). 
The predicted median (90% PI) stead y-state C for the proposed regimen is 86.8 ng/mL 
(45.6 – 168 ng/mL) (Figure 
13).  With this regimen, >99% of participants remain above 
the 5thpercentile of steady  state trough values following oral RPV 25mg(corresponding 
to 2x the PA -IC90).  With a loading dose of 900 mg RPV LA on Day  1, the anticipated  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
53median RPV C at Week 4 is 42 ng/mL , with >98% of participants above the RPV PA -
IC90.
Figure 13 Simulated* Median (90% PI) RPV Plasma Concentrations versus 
Time Profile for the Optimized RPV LA  Q4W regimen (900 mg IM Day  
1, then 600 mg IM Q4W thereafter^)
* Note: current simulations based on interim plasma concentration dataset
^Study Time and Events include a 4 week oral lead in.  Therefore, Day 1 = day of first injections (Week 100 study visit); 
Week 4 = second injections (Week 104 study visit) 
Horizontal line at 72 ng/mL corresponds to median C following oral RPV 25mg once daily in LATTE -2 (oral lead -in) 
and is similar to median RPV C in other studies in HIV -infected patients (LATTE, ECHO/THRIVE)
At steady -state, a one week delay  in dosing for the Q4W regimen is predicted to result in 
a median stead y-state C that remains above the median trough for RPV 25 mg (Figure 
14).  This supports allowance of some flexibility  in the dosing regimen. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419247] of 1 -week Delay in Dosing at Steady  State (Week 40 delay ed 
to Week 41) on Simulated* Median (90% PI) RPV Plasma 
Concentrations versus Time for Optimized RPV LA  Q4W dosing 
regimen (900 mg IM Day 1 and then 600 mg IM Q4W thereafter^)
*Note: current simulations based on interim plasma concentration dataset
^Study Time and Events include a 4 week oral lead in.  Therefore, Day 1 = day of first injections (Week 100 study visit); 
Week 4 = second injections (Week 104study visit)
Horizontal line at 72 ng/mL corresponds to median C following oral RPV 25 mg once daily in LATTE -2 (oral lead- in) 
and is similar to median RPV C in other studies in HIV -infected patients (LATTE, ECHO/THRIVE)
1.11. Benefit: Risk A ssessment
Summaries of findings from both clinical and non-clinical studies conducted with CAB
and CAB LA can be found in the I nvestigator ’s Brochure.  RPV is a recently  authorized 
medicinal product and detailed information on its benefit/risk profile together with any  
riskmitigation measures are described in product labeling.  Summaries of findings from 
both clinical and non -clinical studies conducted with RPV LA can be found in the 
Investigator’s Brochure.  Other medicinal products including ABC/3TC that are 
administered in this protocol have been in clinical use for at least [ADDRESS_419248] well 
established benefit/risk profiles describ ed in detail in their respective product labels.   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
55Relevant mitigation measures are also incorporated in to this protocol. The following 
sections outline the risk assessment and mitigation strategies specific to this protocol : 
1.11.1. Risk A ssessment
[IP_ADDRESS]. CAB and CAB LA
Since CAB is at an earl y stage of clinical development, and exposure in humans with or 
without HI V infection is limited, the clinical safety  profile in humans has yet to be fully  
elucidated. The following risks have primaril y been identified during rout ine preclinical 
testing and/or in the clinical trial experience to date and are considered of potential 
relevance to clinical usage in the context of this protocol.  Additional information about 
the clinical experience to date and possible risks associated with treatment using CAB 
can be found in the Summary  of Data and Guidance for the Investigator section of the IB.
Elevated Liver Transaminases
A small proportion of participants in the CAB program to date (total exposure 
approximately  1198 to 01 April 201 6) have develop ed transaminitis (elevated liver 
transaminases characterised by  [CONTACT_339243]).  In some of these 
participants’ transient transaminitis were explained by [CONTACT_339244] C infection and 
whilst a small number of others did not hav e alternative explanations, suggesting a mild 
form of DILI (drug induced liver injury )without hepatic d ysfunction which resolved 
upon withdrawal of treatment with CAB. 
Of the five participants with possible or probable cases of DILI identified in Phase 2
studies , four participants were receiving oral CAB and one participant developed 
probable DILI following CAB LA or Placebo LA administration.
Mitigation: Liver transaminases will be closely  monitored throughout this study  (refer to 
Time & Events Table) an d the liver chemistry  stoppi[INVESTIGATOR_339156] [IP_ADDRESS] of this protocol. All instances of liver transaminase 
elevations of Grade 2 and above will be followed to resolution. This risk will also be 
mitigated b y exclusion criteria as described in Section 4.3.  In addition, an oral lead in 
period is being implemented in this study , where all subjects will receive CAB oral 
during the Induction Period, to determine individual safet y and tolerability, prior to the 
possible administration of CAB LA.
Elevated Serum Creatinine
This risk was identified from placebo controlled studies which demonstrated slightly  
more pronounced changes from Baseline associated with CAB exposure compared to 
placebo. Changes were generall y small with a maximum change from Baseline observed 
at a dose of 30 mg given to 12 healthy  subjects for 24 day s (~ 0.19 mg/dL at Day  24), 
Levels returned to Baseline after cessati on of CAB dosing. Further Phase I and Phase II 
clinical studies have not demonstrated an increase in creatinine levels with CAB
administration. No pre -clinical signal for renal toxicity  has been demonstrated and  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419249] not been associated with clinically  evident renal dy sfunction or 
proteinuria.
Mitigation: Standard renal toxicity  monitoring procedures and treatment stoppi[INVESTIGATOR_339157] [IP_ADDRESS] . 
Creatine Phosphokinase (CPK) elevations
Occurrences of as ymptomatic, transient instances of elevations of CPK levels have been 
observed in Phase I studies and an ongoing Phase IIb studieswith CAB at dose levels of 
10, 30 and 60 mg (LAI116482) and with CAB LA (200056) . These generally  appeared 
to be related to ph ysical activity , were not associated with clinical sy mptoms and returned 
to pre -treatment levels in all cases.  No subject has required a discontinuation of CAB as 
a result of a CPK elevation. Rhabdomy olysis of uncertain cause has been included in 
labeling for a currently  available integrase inhibitor (raltegravir) but has not been seen in 
any subject receiving CAB to date.
Mitigation: standard laboratory  monitoring as detailed i n Section [IP_ADDRESS] .  Occurrences 
of elevated CPK levels will be reported and managed as described in Section [IP_ADDRESS] .
Bone Marrow depletion
This risk was demonstrate d in high dose (1000 mg/kg/day ) CAB monkey  study  but was 
not apparent from studies conducted in rats or at lower dose levels in monkeys. Blood 
disorders such as anemia and leucopenia are labeled for other drugs of the integrase 
inhibitor class.  No signal for bone marrow depletion has been identified for CAB to date 
through Phase IIb.
Mitigation: Doses used within this study  will result in many  fold lower level exposure 
compared to the effect level in primates. Careful monitoring of adverse hematological 
events (including laboratory  monitoring as in Section 6.10.2 ) will occur during stud y 
conduct. Serious/severe events will be managed appropriatel y including, but not limited 
to, withdrawal of CAB , and will be fol lowed to resolution as per Sponsor’s standard 
medical monitoring practices. 
Gastrointestinal intolerability 
The risk identified in a monkey  toxicity  study  at the highest administered dose of CAB
and considered related to local irritation (rather than a s ystemic effect) leading to 
morbidity  associated with clinical signs of intolerance.
Mitigation: Careful monitoring of adverse GI events will occur throughout the study . 
Serious/severe events will be managed appropriately  including, but not limited to, 
withdrawal of CAB , and will be followed to resolution as per Sponsor’s standard medical 
monitoring practices.    2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
57Injection Site Reactions
The occurrence of ISRs was identified in rats and monkey s at all dose levels of CAB LA 
and associated with both the I Mand SC route of administration. In humans, experience 
to date has demonstrated ISRs occur in the majority of exposed subjects but are generally 
mild (Grade 1) or moderate (Grade 2) and include tenderness, ery thema, or nodule 
formation of several da ys duration. Reactions have been well tolerated and have only 
rarely led to subject withdrawal.
Mitigation: Subjects will be closely  monitored for I SRs particularl y for signs of pain, 
tenderness, infections, erythema, swelling, induration, or nodules (granuloma s or cy sts) 
throughout the stud y. Specialist dermatology  consultation will be sought if warranted for 
individual subjects.
Hypersensitivity Reactions (HSR)
While there have been no clinical cases of h ypersensitivity  to CAB , there is a theoretical 
risk of sy stemic or severe hy persensitivity  reactions with or without hepatic sy mptoms 
associated with use of CAB LA. The long exposures anticipated after a CAB LA 
injection may  complicate the management of a drug hy persensitivity  reaction, were it to 
occur.
Mitigation:  This risk of developi[INVESTIGATOR_007] a h ypersensitivity  reaction post administration of 
CAB LA will be minimized by [CONTACT_339245] -in of CAB to determine individual 
safet y and tolerability prior to the introduction of CAB LA.  An y reactions would be 
managed supportivel y. 
Development of Resistance
Residual concentrations of CAB would remain in the systemic circulation of participants 
for prolonged periods (up to 1 y ear) despi[INVESTIGATOR_339158] (e.g. for tolerability  issues 
or treatment failure). Participants discontinuing CAB LA regimen may  be at risk for 
developi[INVESTIGATOR_339159] -1 resistance to CAB many  weeks after discontinuing injectable therapy .
Mitigation:  Alternative oral HA ART regimens will be prescribed within four weeks 
after participants stop CAB LA.  This would be anticipated to result in rapid 
resuppression of HIV -[ADDRESS_419250] CAB LA injection.
Drug -Drug Interactions (DDIs)
Residual concentrations of CAB would remain in the sy stemic circulation of subjects 
who stopped treatment (e.g. for tolerability  issues or treatment failure) for prolonged 
periods (months). Subjects discontinuing a LA regimen may  be at risk for developi[INVESTIGATOR_339160] y weeks after discontinuing injectable therapy.  Of note, evidence to date 
indicates that significant DDIs with CAB and other antiretrovirals are unlikely  to occur. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
58Mitigation: None needed at this time.  All subjects will be informed of prohibited 
medications throughout the study  and updates provided as needed via informed consent.
Inadvertent Intravenous Injection (Accidental Maladministration)
As with any  intramuscular injection, it is possible that CAB LA can be inadvertently 
administered intravenously  instead of intramuscularly  resulting in higher than expected 
concentrations of CAB.   This could be due to administrator error, improper injection 
technique and / or improper needle length used based on body  type.    The clinical 
consequences of overdose with CAB are currentl y unknown. HIV- 1 viral suppression 
may not be effective following accidental maladministration.
Mitigation:  Training will be provided to all sites on proper injection technique.  Should 
IM maladministration be suspected at an y time (e.g. suspected under or overdose or 
inadvertent IV dosing), a PK sample, post dose ECG, vital signs or an y other supportive 
testing may  be obtained at the discretion of the investigator, and the Medical Monitor 
notified.  Laboratory samples for safety parameters and HIV -[ADDRESS_419251] dose PK samples will be obtained at 
a few earl y timepoints (Day 1, Week 32 and Week 48) for determination of CAB
concentration and possible pharmacokinetic correlation with safet y parameters such as 
ECG changes and virologic response.  Should IM maladministration be suspected at any  
time (e.g. suspected under or overdose or inadvertent IV dosing), a pos t dose ECG or any  
other supportive testing may  be obtained at the discretion of the investigator, and the 
medical monitor notified.  Additionally , an unscheduled PK sample may  be drawn 
approximately  [ADDRESS_419252] dosing for future evaluation of CAB and RPV concentrations.
[IP_ADDRESS]. RPV and RPV LA
For safet y and risk mitigation for RPV ,refer to the rilpi[INVESTIGATOR_339161] 
[Edurant Product I nformation , 2015 ].  Information about the clinical experience to date 
and possible risks associated with treatment using RPV LA can be found in the Summary  
of Data and Guidance for the I nvestigator section of the IB.  Bey ond what has already  
been identified with oral RPV, no new sy stemic adverse reactions to RPV LA (same 
active mo iety) have been observed.  The following risks are considered to be of specific 
clinical relevance in the context of I M use:
Injection Site Reactions
Injection site pain (upon touch) mild to moderate and injection site induration have 
occurred with RPV LA injection. I ncidences vary with dose (volume of administration) 
and site of injection. An y recurrence may be linked to the formulation used and an y 
recurrence will be monitored in future repeated dose clinical studies with RPV LA. 
Mitigation: Local tolera nce will be closel y monitored.
Rash
Some observations of rash with RPV have been reported in clinical studies executed to 
date (the majorit y are Grade 1 or 2) . 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
59Mitigation:  In this study, RPV LA administration will be preceded b y a one month RPV 
lead in t o evaluate safet y and tolerability  in individual participants.
Development of Resistance
Residual concentrations of RPV LA would remain in the sy stemic circulation of subjects 
who stopped treatment (e.g. for tolerability  issues or treatment failure) for pr olonged 
periods (months). Participants discontinuing a LA regimen may  be at risk for developi[INVESTIGATOR_339162] .
Mitigation:  Alternative oral HAART regimens will be constructed for subjects stoppi[INVESTIGATOR_339163] y which would be anticipated to result in rapid resuppression of HIV -[ADDRESS_419253] LA administration.
Drug -Drug Interactions (DDIs)
Residual concentrations of RPV would remain in the systemic circulation of subjects who 
stopped treatment (e.g. for tolerability  issues or treatment failure) for prolonged periods 
(months). Subjects discontinuing a LA regimen may  be at risk for developi[INVESTIGATOR_339164] s 
many  weeks after discontinuing injectable therapy .  Of note, evidence to date indicates 
that significant DDIs with RPV LA and other antiretrovirals are unlikel y to occur.
Mitigation: None needed at this time.  All subjects will be informed of prohibited 
medications throughout the study  and updates provided as needed via informed consent.
Refer to the Investigator Brochure for RPV LA for detailed descriptions of the clinical 
experience to date [TMC278 LA [ Rilpi[INVESTIGATOR_12979], oral and parenteral] Integrated 
Investigator’s Brochure , 201 6]. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
60Inadvertent Intravenous Injection (Accidental Maladministration)
As with any  intramuscular injec tion, it is possible that RPV LA can be inadvertently 
administered intravenously  instead of intramuscularly  resulting in higher than expected 
concentrations of RPV LA.  This could be due to administrator error, improper injection 
technique and / or imprope r needle length used based on body  type.  The clinical 
consequences of overdose with RPV L Aare currently  unknown. HIV-1 viral suppression 
may not be effective following accidental maladministration.
Mitigation:  Training will be provided to all sites on proper injection technique.  Should 
IM maladministration be suspected at an y time (e.g. suspected under or overdose or 
inadvertent IV dosing), a PK sample, post dose ECG monitoring and vital signs or an y 
other supportive testing may  be obtained at the disc retion of the investigator, and the 
Medical M onitor notified.   Laboratory samples for safet y parameters and HIV -[ADDRESS_419254] dose PK samples will 
be obtained at a few early timepoints (Day  1, W eek 32 and Week 48) for determination 
of RPV concentration and possible pharmacokinetic correlation with safet y parameters 
such as ECG changes and virologic response.   Should I M maladministration be suspected 
at an y time (e.g. suspected under or overdose o r inadvertent IV dosing), a post dose ECG 
or an y other supportive testing may be obtained at the discretion of the investigator, and 
the medical monitor notified.  Additionally , an unscheduled PK sample may be drawn 
approximately  [ADDRESS_419255] dosing for fu ture evaluation of CAB and RPV concentrations.
[IP_ADDRESS]. Abacavir/Lamivudine (A BC/3TC)
The most significant toxicity  associated with ABC is the well -characterized drug -related 
hypersensitivity  reaction (HSR). Studies have shown that carriage of the HLA- B*5701 
allele is associated with a significantl y increased risk of a HSR to ABC. In the 
prospective stud y CNA106030 (PREDI CT-1), the use of pre -therap y screening for the 
presence of HLA -B*5701 and subsequentl y avoiding ABC in HLA -B*5701 positive 
patients, significantl yreduced the incidence of clinically  suspected ABC HSR from 7.8% 
(66 of 847) to 3.4% (27 of 803) (p<0.0001). In clinical studies EPZ108859 (ARI ES) and 
CNA109586 (ASSERT), 0.8% (4/515) and 3.1% (6/192) of subjects who were HLA -
B*[ADDRESS_419256] treated with ABC, the clinical diagnosis of suspected HSR (as detailed in 
the L ocal Country  Prescribing Information) must remain the basis of clinical decision 
making. Regardless of HLA -B*5701 status, it is important to permanentl y discontinue 
ABC and not re- challenge with ABC (i.e., ZIAGEN ™, EPZICOM/KIVEXA or 
TRIZIV IR) if a HSR cannot be ruled out on clinical grounds, due to the potential for a 
severe or even fatal reaction.
A de tailed clinical description of this reaction (including the t ype and severity of events 
that can occur on re-challenge or reintroduction following ABC interruption for non- HSR 
reasons) and guidance regarding its management are included in the Local Country
Prescribing Information for EPZICOM.   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
61Mitigation:  Every  potential subject will be screened for the carriage of the HLA -
B*5701 allele.  Subjects who are HLA -B*5701 positive at the Screening visit are allowed 
to enter the stud y on a dual -NRTI backbone tha t does not contain abacavir (see 
Section 5.6).
[IP_ADDRESS]. Study  Procedures
Risks associated with study  procedures include swelling, bleeding, bruising and infection 
from venipuncture required for blood sampling.  These ri sks will be minimized using 
current standard of care techniques for venipuncture.  Additionally , subjects will be 
required to have ECGs conducted periodically  throughout the study ; some discomfort and 
rash may  occur where the ECG pads are removed.
[IP_ADDRESS]. Risk of Treatment Failure
This study employ s an induction / maintenance approach to the treatment of HIV -[ADDRESS_419257] demonstrate d antiviral 
activity  in the Phase 2b studies L AI116482 (oral two drug treatment) and 200056 
(through 48 weeks LA treatment).  Viral loads will be closely  monitored throughout the 
study .
Doses of the CAB LA and RPV LA have been selected to achieve exposures that are 
expected to maintain virologic efficacy  on the basis of available data with the oral 
formulations.  Neither CAB LA nor RPV LA, at any  dose, has been used in HIV -[ADDRESS_419258] could receive an inadequate dose 
of CAB LA or RPV LA.  Sub -therapeutic concent rations of either CAB LA or RPV LA 
could lead to virologic failure and possibly  the development of resistance.  HIV -1 RNA 
viral loads will be closely  monitored throughout the injection period of the study .
Mitigation:  HIV-1 RNA will be closely  monitored throughout the stud y.  Plasma 
samples will be collected throughout the Maintenance Phase for determination of CAB 
and RPV concentration and possible pharmacokinetic correlation with virologic response.
1.11.2. Other Clinically  Relevant Information
Additional detai ls concerning safety observations from clinical studies and for which a 
causal association has not been established or which are of minimal clinical significance 
may be found in the Investigator’s Brochure.  Please refer to Section 6: ‘Summary  of 
Data and Guidance for the Investigator’ 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419259]:
Seizure:
Four cases o f possible or definitive seizures have occurred in the CAB program 
cumulatively  through [ADDRESS_419260] 
contributed to the event, and each case was determined by  [CONTACT_339246] y likel y related to CAB or RPV .Overall, there i s insufficient evidence that 
CAB exposure may  be causally  associated with seizure or with re duction of seizure 
threshold, due to the low frequency  of reports, the confounders present in the cases 
received to date and lack of an y pre -clinical signal or identified plausible mechanism.
However ,seizure and seizure -like events will be closely  monito red in clinical studies , 
including this study  (200056).  Any  case of seizure or possible seizure must be reported 
to the Sponsor within 24 hours o f notification, as detailed in S ection 6.10.14 .
1.11.3. Benefit A ssessment
The antiviral activit y of CAB has been well established through Phase IIa and Phase IIb 
studies and subjects receiving 30 mg of CAB + ABC/3TC are anticipated to benefit from 
attainment of virological suppression. RPV is an established antiviral agent in treatment 
naive patients, with long term durability  (>96 weeks in Phase III and >240 weeks in 
Phase II b). Subjects who achieve virologic suppression will be randomized to either a 
two-drug, two-class ART regimen containing CAB LA + RPV LA or to continue a 
suppressive or al regimen. Subjects randomized to an arm containing CAB LA + RPV
LA will have infrequent, monthly  or every  other month dosing without the need to take 
concomitant daily  oral therapy .  The reduction in ART, and the discontinuation of NRTIs, 
may offer long term safety  and tolerability  benefits in these subjects.
Efficacy  of the two- drug regimen ,as oral agents ,has been demonstrated through 
Week 96of the ongoing LAI116482 study .  Efficacy  of the two -drug regimen, as LA 
agents, has been demonstrated through Week 48 of the ongoing 200056 study .  
1.11.4. Overall Benefit: Risk Conclusion
Taking into account the measures taken to minimize risk to subjects participating in this 
study , the potential risks identified in association with CAB , RPV and the study  as a 
whole a re justified b y the anticipated benefits that may be afforded to treatment -naïve 
patients with HIV infection. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419261] an intramuscular dosing regimen of 
CAB LA plus RPV LA based on a comparison of 
theWeek 32 antiviral activity, tolerability, and 
safety of two IM dosing regimens , relative to 
CAB 30mg plus ABC/3TC orally once daily.The proportion of subjects with HIV -1 RNA 
<50c/mL at Maintenance Week 32based on 
intent to treat -maintenance exposed (I TT-ME) 
population using the Missing, Switch, or 
Discontinuation = Failure (MSDF) algorithm.
Proportion of subjects with protocol defined 
virologic failures over time
Incidence and severity of AEs and laboratory 
abnormalities over time.
Secondary
To eva luate the antiviral activity, tolerability, and 
safety of CAB 30mg plus ABC/3TC orally once 
daily through the Induction and Maintenance 
Periods.Proportion of subjects with plasma HIV -1 RNA 
<200 c/mL and <50 c/mL over time.
Absolute values and change from Baseline in 
plasma HIV -1 RNA.
Absolute values and changes from Baseline in 
CD4+ cell counts.
Incidence of disease progression (HIV -
associated conditions, acquired 
immunodeficiency syndrome [AIDS] and death).
Incidence and severity of AEs and laboratory 
abnormalities over time.
Absolute values and changes in laboratory 
parameters over time.
To evaluate the efficacy, tolerability, and safety 
of CAB LA 400 mg IM plus RPV LA 600 mg IM 
every 4 weeks and CAB LA 600 mg IM plus 
RPV LA 900 mg every 8 weeks , relati ve to CAB
30mg plus ABC/3TC orally once daily, through 
Week 96 of the Maintenance Period.Proportion of subjects with plasma HIV -1 RNA 
<200 c/mL and <50 c/mL over time.
Proportion of subjects with protocol defined 
virologic failures over time.
Absolute values and change from Baseline in 
plasma HIV -1 RNA.
Absolute values and changes from Baseline in 
CD4+ cell counts.
Incidence of disease progression (HIV -
associated conditions, acquired 
immunodeficiency syndrome [AIDS] and death. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
64Objective Endpoint
Incidence and severi ty of AEs and laboratory 
abnormalities over time.
Absolute values and changes in laboratory 
parameters over time.
To characterize CAB LA and RPV LA PK and to 
explore PK-PD relationships.  Plasma PK parameters for CAB LA and RPV LA
(Ctrough and concentr ations post dose [~Cmax]) 
during the Maintenance Period.  
Plasma CAB and RPV trough concentrations
will be used to determine when steady state is 
achieved for each CAB LA and RPV LA
regimen.
Relationship between plasma PK parameters 
and plasma HIV -1 RNA, CD4+ cell counts 
and/or occurrence of adverse events [AEs] 
through Week [ADDRESS_419262] of various demographic 
Baseline characteristics and adherence on 
virologic response of CAB and RPV over time.Proportion of subjects with plasma HIV -1 RNA 
<50c/mL over time.
To evaluate the treatment satisfaction for 
subjects on the long -acting injectable regimen s
with those on the oral regimen through Week 96 
of the Maintenance Period.Summarize treatment satisfaction using the HIV 
Treatment Satisfaction Questionnaire Status 
(HIVTSQ(s)) over time. 
To evaluate the change in treatment satisfaction 
for subjects in both the long -acting injectable 
and oral regimens through Week 32of the 
Maintenance Period.Measure change in treatment satisfaction using 
the H IV Treatment Satisfaction Questionnaire 
Change (HIVTSQ(c)) over time.
To evaluate medication adherence over time. Summarize subject reported medication 
adherence using the HIV Medication 
Questionnaire (HIVMQ) over time.
Exploratory
To evaluate the effic acy, tolerability, and safety 
of optimized IM dosing regimens CAB LA 400 
mg IM plus RPV LA 600 mg IM every 4 weeks
and CAB LA 600 mg IM plus RPV LA 900 mg 
every 8 weeks at Week s128 and 160 for 
subjects switching from the oral regimen 
therapy at the end of the Maintenace Period.Proportion of subjects with a ‘virologic failure’ 
endpoint as per FDA Snapshot algorithm at 
Week 128and 160 (Missing, Switch or 
Discontinuation = Failure, Extension Switch 
population )
Proportion of subjects with Plasma HIV -1 RNA 
<50 copi[INVESTIGATOR_014]/mL (c/mL) at Week 128 and 160  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
65Objective Endpoint
To evaluate the long term efficacy, tolerability, 
and safety of IM dosing regimens CAB LA 400 
mg IM plus RPV LA 600 mg IM every 4 weeks
and CAB LA 600 mg IM plus RPV LA 900 mg 
every 8 weeks at Week 160for subjects who 
continued ran domized IM dosing in the 
Extension Period.using the FDA Snapshot algorithm (Extension 
Switch population )
Proportion of subjects with protocol defined 
virologic failures over time
Proportion of subjects with plasma HIV -1 RNA 
<200 c/mL and <5 0c/mL over time. Absolute
values and changes in CD4+ cell counts over 
time
Incidence of disease progression (HIV -
associated conditions, acquired 
immunodeficiency syndrome [AIDS] and death).
Incidence and severity of AEs and laboratory 
abnormalities over t ime.
Absolute values and changes in laboratory 
parameters over time.
3. INVESTIGA TIONAL PLA N
3.1. Stud y Design Schematic
Induction Period
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419263] of a Screening Period, Induction Period, Maintenance Period, 
Extension Period and a Long -term Follow -up Period (withdrawn subjects only ). 
A subject is considered to have completed the study  if they  complete the Induction and 
Maintenance Period through Week 96.
Supplementary  study  conduct information not mandated to be present in this protocol is 
provided in the accompany ing Study  Procedures Manual (SPM).  The SPM will provide 
the site personnel with administrative and detailed technical information that does not 
impact subject safet y.
3.2.1. Screening Period
Informed consent must be obtained prior to an y study  procedures, including an y 
Screening assessment. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419264] been met.
Subjects who are HLA -B*5701 positive at the Screening visit are allowed to enter the 
study  on a dual -NRTI backbone tha t does not contain abacavir.  The selected dual- NRTI 
backbone may be supplied regionally by [CONTACT_35316] ([COMPANY_004] )or reimbursement will 
be provided.
3.2.2. Induction Period
Following the Screening Period, eligible subjects will be enrolled into the study  and 
begin a 20 week I nduction Period utilizing an oral regimen of CAB 30 mg once dail y 
plus ABC/3TC 600/[ADDRESS_419265] day  on study  treatment.  Further 
weeks of treatment throughout the Induction Per iod will be counted up to Day  1 (Day  1 
initiates the Maintenance Period).
Example:  First day  on study  Week ( -20)
Next visit Week ( -16)
Next visit Week ( -12), etc
Subjects will initiate treatment at Baseline (Week -20) and will be seen every  4 weeks for 
study  treatment dispensing and safet y and efficacy assessments (see Time and Events 
Section 6.1).  
Unless subjects meet a study  withdrawal criteria, their regimen will be modified at 
Week (-4) with the addition of RPV 25 mg once daily  for the remainder of the I nduction 
Period. 
3.2.3. Eligibility  for the Maintenance Period
All subjects with an undetectable HIV -1 RNA (<50 c/mL ) at the Week ( -4) visit are 
eligible to enter the Maintenance Period. A single repeat to determine eligibility  may  be 
allowed ONLY after consultation with the medical monitor.  Subjects with HIV-1 
RNA 400c/mL  at Week ( -4) are not eligible to enter the Maintenance Period and will 
not be allowed a repeat to determine eligibility . 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
68Result of HIV -1 RNA at Week ( -4) Action
<50 c/mL Begin Maintenance Period
50 c/mL but <400 c/mL Single repeat allowed only after consultation 
and approval from medical monitor
Single repeat <50 c/mL Begin Maintenance Period
Single repeat 50 c/mL Cannot begin Maintenance Period andmust be 
withdrawn from study; Complete withdrawal visit 
instead of Day 1.  
400 c/mL Cannot begin Maintenance Period and must be 
withdrawn from study; Complete withdrawal visit 
instead of Day [ADDRESS_419266] from the study  prior to 
Week (-4) to avoid initiating RPV in a subject who is unlikely  to be eligible for the 
Maintenance Period.
In addition to the viral load criteria above, if in the opi[INVESTIGATOR_689], a subject 
experiences a significant safet y event while taking either CAB or RPV, Maintenance 
eligibility  will be determined ONLY in consultation with the medical monitor.  Any rash 
that is possibly related to study drug, and is present between Week ( -4) and Day 1, 
must be discussed with the Medical Monitor prior to initiation of CAB LA or RPV
LA(See Section [IP_ADDRESS] ).
Subjects ineligible for the Maintenance Period will be withdrawn.  
If the subject is ineligible for the Maintenance Period, samples will be sent to a central 
laboratory  for resistance testing and results provided to the Investigator once available.
Sites may  be reimbursed for up to a one month supply  of antiretroviral medication to 
facilitate transition to non -study  ART for subjects that do not qualify  for the Maintenance 
Period.
3.2.4. Maintenance Period
At Day 1, the Maintenance Period begins.  Eligible subjects will be randomized 2:2:1 to 
receive an IM regimen of CAB LA 400 mg + RPV LA 600 mg every  4 weeks for 96 
weeks, an IM regimen of CAB LA 600 mg + RPV LA 900 mg every  8 weeks for 96 
weeks, or to continue o n the oral Induction Period regimen of CAB 30 mg + ABC/3TC  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
69once dail y for 96 weeks (or 100 weeks if continuing on to the Extension Period).  Subject 
randomization will be stratified by  [CONTACT_1766]’ HIV-1 RNA prior to Week (-8)(<50 c/mL, 
yes or no) .
On the fi rst day  of the Maintenance Period (Day  1), subjects will receive their last dose of
the Induction regimen ( CAB +ABC/3TC+RPV )in the clinic andinitiate either IM 
injections or be dispensed the oral regimen depending on the randomization arm.  Add -on 
RPV tre atment will be discontinued for all subjects after Day  1.  
Dosing for each arm is as follows (all injections are single injections per drug unless 
otherwise noted):
IM injections every  8 weeks (Q8W)
Day 1 only  –CAB LA 800 mg ( loading dose delivered as tw o 400 mg IM 
injections) + RPV LA 9 00 mg IM
Week 4 only  -CAB LA 600 mg IM (second loading dose, no RPV )
Week 8 - CAB LA 600 mg IM + RPV LA 900 mg IM every  8weeks for 96 
weeks
IM injections every  4 weeks (Q4W)
Day 1 only  -CAB LA 800 mg ( loading dose deliv ered as two 400 mg IM 
injections) +RPV LA 600 mg IM
Week 4 -CAB LA 400 mg IM + RPV LA 600 mg IM every  4weeks for 96 
weeks
Oral Control Arm
CAB 30 mg + ABC/3TC once dail y for 96 weeks (or 100weeks if continuing on 
to the Extension period)
It is importan t to note that keepi[INVESTIGATOR_85883]’s visit schedule is a very important 
component to the study.  IM dosing is expected to occur during the week in which 
the subject’s projected visit falls (as according to the Day 1 visit).  A (+ or -) 7 day 
window, from the projected visit date, is allowable for IM dosing but not preferred.  
Visits for subjects on the oral dosing arm are expected to occur as projected 
according to the Baseline visit.  There is a (+ or -) 3 day visit window, from the 
projected visit dat e.  However, the number of tablets dispensed should be considered 
when scheduling the next visit.
All subjects are seen approximately  every  4 weeks for safety , efficacy  and PK 
assessments through Week 32.  After Week 32 , subjects will continue to be seen a s per 
the Time and Events Schedule (see Section 6)for dosing, safet y, efficacy and PK 
assessments through Week 96 (or Week [ADDRESS_419267] is continuing on to 
the Extension Period).   2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419268] for 
adverse events, concomitant medications, HIV associated conditions and any other issues 
including injection site reactions or oral compliance issues.  Telephone visits will be 
clearl y noted in the Time and Events Schedule.  
See the Time and Events Schedule Sectio n 6.2and Section 6.3for more information.   See 
Section [IP_ADDRESS] for additional information regarding special requirements from Week 96 
to Week 104 for subjects on the oral arm entering the Extension Period.
If one of the IM dosing regimens ( Q8W or Q4W ) is discontinued as a result of an IDMC 
review or an y subsequent anal ysis, those subjects who have not met any  clinical 
management criteria for discontinuation and who were randomized to the discontinued 
dosing regimen may  be given the option to discontinue permanentl y from the study or to 
continue on the remaining IM dosing regimen at the next scheduled visit. 
3.2.5. Extension Period
Both IM dosing regimen s(Q8W and Q4W) will continue evaluat ionin the Extension 
period.  Subjects who successfull y complete 96 weeks of CAB 30 mg + ABC/3TC 
treatment in the Maintenance Period will have the option of continuing study  
participation by  [CONTACT_339247] I M dosing regimen of their choice (either 
Q8W or Q4W).
[IP_ADDRESS]. Entering from the CABLA + RPV LA Arm
All subjects who successfully  complete 96weeks of CAB LA + RPV LA treatment in the 
Maintenance Period will continue with their current I M dosing regimen of CAB LA and 
RPV LA in the Extension Period until:
study  treatment is locally approved and commercially  available, 
the subject no longer derives clinical benefit, 
the subject meets a protocol- defined reason for discontinuation  
the development of either CAB LA or RPV LA is terminated.  
Subjects will remain on their current regimen after Week 96 and will continue to receive 
their Maintenance Period IM dosing regimen for the remainder of study  participation.  
Safety  and efficacy  assessments will be conduc ted every  16 weeks. Dosing visits will 
occur according to the selected dosing regimen.  See the Time and Events Schedule 
Section 6.5and Section 6.6formore information .
[IP_ADDRESS]. Eligibility for the Extension Period for Subjects Entering From the CA B 
30mg + ABC/3TC A rm
All subjects with an undetectable HIV -1 RNA (<50 c/mL ) at the Week 96 visit are 
eligible to enter the Extension Period. A single repeat to determine eligibility  may  be 
allowe d ONLY after consultation with the medical monitor.  Subjects with HIV-1  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
71RNA 400c/mL  at Week 96are not eligible to enter the Extension Period and will not be 
allowed a repeat to determine eligibility .
Result of HIV -1 RNA at Week 96 Action
<50 c/mL Begin Extension Period
50 c/mL but <400 c/mL Single repeat allowed only after consultation 
and approval from medical monitor
Single repeat <50 c/mL Begin Extension Period
Single repeat 50 c/mL Cannot begin Extension Period and must be 
withdrawn from study ; Complete withdrawal 
visit.  
400 c/mL Cannot begin Extension Period and must be 
withdrawn from study; Complete withdrawal 
visit.
Should a subject be allowed a repeat, results of this repeat must be available prior to next 
visit, therefore the time ne eded for scheduling the visit, lab draws and lab analy sis should 
be considered.  
In addition to the viral load criteria above, if in the opi[INVESTIGATOR_689], a subject 
experiences a significant safety event while taking either CAB or RPV, Extensio n 
eligibility  will be determined ONLY in consultation with the medical monitor.  
Subjects ineligible for the Extension Period will be withdrawn.  
If the subject is ineligible for the Extension Period, samples will be sent to a central 
laboratory  for resi stance testing and results provided to the Investigator once available.
Sites may  be reimbursed for up to a one month supply  of antiretroviral medication to 
facilitate transition to non -study  ART for subjects that do not qualify  for the Extension
Period.
[IP_ADDRESS]. Entering from the CAB 30 mg + ABC/3TC A rm
All subjects who successfully  complete 96 weeks of CAB 30 mg+ ABC/3TC treatment 
in the Maintenance Period will have the option to continue study  participation by  
[CONTACT_339248] I M dosing regimen of thei r choice (either Q8W or Q4W) of 
CAB LA + RPV LA in the Extension Period .  Subjects not choosing to switch to an 
optimized long acting regimen will complete their study  participation at Week 96.
Subjects who choose to continue on to the Extension Period wil l be assessed for 
eligibility  to begin the irselected CAB LA + RPV LA regimen as described in Section  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
[IP_ADDRESS] . Subjects will continue on their oralMaintenance regimen ( CAB 30 mg+ 
ABC/3TC) until Week [ADDRESS_419269] 4 weeks of the Induction Period to evaluate safety and 
tolerability  before being randomized to continu e in the Maintenance Period and thus 
further evaluation is not necessary .
In order to qualify  to receive CAB LA + RPV LA injections at Week [ADDRESS_419270] be undetectable (<50 c/mL ; a single repeat 
HIV-[ADDRESS_419271] may be allowed prior to Week 10 0following consultation with the 
Medical Monitor). 
Ifthe Optimized Q4W IM Dosing Regimen is selected by [CONTACT_31388] :
At visit Week 100, participants will return to the clinic, take the last dose of their oral 
regimen (CAB 30 mg+ ABC/3TC ), and receive the first CAB LA (600 mg) + RPV LA 
(900 mg) injections (within 2 hours of the final oral dose of CAB + ABC/3TC ).  The 
second and third injections ( CAB LA 400 mg + RPV L A 600 mg) will be administered at 
Week [ADDRESS_419272] injections occur within the 
window of Week 107 to Week 10 8, but no later than Week 108.  Subsequent injections 
(CAB LA 400 mg + RPV L A 600 mg) will occur every  4 weeks thereafter, from the 
projected visit date, with a (+ or -) 7 day  dosing window being allowed ( but not 
preferred ).  Following the Week [ADDRESS_419273] :
At visit Week 100, subjects will return to the clinic, take the last dose of their oral (CAB 
30mg+ ABC/3TC ), and receive the first CAB LA (600 mg)+ RPV LA (900 mg) 
injections (within 2 hours of the final oral dose of CAB + ABC/3TC ).  The second 
loading injections will be administered at Week 104(CAB LA 600mg + RPV L A 
900mg), with subsequent injections (CAB LA 600mg + RPV L A 900mg)occurring 
every  [ADDRESS_419274] case management.  Afte r Week 112, a dosing window ( 7 day s) for injections is 
allowed, but not preferred.
Subjects will continue study  treatment until :
study  treatment is locally approved and commercially  available, 
the subject no longer derives clinical benefit, 
the subject meets a protocol- defined reason for discontinuation   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
73the development of either CAB LA or RPV LA is terminated.
Safety  and efficacy  assessments will be conducted as per the Time and Events schedule 
(Section 6.5and Section 6.6for more information).   Dosing will occur according to the 
selected regimen. 
Subjects not eligible to enter the Extension Period will end their study  participation.  
Sites may  be reimbursed for up to a one month supply  of antiretroviral medication to 
facilitate transition to non -study  ART for subjects that do not qualify  for the Extension
Period.
If one of the optimized IM dosing regimens (Q8W or Q4W) is discontinued as a result of 
an IDMC review or an y subsequent anal ysis, those subjects who have not met any  
clinical management criteria for discontinuation and who selecte d a discontinued 
optimized I M dosing regimen may  be given the option to discontinue permanently  from 
the study  or to continue on the remaining IM dosing regimen at the next scheduled visit.
3.2.6. Long -term Follow -Up Period –IM Regimens only
Any subject who rece ives at least a single dose of CAB LA and/or RPV LA and 
discontinues the CAB LA + RPV LA regimen for an y reason must remain on suppressive
Highl y Active Antiretroviral Treatment (HAART) for at least [ADDRESS_419275] dose 
of CAB LA and/or RPV LA in o rder to prevent selective pressure on HIV and the 
potential for selection of resistant mutants.  This period is considered stud y participation 
and subjects will be followed on study  during this time.
In the Long -Term Follow -Up Period, subjects will receive oral HAART and will be 
followed for [ADDRESS_419276] dose of CAB LA and/or RPV LA. Investigators 
must discuss the choice of HAART regimen and timing of initiation with the medical 
monitor before initiating. The [ADDRESS_419277] 
CAB LA and/or RPV LA dose.  These subjects will not complete a Withdrawal visit, but 
will instead move directly into the Long- Term Follow Up Period as per the Time and 
Events Schedule (see Section 6.7). 
Subjects will be assessed with clinic visits at months 1, 3, 6, [ADDRESS_419278] continue to use adequate contraception methods (see Study  
Procedures Manual for list of accepted forms of contraception) for the entir e year of 
follow up.  
In order to assure that subjects have access to HAART during the Long -Term Follow -Up 
Period, [COMPANY_004] may  suppl y HAART regionall y or reimbursement will be provided during 
this period.
3.2.7. Follow Up Visit
A Follow up visit may  be conducted app roximately  [ADDRESS_419279] what is considered medically  necessary   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
74to assess the event(s).  The Follow -up visit may  be conducted via telephone if the subject 
has no ongoing adverse events or other issues that would require a clinic visit.
This visit is not required for subjects in the Long -Term Follow Up Period.
3.2.8. Independent Data Monitoring Committee
An IDMC will evaluate the efficacy , tolerability , and safet y of CAB and RPV before all 
eligible subjects have transitioned from the Induction Period to the Maintenance Period.  
This I DMC review may  be conducted after approximately  [ADDRESS_419280] reached 
Week 8 of the Maintenance Period, depending on IDMC agreement.  The intent of this 
analysis is to identify  any earl y safet y or tolerability signals from the long acting 
regimen.  In addition, futility  guidance (e.g., a Bay esian p osterior probability  approa ch
when 50% of subjects have completed Week 24 of the Maintenance Period) is included to 
monitor the performance of alltreatment arms in order to prevent subjects from 
continuing on a dosing regimen if existing data indic ates that subjects are at unaccept able 
risk of inadequate maintenance of virologic suppression.
If one of the IM dosing regimens ( Q8W or Q4W ) is discontinued as a result of an IDMC 
review or an y subsequent anal ysis, those subjects who have not met any  clinical 
management criteria for disc ontinuation and who were randomized to the discontinued 
dosing regimen, or selected a discontinued optimized I M dosing regimen, may be given 
the option to discontinue permanentl y from the study or to continue on the remaining IM 
dosing regimen at the next scheduled visit. 
As subjects enter the Maintenance Period of the study , if the number of protocol defined 
virologic failures meets or exceeds the pre -specified thresholds specified in the IDMC 
Charter, this will be considered strong evidence of an inadequ ate response and will 
trigger a comprehensive data review b y the IDMC.  Similar thresholds will be used b y the 
IDMC to monitor the number of protocol defined virologic failures for subjects switching 
from oral CAB 30 mg + ABC/3TC to an optimized I M dosing regimen during the 
Extension Period.  The IDMC charter will contain details of this continual monitoring of 
the protocol defined virologic failure rates, the specifics around what will trigger a data 
review, and the safety  summaries and efficacy  analy ses that will be provided should a 
data review be required.
Full details of the analy ses, estimated timing and the decision criteria that will be used to 
determine regimen performance will be pre-specified in the IDMC Charter.
3.2.9. Primary  Analysis
The primary  anal ysis will be conducted when all subjects have completed their 
Maintenance Period Week [ADDRESS_419281] entered into the 
Extension Period may be conducted to more fully  characterize the long -term safet y and
efficacy  profile of CAB and RPV . 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
753.3. Discussion of Design
Study  200056 is a Phase IIb assessment of a regimen consisting of the long -acting 
injectable forms of CAB and RPV to maintain virologic suppression in previously  
untreated HIV -infected subjects without evidence of transmitted resistance who achieve 
virologic suppression on CAB plus ABC/3TC.  The ongoing study  LAI116482 provides 
support for this unique approach of a two -class, two- drug regimen. Results from planned 
analyses of LAI116482 support the choice of [ADDRESS_419282] evaluation of CAB LA or RPV LA in HIV-
infected subjects.  The results to date support CAB LA and RPV LA for continued 
clinical development.  Injection site reactions (I SR) of both agents have been generall y 
mild, self -limited, and well -tolerated in single and multiple dose studies.  
The results of LAI116482 support the use of oral CAB plus NRTIs as a reference 
regimen to the investigational two -drug long -acting regimen. At the primary endpoint of 
Week 48, the response rates (HIV -1 RNA <50 c/mL; ITT, MSDF , Table 1 ) for the three 
doses of CAB in the LAI116482 study  were 80%, 8 0% and 87% for the 10 mg, 30 mg, 
and 60 mg arms, respectively .  These rates compare fav orabl y to the control regimen of 
EFV plus NRTIs in this study  where 71% of subjects achieved HIV -1 RNA <50 c/mL  at 
Week 48. 
These data indicate continued viral suppression after 24 weeks of the two drug CAB and 
RPV regimen.
The ITT- Maintenance Exposed (IT T-ME) Population consists of all randomized subjects 
who received at l east one dose of investigational product during the Maintenance P hase 
of the study .  Of the subjects who entered the Maintenance Phase of the study , the 
majority  remained suppressed thro ugh Week 48 (24 weeks of two drug therapy ) (Table 
3).
Table 3 LAI116482 Proportion of Subjects with Plasma HIV -1 RNA  <50 c/mL 
at Key  Visits -Snapshot (MSDF) A nalysis (ITT-M E Population)
Visit[COMPANY_004]744
10 mg
N=52
n (%)[COMPANY_004]744
30 mg
N=53
n (%)[COMPANY_004]744
60 mg
N=55
n (%)[COMPANY_004]744 
Subtotal
N=160
n (%)EFV 
600 mg
N=47
n (%)
Week 16 -Induction 50 (96) 49 (92) 52 (95) 151 (94) 43 (91)
Week 24 -Induction 50 (96) 50 (94) 53 (96) 153 (96) 45 (96)
Week 48 -Maintenance 48 (92) 48 (91) 53 (96) 149 (93) 44 (94)
The background NRTIs (ABC/3TC) are accepted agents for initiation of antiretroviral 
therap y in treatment guidelines [ EACS , 2012; DHHS , 2013] and as such are considered 
appropriate for this trial.  RPV is approved as Edurant for use in combination ART at an  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
76oral dose of 25 mg, once daily  with a meal in treatment naive patients [ Edurant Product 
Information, 2015].
This trial is designed to evaluate two distinct periods.  First, to evaluate the ability  of 
CAB + background NRTIs to induce virologic suppression during the Induction Period.  
Second, during the Maintenance Period, two different dosing strategies of a long- acting, 
two-drug, two- class regimen will be evaluated on their ability  to maintain virologic 
efficacy  for 96 weeks compared to a control regimen of oral CAB + ABC/3TC.  
The primary  endpoint, proportion of subjects with plasma HIV-1 RNA < 50 c/mL , is a 
well-established surrogate endpoint for prognosis of HIV -1 infection and disease 
progression [ CDER , 2002]. The primary endpoint for this study  is proportion of subjects 
with plasma HIV -1 RNA < 50 c/mL  at Week [ADDRESS_419283] an IM dosing 
regimen (Q8W or Q4W).  Week 32 has been selected to allow a comparable evaluation 
among the dosing regimens.  Q8W begins dosing at Week 8, following a loading dose at 
Day 1 and Week 4.  Therefore, choosing Week 32 as an endpoint allows for a 24 week 
evaluation of the Q8W arm at steady  state.  
The Week 48 analysis will permit an evaluation of the ability  of the investigational two -
drug long -acting combination sto maintain virologic suppression over time, and will 
serve as the dose confirmation of the dosing regimen selected at Week 32.Longer term 
durability  of virologic suppression for theselong-acting two -drug regimens will also be 
evaluated through a formal Week 96 anal ysis.
The Extension Perio d will allow participants on the oral Maintenance Period regimen 
who successfull y complete Week 96 with an HIV -1 RNA viral load <50 c/mL  the 
opportunity  to choose an optimized I M dosing regimen (Q8W or Q4W) .  This will permit 
an evaluation of the ability o f the optimized investigational two- drug long acting 
combinations (see Section 5.1.6 ) to maintain virologic suppression over time.  This 
period will also allow p articipants currentl y on a IM Maintenance Period regimen who 
succe ssfull y complete Week 96 with an HIV -1 RNA viral load <50 c/mL  the ability  to
continue to receive their current IM dosing regimen and to generate additional long-term 
safet y and efficacy data for randomized IM dosing regimens.
A planned Week [ADDRESS_419284] SELECTION A ND WITHDRA WAL CRITERI A
4.1. Number of Subjects
Sufficient subjects will be screened (approximately 350) in order to ensure that a t otal of 
approximately  265subjects are enrolled at the beginning of the Induction Period and to 
ensure approximately  225 subjects are randomized into the Maintenance Period.  Subjects 
will be enrolled from multiple sites which may  include sites in the US, Canada, [LOCATION_009], 
German y, and/or Spain.
4.2. Inclusion Criteria
Deviations from inclusion criteria are not allowed because they  can potentially  jeopardise 
the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, 
adherence to the criteria as specified in the protocol is essential.
In general, subjects screened for this study  must :
be able to understand and comply  with protocol requirements, instructions, and 
restrictions, 
be likely  to complete the study  as planned, 
understand the long term commitment to the study ,
be considered appropriate candidates for participation in an investigative clinical 
trial with oral and intramuscularl y injectable medications (e.g., no active 
substance abuse, acute major organ disease).
Specific i nformation regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on the investigational regimen or other study  treatment 
that may  impact subject eligibility  is provided in the current Investigator’s Brochure (I B) 
for CAB and RPV and in the current prescribing information for ABC/3TC.  
A single repeat of a procedure / lab parameter is allowed to determine eligibility  (unless 
otherwise specified).
Subjects are allowed to re -screen for this study  one time.  This w ill require a new subject 
number.
The following are stud y specific eligibility  criteria unless stated otherwise .  In addition 
to these criteria, Investigators must exercise clinical discretion regarding selection of 
appropriate study subjects, taking into consideration any local treatment practices 
or guidelines and good clinical practice (GCP).  All subjects must be considered 
appropriate candidates for initiation of antiretroviral therapy in accordance with 
local treatment guidelines.
Laboratory  results f rom the central laboratory  services provided by  [CONTACT_339249] . 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419285] meet all of the following criteria:
1.HIV-1 infected subjects  [ADDRESS_419286] is eligible to enter and participate in the study  if she:
a.is of non -child- bearing potential defined as either post -menopausal (12 months of 
spontaneous amenorrhea and 45 years of age) or phy sicall y incapable of 
becoming pregnant with documented tubal ligation, hy sterect omy or bilateral 
oophorectom y or
b. is of child -bearing potential with a negative pregnancy  test at both Screening and 
first day  of the Induction Period and agrees to use one of the following methods 
of contraception to avoid pregnancy  [ADDRESS_419287] 52 weeks after discontinuation of CAB LA 
and RPV LA:
Complete abstinence from intercourse (where this is the subject’s prefe rred 
and usual lifesty le).
Double barrier method (male condom/spermicide, male condom/diaphragm, 
diaphragm/spermicide).
Approved hormonal contraception (see the SPM for a listing of examples of 
approved hormonal contraception).
Any intrauterine device (IUD ) with published data showing that the expected 
failure rate is <1% per year (not all IUDs meet this criterion, see the study  
procedures manual [SPM] for specifics).
Male partner sterilization prior to the female subject’s entry  into the study , 
and this ma le is the sole partner for that subject.
Any other method with published data showing that the lowest expected 
failure rate is <1% per year.
Any contraception method must be used consistently  and in accordance with 
the approved product label.
ALL subjects participating in the stud y must be counseled on safer sexual practices 
including the use of effective barrier methods to minimize risk of HI V transmission.
HIV-1 infection as documented by  [CONTACT_339250] -1 RNA  1000 c/mL .
CD4+ cell count 200 cells/mm3 (or higher as local guidelines dictate).
ART -naive defined as having no more than 10 days of prior therap y with any 
antiretroviral agent following a diagnosis of HIV -1 infection.  An y previous 
exposure to an HIV integrase inhibitor or non -nucleoside rev erse transcriptase 
inhibitor will be exclusionary .
French subjects: In [LOCATION_009], a subject will be eligible for inclusion in this study onl y if 
either affiliated to or a beneficiary  of a social security  category . 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419288] not be enrolled in the study :
Exclusionary  Medical Conditions
1.Women who are breastfeeding.
2.Any evidence at screening of an active Centers for Disease and Prevention Control 
(CDC) Category  C disease [ Centers for Disease Control and Prevention 
(CDC) ,1993], except cutaneous Kaposi’s sarcoma not requiring s ystemic therapy .
3. Subjects with known moderate to severe hepatic impairment.
4.Any pre-existing phy sical or mental condition (including substance abu se disorder) 
which, in the opi[INVESTIGATOR_689], may  interfere with the subject’s ability  to 
comply  with the dosing schedule and/or protocol evaluations or which may  
compromise the safety  of the subject.
5.Subject who, in the investigator's judgment, poses a significant suicide risk.  Recent 
history  of suicidal behavior and/or suicidal ideation may  be considered as evidence 
of serious suicide risk.
6.The subject has a tattoo or other dermatological condition overly ing the gluteus 
region which may interfe re with interpretation of injection site reactions.
7.History  of ongoing or clinically  relevant hepatitis within the previous 6 months, 
including chronic hepatitis B virus (HBV) infection ( Hepatitis B Virus surface 
Antigen [HBsAg ]positive). 
8.Asymptomatic in dividuals with chronic hepatitis C virus (HCV) infection will not be 
excluded, however Investigators must carefull y assess if therap y specific for HCV 
infection is required; subjects who are anticipated to require such therap y must be 
excluded.   
9.History  of liver cirrhosis with or without hepatitis viral co -infection.
10.Ongoing or clinically  relevant pancreatitis.
11.History  of the following cardiac diseases: m yocardial infarction, congestive heart 
failure, documented h ypertrophic cardiomyopathy, sustained ventr icular tachy cardia.
12.Personal or known family history  of prolonged QT sy ndrome.
13.Any condition which, in the opi[INVESTIGATOR_689], may  interfere with the 
absorption, distribution, metabolism or excretion of the drug or render the subject 
unable to rec eive stud y medication.
14.History  or presence of allergy  or intolerance to the study  drugs or their components 
or drugs of their class.  In addition, if heparin is used during PK sampling, subjects 
with a history  of sensitivity  to heparin or heparin -induced t hrombocy topenia must 
not be enrolled. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7041].Current or anticipated need for chronic anti -coagulation.
Exclusionary Laboratory Values or Clinical Assessments at Screening (a single repeat to 
determine eligibility is allowed)
16.Any evidence of primary resistance bas ed on the presence of an y major resistance -
associated mutation (International AIDS Societ y [IAS]-[LOCATION_003], 2013 )in the Screening 
result or, if known, an y historical resistance test result.  Note:  re -tests of Screening 
genot ypes are allowed only at the discretion of the study  virologist.
17.Any verified Grade [ADDRESS_419289]’s participation in the study  of an 
investigational compound.
19. Subject has estimated creatinine clearance <50 mL/min via Cockcroft- Gault 
[Cockcroft , 1976] method.
20.Alanine aminotransferase (ALT) [ADDRESS_419290].  Subjects with AL T > 2xULN but 
<5xUL N may participate in the study , if in the opi[INVESTIGATOR_339165].
21.Alanine aminotransferase (ALT) 3xULN and bilirubin 1.5xUL N (with >3 5% 
direct bilirubin).
22.Any clinically  significant finding on screening or Baseline electrocardiograph 
(ECG), specificall y:
Males Females
Heart rate* <45 and >100 bpm <50 and >100 bpm
QRS duration >120 msec
QTc interval (B or F) >450 msec
*A heart rate from 100 to 110 bpm can be rechecked within 30 minutes to verify eligibility.
Non-sustained ( 3 consecutive beats) or sustained ventricular tachy cardia.
Sinus pauses >2.5 seconds.
2nd degree (Ty pe II) or higher atrioventricular (AV) block.
Evidence of WP W (Wolff - Parkinson -White) s yndrome (ventricular 
preexcitation).
Pathologic Q waves (defined as Q wave > 40msec OR depth >0.4 mV.
Any significant arrh ythmia (either on ECG or b y history ) which, in the opi[INVESTIGATOR_339166], wi ll interfere with the safety  for 
the individual subject.
23.Subjects who are HLA -B*5701 positive and unable to use an alternative NRTI  
backbone (subjects who are HLA -B*5701 positive may  be enrolled if they  use an 
alternative NRTI backbone that does not contai n abacavir ). 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419291] Day  of Induction Period
24.Exposure to an experimental drug and/or experimental vaccine within [ADDRESS_419292] dose of I P.
25.Treatment with an y of the following agents within 28 days of Screening:
radiation therap y
cytotoxic chemotherapeutic agents
tuberculosis therap y
Immunomodulators that alter immune responses (suc h as s ystemic 
corticosteroids, interleukins, or interferons) Note: Subjects using short- term 
(<10 day ) steroid tapers, topi[INVESTIGATOR_2855], inhaled and intranasal corticosteroids are 
eligible for enrollment.
26.Treatment with an HIV -[ADDRESS_419293] labels, and/or local 
prescribing information for detailed information regarding warnings, precautions, 
contraindications, AEs, drug interactions, and other significant data pertaining to the IP 
and the dual NRTI background drugs being used in this study .
4.5. Withdrawal Criteria
Subjects permanentl y discontinuing s tudy treatments prior to Week 96are considered to 
be withdrawn from the study  treatments and also from the study .  Similarly , subjects 
perma nentl y discon tinuing participation from the Extension and L ong-Term Follow -Up 
Period prior to commercially available drug supply  are considered to be withdrawn from 
the study  treatments and also from the study .
A subject may  voluntarily  discontinue partici pation in this study  at any  time.  The 
investigator may  also, at their discretion, discontinue the subject from participating in this 
study  at an y time.  Subjects who are withdrawn from the study  will not be replaced.
Should a subject fail to attend the clinic for a required study  visit, the site should attempt 
to contact [CONTACT_131993] -schedule the missed visit as soon as possible.  The site 
should also counsel the subject on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the subject wishes to and/or should continue in the  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419294] ([ADDRESS_419295]’s last known mailing address) so that they can appropriatel y 
be withdrawn from the study .  These contact [CONTACT_339251] t’s medical record.  Should the subject continue to be unreachable, then and onl y 
then will he/she be considered to have withdrawn from the study  with a primary  reason of 
“Lost to Follow -up”.  For all other subjects withdrawing from the study , an alternative 
reason for discontinuation should be recorded in the electronic case report form (eCRF ).
Subjects are not obligated to state the reason for withdrawal but the Investigator must 
make every  attempt to elucidate a reason.  The efforts must be documented in the source 
including efforts to locate a subject that has been deemed lost to follow up. The reasons 
for withdrawal, or failure to provide a reason, must be documented in the eCRF.
The investigator must make every  effort to perform a Withdrawal visit as well as a 
Follow -Up visit (as needed) as per the Time and Events Table (see Section 6).  Follow -up 
for AEs and SAEs must occur as specified in Section 6.10.12 .
Subje cts with an HIV -1 RNA > 200 c/mL at the time of Withdrawal will have samples 
sent to a central laboratory for resistance testing and results provided to the Investigator 
once available.
All subjects who discontinue prematurel y from the study, irrespective of arm, will be 
asked for additional information to establish the reason for withdrawal.
Reasons for stud y withdrawal may include:
Adverse event/Serious adverse event
Protocol deviation
Intolerability  of injections
Subject lost to follow -up
Subject withdre w consent
Investigator discretion
Subject or investigator non -compliance
Termination of the stud y by [CONTACT_1034]
At the request of the subject, Investigator, or [COMPANY_004]
The subject requires concurrent prohibited medications during the course of the 
study .  If, in the opi[INVESTIGATOR_339167], such 
medication will not interfere with the conduct or interpretation of the stud y or 
compromise the safety  of the subject, then the subject may  remain in the study . 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419296] awn from the stud y for any of the following reasons:
Subjects who are not eligible to continue into the Maintenance Period as per 
Section 3.2.3 .
Subjects who do not wish to continue on the remaining dosing regim en if one dosing 
regimen is discontinued further to an IDMC decision (see Section 3.2.8 ).
Subjects who are not eligible, or do not wish to continue on to the Extension Period 
(see Section [IP_ADDRESS]).
Subjects who cannot or do not wish to continue on to the L ong-Term Follow Up 
Period (see Section 3.2.6 ).
Confirmed virologic failure as described in Section 4.6.
Pregnancy  (intrauterine).
Subject requires a switch of background NRTI therapy  (except as allowed in 
Section 5.6).
Subject requires substitution or dose reduction of CAB or RPV .
Grade 4 AE or toxicity  in the absence of compelling evidence that the AE is not 
causall y related to the IP (See Section [IP_ADDRESS] ).
Liver toxicity  where Stoppi[INVESTIGATOR_339168] 6.10.3 are met and no 
compelling alternative cause is identified.
Renal toxicity  as specified in Section [IP_ADDRESS] and Section [IP_ADDRESS] is met and no 
compelling alternate caus e is identified. 
Subject has a Grade 3 or higher rash or Grade 2 rash with evidence of s ystemic 
involvement as described in Section [IP_ADDRESS] .
The following QT criteria:
Corrected QT interval (QTc)>500 msec
Uncorrected QT >[ADDRESS_419297] be based on the average QTc value of triplicate ECGs. For 
example, if an ECG demonstrates a prolonged QT interval, obtain two more ECGs 
over a brief period, and then use the averaged QTc values of the three ECGs t o 
determine whether the patient should be discontinued from the study .  
For subjects with underlying Bundle Branch Block: 
Baseline QTc with Bundle Branch Block Discontinuation QTc with Bundle Branch Block
<450 msec >500 msec
450-480 msec 530 msec
Efficacy  data for subjects withdrawing from the study  will be considered evaluable up to 
the point at which they  are withdrawn using the same criteria for evaluability as for 
subjects who complete the study . 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
84Safety  data for all subjects who receive any  amoun t of study  drug, including subjects who 
withdraw from the stud y, will be included in evaluations of safet y.
4.5.1. Subjects Receiving CABLA and / or RPV LA
Subjects who have received at least one dose of CAB LA or RPV LA and choose to 
withdraw or are required to withdraw, will be asked to participate in the Long- Term 
Follow Up Period of the study  (See Section 3.2.6 ).  The investigator must make every  
effort to conduct visits as per the Time and Events Table (see Sectio n6.7).
The Investigator must discuss choice of follow -up HAART regimen and timing of 
initiation with the medical monitor prior to initiating the new regimen with the 
subject.
4.6. Virologic Failure
Following stud y entr y, no changes , or intensification of ART will be permitted prior to 
protocol -defined virologic failure, with the exception of the planned addition of RPV at 
Week ( -4), the change to the Maintenance Period regimen, and one allowed alternative 
approved NRTI change for ma nagement of drug toxicity . 
Only  plasma HIV -[ADDRESS_419298] y to subjects in the 
Long -Term Follow -Up Period.  These subjects will be followed for the emergence of 
potential virologic resistance onl y.  If the HIV -1 RNA > 200 c/mL, a confirmation 
sample must be obtained.  If the repeat HIV- 1 RNA is > 200 c/mL  samples will be sent to 
a central laboratory  for resistance testing and results provided to the I nvestigator once 
available.
4.6.1. Definition of Virologic Failure
For the purposes of clinical management in this study , virologi c failure is defined as any
of the following:
Non-response as indicated by  a less than a 1.0 log 10copi[INVESTIGATOR_014]/mL  decrease in 
plasma HIV -1 RNA after 4 weeks of starting the Induction Period, which is 
subsequently  confirmed, unless the plasma HIV- 1 RNA is < 400 c/mL .
Rebound as indicated b y two consecutive plasma HIV -1 RNA levels 200c/mL  
after prior suppression to < 200 c/mL . 
Rebound as indicated b y two consecutive plasma HIV -1 RNA that are 
> 0.5 log 10c/mL  increase in plasma HIV- [ADDRESS_419299] HIV -1 RNA value is  200 c/mL. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419300] step in the management of study  subjects (e.g., at the first indication of in adequate 
virologic response or rebound).
[IP_ADDRESS]. Suspected Virologic Failure
Upon notification that a subject’s HIV -1 RNA plasma level meets an y of the definitions 
of virologic failure, the Investigator should confirm the definition is met by [CONTACT_93976] a 
repeat o f the HIV -1 RNA assessment.  
The following guidelines should be followed for scheduling confirmatory HIV -1 RNA 
testing in an effort to avoid false- positive results: 
Confirmatory  testing should be scheduled [ADDRESS_419301] should receive full dose 
of all I P.
Confirmatory  testing should be scheduled at least [ADDRESS_419302] should receive full dose of all IP.
If therap y is interrupt ed* due to toxicity  management, non -compliance, or other 
reasons, confirmatory  testing should be scheduled 2 to 4 weeks following 
resumption of full dose of all I P.
The subject should have received full dose of IP for at least 2 weeks at the time 
confirmat ory plasma HIV -1 RNA testing is done.
*Note:  treatment interruption guidelines above may not apply for subjects on CAB LA + 
RPV LA treatment.  The study  team should be contact[CONTACT_339252].
In addition, the Investigator should query  the subject regarding intercurrent illness, recent 
immunization, or interruption of therap y.  
Sites should contact [CONTACT_339253], 
whenever necessary.
[IP_ADDRESS]. Confirmed Virologic Failure
Subjects who confirm virologic failure must be discontinued from the study .  However, 
subjects who have received at least one dose of CAB LA or RPV LA prior to confirming 
virologic failure will remain in the study  on oral HAART in the L ong-Term Follow Up 
Period (see Section 3.2.6 ).
A plasma sample from the suspected virologic failure visit as well as the first day  of the 
Induction Period (Baseline) will be sent for genoty pic and pheno typic resistance testing 
and the result made known to the Investigator when available.   A plasma sample from the 
confirmation visit will be obtained for storage.  This sample may  be used for possible  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419303] (IP) refers to CAB , CAB LA, RPV and RPV LA.  
These will be supplied by [CONTACT_339254], respectivel y.  
Epzicom / Kivexa will also be considered I P from Day  1 of the Maintenance Period and 
will be provided by  [CONTACT_23983].  
Other antiretrovirals administered in the study  as dual background NRTIs (e.g. for 
subjects who are HLA -B*5701 positive or switch due to toxicity ) are not consid ered IP.  
These may  be supplied regionall y by [CONTACT_339255].
The contents of the labels will be in accordance with all applicable regulatory  
requirements.
Under normal conditions of handling and administration, investigational produ ct is not 
expected to pose significant safet y risks to site staff.  Take adequate precautions to avoid 
direct ey e or skin contact [CONTACT_23968]. Notify  the monitor of 
any unintentional occupational exposure.  A Material Safet y Da ta Sheet (MSDS) 
describing the occupational hazards and recommended handling precautions will be 
provided to site staff if required by  [CONTACT_339256].
Investigational product and background NRTIs must be sto red in a secure area under the 
appropriate ph ysical conditions for the product.  Access to and administration of the 
investigational product and background NRTIs will be limited to the investigator and 
authorised site staff.  Investigational product and background NRTIs must be dispensed 
or administered onl y to subjects enrolled in the study and in accordance with the 
protocol.
5.1.1. Cabotegravir ([COMPANY_004]1265744) –Tablet ( CAB)
CAB is manufactured b y GlaxoSmithKline and is formulated as white to almost white 
oval sha ped film coated 30 mg tablets for oral administration, packaged in high densit y 
polyethylene (HDPE) bottles with desiccant and child -resistant closure that include an  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419304] kee p 
all IP in its original pack container. [COMPANY_004] will notify  sites if and when data are available 
to support the use of pi[INVESTIGATOR_16582].  CAB tablets are to be stored up to 30°C and protected 
from moisture.
5.1.2. Rilpi[INVESTIGATOR_12979] -Tablet (RPV)
RPV [ Edurant Product I nformation , 2015 ]is provided by [CONTACT_12945] & 
Development, a division of Janssen Pharmaceuticals as 25 mg tablets that are off -white, 
round, biconvex, film -coated and debossed on one side with “TMC” and the other sid e 
with “25”. RPV is manufactured by  [CONTACT_48873] - Cilag S.p.A, Latina, Italy. RPV will be 
provided as globall y marketed product, including US and the European Union, and 
overlabeled, packaged in bottles of 30 tablets.  RPV tablets are to be stored at 25°C 
(excursions permitted to 15°- 30°C [59° -86°F]) and protected from light.
5.1.3. Epzicom / Kivexa
ABC/3TC [ Epzicom Product I nformation , 2012] is manufactured by [CONTACT_339257]/3TC fixed dose combination (FDC) oral tablet, which 
contains 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC. The tablets are 
orange, film -coated, modified capsule -shaped and debossed with GS FC2 on one side 
with no markings on the reverse side. ABC/3TC is packaged in bottl es of 30 tablets. 
ABC/3TC will be supplied by  [CONTACT_339258]. ABC/3TC tablets are to be 
stored at 25°C (excursions permitted to 15°-30°C [59°- 86°F]) .
5.1.4. Cabotegravir ([COMPANY_004]1265744) –Injectable Suspension ( CABLA)
CAB LA is manufactured by  [CONTACT_339259] a sterile white to slightl y colored 
suspension containing 200 mg/mL  of CAB as free acid for administration by  
[CONTACT_33813] (IM) injection.  The product is packaged in a 3 mL USP Ty pe I glass vial 
with a 13 mm gray  stopper and aluminium seal .  Each vial is for single use containing a 
withdrawable volume of 2.0 mL ,and does not require dilution prior to administration.  
CAB LA injectable suspension is to be stored at up to 30°C, do not freeze.
CAB LA is composed of cabotegravir free acid, poly sorbate 20, poly ethylene gl ycol 
3350, mannitol, and water for injection.
5.1.5. Rilpi[INVESTIGATOR_12979] –Injectable Suspension ( RPV LA)
RPV LA, also named JNJ -16150108 -AAA 300 mg/mL Extended Release Suspension for 
Injection (G001), is provided by  [CONTACT_12945] & Development, a division of Janssen 
Pharmaceuticals as a sterile white suspension containing 300 mg/mL  of RPV as free base 
for administration by  [CONTACT_33813] (IM) injection.  The product is packaged in a single 
use 4 mL USP Ty pe I glass vial with a 13 mm grey  stop per and aluminium seal. Each 
vial is for single use containing a nominal fill of 2.0 mL , and does not require dilution 
prior to administration but requires refrigeration.  RPV LA injectable suspension is to be 
stored 2-8°C, do not freeze, protected from lig ht and kept in the outer package. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
88RPV LA is composed of RPV free base, poloxamer 338, sodium dihy drogen phosphate 
monohy drate, citric acid monohydrate, glucose monohy drate, sodium hy droxide, water 
for injection.
5.1.6. Dosage and A dministration
Following is a t able of dosing and administration for all treatment arms:
Induction Period (Week -20 through Day 1)
Week -20 to Week (-4)
(2 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X CAB 30 mg tablet once daily
Week ( -4) to Day 1
(3 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X CAB 30 mg tablet once daily
Take 1 X RPV 25 mg tablet once daily
Take with a meal
Take Day 1 doses in the clinic
Maintenance Period (Day 1 toWeek 96*)
CAB LA 600 mg + RPV LA 900 mg IM every 8 Weeks (Q8W)
Day 1 –loading dose
(3 injections once)Receive last dose of Induction regimen
Receive CAB LA 800 mg given as 2 X 2 mL IM injections 
Receive RPV LA 900 mg given as 1 X 3 mL IM injection 
Week 4 – 2ndloading dose
(1 injection once)Receive CAB LA 600 mg given as 1 X 3 mL IM injections 
(No RPV LA)
Week 8 to Week 88
(2 injections every 8 weeks)Receive CAB LA 600 mg given as 1 X 3 mL IM injection 
Receive RPV LA 900 mg given as 1 X 3 mL IM injection
CAB LA 400 mg + RPV LA 600 mg IM every 4 Weeks (Q4W)
Day 1 –loading dose
(3 injections once)Receive last dose of Induction regimen
Receive CAB LA 800 mg given as 2 X 2 mL IM injections 
Receive RPV LA 600 mg given as 1 X 2 mL IM injection  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
89Week 4 to Week 92
(2 inje ctions every 4 weeks)Receive CAB LA 400 mg given as 1 X 2 mL IM injection
Receive RPV LA 600 mg given as 1 X 2 mL IM injection
CAB 30 mg + ABC/3TC once daily
Day 1Receive last dose of Induction regimen
Day 2 to Week 96
(2 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X CAB 30 mg tablet once daily
If continuing to Extension Period:
Week 96 to Week 100
(2 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X CAB 30 mg tablet once daily
Exten sion Period (Week 96+) 
If subject was randomized to the Q8W regimen during the Maintenance Period:
Week 96plus+
(2 injections every 8 weeks)Receive CAB LA [ADDRESS_419305] :
Week 100– 1stloading dose
(2 injections once)Receive last dose of Maintenance regimen
Receive CAB LA 600 mg given as 1 X 3 mL IM injections 
Receive RPV LA 900 mg given a s 1 X 3 mL IM injection
Week 104 – 2ndloading dose
(2 injection once)Receive CAB LA 600 mg given as 1 X 3 mL IM injections 
Receive RPV LA 900 mg given as 1 X 3 mL IM injection
Week 112 plus+
(2 injections every 8 weeks)Receive CAB LA [ADDRESS_419306] was Randomized to the Q4W regimen during the Maintenance Period:
Week 96 plus+
(2 injections every 4 weeks)Receive CAB LA [ADDRESS_419307] :
Week 100 – 1stloading dose
(2injections once)Receive last dose of Maintenance regimen
Receive CAB LA 600 mg give n as 1 X 3 mL IM injections 
Receive RPV LA 900 mg given as 1 X 3 mL IM injection 
Week 10 4 – 2ndloading dose
(2 injections once )Receive CAB LA 400 mg given as 1 X 2 mL IM injection 
Receive RPV LA 600 mg given as 1 X 2 mL IM injection
Week 10 8plus+
(2 injections every 4 weeks)Receive CAB LA 400 mg given as 1 X 2 mL IM injection 
Receive RPV LA 600 mg given as 1 X 2 mL IM injection
*Or through Week 100 if eligible to enter the Extension Period.
+until locally approved and commercially available, t he subject no longer derives clinical benefit, the subject meets a 
protocol -defined reason for discontinuation or until development of CAB or RPV is terminated
5.1.7. Dosing Considerations for CABLA + RPV LA
Vials of CAB LA and RPV LA are each supplied as a suspension and need no further 
dilution or reconstitution.  However, sites should gently  invert the vials a few times to re-
suspend sediments and allow bubbles to subside, and then use a s yringe to withdraw the 
required volume of suspension for IM injection. Since RPV LA requires refrigeration 
sites should allow the vial to come to approximately  room temperature prior to injecting.
All injections must be given intramuscularl y in the gluteus medius.  Sites may  use their 
discretion as to where in the gluteus muscle each injection is given according to 
individual subject circumstance.  If possible, injections should be spaced approximately  
2cm from one another, from the site of an y previous injection or an y injection site 
reaction.  The time and location of inje ction will be captured in the eCRF.  
IM injections should be administered at a 90 degree angle into the gluteus medius muscle 
using a 1.5” 25 gauge needle for CAB LA and a 1.5” [ADDRESS_419308] subjects .  The needle should be long enough to reach the muscle mass and prevent 
study  drug from seepi[INVESTIGATOR_159193], but not so long as to involve 
underly ing nerves, blood vessels, or bone. Variable needle lengths may  need to be used 
to accommodate individual body  type.  For example, longer needle lengths may  be 
required for subjects with higher bod y mass indexes (BMI s, example > 30), to ensure that 
injections are administered intramuscularl y as opposed to subcutaneousl y.  BMI and 
needle length used will be collected in the eCRF.
On D ay 1, subject should be dosed with the IM regimen within [ADDRESS_419309] intolerance to the single 3 mL  injection, the injection may  be 
administered as 2 separate 1.5 mL  injections with the assent of the medical monitor.  I f 
the injection is split, this will be noted in the eCRF and the intolerance captured as an 
AE.
Should I M maladministr ation be suspected at an y time (e.g. suspected under or overdose 
or inadvertent IV dosing), the investigator may  consider requesting the subject stay  onsite 
for up to [ADDRESS_419310] dosing for future 
evaluation of CAB and RPV concentrations.
Additional dosing instructions and consideration scan be found in the SPM.
5.2. Treatment A ssignment
Subjects will be assigned to study  treatment in accordance with the randomi zation 
schedule.
Following completion of the I nduction Period, subjects eligible to enter the Maintenance 
Period will be randomized 2 :2:1 to Q8W or Q4W of CAB LA + RPV LA or to the oral 
control arm ( CAB 30 mg+ ABC/3TC).  Randomization will be stratified by  [CONTACT_10840]-1 RNA 
result before Week (-8)(<50 c/mL  yes or no).  Randomization will be conducted via a 
central randomization procedure. The central randomization schedule, including 
stratification, will be generated using the [COMPANY_004] validated randomization software 
RANDALL. Study  site personnel will be required to call the central randomization 
service for assignment of a unique identifier (de signating the subject’s randomization 
code and treatment sequence assignment) for each subject participating in the study . A 
unique treatment number will be assigned for each subject participating in the study .
5.3. Blinding
This study  is not blinded.
5.4. Product Accountability
In accordance with local regulatory  requirements, the investigator, designated site staff, 
or head of the medical institution (where applicable) must document the amount of 
investigational product dispensed and/or administered to study  subje cts, the amount 
returned b y stud y subjects, and the amount received from and returned to [COMPANY_004], when 
applicable.  Product accountability  records must be maintained throughout the course of 
the study .
5.5. Treatment Compliance
Treatment compliance will be evaluate d using pi[INVESTIGATOR_339169] ( CAB 30 mgand 
RPV 25mg tablets). This assessment will be conducted each time the subject receives a  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
92new (refill) supply  of oral study  medication.  Additionally , the date and time of each 
injection of CAB LA and RPV LA wi ll be noted.  These data will be recorded in the 
subject’s eCRF.
Treatment compliance will not be assessed during the L ong-Term Follow -Up Period.
Due to the long acting nature of the CAB and RPV, it will be imperative that the subject 
is compliant with dos ing instructions.  Subject awareness and knowledge of these dosing 
instructions will be assessed by  [CONTACT_339260] 6.14.  
Investigators must have plans in place for a dherence counselling.  In addition, 
Investigators must have plans in place to perform visit reminders andto verify  the 
subject’s contact [CONTACT_8964].
5.6. Protocol Permitted Substitutions
Subjects who are HLA -B*5701 positive at the Screening visit are allowed to enter the 
study  on an approved dual-NRTI backbone that does not contain ABC (e.g. TDF/FTC).  
This regimen may  be supplied regionally by [CONTACT_339255].
Switch of background NRTI  therapy  to an alternative approved NRT I therapy  for toxicity  
or tolerability  management is allowed once during the study . Switches of a background 
NRTI  for any  other reason are not permitted in the study . The date of the decision to 
switch background NRTI for toxicity  or tolerability  management must be documented in 
the eCRF.
If a subject needs to change background NRTI t herap y for toxicity management, an 
alternative FDC (e .g.TDF/FTC) should be considered first.  If this switch is not possible 
or appropriate, alternative approved dual NRTI therap y ma y be considered after 
consultation with the study  medical monitor.  This regimen may be supplied regionally
by [CONTACT_339255].
Local prescribing information should be consulted for information regarding use of these 
medicati ons.  
NOTE:  W hen applying the MSDF algorithm (also known as the Snapshot algorithm), 
subjects switching background NRTIs after W eek 2 may be considered a non- responder, 
however, these subjects will be allowed to continue in the study.
5.6.1. Oral Bridging
In ex ceptional circumstances, the medical monitor may  authorize the use of oral CAB 
30mgand/or RPV 25mg as a short -term “bridging” strategy  for subjects who have 
begun CAB LA + RPV LA.  This strategy  would only  be employ ed to address any  
potential gap in CAB LA + RPV LA dosing as a result of unexpected scheduling 
conflicts which would prevent planned dosing.  Should a subject need “oral bridging”, 
sites must contact [CONTACT_339261]  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
93strategies prior to a missed CAB LA + CAB LA dose.  Should a subject not notify  the 
site in advance, the medical monitor must be contact[CONTACT_339262].
5.7. Interruption of Study  Treatment and Visit/Dosing Windows
IP or background NRTI may  be interrupted at the discretio n of the Investigator in the 
event of an AE, according to the severit y of the AE.
If one or more antiretroviral medications is held due to toxicity  or adverse events, all 
antiretroviral medications must be held to reduce the risk of development of resistan ce 
taking into account both the length of the planned interruption and the pharmacokinetic 
half-life of each antiretroviral of the regimen, in a way  to minimize the risk of 
development of resistance.
It is important to note that keepi[INVESTIGATOR_85883]’s visit schedule is a very important 
component to the study.  
Note : All decisions regarding dose interruption / resumption must be discussed with 
the medical monitor in advance.
5.7.1. Oral Dosing Including Long Term Follow Up
Visits for subjects on the oral dosing arm are expected to occur as projected according to 
the Baseline visit.  There is a (+ or -) 3 day  visit window, from the projected visit date.  
However, the number of tablets dispensed should be considered when scheduling the next 
visit.
Any interruption in therapy  (scheduling conflicts, life circumstances, etc) during any  oral 
dosing period that is greater than [ADDRESS_419311] injection.  There is a (+ or -) 3 day  visit window, from the projected visit date.  
5.7.2. IM Dosing
Subjects receiving CAB LA and/or RPV LA are anticipated to be at high risk for 
development of virologic resistance if ART is interrupted.  The time period during which 
subjects are at risk for development of virologic resistan ce may  be determined by  [CONTACT_339263].  This time period will vary  by [CONTACT_339264], inhibit ory concentration and half -life. 
Plasma concentrations of both drugs may  be measurable for approximately  [ADDRESS_419312]’s projected visit falls 
(as according to the Day  1 visit).  An additional (+ or -) [ADDRESS_419313] dose visits 
(Week 1, Week 25, and Week 41), there is no defined visit window, rather visits should 
occur approxim ately  [ADDRESS_419314] injection.
Dosing may  occur without consultation from the medical monitor if performed 
within the (+ or -)7 day  window.  
Any request for the visit/ dosing to occur outside of the allowed window must be 
discussed and agreed with the medical monitor prior to dosing.  In the event of a 
late dose, a revised dosing schedule for subsequent dosing may  be required and 
will be communicated to the site staff at the time of approval for continued 
dosing.  Temporary  switch to oral dosing of CAB 30mg and/or RPV 25mg may 
be an option based on individual subject circumstance as described in Section 
5.6.1 .  
See the SPM for scheduling guidance and further information and examples.
Note : All decisions regarding dose interruption/ resumption must be discussed with 
the medical monitor in advance.
5.8. Discontinuation of Study  Treatment
Subjects unable to manage drug toxicity or tolerate investigational product must have I P 
discontinued.
5.8.1. Discontinuation of ABC /3TC
In the event of a discontinuation of an ABC -containing product for an y reason, re -
initiation of this drug should be undertaken with caution. Health care providers should 
obtain a complete history of the events surrounding the discontinuation of the A BC-
containing product. If there are s ymptoms consistent with a hy persensitivity  reaction, 
ABC must not be reinitiated. If there is no evidence of a prior reaction, the subject may 
restart treatment with the ABC -containing product. The subject and health care provider 
must be aware of the possibility  of a rapid -onset hy persensitivity  reaction upon 
reinitiation of ABC, which may  be life -threatening or fatal, and the subject must be able 
to, if necessary , receive prompt medical evaluation (see also Section [IP_ADDRESS] ).
5.8.2. Discontinuation of CAB LA or RPV LA
Any subject receiving at least one dose of CAB LA and /or RPV LA who discontinue I P / 
Withdraw will initiate treatment with HAART enter the Long -Term Follow -Up Per iod 
for 52 weeks of follow up (see Section 5.8.2 ). 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
955.9. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_278788] (prescription and non- prescription) should be administered 
only as medically  necessary  during the study . Subjects must be advised to notify  their 
Investigator of an y current or proposed concomitant medication, whether prescribed or 
over-the-counter, because of the potential for interactions between such treatments and 
the study  medications.
5.9.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_339170]-associated conditions is encouraged, if appropriate, at the 
discretion of the subject and their ph ysician. All concomitant medications, blood 
products, and vaccines taken during the stud y will be recorded in the eCRF with dates of 
administration.
Because non- HIV vaccines may  cause a temporary  increase in the level of plasma HIV -[ADDRESS_419315] been drawn. This approach will 
minimize the risk of non- specific increases in the level of plasma HIV -1 RNA at the next 
scheduled assessment.
Other IM injectables (with exceptions below) are permitted but must be administered
away  from the site of IP administration.
Oral administration only : Antacid products containing divalent cations (e.g., aluminium, 
calcium and magnesium) must be taken at least [ADDRESS_419316] 4 
hours after taking CAB and RPV.
Concurrent administration of multivitamins is acceptable.
5.9.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_339171] y time during the s tudy. 
Other experimental agents, antiretroviral drugs not otherwise specified in the protocol, 
cytotoxic chemotherapy , or radiation therapy  may  not be administered (see Exclusion 
Criteria #24, Section 4.3). 
Systemicall y administered immunomodulators are prohibited.
Acetaminophen cannot be used in patients with acute viral hepatitis.
Chronic use of oral glucocortioids must be avoided; however, short treatment courses 
(e.g., 10 day s or less) and topi[INVESTIGATOR_2855], inhaled or intranasal use of glucocortioids will be 
allowed. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419317] be discussed with the Med ical Monitor prior to initiation of therapy .
For information on concurrent therapi[INVESTIGATOR_339172] y in the regimen (e.g. Epzicom / Kivexa) , please consult the local 
prescribing information.
[IP_ADDRESS]. Concurr ent with CABand/or RPV
For subjects receiving either formulation of CAB and/or RPV , the following 
medications could significantly  decrease the levels of CAB and/or RPV due to enzy me 
induction and therefore must not be administered concurrently : 
Carbamaze pi[INVESTIGATOR_050]
Oxcarbazepi[INVESTIGATOR_050]
Phenobarbital 
Pheny toin
Rifabutin
Rifampi[INVESTIGATOR_2513] / Rifampin
Rifapentine
St. John’s wort
[IP_ADDRESS]. Concurrent with RPV
In addition, subjects must discontinue the following (or change to an allowable 
alternative) while receiving treatment with oral RPV :
proton pump inhibitors, such as esomeprazole, lansoprazole, omeprazole, 
pantoprazole, rabeprazole ;
systemic dexamethasone (more than a single dose).
If the subject cannot discontinue use or change to an allowable alternative while 
receiving treatment with RPV, the subject should not be randomized into the study .
[IP_ADDRESS]. Concurrent with either CABLA or RPV LA
In addition, for subjects receiving CAB LA and RPV LA, use of anticoagulation agents 
greater than [ADDRESS_419318] -
study  care of the patient’s medical condition whether or not [COMPANY_004] is pr oviding specific 
post study  treatment.
All subjects who successfully  complete the Maintenance Period will be considered for 
inclusion in the Extension Period (see Section 3.2.5 ).
5.10.1. Long -Term Follow -Up Period
Any subject who receives at least a single dose of CAB LA and/or RPV LA and 
discontinues the CAB LA + RPV LA regimen will enter the Long -Term Follow -Up 
Period (see Section 3.2.6 ).  Since these subjects are anticipate d to be at high risk for the 
development of virologic resistance if ART is interrupted, they must switch to an 
Investigator selected HAART regimen and remain on study  for at least [ADDRESS_419319] dose of CAB LA and / or RPV LA. 
Investigators must discuss choice of HAART regimen and timing of initiation with 
the medical monitor before initiating.  Subjects will continue to be dosed according to 
the agreed regimen selection for [ADDRESS_419320] y HAART regionall y or reimbursement will be provided
5.11. Treatment of Study  Treatment Overdose
For subjects receiving CAB , any tablet intake exceeding a total dail y dose of 30 mg will 
be considered an overdose. For subjects receiving RPV, any  dose exceeding a total daily  
dose of 25 mg will be consider ed an overdose. For subjects receiving Epzicom / Kivexa, 
any tablet intake exceeding the protocol defined daily number of tablets (one tablet daily ) 
will be considered an overdose.  
For CAB LA and RPV LA, an y single dose in excess of the studied dose swill be 
considered an overdose.   
Should I M maladministration be suspected at an y time (e.g. suspected under or overdose 
or inadvertent IV dosing), the investigator may  consider requesting the subject stay  onsite 
for up to [ADDRESS_419321] dosing for future 
evaluation of CAB and RPV concentrat ions.
For the purposes of this study , an overdose is not an AE (refer to Section [IP_ADDRESS] ) unless 
it is accompanied b y a clinical manifestation associated with the overdose. If the clinical 
manifestation prese nts with serious criteria, the event is a SAE (see Section [IP_ADDRESS] ).
If an overdose occurs and is associated with an adverse event requiring action, all study  
medications must be temporaril y discontinued until the adverse event resolves. 
The Investigator should use clinical judgement in treating overdose, as [COMPANY_004] is unable to 
recommend specific treatment. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
986. STUDY A SSESSMENTS A ND PROCEDURES
6.1. Time and Events Table –Induction Period
Procedures  for Induction Screenin g 
Period aBaseline / 
Week ( -20) Week 
(-16) Week
(-12)Week
(-8)Week
(-4)WD Notes 
Written Informed Consent Xa. Complete all Screening assessments within [ADDRESS_419322] management and / 
or care. 
c. Height collected at Baseline only.
d. Measure vital signs after about [ADDRESS_419323] in a 
semi -supi[INVESTIGATOR_2547].
e. Perform ECG at Baseline in triplicate prior to dosing; 
preferably 2 – [ADDRESS_419324] full routine medical history plus (report at 
Baseline visit): HIV risk factors (may be collected at a 
later study visit), cardiovascular risk factors 
(assessments include smoking status and history, 
family history of cardia c events), recent [ 6months] 
illicit drug use, intravenous drug use, gastrointestinal 
disease, metabolic, psychiatric, renal and neurologic 
disorders.
g. Collect SAEs at Screen only if associated to study 
participation.
h. Confirmation of eligibility to enter t he Maintenance 
Period.  See Section 3.2.3.Demography X
Eligibility Verification X X X h
Physical Exam b X
Symptom Directed Physical Exam and 
Medical Assessment bX X X X X X smoking 
status also
Weight and Height c X X
Vital Signs (BP, HR)d X X X X
12-Lead ECG e X Xpre-dose x3 X X
Medical History f X
Medication History / Pri or ART History X
CDC Classification X X
HIV Associated Conditions X X X X X
AE and SAE Assessment, Con Meds X g X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
99Procedures  for Induction Screenin g 
Period aBaseline / 
Week ( -20) Week 
(-16) Week
(-12)Week
(-8)Week
(-4)WD Notes 
Columbia Suicide Severity Rating Scale 
(eC-SSRS) iX X X X X X Xi. Preferably completed at the beginning of the visit.
j. Collect for women of childbearing potential only.  A 
negative urine pregnancy test is required prior to 
beginning the Induction Period. S=Serum/U=Urine
k. Plasma for storage will be used: to determine 
genotypic eligibility at Screen, for possible future 
analyses, as back -up in case samples are lost or 
damaged in transit to the lab and for genotypic and 
phenotypic analys es in cases of virologic failure.
l. Overnight fast is preferred; however, a minimum of a [ADDRESS_419325] pharmacogenetics (PGx) sample at Baseline.  
May be collected later during the study if necessary.HIVTSQ(s) i X X X
HIVMQ X 
Clinical Chemistry 
and HematologyX X X X X X X
Pregnancy Testingj S U S S S S S
HIV-1 RNA and sample for storage k Xand genotype X X X X X X
CD4+ X X X X X X
CD8+ X X
Urinalysis X X X
Fasting Lab Assessments:  Glucose, 
Cholesterol (Total, HDL and LDL) and 
Triglycerides lX X X
Hepatitis B (HBsAg) and Hepatitis C 
(anti-HCV Ab), HLA -B*5701X
PT/PTT/INR X X
PGx m X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
100Procedures  for Induction Screenin g 
Period aBaseline / 
Week ( -20) Week 
(-16) Week
(-12)Week
(-8)Week
(-4)WD Notes 
PK Sample 
(S)torageSn. Instruct subje cts to continue to take the Induction 
regimen (including RPV) through Day [ADDRESS_419326] s in case they are randomized to continue on 
the CAB 30 mg + ABC/3TC arm.
o. Remind subjects of the potential change in study 
treatment and visit frequency beginning at Day 1.Study Treatment Dispensation X X X X X n
Add RPV 
Study Treatment Accountability
(pi[INVESTIGATOR_10685])X X X X X
PK Diary Dispensation Xn
Subject Visit Reminder Contact X X X X X X o X
Subject Contact [CONTACT_339265] X X X X X X
Follow Up Visit:  Conduct approximately [ADDRESS_419327] on -study visit.  This visit may be conducted by [CONTACT_756]. 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7042].2. Time and Events Table –Maintenance Period for IM Regimen ( CABLA+RPV LAQ8W )
Procedures
For Maintenance 
–Q8W  regimenD1 W
1W
4W
8W
12W
16W
20W
24W 
25W
28W
32W
36W
40W 
41W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD
p
Verify Eligibility X
Randomization X
Sympto m Directed 
PE, ISR & Medical 
Assessment aX X X X X X X X X X X X X X X X X X X X X X X 
and 
smoking 
status
Vital Signs
(BP, HR) bX X X X X X X X X X X X X X
Weight and BMI X X X X X
ECG c Xpre X X X X Xc Xc X X X X
HIV Associated 
Conditions, AE 
and SAE 
Assessment, Con  
Meds X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
ISR Diary 
(D)aily/(E)pi[INVESTIGATOR_49564])dD E E E E E E D E E E E D E E E E E E E E E E
Exercise Habit 
Assessme nt eX X X
eC-SSRSf X X X X X X X X X X X X X X X X X X
HIVTSQ(s) g Xpre X X X X X
HIVTSQ(c)g X X
HIVMQ g X X X X X g 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
102Procedures
For Maintenance 
–Q8W  regimenD1 W
1W
4W
8W
12W
16W
20W
24W 
25W
28W
32W
36W
40W 
41W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD
p
Clinical Chemistry 
and HematologyX X X X X X X X X X X X X X X X X X X X X
Pregnancy Test 
(U)rine/(S)erum hU U U U U U U U U U U U U U U U U U U S
HIV-1 RNA &
sample for 
storageiX X X X X X X X X X X X X X X X X X X X
CD4+ X X X X X X X X X X X
CD8+ X X X X
Urinalysis X X X X X X
Fasting:  Glucose,  
Cholesterol (Total, 
HDL and LDL) 
and 
Triglycerides jX X X X X X X
PT/PTT/INR X X X X X
PK Sample 
(S)torage kX k X X X X X X X X X XkX X X X Xk S S S S S S X
Study Treatment 
Administration mX l X X X X X X X X X X X X Xn
Visit Reminder 
ContactX X X X X X X X X X X X X X X X X X X X X X X X X X X X X
Subject Contact 
[CONTACT_339266] X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
103D=Day     W=Week    Pre=Pre -dosing   PE = Physical Exam  BMI=Body Mass Index
Gray shading indicates telephone safety assessments that will include interviewing the 
subjec t for adverse events, concomitant medications, HIV associated conditions and any 
other issues including injection site reactions.
a) Physical exams should be conducted as part of normal routine clinical care but data will not 
be collected in the eCRF. Medical assessments include any decisions the study staff must 
make for subject management and/or care of the subject.  See Section 6.10.1 for ISR 
assessment requirements.
b) Measure vital signs after about [ADDRESS_419328] in a semi -supi[INVESTIGATOR_2547].
c) 12-Lead ECG – Conduct pre -dose at Day 1.  At all other visits, the ECG may be done at any 
time during the visit. At Week [ADDRESS_419329] dose PK 
sampling.
d) Subjects will complete a (D)aily diary of injection site reactions from Day [ADDRESS_419330] experiences a reaction ((E)pi[INVESTIGATOR_49564]).  Subjects will be 
dispensed a new diary at each visit. Diary data will be entered into the eCRF.
e) Subject’s exercise habits will be assessed daily from Day 1 to Week 1, from Week 24 to 
Week 25 and again from Week 40 to Week 41.  Assessments will include type and duration 
of cardiovascular exercise and duration of any strength or other strenuous exercises. This 
information will be collected via the daily ISR diary and entered into the eCRF.
f) Preferably completed at the beginning of the visit. 
g) Conduct the HIVTSQ(s) at Day 1 pre -dosing; at all other visits conduct post -dosing.  
Conduct the HIVTSQ(c, WD) at WD ONLY if the subject WD between Week [ADDRESS_419331] injection.
h) Women of childbearing potential only.  A (- ) urine pregnancy test is required prior to any 
injection and as required by [CONTACT_339267] a treatment interruption. A positive urine 
test should be confirmed with a stat serum test.  If positive, subject will need to be WD.
i) Plasma for storage samples collected for possible analyses, back -up in case samples are 
lost or damaged in transit to lab, for geno/pheno analyses and virologic failures.
j) Fast overnight; however, a minimum of a [ADDRESS_419332] is acceptable.k) Take PK samples pre -dose except Weeks 1, 12, 20, 25, 28, 36, 41 and 44 which can be 
taken at any time during the visit.  Day 1 PK sample should be taken after review of PK 
diary and pre- dose of CAB 30 mg+ABC/3TC+RPV 25mg.  A second Day 1, Week [ADDRESS_419333] injection.
l) Subjects should take CAB 30 mg+ABC/3TC+RPV 25mgon Day 1 in the clinic after PK 
sampling and injections should be administered within 2 hours of this where possible.  
m) Subjects will take final dose of Induction regimen in the clinic at Day 1 and begin 
injections.   Day 1 injections are 2 x CAB LA 400 mg IM + 1 x RPV LA 900 mg IM.    
Week 4 injection is 1 x CAB LA 600 mg IM (no RPV LA).  At Week 8 and Q8W, 
injections are 1 x CAB LA 600 mg IM + 1 x RPV L A 900 mg IM.  If possible, injections 
should be spaced approximately 2 cm from one another and from the site of any 
previous injection and or any injection site reaction.  Bring RPV LA to approximately 
room temperature prior to injecting.  Time and locatio n of injection (right or left) as well 
as needle length used will be collected in the eCRF.  IM dosing expected to occur 
during week subject’s projected visit falls (as according to the Day 1 visit).  An 
additional (+ or - ) 7 day window, from date of proje cted visit, is allowable for IM 
dosing but not preferred.  All decisions regarding dose interruption/ resumption 
must be discussed with the Medical Monitor in advance.  
n) Subjects will continue to receive the irMaintenance Period dosing regimen in the 
Exten sion period (Q8W) at this visit.  
o) Subjects who WD must enter Long -Term Follow Up (see Section 3.2.6 ) instead of 
completing the WD visit.  If they cannot enter Long -Term Follow -Up complete WD and 
Follow Up asses sments.
p) Follow Up Visit:  Conduct approximately [ADDRESS_419334] on -study visit.  This visit may be conducted by [CONTACT_648]. 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7043].3. Time and Events Table –Maintenance Period for IM Regimen ( CABLA+RPV LAQ4W )
Procedures
For Maintenance 
–Q4W   regimenD1 W
1W
4W
8W
12W
16W
20W
24W 
25W
28W
32W
36W
40W 
41W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD
p
Verify Eligibility X
Randomization X
Symptom 
Directed PE, ISR 
& Medical 
Assessment aX X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
and 
smokin
g status
Vital Signs
(BP, HR) bX X X X X X X X X X X X X X
Weight and BMI X X X X X
ECG c Xpre X X X X Xc Xc X X X X
HIV Associated 
Conditions, AE 
and SAE 
Assessment, Con  
Meds X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
ISR Diary 
(D)aily/(E)pi[INVESTIGATOR_339173] E E E E E E D E E E E D E E E E E E E E E E E E E E E E
Exercise Habit 
Assessment eX X X
eC-SSRSf X X X X X X X X X X X X X X X X X X
HIVTSQ(s) g Xpre X X X X X
HIVTSQ(c)g X X
HIVMQ g X X X X X g 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
105Procedures
For Maintenance 
–Q4W   regimenD1 W
1W
4W
8W
12W
16W
20W
24W 
25W
28W
32W
36W
40W 
41W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD
p
Clinical Chemistry 
and HematologyX X X X X X X X X X X X X X X X X X X X X
Pregnancy Test 
(U)rine/(S)erum hU U U U U U U U U U U U U U U U U U U U U U U U U S
HIV-1 RNA &
sample for 
storageiX X X X X X X X X X X X X X X X X X X X
CD4+ X X X X X X X X X X X
CD8+ X X X X
Urinalysis X X X X X X
Fasting:  Gl ucose,  
Cholesterol (Total, 
HDL and LDL) 
and 
Triglycerides jX X X X X X X
PT/PTT/INR X X X X X
PK Sample 
(S)torage kX X X X X X X X X X XkX X X X Xk S S S S S S X
Study Treatment 
Administratio n mX l X X X X X X X X X X X X X X X X X X X X X X X Xn
Visit Reminder 
ContactX X X X X X X X X X X X X X X X X X X X X X X X X X XoX X
Subject Contact 
[CONTACT_339266] X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
106D=Day     W=Week    Pr e=Pre -dosing   PE = Physical Exam  BMI=Body Mass Index
a) Physical exams should be conducted as part of normal routine clinical care but data will not 
be collected in the eCRF. Medical assessments include any decisions the study staff must 
make for subject ma nagement and/or care of the subject.  See Section 6.10.1 for ISR 
assessment requirements.
b) Measure vital signs after about [ADDRESS_419335] in a semi -supi[INVESTIGATOR_2547].
c) 12-Lead ECG – Conduct pre -dose at Day 1.  At all other visits, the ECG may be done at any 
time during the visit. At Week [ADDRESS_419336] dose PK 
sampling.
d) Subjects will complete a (D)aily d iary of injection site reactions from Day [ADDRESS_419337] experiences a reaction ((E)pi[INVESTIGATOR_49564]).  Subjects will be 
dispensed a new diary at each visit. Diary data will be entered into the eCRF.
e) Subject’s exercise habits will be assessed daily from Day 1 to Week 1, from Week 24 to 
Week 25 and again from Week 40 to Week 41.  Assessments will include type and duration 
of cardiovascular exercise and duration of any strength or other strenuous exercises. This 
information will be collected via the daily ISR diary and entered into the eCRF.
f) Preferably completed at the beginning of the visit. 
g) Conduct the HIVTSQ(s) at Day 1 pre -dosing; at all other visits conduct post -dosing.  
Conduct the HIVTSQ(c, WD) at WD ONLY if the subject WD between Week [ADDRESS_419338] injection.
h) Women of childbearing potential only.  A ( -) urine pregnancy test is required prior to any 
injection a nd as required by [CONTACT_339267] a treatment interruption. A positive urine 
test should be confirmed with a stat serum test.  If positive, subject will need to be WD.
i) Plasma for storage samples collected for possible analyses, back- up in case sample s are 
lost or damaged in transit to lab, for geno/pheno analyses and virologic failures.
j) Fast overnight; however, a minimum of a [ADDRESS_419339] is acceptable.k) Take PK samples pre -dose except Week 1, Week 25 and Week 41 which can be taken 
at any time during the visit.  Day 1 PK sample should be taken after review of PK diary 
and pre -dose of CAB 30 mg+ABC/3TC+RPV 25mg.  A second Day 1, Week [ADDRESS_419340] injection.
l) Subjects should take CAB 30 mg+ABC/3TC+RPV 25mgon Day 1 in the clinic after PK 
sampling and injections should be administered within 2 hours of this where possible.  
m) Subjects will take final dose of Induction regimen in the clinic at Day 1 and begin 
injections.   Day 1 injections are 2 x CAB LA 400 mg IM + 1 x RPV LA 600 mg IM.  At 
Week 4 and Q4W, injections are 1 x CAB LA 400 mg IM + 1 x RPV LA 600 mg IM.  If 
possible, injections should be spaced approximately 2 cm from one another and from 
the site of any previous injection and or a ny injection site reaction.  Bring RPV LA to 
approximately room temperature prior to injecting.   Time and location of injection (right 
or left) as well as needle length used will be collected in the eCRF.  IM dosing is 
expected to occur during the week in which the subject’s projected visit falls (as 
according to the Day 1 visit).  An additional (+ or -) 7 day window, from date of 
projected visit, is allowable for IM dosing but not preferred.  All decisions 
regarding dose interruption/ resumption must be discussed with the medical 
monitor in advance. 
n) Subjects will continue to receive theirMaintenance Period dosing regimen in the 
Extension period (Q4W) at this visit.  
o) Subjects who WD must enter Long -Term Follow Up (see Section 3.2.6 ) instead of 
completing the WD visit.  If they cannot enter Long -Term Follow -Up complete WD and 
Follow Up assessments.
p) Follow Up Visit:  Conduct approximately [ADDRESS_419341] on -study visit.  This visit may be conducted by [CONTACT_648]. 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7044].4. Time and Events Table –Maintenance Period for Oral Regimen (CA B 30 mg+A BC/3TC)
Procedures For 
Maintenance –
ORAL regimenD1 W
4W
8W
12W
16W
20W
24W
28W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD p
Verify Eligibility X X k
Randomization X
Symptom 
Directed PE & 
Medical 
Assessment aX X X X X X X X X X X X X X X X X X X X and smoking 
status
Vital Signs
(BP, HR) bX X X X X X X X X X X X X
Weight and BMI c X X X X X
ECG c X
preX X X X X X X X X
HIV Associa ted 
Conditions, AE 
and SAE 
Assessment, Con  
Meds X X X X X X X X X X X X X X X X X X X X X X X X X X
PK Diary 
(D)ispensation 
and (R)eview dR D R D R D
eC-SSRSe X X X X X X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
108Procedures For 
Maintenance –
ORAL regimenD1 W
4W
8W
12W
16W
20W
24W
28W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD p
HIVTSQ(s) f X
preX X X X X
HIVTSQ(c)f X X
HIVMQ f X X X X X f
Clinical Chemistry 
and HematologyX X X X X X X X X X X X X X X X X X X X
Pregnancy Test 
(S)erum/(U)rine gS S S S S S S S S S S S S S S S S S S S
HIV-1 RNA &
sample for 
storage hX X X X X X X X X X X X X X X X X X Xm X
CD4+ X X X X X X X X X X X
CD8+ X X X X
Urinalysis X X X X X X
Fasting:  Glucose, 
Insulin, 
Cholestero l 
(Total, HDL and 
LDL) and 
Triglycerides iX X X X X X X
PT/PTT/INR X X X X X
PK Sample j X X X S X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
109Procedures For 
Maintenance –
ORAL regimenD1 W
4W
8W
12W
16W
20W
24W
28W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD p
Study Treatment 
Dispensation and 
Accountability nX X X X X X X X X X X X X X X X X X Xq
Study Treatment
Administration 
Visit Reminder 
ContactX X X X X X X X X X X X X X X X X X X X X X X Xo Xl,o X
Subject Contact 
[CONTACT_339266] X X X X X X X X X X X X X X X X X X X X X X X Xl X
D=Day     W=Week    Pre= Pre-dosing  PE = Physical Exam   BMI=Body Mass Index
Gray shading indicates telephone safety assessments that will include interviewing the subject for 
adverse events, concomitant medications, HIV associated conditions and any other issues 
including compli ance. 
a. Physical exams should be conducted as part of normal routine clinical care but data will not 
be collected in the eCRF. Medical assessments include any decisions the study staff must 
make for subject management and/or care of the subject.
b. Measure vital signs after about [ADDRESS_419342] in a semi -supi[INVESTIGATOR_2547].
c. 12-Lead ECG –Conduct pre -dose at Day 1.  At all other visits, it is preferable to conduct 2 –[ADDRESS_419343]’s last dose is not within window.  Visit may need to be 
rescheduled.h. Plasma for storage samples are collected for possible future analyses, as 
back -up in case of lost or damaged in transit to the lab and for geno/pheno 
analyses for virologic failur es
i. Fast overnight; however, a minimum of a [ADDRESS_419344] 
dose of IP taken.  Subjects will take their dose of IP in the clinic at PK visits. 
S=Storage
k. Assess subject’s willingness to continue on to the Extension Period.  If not 
continuing into the Extension Period, this is the subject’s last study visit.
l. For subjects continuing into the Extension Period only.  
m. The Week 96 HIV -1 RNA result (or single re -test prior to Week 100) must be 
<50 c/mL to be eligible to continue into the Extension Period.  See Section 
[IP_ADDRESS] .  Subjects ineligible for Extension will end their study participation at 
Week 96 (withdrawal visit needed). 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419345] the HIVTSQ(s) at Day [ADDRESS_419346] the HIVTSQ(c, WD) at WD ONLY if the subject WD between Week [ADDRESS_419347] the HIVMQ preferably at the beginning of the v isit, but may be completed 
at any time during the visit.
g. Women of childbearing potential only. A ( -) urine pregnancy test is required prior to any 
injection and as required by [CONTACT_339267] a treatment interruption. A positive urine 
test should be confirmed with a stat serum test.  If positive, subject will need to be WD.n. Subjects will discont inue RPV at Day 1 and begin taking 1 x CAB 30 mg + 1 
x ABC/3TC tablet once daily. At Week 96, while awaiting eligibility for 
Extension, subjects will continue their CAB 30 mg+ABC/3TC regimen.  
o. Remind subjects of the change in study and assessments for eli gibility into 
Extension.
p. Follow Up Visit:  Conduct approximately [ADDRESS_419348] 
on-study visit.  This visit may be conducted by [CONTACT_756].
q. Assess Treatment A ccountability only 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7045].5. Time and Events T able –Extension Period for IM Regimen (CA B LA + RPV LA -Q8W)
Procedures for 
Extension -
Q8W W 
100 
nW 
101 nW 
104 oW 
112W 
120W 
121 
nW 
128W
136 W 
144W
152W
160W
168W
176W 
184W 
192 aW 
200 
aWD 
l, mNotes
Symptom 
Directed 
Physical Exam, 
ISR and 
Medical 
Assessment bX X X X X X X X X X X X X X X X XSee footnote “a” for continuation of visit 
schedule after Week 200.  Continue until 
either locally approved and commercially 
available, the subject no l onger derives 
clinical benefit or meets a protocol- defined 
reason for discontinuation or until 
development is terminated.
a. Continue this pattern for visits for the 
remainder of the study.  For example, Week 
[ADDRESS_419349] in a semi -supi[INVESTIGATOR_2547].
d. Can be done at any time during the visit.
e. A (-) urine pregnancy test is required prior 
to any injection and as required by [CONTACT_339268] a treatment interruption. A (+) 
urine test should be confirmed with a stat 
serum test.  If (+), subject will need to be 
WD.
f. Plasma for storage samples are collected Vital Signs
(BP, HR) cX X X X X X X X X
Weight & BMI X X X X X X X X X
HIV Associated 
Conditions, AE 
and SAE 
Assessments, 
Con MedsX X X X X X X X X X X X X X X X X
12-Lead ECG dX X X X X X X X X
Clinical 
Chemistry and 
HematologyX X X X X n X X X X X X X
Pregnancy 
Testing
(U)rineeU U U U U U U U U U U U U U U U U 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
112Procedures for 
Extension -
Q8W W 
100 
nW 
101 nW 
104 oW 
112W 
120W 
121 
nW 
128W
136 W 
144W
152W
160W
168W
176W 
184W 
192 aW 
200 
aWD 
l, mNotes
HIV-1 RNA and 
sample for 
storage fX X X X n X X X X X Xfor possible future analyses, back -up in 
cases of loss/damage in transit and 
geno/pheno analyses for virologic failures.
g. Fast overnight; however, a minimum of a [ADDRESS_419350] experiences a reaction ((E)pi[INVESTIGATOR_49564]).  
Subjects will be dispensed a new diary at 
each visit. Diary data will be entered into the 
eCRF.
j. Q8W Injectio ns are 1 x CAB LA 600 mg 
IM + 1 x RPV LA 900 mg IM.  If possible, 
injections should be spaced approximately 
2 cm from one another and from the site of 
any previous injection and or any injection 
site reaction.  Bring RPV LA to 
approximately room temperatur e prior to 
injecting.   Time and location of injection 
(right or left) as well as needle length used 
will be collected in the eCRF.  IM dosing is 
expected to occur during the week in 
which the subject’s projected visit falls 
(as according to the Day 1 visit).  An 
additional (+ or - ) 7 day window from 
date of projected visit is allowable for IM 
dosing but not preferred.  All decisions 
regarding dose interruption/ resumption CD4+ X X X X n X X X X X X
Urinalysis X X X X n X X X X X X
Fasting 
Glucose, 
Cholester ol 
(Total, HDL 
and LDL) and 
Triglycerides gX X X X n X X X X X X
PT/PTT/INR X
PK Diary 
(D)ispensation 
and (R)eviewRn
PK Sample 
(S)torage hS S S S S n S S S S S S X
ISR Diary 
Dispensation iE E E E E E E E E E E E E E E 
review
Study 
Treatment 
Administration jXk X k X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419351] be discussed with the medical 
monitor in advance .
k. At Week 100, oral Maintenance subjects 
eligible for extension dosing will take final 
dose of CAB 30 mg+ABC/3TC in the clinic 
within 2 hours of the optimized Q8W IM 
regimen.  See Section 5.1.6 for IM dosing 
administration as loading doses a re 
required. (W100=1stloading dose; 
W104=2ndloading dose)
l. Or Long -Term Follow Up
m. Follow Up Visit -Conduct ~[ADDRESS_419352] Detail 
ConfirmationX X X X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7046].6. Time and Events Table –Extension Period for IM Regimen (CA B LA + RPV LA -Q4W )
Procedures for 
Extension - Q4W W 
100 W 
101 
mW 
104 W 
108W 
112W
116W 
120W 
121 
mW
124W 
128 W 
132 
aW 
136 
aW 
140 
aW 
144
aWD 
k,lNotes
Symptom Directed 
Physical Exam, ISR 
and Medical 
Assessment bX X X X X X X X X X X X X X XSee footnote “ a” for continuation of visit schedule 
after Week 144.  Continue until either locally 
approved and commercially available, the subject 
no longer derives clinical benefit or meets a 
protocol -defined reason for discontinuation or until 
development is terminated. 
a. Continue this pattern for visits for the remainder of 
the study.  For example, Week [ADDRESS_419353] in 
a semi -supi[INVESTIGATOR_2547].
d. Can be done at any time during the visit.
e. A (-) urine pregnancy test is required prior to any 
injection and as required by [CONTACT_339269] 
a treatment interruption. A (+) urine test should be 
confirmed with a stat serum test.  If (+), subject will 
need to be WD.
f. Plasma for storage samples are collected for 
possible future analyses, back -up in cases of 
loss/damage in transit and geno/ pheno analyses Vital Signs (BP, HR)c X X mXmX X X X
Weight & BM I X X X X X X
HIV Associated 
Conditions, AE and 
SAE Assessments, 
Con MedsX X X X X X X X X X X X X X X
12-Lead ECG d X X mXmX X X X
Clinical Chemistry and 
HematologyX X X X X X mX mX X mX X X
Pregnancy Testing
(U)rineeU U U U U U U U U U U U U U U
HIV-1 RNA and 
sample for storage fX X X X X mX m XmX X X
CD4+ X X X X X mX m XmX X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419354] overnight; however, a minimum of a [ADDRESS_419355] is acceptable.
h. Take PK samples pre -dose except Week 101and 
Week 121 which can be taken at any time during 
the visit.  Week 100PK sample should be taken 
after review of PK diary and pre- dose of CAB 
30mg+ABC/3TC.  A second Week [ADDRESS_419356] 
experiences a reaction ((E)pi[INVESTIGATOR_49564]).  Subjects w ill 
be dispensed a new diary at each visit. Diary data 
will be entered into the eCRF.
j. Q4W Injections are 1 x CAB LA 400 mg IM + 1 x 
RPV LA 600 mg IM.  If possible, injections should 
be spaced approximately 2 cm from one another 
and from the site of any pr evious injection and or 
any injection site reaction.  Bring RPV LA to 
approximately room temperature prior to injecting.   
Time and location of injection (right or left) as well 
as needle length used will be collected in the 
eCRF.  IM dosing is expected t o occur during 
the week in which the subject’s projected visit 
falls (as according to the Day 1 visit).  An 
additional
(+ or -) 7 day window from date of projected 
visit is allowable for IM dosing but not 
preferred.  All decisions regarding dose 
interrupt ion/ resumption must be discussed 
with the medical monitor in advance .
k. Or Long -Term Follow Up
l. Follow Up Visit -Conduct ~[ADDRESS_419357] Fasting Glucose, 
Cholesterol (Total, 
HDL and LDL) and 
Triglycerides gX X mXm X X mXm XmX X X
PT/PTT/INR X
PK Diary 
(D)ispensation and 
(R)eviewRm
PK Sample 
(S)torage  hS S S S S S mSmS S mS S X
ISR Diary 
DispensationiE E E E E E E E E E E E E 
review
Study Treat ment 
Administration jXn X X X X X X X X X X X
Subject Visit Reminder 
ContactX X X X X X X X X X X X X X
Subject Contact [CONTACT_339270] X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419358] on- study visit.  May be 
conducted by [CONTACT_756].
m. Procedures and visits f or subjects who switch from 
oral to the optimized Q4W IM dosing regimen.
n. At Week 100, oral Maintenance subjects eligible 
for extension dosing will take final dose of CAB 
30mg+ABC/3TC in the clinic within 2 hours of the 
optimized Q4W IM regimen.  See Section 5.1.6 for 
IM dosing administration as loading doses are 
required. 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7047].7. Time and Events Table –Long -Term Follow Up Period
Procedures for Long -Term Follow Up Month [ADDRESS_419359] one dose of CAB LA and / or RPV LA.
a) The start of the [ADDRESS_419360] CAB LA and/or RPV LA dose.
b) Women of childbearing potential only.  S = Serum
c) Fast overnight; however, a minimum of a [ADDRESS_419361] is 
acceptable.
d) Women of childbearing potential should continue to 
receive counselling on the need to use adequate 
contraception for the entirety of the Long -Term Follow -Up 
Period. 
e) Investigators must discuss choice of HAART 
regimen and timing of ini tiation with the medical 
monitor before initiating.  This regimen may be 
supplied regionally by [CONTACT_339271].HIV-1 RNA X X X X X X
CD4+ X X X X X X
Plasma for Storage X X X X X X
PK Sample for Storage S S S S S S
Clinical Chemistry and Hematology X X X X X X
Pregnancy Testing b S S S S S S
Urinalysis X X X
Fasting:  Glucose, Cholesterol (Total, 
HDL and LDL) and TriglyceridescX X
PT/PTT/INR X X
Contraception Counselling d X X X X X X
HAART Dispens ation e X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7048].8. Critical Screening and Baseline A ssessments
Written informed consent must be obtained from each potentiall y eligible subject by 
[CONTACT_339272].  The consent form must have been approved by [CONTACT_1636]/Institutional Ethics Committee (I RB/IEC).  After signing an informed consent, 
subjects will complete Screening assessments to determine subject eligibility.  Each 
subject being scre ened for study  enrollment evaluation will be assigned a subject number.  
This number will be given sequentially  in chronological order of subject presentation 
according to a numeric roster provided b y [COMPANY_004].
Subjects must be counseled on the practice of safe r sexual practices including the use of 
effective barrier methods (e.g. male condom/spermicide) and the length of time in which 
they are required for participation in this study  as part of the eligibility  process.
6.8.1. Screening
All clinical and laboratory asse ssments of eligibility  must be performed and reviewed 
within [ADDRESS_419362] not be enrolled into this study , as 
HCV therap y currentl y includes the prohibited medication interferon.  The length of this 
study  should be considered when assessing the potential need for therap y.
Physical exams should be conducted as part o f normal routine clinical care but will not be 
collected s ystematicall y in the eCRF.
The electronic Columbia Suicidality Severit y Rating Scale (eC-SSRS ) (see Section 
6.10.10 ) assessed at the Screening visit will assess the subject’s lifetime risk (any  suicidal 
ideation, behavior, etc occurring over the subject’s lifetime).  A positive alert (indicating 
some risk) is not necessarily  exclusionary , rather a means to assess overall risk. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7049].8.2. Baseline
Subjects will have “ Baseline” assessments completed at the beginning of the Induction 
Period.
Any changes to the eligibility  parameters must be assessed and any  results required must 
be available and reviewed prior to enrollment (e.g. urine pregnancy  test for women of 
child b earing potential).
HIV-[ADDRESS_419363] be available prior to the Baseline visit.
In addition to a full routine medical history , more detailed information will be collected 
for some disease processes such as:
cardiovascular risk factors (assessments will include smoking status and history ; 
family  history  of cardiac events; 
history  of illicit drug use [e.g. cocaine, heroin, and methamphetamine use]);
intravenous drug use history ;
gastrointestinal disease (e.g. GI bleeding, PUD, etc);
metabolic (e.g. Ty pe I or II diabetes mellitus);
psychiatric (e.g. depression);
renal (e.g. nephrolithiasis, nephropath y, renal failure); and,
neurologic disorders.
6.9. Efficacy
6.9.1. Plasma HIV -1 RNA
Plasma for qu antitative HIV -1 RNA will be collected according to the Time and Events 
schedule (Section 6).  Methods to be used may include but are not limited to the Abbott 
RealTime HIV -1 Assay  lower limit of detection (LLOD ) 40 c/mL. In some cases (e.g., 
where the HIV -1 RNA is below the lower limit of detection for a given assay ) additional 
exploratory  methods will be used to further characterize HIV -1 RNA levels.
6.9.2. Lymphocyte Subsets , CD4+ and CD8+
Lym phocy te subsets will be collected for assessment by  [CONTACT_4133]  (total 
lymphocy te counts, percentage and absolute CD4+ and CD8+ l ymphocy te counts, ratios) 
according to Time and Events schedule (Section 6)and Labroatory  Assessments
(Section 6.10.2 ). 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7050].9.3. HIV A ssociated Conditions
HIV-associated conditions will be recorded as per Time and Events schedule (Section 6).  
HIV-associated conditions will be assessed according to the 1993 CDC Revised 
Classification Sy stem for HIV Infection in Adults (see Section 11.1).  Indicators of 
clinical disease progression are defined as:
CDC Category  A at enrollment Category  B event;
CDC Category  A at enrollment Category  C event;
CDC Category  B at enrollment Category  C event;
CDC Category  C at enrollment New Category  C Event;
CDC Category  A, B or C at enrollment  Death.
6.10. Safet y
6.10.1. Clinical evaluations
The following clinical evaluations will be performed according to the Time and Events 
schedule (see Section 6):
Monitoring and recording of all AEs and SAEs. Additional information on the Time 
Period and Frequency  of Detecting AEs and SAEs is pr ovided in Section 6.10.12 .
Physical exams should be conducted as part of normal routine clinical care but will 
not be collected s ystematically  in the eCRF. Abnormalities noted during any  exam 
must be recorded i n the eCRF (e.g., in the current medical conditions or AE logs).
Height and weight will be measured and recorded.  Height collected on the first day 
of the Induction Period only .
Vital Signs will include systolic and diastolic blood pressure and heart rate collected 
after resting for about 5 minutes.
Past medical history , family  history , social history , medication history .  Targeted 
history  on cardiovascular risk (smoking history , family  and personal history).
Exercise habits will be assessed for subjects o n the CAB LA+ RPV LA regimen.
HIV-associated conditions will be recorded.
Electrocardiogram: A [ADDRESS_419364]. Regardless, each ECG should be reviewed b y a qualified ECG 
reader. The qualified ECG reader will make the non -calculated ECG interpretations. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
121Regular m onitoring of hematology , blood chem istry, urinal ysis and fasting glucose 
and lipi[INVESTIGATOR_805] (parameters to be tested listed below).  
Pregnancy  testing.  A negative urine pregnancy  test is required prior to initiation of 
IP, an y dose of CAB LA or RPV LA or as required by  [CONTACT_339273] 
a treatment interruption(s).
Evaluation and documentation of all concomitant medications and blood products. 
Injection Site Reactions (ISRs) will be assessed for the following clinically  as well as 
patient -reported by [CONTACT_14662] a subject diary :
Daily  from Day 1 – 7, from Week 24 –Week 25 and again dail y from Week 40
to Week 41:  Pain, tenderness, pruritis, warmth, bruising, discoloration, 
infections, rash, ery thema, swelling, induration, and nodules (granulomas or 
cysts).  
Epi[INVESTIGATOR_49564] (as reported b y subject) for the Maintenance and Extension Period for 
the above parameters
The investigator should utilize subject diary  reports to assist with a clinical 
assessment (using Division of Acquired Immunodeficiency S yndrome [DAIDS] 
grading scale).  A clinical ass essment should be performed both before and after 
an injection to identify  resolving and new I SRs.  All injection site reactions are 
considered adverse events.  The clinical assessment and interpretation of any  
ISR, including those reported by  [CONTACT_339274] , will be documented in the 
ISR AE eCRF.  Dail y diary data, or subject assessment, will be documented 
verbatim in the diary  eCRF.
Columbia Suicide Severity  Rating Scale (eC- SSRS) will be assessed as per the Time 
and Events Schedule (see Section 6and Section 6.10.10 ).
Any appropriately  qualified site personnel (e.g., Investigator, sub- Investigator, or study  
coordinator/nurse) can perform assessments.
6.10.2. Laboratory  Assessments
All protocol required laboratory  assessments, as defined in the Time and Events Schedule 
(see Section 6), must be performed b y the central laboratory .  Laboratory  assessments 
must be conducted in accordance with t he Central Laboratory  Manual and Protocol Time 
and Events Schedule.  Laboratory  requisition forms must be completed and samples must 
be clearly  labeled with the subject number, protocol number, site/centre number, and visit 
date.  Details for the preparation and shipment of samples will be provided by  [CONTACT_11378] .  Reference ranges for all safet y parameters will be provided to the site by [CONTACT_19979] .
Refer to the lab manual for appropriate processing and handling of samples to avoid 
duplicate and/or additional blood draws.
Labs will be automatically  graded by  [CONTACT_339275] (See Section 11.2 “Division of AIDS Table for Grading the Severit y of Adult and
Pediatric Adverse Events”). 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419365] is preferred; however, a minimum of 
a [ADDRESS_419366] is acceptable.
Following are the lab parameters to be assessed as per the Time and Events Schedule (see 
Section 6):
Hematology Chemistry
Platelet Count Automated WBC 
Differential: BUN Total CO 2 Total bilirubina 
RBC Count Neutrophils Creatinineb Lipase Albumin
WBC Count 
(absolute) Lymphocytes Glucosed AST Creatine 
phosph okinase 
Hemoglobin Monocytes Sodium ALT Total 
Cholesterold
Hematocrit Eosinophils Potassium Alkaline 
phosphatase HDL and LDL 
Cholesterold
MCV Basophils Chloride Triglyceridesd
Other Laboratory Assessments
Plasma HIV -[ADDRESS_419367] orageHepatitis B 
(HBsAg) and 
Hepatitis C (anti -
HCV Ab)e at 
Screening onlyUrine Pregnancy test 
for women of child 
bearing potentialProthrombin Time 
(PT)/International Normalized 
Ratio (INR)/ Partial 
Thromboplastin Time (PTT)
CD4+ and CD8+ 
cell counts 
[CD4/CD8 ratio]cHLA-B*5701 at 
Screening onlyUrinalysis and urine 
microalbumin/creatinine 
ratioPharmacogentics Sample (PGx)
a) Direct bilirubin will be reflexively performed for all total bilirubin values > 1.5X ULN.
b) Creatinine clearance will be estimated by [CONTACT_339276], Baseline, Week ( -12), 
Week ( -4), Day 1 and Weeks 4, 16, 32, 48 and 96.
c) CD8+ cells will only be reported at Baseline, Week ( -4), Day 1 and Weeks 32, 48 and 96.
d) Fasting overnight preferred; [ADDRESS_419368] is acceptable.
e) HCV RNA may be requested through the central lab within [ADDRESS_419369].
6.10.3. Liver Chemistry Stoppi[INVESTIGATOR_53051] u p Criteria
[IP_ADDRESS]. Liver Chemistry  Stoppi[INVESTIGATOR_339174] y
and to evaluate liver event etiology  during administration of I P and the follow -upperiod. 
IP will be stopped if an y of the following liver chemistry  criteria are met:
ALT 3xULN andbilirubin 2xUL N (>35% direct bilirubin, bi lirubin 
fractionation required ).
NOTE: serum bilirubin fractionation should be performed if testing is available. If testing 
is unavailable, record presence of detectable urinary  bilirubin on dipstick, indicating 
direct bilirubin elevations and suggesting liver injury .  If testing is unavailable and a 
subject meets the criterion of total bilirubin 2xULN, then the event meets liver stoppi[INVESTIGATOR_31732]. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
123ALT 8xULN.
ALT ≥3xULN (if B aseline ALT is < ULN) with sy mptoms or worsening of 
acute hepatitis or hy persensitivity  such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, or eosinophilia, OR;
ALT ≥3x Baseline ALT with sy mptoms or wors ening of acute hepatitis or 
hypersensitivity  such as fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash, or eosinophilia;
ALT ≥5xULN and <8xULN that persists ≥2 weeks (with bilirubin <2 UL N & no 
signs or s ymptoms of acute hepat itis or hy persensitivity ).
ALT ≥5xULN but <8xULN and cannot be monitored weekly  for >2 weeks.
NOTE: if serum bilirubin fractionation is not immediatel y available, withdraw study drug 
for that subject if ALT 3xULN andbilirubin 2xULN. Serum bilirubin fr actionation 
should be performed if testing is available. If testing is unavailable, sites should evaluate 
the presence of detectable urinary bilirubin on dipstick , which indicates direct 
bilirubin elevations and suggests liver injury .
[IP_ADDRESS]. Liver Chemistry  Stopp ing Criteria, Subject Management
Subjects who d evelop ALT ≥5xULN must be followed weekly  until resolution or
stabilization (ALT <5xULN on 2 consecutive evaluations).
When any of the liver chemistry stoppi[INVESTIGATOR_339175], do the following:
Immediately  hold I P.  
Report the event to the medical monitor within 24 hours of learning its 
occurrence (Section 6.10.12 , Section 6.10.14 ).
Complete the liver event eCRF and SAE eCRF, where applicable, (see 
Section 6.10.12 ).
Complete the liver imaging and/or liver biopsy  eCRFs if these tests are 
performed.
Perform liver event follow up assessments (described below), and monitor the 
subject until liver chemistries resolve, stabilize, or return to Baseline values as
described below.
Make every  reasonable attempt to have subjects return to clinic within 24 hours 
forrepeat liver chemistries, liver event follow up assessments (see below), and 
close monitoring.
A specialist or hepatology c onsultation is recommended.
Monitor subjects twice weekl y until liver chemistries (ALT, AST, alkaline
phosphatase, bilirubin) resolve, stabilize or return to within Baseline values.
Make every  attempt to carry  out the liver event follow up assessments described below: 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
124Viral hepatitis serology  including:
oHepatitis A IgM antibody;
oHBsAg and Hepatitis B Core Antibody  (IgM);
oHepatitis C RNA;
oHepatitis E IgM antibody;
Cytomegalovirus IgM antibody ;
Epstein -Barr viral capsid antigen IgM antibod y(or if unavailable , obtain 
heterophile antibody  or monospot testing);
Syphilis screening;
Drugs of abuse screen including alcohol;
Serum acetaminophen test (APAP adduct test). The site must contact [CONTACT_339277]. Please refer to the central laboratory  manual.
Blood sample for pharmacokinetic (PK) anal ysis, obtained within [ADDRESS_419370] the date/time of the PK blood sample draw and the date/time 
of the last dose of investigational product prior to blood sample draw on the 
eCRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. I f the date/time of the last dose cannot be approximated OR a 
PK sample cannot be collected in the time period indicated above, do not obtain 
a PK sample. Instructions for sampl e handling and shippi[INVESTIGATOR_23915].
Serum creatine phosphokinase (CPK) and lactate dehy drogenase (LDH);
Fractionate bilirubin, if total bilirubin is greater than 1.5xUL N;
Obtain complete blood count with differential to assess eosinophilia;
Anti- nuclea r antibody , anti -smooth muscle antibody , and Ty pe 1 anti -liver 
kidney microsomal antibodies;
Liver imaging (ultrasound, magnetic resonance, or computerized tomography ) to
evaluate liver disease;
Record the appearance or worsening of clinical s ymptoms of he patitis, or
hypersensitivity , fatigue, decreased appetite, nausea, vomiting, abdominal pain,
jaundice, fever, or rash as relevant on the AE report form;
Record use of concomitant medications, acetaminophen, herbal remedies, other 
over the counter medicatio ns, or putative hepatotoxins, on the concomitant 
medications report form. Record alcohol use on the liver event alcohol intake 
case report form.
[IP_ADDRESS]. Liver Chemistry  Stoppi[INVESTIGATOR_2121] -Rechallenge
Subjects who meet liver toxicity  stoppi[INVESTIGATOR_339176] b y the ViiV Safet y and 
Labeling Committee ( VSLC ).  The guideline for Rechallenge/Restart approved by  [CONTACT_941]  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
125VSL C, which is maintained as a separate document (See Section 11.4, Appendix 4 ), must 
be followed.
Drug Restart/Rechallenge Following Liver Events that are Possibly Related to IP
Approval b y the VSLC for drug restart or additional I M administration can be considered 
where:
The subject is receiving compelling benefit, benefit of drug restart exceeds risk, 
andno effective alternative therap y is available. Ethics Committee or 
Institutional Review Board approval of drug restart/rechallenge must be 
obtained, as required.
If the r estart/rechallenge is approved by  [CONTACT_339278], the subject must 
be provided with a clear description of the possible benefits and risks of drug
administration, including the possibility  of recurrent, more severe liver injury  or
death.
The subject m ust also provide signed informed consent specificall y for the IP
restart/rechallenge. Documentation of informed consent must be recorded in the
study  chart.
Study  drug must be administered at the dose specified by  [CONTACT_339279] C.
Subjects approved b y the VSL C for rechallenge of I P must return to the clinic
twice a week for liver chemistry  tests for a minimum of one month and 
thereafter for as long as clinically  indicated and then laboratory  monitoring may  
resume as per protocol.
Drug Restart Following Transient Resolving Liver Events Not Related to IP
Approval b y the VSLC for drug restart or additional I M administration can be considered 
where:
Liver chemistries have a clear underl ying cause (e.g., biliary  obstruction,
hypotension and liver chemistries have impro ved to normal or are within 
1.5 x baseline and AL T<3xULN). Ethics Committee or Institutional Review 
Board approval of drug restart/rechallenge must be obtained, as required.
If restart of drug or continuation of LA dosing is approved by  [CONTACT_339280], the subject must be provided with a clear description of the possible 
benefits and risks of drug administration, including the possibility  of recurrent, 
more severe liver injury  or death.
The subject must also provide signed informed consent specifical ly for the 
restart.  Documentation of informed consent must be recorded in the study  chart.
Study  drug must be administered at the dose specified by  [CONTACT_339279] C.
Subjects approved b y the VSL Cfor restarting or re-dosing IP must return to the clinic 
once a wee k for liver chemistry  tests for a minimum of one month and thereafter for as 
long as clinically  indicated and then laboratory  monitoring may  resume as per protocol.  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419371] be stopped.
See Section 11.4, Appendix 4 for further details.
6.10.4. Adverse Events
The investigator or site staff will be responsible for detecting, documenting and reporting 
events that meet the definition of an AE or SAE.
[IP_ADDRESS]. Definition of an AE
Any untoward medical occurrence in a patient or clinical investigation subject, 
temporally  associated with the use of a medicinal product, whether or not considered 
related to the medicinal product.
Note: An AE can ther efore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.  For marketed medicinal products, this 
also includes failure to pro duce expected benefits (i.e., lack of efficacy ), abuse or misuse.
Events meeting the definition of an AE include:
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE) unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequelae.
All injection site reactions.
“Lack of efficacy ” or “failure of expected pharmacological action” per se will not be 
reported as an AE or SAE. However, the signs and sy mptoms and/or clinical sequelae 
resulting from lack of efficacy will be repor ted if they  fulfill the definition of an AE or 
SAE.  
Events that do not meet the definition of an AE include:
Medical or surgical procedure (e.g., endoscop y, appendectom y); the condition that 
leads to the procedure is an AE
Situations where an untoward me dical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]) 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
127Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen
The disease/disorder being studied, or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition
[IP_ADDRESS]. Definition of an SA E
A serious adverse event is any  untoward medical occurrence that, at any  dose:
a.Result s in death
b.Is life -threatening
NOTE:  The term 'life -threatening' in the definition of 'serious' refers to an event in 
which the subject was at risk of death at the time of the event.  It does not refer to an 
event, which h ypothetically  might have caused d eath, if it were more severe.
c.Requires hospi[INVESTIGATOR_23916]:  In general, hospi[INVESTIGATOR_5184] 
(usually  involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_23919], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred, or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from Baseline is not cons idered an AE.
d.Results in disability /incapacity , or
NOTE:  The term disability  means a substantial disruption of a person’s ability  to 
conduct normal life functions.  This definition is not intended to include experiences 
of relativel y minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (e.g. sprained ankle) which may  
interfere or prevent everyday  life functions but do not constitute a substantial 
disruption.
e.Is a congenital anomal y/birth de fect
f.Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_339177].  These should also be considered 
serious.  Examples of such events are invasive or malignant cancers, intensive 
treatment in a n emergency  room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug dependency  or drug abuse. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
128g.All events of possible drug -induced liver injury  with hy perbilirubinaemia defined as 
ALT 3xULN andbilirubin 2xUL N (>35% direct) (or ALT 3xUL N and 
INR>1.5, if INR measured) termed ‘Hy ’s Law’ events ( INR measurement is not 
required and the threshold value stated will not apply  to patients receiving 
anticoagulants).
NOTE: bilirubin fractionation is performed if testing is available. If testing is 
unavailable, record the presence of detectable urinary  bilirubin on dipstick which 
may indicate direct bilirubin elevations and may  suggest liver injury . If testing is 
unavailable and a sub ject meets the criterion of total bilirubin  2xUL N, then the 
event is still reported as an SAE. If INR is obtained, include values on the SAE form. 
INR elevations >1.[ADDRESS_419372] results (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (e.g., ECGs, radiological scans, vital signs measurements), 
including those that worsen from Baseline, and felt to be cl inically  significant in the 
medical and scientific judgement of the investigator are to be recorded as AEs or SAEs. 
However, an y clinicall y significant safet y assessments that are associated with the 
underly ing disease, unless judged by  [CONTACT_23996]’s condition, are notto be reported as AEs or SAEs.
6.10.6. Specific Toxicities / A dverse Event Management
Adverse events that occur during the trial should be evaluated b y the Investigator and 
graded according to the Division of AIDS (DAIDS) toxicity  scales (See Section 11.2
“Division of AIDS Table for Grading the Severit y of Adult and Pediatric Adverse 
Events”). Additional information regarding detecting, documenting and re porting AEs 
and SAEs are available in Section 6.10.12 , “Adverse Events”.
[IP_ADDRESS]. Treatment Interruption Due to an A dverse Event
The AE profile for CAB in combination with ABC/3TC or in combination with RPV has 
not y et been full y defined.  I P or background NRTI  may  be interrupted at the discretion 
of the Investigator and according to the severit y of the AE. If one or more antiretroviral 
medications is held due to toxicity  or adverse events, all antiretroviral medications must 
be held to reduce the risk of development of resistance taking into account both the 
length of the planned interruption and the pharmacokinetic half- life of each antiretroviral 
of the regimen, in a way  to minimize the risk of development of resistanc e.
No toxicity -related dose reductions of IP will be allowed. IP and background NRTI s 
should be restarted as soon as medicall y appropriate; in general, for oral dosing, this 
should be no longer than 14 day s after discontinuation (unless Grade [ADDRESS_419373]). Decisions regarding sequential reintroduction of I P or temporary  interruption of 
one or more but not all drugs within the ART regimen should be made with the  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419374] be c ontacted 
upon becoming aware of resumption in therap y, if therap y was resumed without prior 
approval (Section 5.7).  IM dosing is expected to occur during the week in which the 
subject’s projected visit falls (as according to t he Day 1 visit).  An additional (+ or - ) 
[ADDRESS_419375] be discussed with the 
medical monitor prior to reinitiating IM IP (see Section 5.7.2 ).
Guidance is provided below on general subject management and IP interruptions based 
on the severity of the AE. Information regarding permitted substitutions of background 
therap y is provided in Section 5.6.  All changes in the I P or background NRTI  regimen 
must be accurately recorded in the subject’s eCRF.
In the event of a discontinuation of an ABC -containing product for an y reason, re -
initiation of this drug must be unde rtaken with caution. Health care providers should 
obtain a complete history of the events surrounding the discontinuation of the ABC -
containing product. If there are s ymptoms consistent with a hy persensitivity  reaction, 
ABC should not be reinitiated. Ifthere is no evidence of a prior reaction, the subject may  
restart treatment with the ABC -containing product. The subject and health care provider 
should be aware of the possibility  of a rapid -onset hy persensitivity  reaction upon 
reinitiation of ABC, whic h may  be life -threatening, and the subject should be able to, if 
necessary , receive prompt medical evaluation (see also Section [IP_ADDRESS] ).
[IP_ADDRESS]. Grade 1 or Grade 2 Toxicity /Adverse Event
Subjects who develop a Grade 1 or Grade 2 AE or toxicity  may  continue IP at the 
discretion of the Investigator. (NOTE: See Section 6.10.6 “Specific Toxicities/Adverse 
Event Management” for exceptions to this guideline).  Subjects who choose to withdraw 
from study  due to a Grade [ADDRESS_419376] study  withdrawal and follow -up 
evaluations completed.
Subjects who develop a Grade 1 or 2 AE or toxicity , which the Investigator considers 
related or possibl y related the background NRTI medicati ons, may  be addressed by  
[CONTACT_339281] , as 
described in Section 5.6“Protocol -Permitted Substitutions”.
[IP_ADDRESS]. Grade 3 Toxicity /Adverse Event
Subjects who develop a Grade 3 AE or toxicity  should be managed as follows:
If the Investigator has compelling evidence that the Grade 3 AE or toxicity  has 
not been caused b y IP, dosing may  continue after discussion with [COMPANY_004] medical 
monitor. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
130Subjects who develop a Gra de [ADDRESS_419377] the I P withheld and be 
rechecked each week until the AE returns to Grade 2. Once the AE is Grade 2, 
IP may  be re -started. 
Should the same Grade [ADDRESS_419378] withdrawn from study . 
Subjects experiencing Grade [ADDRESS_419379] one dose of 
CAB LA and /or RPV LA who discontinue I P / Withdraw will initiate treatment 
with HAART and enter the L ong-Term Follow -Up Period for 52 weeks of 
follow up. 
Subjects who develop a Grade 3 AE or toxicity , which the Investigator considers 
related or possibl y related to one of the background ART medications may be 
addressed b y substitution of the medication for another approved compound in 
the same class (e.g., a switch of ABC/3TC FDC for TDF/FTC FDC) one time 
during the stud y, as indicated in Section 5.6“Protocol -Permitted Substitutions.”  
Subjects should be rechecked each week until the AE returns to Grade 2.
Subjects with Grade 3 asymptomatic laboratory  abnormalities should be 
investigated for all potential non -drug related causes, and, following discussion 
with [COMPANY_004] medical monitor, may  continue if the Investigator has compelling 
evidence that the toxicity  is not related to I
P, with the exception of liver 
chemistry  stoppi[INVESTIGATOR_3418] (See Section 6.10.3 ).  Isolated Grade 3 and Grade 4 
lipid abnormalities do not require withdrawal of IP.
[IP_ADDRESS]. Grade 4 Toxicity /Adverse Event
Subjects who develop a Grade [ADDRESS_419380] I P permanently  
discontinued.  However, if the Investigator has compelling evidence that the AE 
is not causally  related to the IP, d osing may  continue after discussion with and 
assent from [COMPANY_004].  Subjects should be rechecked each week until the AE returns 
to Grade 2.
Grade 4 AEs that the Investigator considers related or possibly  related to one of 
the background ART medications may  be a ddressed by  [CONTACT_339282] (e.g., a switch of 
ABC/3TC FDC for TDF/FTC FDC) one time during the stud y, as indicated in 
Section 5.6“Protocol -Permitted Substitutions”. Subjects should be rechecked 
each week until the AE returns to Grade 2.
Subjects experiencing Grade [ADDRESS_419381] one dose of CAB LA and /or RPV LA who discontinue  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
131IP / Withdraw will initiate treatment with HAART and enter the Long -Term 
Follow -Up Period for 52 weeks of follow up. 
Subjects with Grade 4 asymptomatic laboratory  abnormalities should be 
investigated for all potential non -drug related causes, and, following discussion 
with [COMPANY_004], may  continue therapy if the Investigator has compelling evidence 
that the toxicity  is not relate d to I P, with the exception of liver chemistry  
stoppi[INVESTIGATOR_3418] (See Section 6.10.3 ). A follow -up visit should be performed [ADDRESS_419382] dose of study  medication if AEs or laboratory  abnormalities 
areongoing.
[IP_ADDRESS]. Diarrhea
Subjects with Grade 1 or 2 diarrhea may  continue study  treatment without interruption. 
Subjects with diarrhea of any  toxicity  grade may  be treated s ymptomatically  with anti -
motility  agents; however, the recommended dail y dose of the chos en anti -motility  agent 
must not be exceeded. If symptoms persist or get worse on the recommended daily  dose 
of the chosen anti -motility  agent, then the anti -motility  agent must be discontinued and 
consultation made with [COMPANY_004].
For subjects with Grade 3 dia rrhea that is unresponsive to the recommended dose of the 
anti-motility  agents and for which an alternative etiology  (e.g., infectious diarrhea) is not 
established, the treatment with the anti- motility  agent and IP must be interrupted until 
resolution of d iarrhea to Grade 2 or Baseline, after which IP and background ART may  
be resumed after discussion and agreement with [COMPANY_004]. If Grade  [ADDRESS_419383] one dose of CAB LA 
and /or 
RPV LA who discontinue I P / Withdraw will initiate treatment with HAART and 
enter the Long -Term Follow -Up Period for [ADDRESS_419384] to dose and frequency  of administration.  L operamide dosing 
should not exceed local prescribing information.
[IP_ADDRESS]. Hypertrigly ceridemia/ Hy percholesterolemia
Samples for lipid measuremen tsmust be obtained in a fasted state according to the Time 
and Events table (Section 6). Subjects who experience as ymptomatic trigly ceride or 
cholesterol elevations may continue to receive IP. Clinical manageme nt of subjects with 
hypertrigly ceridemia/hy percholesterolemia should not be based upon non- fasting 
samples (obtained in the fed state). A confirmatory  fasting trigl yceride and/or cholesterol 
level should be obtained prior to the institution of medical ther apy for h yperlipi[INVESTIGATOR_035].  
Isolated Grade 3 and Grade 4 lipid abnormalities do not require withdrawal of I P.
Please see the Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular 
Disease Focus Group [ Dube , 2003] for full discussion of management of hyperlipi[INVESTIGATOR_339178] V therapy . 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7051].10.6.7. Creatine Phosphokinase (CPK) Elevation
A Grade 3 or higher elevation in CPK should result in a repeat assessment within 2 -4 
weeks to ensure the result is transient or due to exercise and will not require a change in 
study  treatment. A history  regarding use of drugs known to cause increase of CPK (such 
as statins) phy sical activity  or exercise preceding the CPK evaluation should be obtained. 
Grade [ADDRESS_419385] has 
abstained from exercise for >[ADDRESS_419386] one dose of CAB LA 
and /or RPV LA who discontinue I P / Withdraw will initiate treatment with HAART 
enter the Long -Term Follow -Up Period for 52 weeks of follow up.
[IP_ADDRESS]. Lipase Elevations and Pancreatitis
Subjects with asy mptomatic Grade 1 or 2 elevations in lipase may  be followed closel y for 
the development of s ymptoms.
Subjects with as ymptomatic Grade ≥[ADDRESS_419387] IP interrupted until serum lipase returns to Grade 2.  
The lipase assay  should be repeated within 2 weeks of any  Grade ≥3 result. Subjects with 
persistence of Grade ≥3 lipase in the absence of other diagnoses or reoccurrence of lipase 
elevation (at Grade ≥2) following reintroduction of I P should permanentl y discontinue I P.
Subjects with a confirmed diagnosis of clinical pancreatitis that is considere d possibly  or 
probably  related to I P should have IP held. After complete resolution of the epi[INVESTIGATOR_1865], 
subjects may be re -challenged with I P after discussion with the medical monitor, only  if 
the Investigator has compelling evidence that the event was not cau sed b y IP. Upon re -
challenge, lipase determinations should be performed every  [ADDRESS_419388] 6 weeks 
after re -initiation of treatment. With any  elevation of lipase of Grade ≥[ADDRESS_419389] one dose of CAB LA and /or RPV LA who discontinue I P / 
Withdraw will initiate treatment with HAART and enter the Long -Term Follow -Up 
Period for 52 weeks of follow up.
[IP_ADDRESS]. Decline in Renal Function
The following criteria are defined based on Cockcroft -Gault estimates of GFR.  The 
Cockcroft -Gault criteria are based on recommendations for changes in dosing 
administration for both ABC/3TC FDC and TDF/FTC FDC.  Current local prescribing 
information should be consulted for addi tional details on dosing in renall y impaired 
subjects. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
133Subjects who experience progression to an estimated GFR (calculated by  [CONTACT_3158] -
Gault equation) of <50 mL/min must return for a confirmatory  assessment within 4 
weeks.  A urinaly sis should also be don e at this confirmatory  visit. If an estimated GFR 
of <50 mL /min is confirmed, any  subjects receiving TDF/FTC FDC must be switched to 
an alternative nucleoside combination at the discretion of the I nvestigator and medical 
monitor.  Subjects on ABC/3TC FDC m ay switch to the individual components dose 
adjusted for renal d ysfunction according to approved prescribing information, or switch 
to alternative nucleosides at the discretion of the Investigator and [COMPANY_004] Medical Monitor.
Proximal Renal Tubule Dy sfunction (PRTD) is defined as:
Confirmed rise in serum creatinine of ≥0.5 mg/dL from Baseline AND serum 
phosphate <2.0 mg/dL
Either of the above accompanied by  [CONTACT_339283]:
Glycosuria ( ≥250 mg/dL) in a non -diabetic
Low serum potassium (<3 mEq/L )
Low serum bicarbonate (<19 mEq/L )
Subjects meeting criteria for PRTD must return for a confirmatory  assessment within 4 
weeks.  A urinaly sis should be done at the time of the confirmatory  assessment.  If PRTD 
is confirmed subjects receiving TDF/FTC FDC must be switched to an alternat ive 
nucleoside combination.  Subjects on ABC/3TC FDC may  switch to the individual 
components dose adjusted for renal dy sfunction according to approved prescribing 
information, or switch to alternative nucleosides at the discretion of the Investigator and 
[COMPANY_004] Medical Monitor.
[IP_ADDRESS]. Proteinuria
Subjects with an abnormal urine microalbumin/creatinine ratio (>0.3 mg/mg, >300 mg/g  
or >34 mg/mmol) that represents a change from Baseline and no associated increase in 
creatinine, should have a repeat spot urine microalbum in/creatinine ratio performed 
within 2 to 4 weeks. If confirmed, then consideration should be made for additional 
evaluation after consultation with the Study  medical monitor. Additional evaluation may  
include a 24 hr urine protein and creatinine measureme nt and nephrology  referral.
Subjects with an abnormal urine albumin/creatinine ratio (>0.3 mg/mg, 300 mg/g 
or>34 mg/mmol and representing a change from Baseline) and a serum creatinine 
increase >45 Mol/L  (or 0.5 mg/dL) should have confirmation of both res ults within 2 
weeks.  If confirmed, the study  Medical Monitor should be immediately  contact[INVESTIGATOR_530].  
Further management should be agreed between the investigator and medical monitor. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7052].10.6.11. QTc Prolongation
Subjects with an average QTc interval > 500 msec or a >[ADDRESS_419390] I P discontinued. 
These criteria are based on an average QTc value of triplicate ECGs. If an ECG 
demonstrates a prolonged QT interval, obtain 2 more ECGs over a brief period (~5-10 
minutes) and use the averaged QTc values of the [ADDRESS_419391] should be discontinued from the study . If an alternative cause of the QT 
prolongation is determined (e.g., subject receiving drug known to cause p rolonged QT or 
TdP), then I P may  be restarted after consultation with and agreement by  [CONTACT_339284]. 
[IP_ADDRESS]. Injection Site Reactions (ISRs)
Injection site reactions will be managed through investigator assessment and subject
diary  collection through out the study .  All Grade [ADDRESS_419392] an injection site reaction 
considered serious, Grade 3 or above, or if clinically  signi ficant and persistent bey ond 
30days and others if the Investigator or Medical Monitor feels it is medically  necessary .
Details regarding photo collection and an y other follow up will be given by [CONTACT_339285].
ISR discomfort can be managed s ymptomaticall y (e.g. cold/warm compress, 
acetaminophen, ibuprofen) if the reaction is interfering with the subject’s ability  to 
perform activities of daily living.  The required intervention should be documented on the 
appropriate eCRF page.
[IP_ADDRESS]. Allergic Reaction
Subjects m ay continue IP for Grade [ADDRESS_419393] amines, topi[INVESTIGATOR_11930], or antipruritic agents may be prescribed. 
Subjects with Grade ≥[ADDRESS_419394] one dose of CAB LA and /or RPV LA who discontinue I P / 
Withdraw will initiate treatment with HAART and enter the Long- Term Follow -Up 
Period for 52 weeks of follow up.
As EPZICOM is being used as background therapy , subjects should also be assessed for 
clinically  suspected ABC hypersensitivity , as described below.
[IP_ADDRESS]. Abacavir Hy persensitivity  Reaction (A BC HSR)
The most significant toxicity  associated with ABC is the well -characterized drug -related 
hypersensitivity  reaction (HSR). A detailed clinical description of this reaction (including 
the ty pe and severity  of events that can occur on re -challenge or reintroduc tion following 
ABC interruption for non -HSR reasons) and guidance regarding its management are 
included in the L ocal Country  Prescribing Information for EPZICOM.  Investigators must 
familiarize themselves with this information on ABC HSR in the L ocal Count ry 
Prescribing Information for each of these products prior to initiating subjects on ABC 
therap y.
Studies have shown that carriage of the HLA -B*5701 allele is associated with a 
significantl y increased risk of a HSR to ABC. In the prospective stud y CNA1060 30 
(PREDI CT-1), the use of pre -therapy  screening for the presence of HLA -B*5701 and 
subsequently  avoiding ABC in HLA -B*5701 positive patients, significantly reduced the 
incidence of clinicall y suspected ABC HSR from 7.8% (66 of 847) to 3.4% (27 of 803) 
(p<0.0001). In clinical studies EPZ108859 (ARIES) and CNA109586 (ASSERT), 0.8% 
(4/515) and 3.1% (6/192) of subjects who were HLA -B*[ADDRESS_419395] treated with ABC, the clinical diagnosis of suspected HSR (as 
detailed in the Local Country Prescribing Information) must remain the basis of 
clinical decision making. Regardless of HLA -B*5701 status, it is important to 
permanently discontinue ABC and not re- challenge with ABC (i.e., ZIAGEN, 
EPZICOM/KIVEXA or TRIZIVIR) if a HSR cannot be ruled out on clinical 
grounds, due to the potential for a severe or even fatal reaction.
[IP_ADDRESS].1. Essential Patient Information
With reference to Local Country  Prescribing Information and the ‘Subject In formation 
and Consent Form’, Investigators must ensure that subjects are fully informed regarding 
the following information on the hy persensitivity  reaction prior to commencing ABC 
therap y:
Subjects must be made aware of the possibility  of a hy persensitivi ty reaction to 
abacavir that may  result in a life -threatening reaction or death and that the risk of a 
hypersensitivity  reaction is increased in individuals who are HLA -B*5701 positive.
Subjects must also be informed that HLA -B*[ADDRESS_419396] their doctor IMMEDIATELY.
Subjects who are h ypersensitive to abacavir should be reminded that they  must never 
take an y abacavir containing medicinal products (e.g. ZIAGEN, EPZICOM, 
KIVEXA or TRIZIVI R) again, regardless of their HLA -B*5701 status.
In order to avoid restarting abacavir, subjects who have experienced a 
hypersen sitivity  reaction should be asked to return any  remaining EPZICOM / 
KIVEXA tablets to the Investigator or site staff.
Subjects, who have stopped abacavir for an y reason, and particularly due to possible 
adverse reactions or illness, must be advised to cont act their doctor before restarting 
EPZICOM / KIVEXA as more severe s ymptoms may  recur within hours and may  
include life -threatening hy potension and death.
Each subject should be reminded to read the Package Leaflet included in the 
EPZICOM / KIVEXA pack. They  should be reminded of the importance of 
removing the Alert Card included in the pack, and keepi[INVESTIGATOR_227319]. 
[IP_ADDRESS].2. Reporting of Hypersensitivity Reactions
If a clinically  suspected case of HSR to ABC meets one of the International Conference 
on Harmonization (I CH)-E2A, 1994 definitions of seriousness listed in Section [IP_ADDRESS]
then, in addition to reporting the case as an SAE, the ABC HSR eCRF should also be 
completed within one w eek of the onset of the h ypersensitivity  reaction.  Clinically  
suspected cases of HSR to ABC that do not meet criteria as an SAE can be recorded as an 
AE.
[IP_ADDRESS]. Rash Without A BC HSR Sy mptoms
Including serious skin reactions such as Stevens- Johnson Syndrome, Toxi c 
Epi[INVESTIGATOR_19342], Erythema Multiforme or rash with significant liver 
dysfunction 
Subjects should be instructed to contact [CONTACT_339286] a rash on study .
Subjects who develop rash of an y grade should be evaluate d for the possibility  of an 
ABC HSR or a serious skin reaction such as Stevens -Johnson sy ndrome (SJS), Toxic 
Epi[INVESTIGATOR_13031] (TEN) or Ery thema Multiforme. SJS, TEN and Ery thema 
Multiforme have been reported very  rarely  in patients taking ABC -contain ing products.  
These patients generall y do not have the cluster of additional sy mptoms (e.g., 
gastrointestinal and respi[INVESTIGATOR_696] ) that characterize the ABC HSR, but they  do have 
features ty pi[INVESTIGATOR_227310].
If a serious skin reaction dev elops, ABC (and / or all other concurrent medication(s) 
suspected in the Investigators causalit y assessment) should be discontinued, and the  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419397] (i.e., 
ZIAGEN, TRIZIVIR, EPZICOM or K IVEXA).
As many  products other than abacavir also cause rash and/or serious skin reactions, all 
other medicinal products that the subject is receiving should also be reviewed and 
discontinued as appropriate.
The following guidance is provided for clinical management of subjects who experience 
rash alone in the absence of accompan ying diagnosis of ABC HSR, sy stemic or allergic 
symptoms or signs of mucosal or target lesions.
Subjects with an isolated Grade 1 rash may  continue I P and background ART at the 
Investigator’s discretion. The subject should be advised to contact [CONTACT_339287], if any  systemic signs or sy mptoms 
worsen, or if mucosal involvement develops.
Subjects may  continue IP and background ART for an isolated Grade 2 rash. However, I P 
and background ART (and all other concurrent medication(s) suspected in the 
Investigators causality assessment) should be permanently  discontinued for any  Grade ≥[ADDRESS_419398] 
the phy sician immediately  if rash fails to resolve (after more than two weeks), if there is 
any worsening of the rash, if any  systemic signs or allergic s ymptoms develop, or if 
mucosal involvement develops.
Subjects should permanently  discontinue IP and background ART (and all other 
concurrent medication(s) suspected in the Investigators causalit y assessment) for an 
isolated Grade [ADDRESS_419399] one dose of CAB LA and /or RPV LA who discontinue I P / 
Withdraw will initiate treatment with HAART and enter the Long -Term Follow -Up 
Period for 52 weeks of follow up.
The ras h and any  associated sy mptoms should be reported as adverse events and 
appropriate toxicity  ratings should be used to grade the events (see Section 11.2).
If the etiology  of the rash can be definitely  diagnosed as being unrelated to IP and due to 
a specific medical event or a concomitant non -study  medication, routine management 
should be performed and documentation of the diagnosis provided.
Any rash that is possibly related to study drug, and is present between Week ( -4) 
and Day 1, must be discussed with the Medical Monitor prior to initiation of CAB
LA or RPV LA.
[IP_ADDRESS]. Seizures
Seizures that occur on study  should be managed according to the local guidelines on 
emergency  seizure management which may  include treatment w ith benzodiazepi[INVESTIGATOR_1651], 
general supportive treatment, exclusion of metabolic and toxicological abnormalities 
using laboratory  tests, and septic workup and excluding underly ing structural 
abnormalities with neuroimaging. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
138Where seizures occur, the Sponsor would like to better characterize these occurrences to 
enable s ystematic anal yses.
Investigators are requested to document and report seizure or possible seizure events 
promptly  (within 24 hours of learning of the event) to the Sponsor for evaluation and 
onward reporting.  Data should be documented on the appropriate eCRF page.
6.10.7. Cardiovascular Events
Investigators will be required to fill out event specific data collection tools for the 
following AEs and SAEs:  
Myocardial infarction/unstable angina
Congestive he art failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularisation
This information should be recorded in t he specific cardiovascular eCRF within one week 
of when the AE/SAE(s) are first reported.
6.10.8. Death Events
In addition, all deaths will require a specific death data collection tool to be completed.  
The death data collection tool includes questions regarding cardiovascular (including 
sudden cardiac death) and noncardiovascular death.
This information should be recorded in the specific death eCRF within one week of when 
the death is first reported.
6.10.9. Disease -Related Events and/or Disease -Related Outcomes Not 
Qualify ing as SA Es
The following disease related events (DREs) are common in subjects with HIV -1 
infection and can be serious/life threatening:
events or outcomes listed in the CDC Classification Sy stem for HIV-1 
Infections (see Section 11.1) 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
139sign, s ymptom, diagnosis, illness, and/or clinical laboratory  abnormality  that can 
be linked to an y of these events or outcomes 
Because these events are ty pi[INVESTIGATOR_1306] y associated with the disease under study, they will not 
be report ed according to the standard process for expedited reporting of SAEs to [COMPANY_004] 
(even though the event may  meet the definition of a serious adverse event).  These events 
will be recorded on the DRE page in the subject’s eCRF using the HIV Associated 
Conditions eCRF.  These DREs will be monitored by [CONTACT_7195], IDMC, and 
study  team on routine basis.   
However, if any of the following conditions apply, then the event should be reported as 
an SAE using the standard process: 
The event is, in the Investig ator’s opi[INVESTIGATOR_1649], of greater intensity , frequency , or duration 
than expected for the individual subject, or
The Investigator considers that there is a reasonable possibility  that the event was 
related to treatment with the investigational product. or
Death o ccurring for an y reason during a stud y, including death due to a disease 
related event, will alway s be reported promptly . or
Lym phomas and invasive cervical carcinomas are excluded from this exemption; 
they must be reported as SAEs even if they are conside red to be HIV related
If either of the above conditions is met then record the DRE on the SAE page rather 
than the HIV Associated Conditions eCRF page and report promptly (i.e., expedited 
reporting, see Section 6.10.12 ) to [COMPANY_004].
6.10.10. Monitoring Suicidal Ideation and Behavior
Patients with HI V infection may  occasionall y present with sy mptoms of depression 
and/or suicidal ideation or behavior. Therefore, it is appropriate to monitor subjects 
prospectively for suicidal id eation and / or behavior before and during treatment. I t is 
recommended that the Investigator consider mental health consultation or referral for 
subjects who experience signs of suicidal ideation or behavior.
Suicidal ideation or behavior will be monitored during this study  using the electronic 
version of the Columbia Suicide- Severit y Rating Scale (eC -SSRS). The behavioral 
suicidal events used in this scale are based on those used in the Columbia Suicide History 
Form [ Oquendo , 2003]. Questions are asked on suicidal behavior, suicidal ideation and 
intensity  of ideation. Screening visit questions will be in relation to lifetime experiences 
and current experiences (within the past 2 months) and all subsequent questioning in 
relation to the last assessment. The eC -SSRS is to be administered at the time -points 
specified in the Time and Events Table (see Section 6).
Additionally , the investigator will collect information using the Possible Suicidality -
Related AE (PSRAE) eCRF form in addition to the Adverse Event (Non -serious or 
Serious Adverse Events) eCRF form on an y subject that experiences a possible  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419400] imminent 
suicidal behavior, a suicide attempt, or a completed suicide.  The investigator will 
exercise his or her medical and scientific judgment in deciding whether an event is 
possibly  suicide -related.  PSRAE forms should be completed and reported to [COMPANY_004] within 
one week of the investigator diagnosing a possible suicidality -related adverse event.
6.10.11. Pregnancy
[IP_ADDRESS]. Pregnancy  Testing
Women of childbearing potential must have a negative pregnancy  test at Screening, the 
first I nduction Period visit and prior to administration of each CAB LA and / or RPV LA 
injection.   Pregnancy  testing will also be conducted as per the Time and Events Table 
(see Section 6) and at any time during the trial when pregnancy  is suspected. 
Additionally , the medical monitor may  request that a pregnancy  test be performed in the 
event of a treatment interruption greater than 7 days. 
[IP_ADDRESS]. Time Period for Coll ecting Pregnancy Information
Pregnancy  information will be collected after the start of Induction until the last follow -
up assessment.  This includes the entiret y of the Long -Term Follow -Up Period.
Female subjects that have received at least one dose of CABLA or RPV LA and do not 
enter the Long -Term Follow -Up Period should use an acceptable method of 
contraception ( see the SPM for a listing of examples of acceptable hormonal 
contraception) until at least [ADDRESS_419401] should 
notify  the study  site.  
[IP_ADDRESS]. Action to be Taken if Pregnancy  Occurs
Any female who becomes pregnant (intrauterine) while participating in this study  must be 
withdrawn from the study  and must immediatel y discontinue I P.  Subjects who have 
received at least one dose of CAB LA and/or RPV LA should discontinue further dosing 
and continue oral HAART in the L ong-Term Follow -Up Period (see Section 3.2.6 ), after 
discussion with the medical monitor.
Any pregnancy  that occurs during stud y participation must be reported using a clinical 
trial pregnancy  form.  To ensure subject safet y, each pregnancy  must be reported to [COMPANY_004] 
within [ADDRESS_419402] be followed up to 
determine outcome (including premature termination) and status of mother and child.  
Pregnancy  complications and elective terminations for medical reasons must be reported 
as an AE or SAE.  Spontaneous abortions must be reported as an SAE. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
141Any SAE occurring in association with a pregnancy  brought to the investigator’s 
attention after the subject has completed the stud y and considered b y the investigator as 
possibly  related to the study  treatm ent, must be promptly  reported to [COMPANY_004].
[COMPANY_004]’s central safet y department will also forward this information to the Antiretroviral 
Pregnancy  Registry . The international registry  is jointly  sponsored by  [CONTACT_339288]. Ad ditional information and a list of participating 
manufacturers/licensees are available from http://apregistry .com/index.htm.
6.10.12. Time Period and Frequency  of Detecting AEs and SA Es
The investigator or site staff is responsible for detecting, documenting and re porting 
events that meet the definition of an AE or SAE.
AEs will be collected from the start of study  treatment and until the follow up contact.  
SAEs will be collected over the same time period as stated above for AEs. However, any  
SAEs assessed as related to study  participation (e.g., study  treatment, protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] concomitant 
medication, will be recorded from the time a subject consents to participate in the study  
up to and including an y follow up contact. All SAEs will be reported to [COMPANY_004] within [ADDRESS_419403] be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence. Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y our last visit/contact?” 
“Have you taken any  new medicines, other than those provided in this study , since your 
last visit/contact?” 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7053].10.14. Prompt Reporting of Serious A dverse Events and Other Events 
to [COMPANY_004]
SAEs, pregnancies, and liver function abnormalities meeting pre- defined criteria will be 
reported promptl y by [CONTACT_23979].
Initial Reports Follow -up Information on a Previous 
Report
Type of Event Time F rame Documents Time Frame Documents
All SAEs 24 hours “SAE” data 
collection tool24 hours Updated “SAE” 
data collection tool
Cardiovascular (CV) 
or death eventInitial and 
follow up 
reports to be 
completed 
within one 
week of when 
the 
cardiovascular 
event or death 
is reported “CV events” 
and/or “death” 
data collection 
tool(s) if 
applicableInitial and follow 
up reports to be 
completed within 
one week of when 
the cardiovascular 
event or death is 
reportedUpdated “CV 
events” and/or 
“death” data 
collectio n tool(s) if 
applicable
PRSAE 1 week PRSAE data 
collection tool1 weeks Updated PRSAE 
data collection tool
Suspected ABC 
HSR324 hours ABC HSR eCRF 1 Week Updated ABC HSR 
eCRF
Pregnancy 2 weeks “Pregnancy 
Notification Form”2 weeks “Pregnancy Follow -
upForm”
Seizure or suspected 
seizure24 hours eCRF 24 hours eCRF
Non-serious adverse 
events related to 
study treatment5 calendar 
days“Adverse 
Reaction” data 
collection tool2 weeks Updated “Adverse 
Reaction” data 
collection tool
Liver chemistry abnorma lities see Section 6.10.31,2:
ALT≥3xULN plus 
Bilirubin ≥2xULN 
(35% direct) 24 hours SAE data 
collection tool 
Liver Event eCRF 
and liver imaging 
and/or biopsy 
eCRFs if 
applicable 24 hours Updated SAE data 
collection tool 
Updated Liver 
Event eCRF 
ALT≥5xULN that 
persists ≥2 weeks 24 hours Liver Event eCRF 24 hours Updated Liver 
Event eCRF 
ALT ≥8xULN 24 hours Liver Event eCRF 24 hours Updated Liver 
Event eCRF  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
143Initial Reports Follow -up Information on a Previous 
Report
Type of Event Time F rame Documents Time Frame Documents
ALT ≥3xULN or ALT 
≥[ADDRESS_419404] safety.
2. Liver Event Do cuments (i.e., “Liver Event eCRF” and “Liver Imaging eCRF” and/or “Liver Biopsy eCRF”, as 
applicable) should be completed as soon as possible.
3. ABC HSR eCRF required only if event meets one of the ICH- E2A, 1994 definitions of seriousness (see 
Section [IP_ADDRESS].2 ).
The method of recording, evaluating and follow -up of AEs and SAEs plus procedures for 
completing and transmitting SAE reports to [COMPANY_004] are provided in the SPM.  Procedures 
for post -study AEs/SAEs are provided in the SPM.
[IP_ADDRESS]. Regulatory  Reporting Requirements for SA Es
Prompt notification of SAEs by  [CONTACT_23997] y of subjects are met.
[COMPANY_004] has a leg al responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements.
6.11. Pharmacokinetics
Plasma samples for determination of CAB and RPV concentration will be collected 
throughout the Maintenance Period and from Week 100 –Week 128 in the Extension 
Period of the study for subjects switching from oral Maintenance period regimen to the 
optimized I M dosing regimen of their choice .  Additional samples will be collected for 
storage during the Extension and L ong-Term Follow Up Period.  Samples for 
determination of RPV will be pro tected from light until analy zed. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7054].11.1. PK Sample Collection
Blood samples for evaluation of CAB (2mL each) and RPV (2mL each) plasma PK will 
be collected from all subjects randomized to receive CAB LA + RPV LA for 
determination of CAB and RPV concentrations a s described in Table 4.  All PK samples 
will be collected prior to IM dosing a nd may  be collected at anytime during visits that 
study  treatment is not administered .  The exact date and time of the PK sample should be 
recorded in eCRF .
For subjects randomized to CAB 30mg, pre-dose b lood samples for evaluation of CAB
(2mL each) and RPV (2 mL, Day  1 pre -dose onl y) will be collected as described in 
Table 4. These samples must be collected within the window of [ADDRESS_419405] be recorded on the e CRF.  Subjects will 
take their dose of oral IP in the clinic at PK visits. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
145Table 4 CABand RPV Plasma Pharmacokinetic Sample Schedule
Group Analyte Week Sample Times Relative to Dose
IM CAB Day 1 (prior to LA and 
last oral Induction 
dose), Weeks: 1, 4, 8, 
12, 16, 20, 24, 25, 28,  
32, 36, 40, 41, 44 and
48
100* (prior to LA and 
last oral Maintenance 
dose), 104 *, 108 *, 112 *, 
116*, 120 *, 124 *and 
128*Pre-Dose (Q8W):  Day 1, Weeks 4, 8, 
16, 24, 32, 40 ,48, 100 *, 104 *, 112 *, 
120* and 128 *
Pre-Dose (Q4W):  Day 1, Weeks 4, 8, 
12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 
100*, 104 *, 108 *, 112 *, 116 *, 120 *, 
124* and 128 *
[ADDRESS_419406] Dose:  Day 1 , Weeks
32, 48, 100 *aand 128*a
[ADDRESS_419407] Dose: Week 1, Weeks
25,41, 101 *aand Week 121 *a
[ADDRESS_419408] Dose (Q8W):  Weeks 
12, 20, 28, 36 and 44
RPV Day1 (prior to LA and 
last oral Induction 
dose), Weeks: 1, 4, 8, 
12, 16, 20, 24, 25, 28, 
32, 36, 40, 41, 44 and
48
100* (prior to LA and 
last oral Mai ntenance 
dose), 104*, 108*, 112*, 
116*, 120*, 124* and 
128*Pre-Dose (Q8W):  Day 1, Weeks 4, 8, 
16, 24, 32, 40 ,48, 100*, 104*, 112*, 
120* and 128*
Pre-Dose (Q4W):  Day 1, Weeks 4, 8, 
12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 
100*, 104*, 108*, 112*, 116*, 12 0*, 
124* and 128*
[ADDRESS_419409] Dose:  Day 1 , Weeks
32,48, 100*aand 128*a
[ADDRESS_419410] Dose:  Week 1, Week s
25,41, 101*aand Week 121*a
[ADDRESS_419411] Dose (Q8W):  Weeks 
12, 20, 28, 36 and 44
Oral CAB Day 1, Weeks: 32 and 
48Pre-Dose:  Day 1, Weeks 32 and 48
RPV Day 1 Pre-Dose:  Day 1
*Denotes PK sample times for subjects in the Extension Period .  Samples will be placed in storage.
a. PKsample time for subjects switching from oral to an optimized IM dosing regimen only. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
146Additional CAB and RPV PK samples for storage will be collected pre -dose at Weeks 
56, 64, 72, 80, 88 and 96 for subjects on CAB LA+ RPV LA as per the Time and Events 
Table (see Section 6.2and Section 6.3) and in the Extension Period (see Section 6.5and 
Section 6.6).  Samples for storage will also be collected at Week 96 subjects on CAB 
30mg+ABC/3TC ,Weeks 10 0, 101, 104, 108, 112, 116, 120, 124 and 128 for subjects in 
the Extension Period, and at Months 1, 3, 6, 9 and 12 for subjects in the Long- Term 
Follow Up Period.  These samples may  be anal yzed in case of protocol-defined virologic 
failure or to investigat e any  PK related issues (such as missing dose, missing sample, 
suspected non- adherence etc.) .
In addition, if a subject withdraws from the stud y a PK sample should be collected as 
early as practically possible (i.e. at withdrawal visit or on the day  the wi thdrawal decision 
was made). 
Additional details concerning handling of PK samples, labeling and shippi[INVESTIGATOR_339179] .
6.11.2. Rationale of PK Sampling Strategy
Given that PK data has been collected following oral administration of CAB and RPV 
(LAI116482), there will be no sampling during the Induction Period of the study .  Blood 
sampling for CAB and RPV concentrations will be performed during the Maintenance 
and Extension Periods of the study  to evaluate PK in HIV infected subjects.  The 
proposed PK visits and sampling scheme at each visit presented in Table 4 is based on 
consideration of available PK data to support interim and final PK and 
PK/Pharmacod ynamic (PD) anal ysis planned in this study .
6.11.3. Bioanaly sis of CABand RPV
Plasma CAB analysis will be performed under the control of [COMPANY_004] PTSDMPK/ Scinovo .  
Concentrations of CAB will be determined in plasma samples using the currentl y 
approved bioanaly tical methodology . Raw data will be archived at the bioanaly tical site.
Once the plasma has been anal yzed for CAB any remaining plasma may  be anal yzed for 
other compound -related metabolites and the results reported under a separate [COMPANY_004] PTS -
DMPK protocol.
Once the plasma has been anal ysed for RPV any remaining plasma may  be used by  [CONTACT_339289], metabolites, plasma protein 
binding, protein analy sis, and biochemistry . No human DNA analy sis will be performed.
Plasma CAB analysis will be pe rformed under the control of Janssen R&D. 
Concentrations of CAB will be determined in plasma samples using the currentl y 
approved bioanaly tical methodology . Raw data will be archived at the bioanaly tical site. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7055].12. Viral Genoty pi[INVESTIGATOR_339180] “plasma for 
storage samples” according to the Time and Events Schedule in Section 6(for potential 
viral genoty pic and phenoty pic anal yses). 
Details c oncerning the handling, labeling and shippi[INVESTIGATOR_339181] .  Genot ypic and phenotypic anal yses may  be carried out by  [CONTACT_339290], but not limited to, their Standard Phenosense and GenoSure testing 
methods for protease (PRO) and reverse transcriptase (RT), or with their GeneSeq 
Integrase and PhenoSense Integrase assay s.
For Screening virologic evaluations, only  viral genoty pe will be anal yzed and this will be 
performed through the central laboratory .
6.12.1. HIV-[ADDRESS_419412] plasma samples tested for 
HIV-1 PRO and RT genoty pe and phenot ype and HIV -1 integrase genot ype and 
phenoty pe from both Baseline samples and from samples collected at the time of 
suspected virologic failure; these results will be reported to the Investigator as soon as 
available to provide guidance for election of a switch regimen.
6.12.2. HIV-1 Exploratory  Analysis
Additional exploratory  analy ses for HIV -1 pol resistance may  include viral genot ypi[INVESTIGATOR_161862]/or phenot ypi[INVESTIGATOR_54139] a representative subset of Baseline samples or virologic anal ysis 
on stored plasma samples from other time points. These analy ses may  also include but 
are not limited to additional viral genot ypi[INVESTIGATOR_6926]/or phenotypi[INVESTIGATOR_007], as well as other 
virologic eva luations such as linkage and minorit y species analyses, super low HIV -[ADDRESS_419413] HIV -1 RNA >200 c/mL regardless of confirmatory  HIV -1 RNA.
6.13. Pharmacogenetic Research
Information regarding pharmacogenetic (PGx) research is included in Section 11.3.  
TheIEC/I RB and, where required, the ap plicable regulatory  agency  must approve the 
PGx assessments before these can be conducted at the site. The approval(s) must be in 
writing and will clearl y specify  approval of the PGx assessments (i.e., approval of 
Section 11.3).  In some cases, approval of the PGx assessments can occur after approval 
is obtained for the rest of the study . If so, then the written approval will clearly  indicate 
approval of the PGx assessments is being deferred and the study , except for PGx  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419414] of the study  will clearl y indicate this and therefore, PGx assessments 
will not be conducted.
6.14. Health Outcomes
The HIV Treatment Satisfaction Questionnaire (HIVTSQ) [ Woodcock , 2001 and 
Woodcock , 2006] was developed to evaluate treatments for HIV and patient satisfaction. 
The higher the score, the greater the improve ment in treatment satisfaction as compared 
to the past few weeks. A smaller score represents a decline in treatment satisfaction 
compared to the past few weeks.  The HIVTSQ items are summed up to produce a 
treatment satisfaction score (0 to 60) and an indi vidual satisfaction rating for each item 
(0 to 6) and two subscales: general satisfaction/clinical and lifest yle/ease subscales.
This study  will be using the HIVTSQ(s) (status version) and the revised HIVTSQ(c) 
(change version). These measures will assess change in treatment satisfaction over time 
(in the same subjects) and compare current satisfaction with previous treatment 
satisfaction, from an earlier time point. 
The HIV Medication Questionnaire (HIVMQ) was developed to assess subject reported 
medicat ion adherence.
The HIVTSQ (s)will be administered at the following time points: 
Induction: Week -(-16) and Week (-4)(pre-dose if possible ) 
Maintenance:  pre -dose at Day  1, and post -dose (where possible in oral dosing 
arm) Week 8, Week 32, Week 48 andWeek 96 
Withdrawal
The HIVTSQ(c) will be administered at the following time points:  
Maintenance:  Week 32
The HIVTSQ(c, WD) will be administered at the following time points:   
Withdrawal for subjects withdrawn between Week 8 and Week 32
HIVMQ will be a dministered at the following time points:
Induction: Week (-4)
Maintenance:  Week 8, Week 32, Week 48, Week 96 & Withdrawal
oIM Regimen:  Complete post- injection
oOral Regimen:  Preferably completed at the beginning of the visit, but may 
be completed at an y time during the visit . 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419415]’s 
experience on the injection regimen. This would be conducted under a separate IRB/IEC 
approved consent. Participation in the interviews would be vo luntary .
7. DATA MANAG EMENT
For this study ,subject data will be entered into [COMPANY_004] defined electronic case report forms 
(eCRFs), transmitted electronicall y to [COMPANY_004] or designee and combined with data provided 
from other sources in a validated data s ystem.  
Mana gement of clinical data will be performed in accordance with applicable [COMPANY_004] 
standards and data cleaning procedures to ensure the integrity of the data, e.g., removing 
errors and inconsistencies in the data.  Adverse events and concomitant medications 
terms will be coded using MedDRA and an internal validated medication dictionary , 
[COMPANY_004]Drug.  eCRFs (including queries and audit trails) will be retained b y [COMPANY_004], and 
copi[INVESTIGATOR_339182] y.  In all cases, 
subject initials will not be collected or transmitted to [COMPANY_004] according to [COMPANY_004] policy .
8. DATA ANALYSIS AND ST ATISTICAL CONSIDERA TIONS
8.1. Hypotheses
The study  is designed to evaluate the efficacy  and safet y ofCAB LA 400 mg IM plus 
RPV LA 600 mg IM every 4 weeks and CAB LA 600 mg IM plus RPV LA 900 mg IM 
every  8 weeks , relative to CAB 30mg once daily  plus ABC/3TC once daily , through 
Week 32 of the Maintenance Period.
To claim positive outcome, the following h ypotheses will be tested:
H0: Response rate for CAB LA plus RPV LA two -drug regimen  CAB plus 
ABC/3TC -10%
H1: Response rate for CAB LA plus RPV LA two -drug regimen > CAB plus 
ABC/3TC -10%
8.2. Stud y Design Considerations
8.2.1. Sample Size A ssumptions
IMtreatment relative to Oral treatment
The sample size of 45subjects inthe oral treatment arm and 90 subjects each in the IM
treatment arms were chosen to ensure a high probability that a long -acting two drug 
treatment with truly  poor response relative to CAB 30mg once daily  plus ABC/3TC once 
daily  will not be studied further, while allowing for formal considerations of other factors 
should efficacy  be similar between the treatment arms.  I t is assumed that 85% subjects 
enrolled will be suppressed at Week (-16),approximately  [ADDRESS_419416] the comparability  of CAB LA plus RPV LA two -drug 
regimen to CAB 30mg once dail y plus ABC/3TC. The primary  comparison of interest 
will be performed using a Bay esian probability  model. If the pos terior probability  that the 
difference is greater than -10% is large (i.e., 90%), then sufficient statistical evidence 
has been provided for the positive outcome. A response rate of 8 2% in the CAB LA plus 
RPV LA two -drug regimen (compared with an CAB 30 mgplus ABC/3TC response rate 
of 92%) would result in a rejection of the null h ypothesis with a probability of 
approximately  0.06 4(typeI error). The given sample size is unlikely  to select a random 
sample that would falsely  conclude that CAB LA plus RPV LA two -drug regimen is 
comparable with CAB 30 mgplus ABC/3TC if the response rates are trul y 82% versus 
92%, respectively . If the CAB LA plus RPV LA two -drug regimen y ields a response rate 
of greater than 92%, then there is a high probability  of rejectin g the null h ypothesis and 
correctly  concluding that CAB LA plus RPV LA two -drug regimen is at least as good as 
CAB 30 mgplus ABC/3TC.
Historical response rates of dolutegravir, an integrase compound similar to CAB , were 
used as reference for the oral cont rol arm.  Response rates for dolutegravir plus 
ABC/3TC ranged from 9 2% to 94% at Week 60 in studies SPRI NG-1, SPRI NG-2 and 
SINGLE among subjects who were suppressed (HIV- 1 viral load <50 c/mL) at Week 24. 
The probability  of a positive outcome assuming the true response rate for CAB LA plus 
RPV LA two -drug regimen is presented in Table 5.
Table 5 Probability of Positive Outcome A ssuming True Response Rates of 
CABLA plus RPV LA
True Response Rate for CAB LA 
plus RPV LA two- drug regimen 
(Q4W or Q8W)80% 82%a 86% 90% 92% 94% 96%
Probability of Positive 
Outcomeb2.8% 6.4% 26% 63% 82% 95% 99%
a. Type I error is <10% .
b. It is assumed that the response rate for CAB 30 mg plus ABC/3TC is 92%.
Incorpor ation of prior beliefs and information about population parameters is a required 
part of an y Bayesian probability  model. The assumptions made will help provide a more 
reliable estimate when the prior beliefs are combined with the observed data than the da ta 
alone as long as the beliefs are reasonable. Therefore, the trial will utilize a Beta ( 23, 2) 
distribution with the me anresponse rate being 9 2%, with 97.5thpercentile of 99% and 
2.5thpercentile of 78%.
Furthermore, a non -informative prior belief is assumed for the response rate for CAB LA 
plus RPV LA two -drug regimen. Therefore, the trial will conservativel y utilize a Beta (1, 
1) distribution. These priors are displayed in Figure 15. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
151Figure 15 Plot of Prior Distribution for Response Rate for CABLA plus RPV LA 
two-drug regimen and CAB 30 mgplus A BC/3TC
The posterior probability limit is used as a measure of evidence in support of a 
hypothesis. Selection of the critical value to base a decision of comparability  can be 
made so that the ty pe I error rate is controlled and the desired power profile is attained.
The total number of responders in each treatment arm (experimental and active control) is 
modelled as independent binomially  distributed ran dom variables. Conjugate beta priors 
are selected to reflect the beliefs about the response rates previously described.
8.2.2. Sample Size Sensitivity
Long Acting IM treatment relative to Oral treatment
The operating characteristic (power) curve is used to evalu ate an y decision criteria 
(Bayesian and non -Bayesian alike). The operating characteristic curve for the proposed 
sample sizes for each treatment arm and prior information is shown in Figure 16. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
152Figure 16 Operating Characteristic Curve of Probability  of Positive Outcome of 
CABLA plus RPV LA two-drug regimen and CAB 30 mgplus 
ABC/3TC
8.2.3. Sample Size Re -estimation
No sample size re -estimation is planned for this study .
8.3. Data Analysis Considerations
8.3.1. Analysis Pop ulations
The following populations will be assessed:
[IP_ADDRESS]. Intent -to-Treat Exposed Population (ITT -E)
The ITT- E population consists of all enroll ed subjects who receive at least one dose of IP. 
Subjects will be analy zed according to the irrandomized treatment r egardless of what 
treatment was actuall y received. Those that are not randomized will be summarized 
together under a ‘Not Randomized’ category . The ITT -E population will be the 
secondary population for some efficacy  anal yses.   2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7056].3.1.2. Intent -to-Treat Maintenance Exposed Population (ITT -ME)
The ITT- ME population consists of all randomized subjects who receive at least one dose 
of IP during the Maintenance Period of the study .  Subjects will be analy zed according to 
the randomized treatment regardless of what treatment was actuall y received. Unless 
stated otherwise, the ITT-ME population will be the primar y population for efficacy 
analyses.
[IP_ADDRESS]. Per Protocol Maintenance Exposed Population (PP -ME)
This population will consist of subjects in the I TT-ME population with th e exception of 
major protocol violators (these will be defined in the RAP of this study ).  The PP -ME
population will be a secondary  population for efficacy  purposes. 
[IP_ADDRESS]. PK Population
The PK Population will include all subjects who receive CAB and /or RPV andundergo 
PK sampling during the study , and provide evaluable CAB and /or RPV plasma 
concentration data. Subjects in this population will be included in the PK analy sis. 
[IP_ADDRESS]. Safety  Population
The Safet y Population consists of all enrolled subjects who were ex posed to 
investigational products with the exception of any subjects with documented evidence of 
not having consumed any  amount of investigational product.  Subjects will be anal yzed 
according to the actual treatments received.  Subjects will not be exclud ed from this 
population as a result of changes to the background regimen.  The safet y population will 
be the primary  population for safety  anal yses.  All safet y analyses will be produced using 
the safety population.
Analy sis populations for genot ypic and p henot ypic anal yses will be described in the 
RAP.
[IP_ADDRESS]. Extension S witch Population
The Extension Switch population will include all subjects randomized to the oral 30 mg + 
ABC/3TC arm who switch to and receive at least on edose of the optimized I M dosing 
regimen of their choice (either Q8W or Q4W) in the Extension Period.
The Extension Switch population will be used to evaluate safet y and efficacy of the 
optimized I M dosing regimens during the Extension Period.
8.3.2. Analysis Data Sets
The primary  efficacy  analy sis dat a set will be based on the ITT -ME population described 
in Section [IP_ADDRESS] . The efficacy  dataset will include missing, switch, or discontinuation 
equals failure (MSDF) (also referred to as Snapshot), and the obs erved case (OC) 
endpoints for the proportion of subjects with plasma HIV -1 RNA less than the pre - 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
154defined threshold (e.g., <200 c/mL  and <50 c/mL). The MSDF endpoint will be 
considered the primary  analy sis approach and will be determined based on the curre nt 
Food and Drug Administration ( FDA )definition of the Snapshot algorithm. Full details 
on this algorithm will be contained in the RAP.  The OC endpoint will not impute for an y 
missing assessments. Details of the endpoint derivations will be described in the RAP for 
this study .
8.3.3. Treatment Comparisons
[IP_ADDRESS]. Primary  Comparisons of Interest
The primary  efficacy  analy sis will be performed at Week 32 based on the proportion of 
subjects in the ITT -ME population with plasma HIV -1 RNA <50 c/mL using MSDF 
algorithm. Theprimary  comparison of interest will be the response rate of each IM 
dosing arm to the oral control arm performed using a Bay esian probability  model.  The 
probability  of (Response rate for IMarm > Response rate for Oral arm -10%) will be 
calculated.
[IP_ADDRESS]. Other Comparisons of Interest
The probability  of Q8W comparable to Q4W will be provided using the Bay esian 
probability  model .
Measures of safety  and tolerability  will be assessed as detailed in the RAP.
8.3.4. Planned Analysis
The ITT-M E population will be primary  efficacy  population and the safet y population 
will be the primary  safety  population for all anal yses.  All available data will be included 
in all interim analy ses, including data bey ond the designated time point except for the 
Day [ADDRESS_419417] interim anal ysis the I DMC will evaluate the efficacy , safet y and tolerability of 
CAB to determine if the CAB regimen is suboptimal such that it should be discontinued 
before all subjects transi tion into the Maintenance Period of the study .  Full details of the 
analyses, estimated timing and the decision criteria that will be used to determine 
regimen performance will be pre-specified in the IDMC Charter.
This interim analy sis schedule does not r equire an adjustment for multiplicity  since there 
is no possibility  of a false positive finding at any  of the interim anal yses conducted before 
Week 32, and since the Week 48 and 96 anal yses will be used to further characterise the 
long-term safet y and eff icacy  profile of CAB .  As no hy pothesis is being tested for 
rejection during the constant monitoring of virologic response, no adjustment for 
multiplicity  will be performed. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7057].3.4.1. IDMC Interim A nalyses
The purpose of these analy ses is for the IDMC to evaluate th e efficacy , safety  and 
tolerability  of CAB at early  time points in the study and to monitor the occurrence of 
protocol defined virologic failure in subjects switching from oral CAB 30 mg +ABC/3TC 
to an optimized I M dosing regimens during the Extension Period.  
The IDMC intends to review at least one anal ysis before all eligible subjects have 
transitioned from the Induction Period to the Maintenance Period , or as soon as 
reasonabl y possible after subjects begin to enter the Maintenance Period.   Full details of 
the anal yses, estimated timing and the decision criteria that will be used to determine 
regimen performance will be pre-specified in the IDMC Charter, with IDMC agreement.
All of the IDMC reviews will be produced b y a Statistics and Data Analysis Centr e 
(SDAC).  
[IP_ADDRESS]. Futility  Interim Monitoring
Continuous monitoring of the number of protocol defined virologic failures during the 
Maintenance Period and a futility  interim anal ysis when 50% subjects have completed 
Week 24 is planned.
Continuous monitoring of the number of protocol defined virologic failures for subjects 
switching from oral CAB 30 mg + ABC/3TC to the optimized I M dosing regimen of their 
choice (Q8W or Q4W) will also be monitored during the Extension Period.
Continuous Monitoring
Plasma HIV -[ADDRESS_419418] 4 weeks of either of the M aintenance Period 
IM dosingregimen s(Week 4). If the number of failures meets or exceeds the thresholds 
specified in the table below ( Table 6), this will be considered strong evidence of an 
inadequate response and will trigger a comprehensive IDMC data review and possible 
discontinuation of that treatment arm.  If an i nadequate response is seen in anyarm and it 
is determined by [CONTACT_339291], then subjects on that 
treatment arm can be switched to the remaining IM arm .
Table [ADDRESS_419419] 
four weeks of maintenance dose on IMNumber of protocol -defined virologic 
failures after maintenance dose on IM
3-21 >=3
22-32 >=4
33-43 >=5
44-54 >=[ADDRESS_419420] 
four weeks of maintenance dose on IMNumber of protocol -defined virologic 
failures after maintenance dose on IM
55-65 >=7
66-75 >=8
76-86 >=9
87-97 >=10
98-100 >=11
The thresholds described in this table are derived on the basis of the ratio of the 
likelihoods for the null hy pothesis (H 0) that there is a subgroup of subjects with 
inadequate maintenance of virologic suppression and the alternative h ypothesis (H 1) that 
the only  failures in the study  are due to poor compliance. For this anal ysis, H 0translates 
to a protocol defined virologic failure rate of 20% or higher (as defined in Section 4.6) 
and H 1translates to an expected 3% rate of protocol defined virologic failures.   For the 
first IDMC review, if the true rate of virologic failure is 20% as specified in H 0, the 
probability  to dete ct the inadequate virologic suppression is greater than 70%.  If the true 
rate of virologic failure is 3%, the probability  that the number of virologic failures 
observed will exceed the threshold is less than<1%. Further details on this method are 
contain ed in the IDMC charter . Each threshold represents strong evidence in favour of H 0
over H 1[Royall, 1997].
The scenarios described above are not exhaustive – it is possible that the overall failure 
rate does not meet the threshold but that a subgroup of subjects (e.g. with a given 
combination of mutations or fold resistance to CAB above an as yet unknown threshold) 
are consistentl y failing. [COMPANY_004] will monitor virologic response b y Baseline genot ype and 
may halt one or mor e treatment arms if at any  time subjects are deemed to be at an 
unacceptable risk of an inadequate response on the basis of such monitoring, although the 
high number of possible genotypic subgroups precludes pre -specification of precise 
thresholds for such action.
The number of protocol defined virologic failures will also be monitored in subjects 
switching from oral CAB 30 mg + ABC/3TC to the optimized I M dosing regimen of their 
choice (Q8W or Q4W) during the Extension Period.  For subjects that ha veat least 4 
weeks of treatment with an optimized I M dosing regimen, ifthe number of protocol 
defined virologic failures meets or exceeds the thresholds specified in the table below 
(Table 7) prior to all subjects completing Week 160, this will be considered strong 
evidence of an inadequate response and will trigger a comprehensive IDMC data review.  
If an inadequate response is seen in any
arm and it is determined by [CONTACT_339292], then subjects on that treat ment arm can be switched to the 
remaining IM dosing regimen s. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
157Table 7 Number of prot ocol-defined virologic failures for each Extension 
Period optimized IM dosing regimen that constitutes strong 
evidence of inadequate virologic resp onse –Subjects switching 
from Maintenance oral CA B + A BC/3TC only  
Number of subjects with at least four 
weeks of IM dosingNumber of protocol -defined virologic 
failures needed to trigger IDMC revie w 
3-21 >=3
22-32 >=4
33-43 >=5
44-54 >=6
Futility Analysis after 50% of subjects complete Week 24
An interim anal ysis for the purpose of review b y the IDMC will be performed after 
approximately  50% of subjects complete Week 24.   A futility  rule based on Bayesian
posterior probability  approach will be appl ied to assess the probability  that the IM
treatment arm demonstrates comparabilit y with the oral control arm given the partial data
set.Posterior probabilities of success (Prob(pIM> p oral-0.1 | data) )are provided in 
Table 8 for a subset of possible outcomes that could occur at the interim. Those outcomes 
associated with a posterior probability  of success <40 % may trigger a comprehensive 
IDMC data review and possible discontinuation of that treatment arm , although all data 
will be taken into consideration for making this decision.
Table 8 Posterior Probability  of Successaat the Interim A nalysis Under 
Various Scenarios
# Successes in IM arm (out of 45)
# 
Successes 
in Oral 
arm (out 
of 23)35
(78% )36
(80% )37
(82% )38
(84% )39
(87% )40
(89% )41
(91% )42
(93% )
18(78% ) 0.564 0.678 0.753 0.850 0.913 0.955 0.979 0.993
19(83% ) 0.454 0.558 0.679 0.782 0.859 0.931 0.966 0.986
20(87% ) 0.346 0.465 0.574 0.694 0.805 0.890 0.942 0.974
21(91% ) 0.244 0.348 0.455 0.584 0.706 0.829 0.907 0.961
22(96% ) 0.146 0.231 0.335 0.461 0.604 0.736 0.845 0.926
23(100% ) 0.081 0.135 0.218 0.324 0.473 0.612 0.755 0.874
a. Posterior probability of success is defined as (prob (pIM> p oral-0.1 | data)) with informative pri or Beta (23,2) for oral 
arm and non- informative prior Beta (1,1) for IM arm.
b. Highlighted cells represent outcomes with posterior probability <0.4 that may trigger a comprehensive IDMC data 
review.
Theproposed futility  analy sis has 91% chance to stop the study at the interim analysis if 
the true response rates are 92% and 72% for the oral arm and IM arm, respectivel y.  The 
power to stop the study is 46% if the true response rates are 92% and 82% for the oral 
arm and IM arm, respectively . The chance of st oppi[INVESTIGATOR_271436] y by [CONTACT_339293] 2% if the true 
response rates are 92% for both the oral arm and IM arm. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[PHONE_7058].3.4.3. Day 1 Interim A nalysis
A Day  1 interim analy sis may  be conducted to support regulatory  submissions and/or 
scientific conference presentations once the last randomized subject has completed the 
Day 1 study  visit and the database has been cleaned and released for anal ysis. The results 
of this analy sis will be used to evaluate efficacy , safet y and tolerability of CAB 30mg 
once dail y plus ABC/3TC once daily in the Induction Period.  Only  data from the 
Induction Period would be summarized in this analysis.
[IP_ADDRESS]. Week 32Primary  Analysis
The Week [ADDRESS_419421] has 
completed the Week 32study  visit and the database has been cleaned and released for 
analysis.  The results of this analy sis will be used to characterize safety , tolerability  and 
durability  of antiviral response of both IM dosing regimens of CAB LA + RPV LAand 
to select a regimen for further development should both I M dosing regimens be 
comparable to the oral control arm .
[IP_ADDRESS]. Week [ADDRESS_419422] has completed 
the Week 48 study  visit and the database has been cleaned and released for anal ysis.  The 
results of this anal ysis will be used to characterize the safet y, tolerability  and durability  of 
antiviral response of both IM dosing regimen sof CAB LA + CAB LAand to confirm the 
selected regimen for further development should both I M dosing regimens be comparable 
to the oral control arm.
[IP_ADDRESS]. Week [ADDRESS_419423] has completed 
the Week 96 study  visit and the database has been cleaned and released for anal ysis.  The 
results of this anal ysis will be used to fully  characterise the long term safet y and efficacy 
profile of both IM dosing regimens of CAB LA and RPV LA.
[IP_ADDRESS]. Week [ADDRESS_419424] has 
completed the Week 128 study  visit and the database has been cleaned and released for 
analysis.  The results of this analy sis will be used to characterize the efficacy , tolerability , 
and safet y of optimized IM dosing regimens for subjects switching from the oral regime n 
therap y at the end of the Maintenace Period .
[IP_ADDRESS]. Week [ADDRESS_419425] has 
completed the Week 160study  visit and the database has been cleaned and released for 
analysis.  The results of this analy sis will be used to characteri ze the following: (a) the 
long-term safet y and efficacy  profile of both IM dosing regimens for subjects who  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
159continued randomized IM dosing in the Extension Period and (b) t he safety , tolerability  
and durability  of anti viral response of the optimized IM dosing regimens for subjects 
switching from the oral regimen therap y at the end of the Maintenace Period .
Follow -up analy ses after the Week 160analysis may  be conducted to more fully  
characterize the long- term safet y and efficacy  profile of CAB LA + RPV LA dosing 
regimens .
8.3.5. Key Elements of A nalysis Plan
[IP_ADDRESS]. Efficacy  Analyses
All efficacy  analy ses, except as stated otherwise, will be based on the ITT-M E 
population.
The primary  efficacy  analy sis will be based on the MSDF approac h mentioned in 
Section 8.3.[ADDRESS_419426] to the target visit date. 
Detailed explanations of the derivation of visit windows will be included in the RAP.
Any deviatio ns from the planned anal yses described in this protocol or the RAP will be 
detailed in the clinical study  report (CSR).
For the anal ysis of CAB LA+ RPV LA arm s (IMarms ) response rate relative to CAB 
30mg+ ABC/3TC (oral arm), let:
XLA= number of responde r in IMarm, and 
Xoral= number of responder in oral arm
The binomial distribution is the assumed likelihood of the response data, as follows:
XLA~ Binomial ( 90, pIM)  
Xoral~ Binomial ( 45, poral)  
Since the true response rate is unknown, prior distr ibutions are placed on these 
parameters of interest to reflect current beliefs and balanced with acceptable decision 
criteria performance. Conjugate beta densities are assumed. The information pertaining 
to the oral arm response rate is well understood a nd the prior that was chosen reflects the 
belief that the response rate is between 78% and 99% with 9 5% certainty . There is very  
few information about the response rate for IMarm, therefore, a non- informative prior 
assumed. 
PLA~ Beta (1, 1) 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
160Poral~ Beta (23, 2)
The posterior probability that the response rate for IMarm demonstrates the 
comparability  of oral arm is as follows: 
p1= P (P IM> p oral-0.1 | data)
A posterior probabilit y of at least 90% (i.e., p 1>0.90) corresponds to “substantial 
evide nce of positive outcome” and is chosen as the weight of evidence threshold. 
Sensitivity  analy ses may  be performed to assess the impact of the choice of informative 
prior for oral arm response rate though the anal ysis described above will remain primary  
for indication of efficacy  decision -making purposes. As an alternative to the informative 
prior, a Beta (1, 1) prior distribution for oral arm may  be considered. Full details of the 
planned Bay esian anal yses will be provided in the RAP.
The proportion of subjects with plasma HIV -1 RNA <50 c/mL as determined by  [CONTACT_339294] b y treatment group over the entire time on study b y 
visit for the I TT-ME population and the ITT -E population. 
In addition, an OC anal ysis may be performed for suppor tive purposes.
For the probability  of comparability between two IM arms, a non -informative prior of 
Beta (1, 1) will be used for both I M treatment arms.
[IP_ADDRESS]. Safety  Analyses
The study  is designed to characterize a regimen for further evaluation on the basis of 
tolerability  and virologic efficacy  in conjunction with immunological response, safet y 
and pharmacokinetic measures. Measures of safety  and tolerability  will be used to assess 
the regimen as detailed in the RAP of the study .
Exposure to study  medication, measured b y the number of weeks on study drug, will be 
summarized by  [CONTACT_2939]. The proportion of subjects reporting adverse events (AEs) 
will be tabulated for each treatment arm. The following summaries of AEs will be 
provided:
Incidence and severit y of All AEs including injection site reactions ;
Incidence and severit y of treatment related AEs;
Incidence and severit y of AEs leading to withdrawal from study;
Incidence of serious AEs (SAEs).
Laboratory  data, vital signs and ECG data (absolute values an d change from Baseline) 
will be summarized by  [CONTACT_3232]. In addition, the number and percentage 
of subjects with laboratory values of clinical concern will be summarized by [CONTACT_6490]. The proportion of subjects experiencing changes from Baseline in their National  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
161Cholesterol Education Program (NCEP) and DAIDS lipid categories will be summarized 
by [CONTACT_2939].
Framingham Risk assessment will be calculated as detailed in the RAP and will be 
summarized by  [CONTACT_2939].
[IP_ADDRESS]. Treatment Com pliance
The overall proportion of I P study  medication taken relative to the planned amount will 
be estimated via pi[INVESTIGATOR_339183].
[IP_ADDRESS]. Health Outcomes A nalyses
Data from the eC -SSRS, HIVTSQ(s), HI VTSQ(c), and HIVMQ will be summarised by  
[CONTACT_765].  Total satisfaction scores and lifesty le/ease sub -scores will be summarised at each 
time point by  [CONTACT_339295], SD, median, min and max.
In an effort to reduce ‘potentially  avoidable’ study discontinuations (for example, lost to 
follow up, subject withdrawal, non -compliance, protocol violation) and to improve data 
quality , patient characteristics will be studied to focus retention efforts on subgroups of 
subjects more likely  to withdraw prema turely from the study.
Further details of the analy ses to be performed will be specified in the reporting and 
analysis plan (RAP).
[IP_ADDRESS]. Pharmacokinetic A nalyses
The [COMPANY_004] Division of Clinical Pharmacology Modelling and Simulation (CPMS) will be 
responsible for the PK analy sis of CAB . The Divisions of Clinical Pharmacology  and 
Model -Based Drug Development at Janssen Research and Development will be 
responsible for conduct or oversight of the PK analy sis for RPV .
PK analy sis of the plasma CAB and RPV concentration -time data will be conducted 
using non-compartmental methods with WinNonlin (Version 5.2 or higher).  Actual 
sampling and dosing times as recorded in the eCRF will be used for anal ysis.  Predose 
concentration (C0) for CAB and RPV will be estimated.
Plasma CAB and RPV concentration data will be listed and summarized by  [CONTACT_5875], day , 
and planned sampling time in both tabular and graphical forms. Plasma CAB and RPV
PK parameters will be listed and summarized by  [CONTACT_339296].  
Details of the PK anal yses in the PK Population for CAB will be provided in the RAP.
Population PK Analysis:
A population -based PK model may  be constructed based on the CAB and/or RPV PK 
data and individual Bay esian PK parameter estimates may  be obtained, if the quality  of 
the data permits.  Data from the study  could be merged with some previous data to help  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419427] of age, body  size (weight, height, body  surface 
area, and bod y mass index), gender, ethnic origin, HIV status, and concurrent 
medications (such as oral and injectable contraceptives) on CAB and/or RPV PK may  be 
explored. P opulation PK anal yses will be done under separate Population -PK Reporting 
and Anal ysis Plan s.
[IP_ADDRESS]. Pharmacokinetic/Pharmacody namic A nalyses
Relationships between various plasma CAB and / or RPV PK parameters and 
pharmacod ynamic measures (e.g., HIV -1 RNA, or safet y measures) may be explored 
using simple correlation anal yses or population -based PK/PD approach.  Additional 
factors that may  be considered include age, weight, BMI, gender, race, Baseline HIV-1 
RNA, HIV risk factors, CDC classification, and CD4+ cell count.  Details of the PK/PD 
analyses plans for CAB and / or RPV will be provided in separate RAP s.
[IP_ADDRESS]. Viral Genoty pi[INVESTIGATOR_007]/Phenoty pi[INVESTIGATOR_007] A nalyses
The incidence of treatment emergent genot ypic and phenoty pic resistance to NRTI s and 
INIs will be summarized by [CONTACT_2939]. Details of the anal yses to be performed will 
be specified in the reporting and anal ysis plan (RAP).
[IP_ADDRESS]. Pharmacogenetic A nalyses
See Section 11.[ADDRESS_419428] CONSID ERA TIONS
9.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrolment of subjects begins.
9.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a study site, [COMPANY_004] will obtain favourable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the stud y in accordance with I CH Good Clinical 
Practice (GCP) and applicable country -specific regulatory  requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements.
The study  will be conducted in accordanc e with ICH GCP, all applicable subject privacy  
requirements, and the ethical principles that are outlined in the Declaration of Helsinki 
2008, including, but not limited to: 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419429] (IRB)/Independent Ethics Committee (I EC) review and 
favourable opi[INVESTIGATOR_1649]/approval of study  protocol and any  subsequent amendments.
Subject informed consent.
Investigator reporting requirements.
[COMPANY_004] will provide full details of the above procedures, either verball y, in writing, or 
both.
Written informed consent m ust be obtained from each subject prior to participation in the 
study .
In approving the clinical protocol the IEC/I RB and, where required, the applicable 
regulatory  agency  are also approving the optional assessments e.g., PGx assessments 
described in Secti on 11.3, unless otherwise indicated.  Where permitted by  [CONTACT_23999], approval of the optional assessments can occur after approval is obtained for 
the rest of the stud y.  If so, then the written appr oval will clearl y indicate approval of the 
optional assessments is being deferred and the study , except for the optional assessments, 
can be initiated.  When the optional assessments are not approved, then the approval for 
the rest of the stud y will clearl y indicate this and therefore, the optional assessments will 
not be conducted .
9.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations, GCP, and [COMPANY_004] procedures, [COMPANY_004] monitors 
will contact [CONTACT_339297], 
study  requirements, and their responsibilities to satisfy  regulatory , ethical, and [COMPANY_004] 
requirements.  When reviewing data collection procedures, the discussion will include 
identification, agreement and documentation of data items for which the eCRF will serve 
as the source document.
[COMPANY_004] will monitor the study  to ensure that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  other 
study  agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents.
9.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, [COMPANY_004] may  
conduct a qualit y assurance assessment and/or audit of the site records, and the regulatory  
agencies may  conduct a regulatory  inspection at any  time during or after completion of 
the study . In the event of an assessment, audit or inspection, the investigator (and 
institution) must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419430] of the stud y, an y findings/relevant issues and to implement any  corrective and/or 
preventative actions to address an y findings/issues identified.
9.5. Stud y and Site Closure
The study  is considered complete once all subjec ts have transitioned to commerciall y 
available IP, transitioned to another study  for access to I P, withdrawn or completed the 
study  per Section 3.2.
Upon completion or termination of the study , the [COMPANY_004] monitor w ill conduct site closure 
activities with the investigator or site staff (as appropriate), in accordance with applicable 
regulations, GCP, and [COMPANY_004] Standard Operating Procedures.
[COMPANY_004] reserves the right to temporaril y suspend or terminate the stud y at an y tim e for 
reasons including (but not limited to) safety issues, ethical issues, or severe non -
compliance.  If [COMPANY_004] determines that such action is required, [COMPANY_004] will discuss the 
reasons for taking such action with the investigator or head of the medical institut ion 
(where applicable).  When feasible, [COMPANY_004] will provide advance notice to the investigator 
or head of the medical institution of the impending action.
If a study is suspended or terminated for safety reasons
, [COMPANY_004] will promptly inform all 
investigators, he ads of the medical institutions (where applicable ), and /or institutions 
conducting the study .  [COMPANY_004] will also promptly  inform the relevant regulatory  authorities 
of the suspension/termination along with the reasons for such action.  Where required b y 
applic able regulations, the investigator or head of the medical institution must inform the 
IRB/IEC promptly  and provide the reason(s) for the suspension/termination.
9.6. Records Retention
Following closure of the study , the investigator or head of the medical insti tution (where 
applicable) must maintain all site study records (except for those required by  [CONTACT_24000]) in a safe and secure location.  The records must 
be easil y accessible when needed (e.g., for a [COMPANY_004] audit or regulator y inspection) and 
must be available for review in conjunction with assessment of the facility , supporting 
systems, and relevant site staff.
Where permitted b y local laws/regulations or institutional policy, some or all of the 
records may  be maintained in a format other than hard cop y (e.g., microfiche, scanned, 
electronic); however, caution must be exercised before such action is taken.  The 
investigator must ensure that all reproductions are legible and are a true and accurate 
copy  of the original.  In addition, they  must meet accessibility  and retrieval standards, 
including regeneration of a hard cop y, if required.  The investigator must also ensure that 
an acceptable back -up of the reproductions exists and that there is an acceptable quality  
control proce dure in place for creating the reproductions.
[COMPANY_004] will inform the investigator of the time period for retaining the site records in order 
to comply  with all applicable regulatory  requirements.  The minimum retention time will  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419431] ap plicable to a particular site, as dictated b y local 
laws/regulations, [COMPANY_004] standard operating procedures, and/or institutional requirements.
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, including, 
but not limited to archival of records at an off -site facility  or transfer of ownership of the 
records in the event that the investigator is no longer associated with the site.
9.7. Provision of Study  Results to Investigators, Posting of 
Information on Publicly  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
The results summary  will be posted to the Clinical Study  Register no later than eight 
months after the final primary completion date, the date that the final subject was 
examined or rece ived an intervention for the purposes of final collection of data for the 
primary  outcome.  In addition, a manuscript will be submitted to a peer reviewed journal 
for publication no later than [ADDRESS_419432]’s last visit (L SLV).  When 
manuscript publication in a peer reviewed journal is not feasible, a statement will be 
added to the register to explain the reason for not publishing.
9.8. Independent Data Monitoring Committee (IDMC)
An IDMC will be utilised in this study  to ensure external objec tive medical and/or 
statistical review of safety  and/or efficacy  issues in order to protect the ethical and safet y 
interests of subjects and to protect the scientific validity  of the study .  The schedule of 
any planned interim analy sis and the anal ysis pla n for IDMC review is described in the 
charter, which is available upon request. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
[ZIP_CODE]. REFERENCES
Arribas J, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklingoff C. The MONET 
trial: week 144 analy sis of the efficacy  of darunavir/ritonavir (DRV/r) monotherapy  
versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral 
load <50 copi[INVESTIGATOR_014]/ml at baseline. HIV MED, 2012 Aug;13(7):398 -405.
Bierman WF, van Aqtamael MA, Nijhuis M, Danner SA, Boucher CA. HIV 
monotherap y with ritonavir -boosted protease inhibitors: a sy stematic review. AIDS, 2009; 
23(3):279-91.
Centers for Disease Control and Prevention (CDC) 1993 revised classification sy stem for 
HIV infection and expanded surveillance case definition for AIDS among adolescents 
and adults. MMWR 1992; 41(No. RR -17):1-19.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. 
Nephron 1976; 16:31-41.
Cohen C, Andrade -Villanueva J, Clotet B, et al. Rilpi[INVESTIGATOR_339184]- naïve 
adults infected with HIV -1 (THRIVE): a Phase 3, randomized, non- inferiority  trial. 
Lancet. 2011; 378:229-37.
Cohen C, Molina JM, Cahn P, et at.  Efficacy  and Safety  of Rilpi[INVESTIGATOR_12979] (TMC278) Versus 
Efavirenz at 48 Weeks in Treatment- Naïve HIV -1-Infected Patients:  Pooled Results 
From the Phase 3 Double -Blind Randomized ECHO and THRIVE Trials.  JAIDS .  2012; 
60 (1):33-42.
Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of 
dyslipi[INVESTIGATOR_339185] (HIV)- infected adults receiving 
antiretroviral therap y: recommendations of the HIV Medical Association of the Infectious 
Disease Societ y of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 
2003; 37(5) :613-27.
Edurant Product Information (rilpi[INVESTIGATOR_12979]) May , [ADDRESS_419433] I nformation (abacavir/lamivudine) May , 2012.
European AIDS Clinical Society  (EACS) Guidelines for the clinical management and 
treatment of HIV Infected Adults in Europe, Version 6.1, 2012. Available at 
http://www.europeanaidsclinicalsociet y.org/guidelines.asp
GlaxoSmithKline Document Number 2011N112455_03: L AI115428 A Randomized, 
Open Label Stud y to Investigate the Safet y, Tolerability  and Pharmacokinetics of Repeat 
Dose Administr ation of Long -Acting [COMPANY_004]1265744 and Long -Acting TMC278 
Intramuscular and Subcutaneous Injections in Healthy  Adult.  Effective Date:  
04Feb2013.   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
167GlaxoSmithKline Document Number 2011N117114_01:  I NG112276 A Phase IIb study  
to select a once dail y oral dose of [COMPANY_004]1349572 administered with either 
abacavir/lamivudine or tenofovir/emtricitabine in HIV- 1 infected antiretroviral therapy  
naïve adult subjects.  Effective Date:  16Nov2012
GlaxoSmithKline Document Number 2012N134026_02:  L AI116482 A Phase IIb, dose 
ranging stud y of oral [COMPANY_004]1265744 in combination with nucleoside reverse transcriptase 
inhibitors for induction of HIV -1 virologic suppression followed by  [CONTACT_339298]1265744 is combined with oral 
rilpi[INVESTIGATOR_339186] V-1 infected, antiretroviral therapy naive adult subjects.  Effective Date:  
11June2012.
GlaxoSmithKline Document Number RH2009/[ZIP_CODE]/03:  [COMPANY_004]1265744 Investigator’s 
Brochure.  Effective Date:   3Sep2013.
GlaxoSmithKline Document Number RM2008/006 33/00: I TZ111451 A Double -Blind, 
Parallel, Randomized, Placebo -Controlled, Single and Repeat Dose Escalation First Time 
in Human Study  to Investigate the Safet y, Tolerability  and Pharmacokinetics of 
[COMPANY_004]1265744 in Healthy  Male and Female Subjects and Subjec ts Infected with HI V. 
May 2009.
GlaxoSmithKline Document Number RM2009/[ZIP_CODE]/00. I TZ112929 A Phase 2a Study  
to Compare Antiviral Effect, Safet y, Tolerability and Pharmacokinetics of [COMPANY_004]1265744 
Monotherap y Versus Placebo in HIV -1 Infected Adults.  Effective Date: 14May 2010.
GlaxoSmithKline Document Number RM2010/[ZIP_CODE]/04: L AI114433 An Observer -and 
Subject -Blinded, Randomized, Placebo- Controlled, Single Dose Escalation Study  to 
Investigate the Safety , Tolerability  and Pharmacokinetics of Intramuscular and 
Subcutaneous Long Acting [COMPANY_004]1265744 in Healthy  Subjects.  Effective Date: Oct 2011
Guidance for Industry . Antiretroviral Drugs Using Plasma HIV RNA Measurements -
Clinical Considerations for Accelerated and Traditional Approval. U.S. Department of 
Health and Human Services Food and Drug Administration Center for Drug Evaluation 
and Research (CDER). October 2002.
http://www.ich.org/fileadmin/Public_Web_Site/I CH_Products/Guidelines/Efficacy /E2A/
Step4/E2A_Guideline.pdf , 27 October 1994
International AIDS Society  (IAS) Guidelines - Update of the Drug Resistance Mutations 
in HIV -1: March 2013. Topi[INVESTIGATOR_339187]; 21(1):4 -12.
Lou Y, Chen S.  Analy sis of Aggregated Safet y Data to Support HIV 744 LAP 
[COMPANY_004]1265744 Phase IIb/III Clinical Development.  53rd I CAA C Interscience Conference 
on Antimicrobial Agents and Chemotherap y September 10-13, 2013
Margolis, D, et al.  Cabotegravir and Rilpi[INVESTIGATOR_339188] -Drug Oral Maintenance 
Therap y: LATTE Week 96 Results.  22nd Conference on Retroviruses and Opportunistic 
Infections; February  23-26, 2015 Poster 554LB 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
168Molina JM, Cahn, P, Grinsztejn B, et al. Rilpi[INVESTIGATOR_339189]-naive adults infected with HIV- 1 (ECHO): a phase 3 
randomised double -blind active -controlled trial. Lancet. 2011;378:238-46.
Oquendo MA, Mann J. Risk Factors for suicidal behaviour: utility  and limitations of 
research instruments (2003). In M.B. First [Ed] Standardized Evaluation in Clinical 
Practice, pp 103- 130.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of 
antiretroviral agents in HIV -1-infected adults and adolescents. Department of Health and 
Human Services. DHHS 2013 Available at 
http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
Rashbaum B, Girard P, et al Initial tolerabilit y of rilpi[INVESTIGATOR_339190]: grade 1 events 
during weeks 0–[ADDRESS_419434] P, et al Rilpi[INVESTIGATOR_12979] (TMC278) tolerability over the first [ADDRESS_419435] M. (1997). Statistical Evidence: A L ikelihood Paradig m. London:  
Chapman & Hall.
TMC278 [Rilpi[INVESTIGATOR_12979], oral and parenteral] I ntegrated I nvestigator’s Brochure. 201 6
Effective Date: April 2016.
UNAIDS:  2012 AIDS Epi[INVESTIGATOR_339191]:  
http://www.unaids.org/en/media/unaids/contentassets/documents/epi [INVESTIGATOR_623] /2012/gr2
012/20121120_UNAIDS_Global_Report_2012_with_annexes_en.pdf
Woodcock A, Bradley  C(2001). Validation of the HIV Treatment Satisfaction 
Questionnaire (HIVTSQ). Quality of Life Research. 10:517-531.
Woodcock A, Bradley  C(2006). Validatio n of the Revised 10- item HIV Treatment 
Satisfaction Questionnaire Status Version and New Change Version. Value in Health.
9:320-333 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
[ZIP_CODE]. APPENDICES
11.1. Appendix 1: CDC Classification Sy stem for HIV -1 Infections 
(1993)
Clinical Categories
The clinical categories of HIV infection are defined as follows:
Category A
Category  A consists of one or more of the conditions listed below in an adolescent or 
adult (>13 years) with documented HIV infection.  Conditions listed in Categories B and 
C must not have occurred.
Asymptomatic HIV infection
Persistent generalized l ymphadenopath y
Acute (primary ) HIV infection with accompany ing illness or history  of acute 
HIV infection
Category B (Symptomatic non -AIDS conditions)
Category  B consists of symptomatic conditions in an HIV -infec ted adolescent or adult 
that are not included among conditions listed in clinical Category  C and that meet at least 
one of the following criteria:  a) the conditions are attributed to HIV infection or are 
indicative of a defect in cell -mediated immunity ; or b) the conditions are considered b y 
physicians to have a clinical course or to require management that is complicated by  [CONTACT_339299].  
Examples of conditions in clinical Category  B include, but are not limited to:
Bacillary  angiomatosis
Candidiasis, o rophary ngeal (thrush)
Candidiasis, vulvovaginal; persistent, frequent, or poorly  responsive to therapy
Cervical d ysplasia (moderate or severe)/cervical carcinoma in situ
Constitutional sy mptoms, such as fever (38.5 C) or diarrhea lasting >1 month
Hairy  leukoplakia, oral
Herpes zoster (shingles), involving at least two distinct epi[INVESTIGATOR_339192]
Idiopathic thrombocy topenic purpura
Listeriosis
Pelvic inflammatory  disease, particularl y if complicated b y tubo -ovarian abscess 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
170Peripheral neuropa thy
For classification purposes, Category  B conditions take precedence over those in 
Category  A.  For example, someone previously  treated for oral or persistent vaginal 
candidiasis (and who has not developed a Category  C disease) but who is now 
asymptomati c should be classified in clinical Category  B.
Category C (AIDS indicator conditions as defined by  [CONTACT_339300]).
Category  C includes the clinical conditions listed in the AIDS surveillance case 
definition.  For classification purpose s, once a Category  C condition has occurred, the 
person will remain in Category  C.
Conditions in Category  C include:
Candidiasis of bronchi, trachea, or lungs
Candidiasis, esophageal
Cervical cancer, invasive
Coccidioidomy cosis, disseminated or extrapulmon ary
Cryptococcosis, extrapulmonary
Cryptosporidiosis, chronic intestinal (>1 month’s duration)
Cytomegalovirus disease (other than liver, spleen, or nodes)
Cytomegalovirus retinitis (with loss of vision)
Encephalopath y, HIV-related
Herpes simplex:  chronic ulcer(s) (>1 month’s duration);or bronchitis, 
pneumonitis, or esophagitis
Histoplasmosis, disseminated or extrapulmonary
Isosporiasis, chronic intestinal (>1 month’s duration)
Kaposi’s sarcoma
Lym phoma, Burkitt’s (or equivalent term)
Lym phoma, immunoblast ic (or equivalent term)
Lym phoma, primary , of brain
Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary
Mycobacterium tuberculosis, any  site (pulmonary or extrapulmonary )
Mycobacterium, other species or unidentified species, dissemin ated or 
extrapulmonary
Pneumocy stis carinii pneumonia
Pneumonia, recurrent 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
171Progressive multifocal leukoencephalopathy
Salmonella septicemia, recurrent
Toxoplasmosis of brain
Wasting sy ndrome due to HIV
Non-CDC, HIV -associated conditions. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
[ZIP_CODE].2. Appendix 2: Divis ion of A IDS Table for Grading the Severity  
of Adult and Pediatric A dverse Events
VERSI ON 1.0, DECEMBER 2004; CL ARIFICATION AUGUST 2009
The Division of AIDS Table for Grading the Severity  of Adult and Pediatric Adverse 
Events (“DAIDS AE Grading Table”) is a descriptive terminology  which can be utilized 
for Adverse Event (AE) reporting. A grading (severity ) scale is provided for each AE 
term. 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
173CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
ESTIMATING SE VERITY GRADE1
Clinical adverse event NOT 
identified elsewhere in this DAIDS 
AE grading tableSymptoms causing no or minimal 
interference with usual social & 
functional activities3, 4Symptoms causing greater than 
minimal interference with usual 
social & f unctional activities3, 4Symptoms causing inability to 
perform usual social & functional 
activities3, 4Symptoms causing inability to perform 
basic self -care functions1, 2OR Medical 
or operative intervention indicated to 
prevent permanent impairment, 
persistent disability, or death
SYSTEMIC
Acute systemic allergic reaction Localized urticaria (wheals) with 
no medical intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild bronchospasmAcute anaphylaxis OR Life -threatening 
bronchospasm OR laryngeal edema
Chills Symptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activitiesNA
Fatigue
MalaiseSymptoms causing no or minimal 
interference with usual so cial & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activitiesIncapacitating fatigue/malaise 
symptoms
causing inability t o perform basic self -
care functions
Fever (nonaxillary) 37.7 – 38.6C 38.7 – 39.3C 39.4 – 40.5C > 40.5 C
Pain (indicate body site)
DO NOT use for pain due to 
injection (See Injection Site 
Reactions: Injection site pain)
See also Headache, Arthralgia,
and MyalgiaPain causing no or minimal 
interference with usual social & 
functional activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to perform 
usual social & functional activitiesDisabling pain causing inability to 
perform basic self -care functions OR 
Hospi[INVESTIGATOR_059] (other than emergency 
room visit) indicated
Unintentional weight loss NA 5 –9% loss in body weight from 
baseline10 –19% loss in body weight from 
baseline20% loss in body weight from 
baseline OR Aggressive intervention 
indicated [e.g., tube feeding or total 
parenteral nutrition (TPN)] 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
174CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
INFECTION
Infection (any other than HIV 
infection)Localized, no systemic 
antimicrobial treatment indicated 
AND Symptoms causing n o or 
minimal interference with usual 
social & functional activitiesSystemic antimicrobial treatment 
indicated OR Symptoms causing 
greater than minimal interference 
with usual social & functional 
activitiesSystemic antimicrobial treatment 
indicated AND Sy mptoms causing 
inability to perform usual social & 
functional activities OR Operative 
intervention (other than simple 
incision and drainage) indicatedLife-threatening consequences (e.g., 
septic shock)
INJECTION SITE REACTIONS
Injection site pain (pain w ithout 
touching)
Or
Tenderness (pain when area is 
touched)Pain/tenderness causing no or 
minimal limitation of use of limbPain/tenderness limiting use of limb 
OR Pain/tenderness causing 
greater than minimal interference 
with usual social & functional 
activitiesPain/tenderness causing inability to 
perform usual social & functional 
activitiesPain/tenderness causing inability to 
perform basic self -care function OR 
Hospi[INVESTIGATOR_059] (other than emergency 
room visit) indicated for management 
of pain/tendernes s
Injection site reaction (localized)
Adult > 15 years Erythema OR Induration of 5x5 cm 
–9x9 cm (or 25 cm2–81cm2)Erythema OR Induration OR
Edema > 9 cm any diameter (or > 
81 cm2)Ulceration OR Secondary infection 
OR Phlebitis OR Sterile abscess OR 
DrainageNecrosis (involving dermis and deeper
tissue)
Pediatric 15 Years Erythema OR Induration OR 
Edema present but  2.5 cm 
diameterErythema OR Induration OR 
Edema > 2.5 cm diameter but < 
50% surface area of the extremity 
segment (e.g., upper arm/th igh)Erythema OR Induration OR Edema 
involving 50% surface area of the 
extremity segment (e.g., upper 
arm/thigh) OR Ulceration OR 
Secondary infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis and deeper 
tissue)
Pruritis asso ciated with injection
See also Skin: Pruritis (itching -no 
skin lesions)Itching localized to injection site 
AND Relieved spontaneously or 
with < 48 hours treatmentItching beyond the injection site but 
not generalized OR Itching 
localized to injection s ite requiring 
48 hours treatmentGeneralized itching causing inability 
to perform usual social & functional 
activitiesNA 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
175CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
SKIN –DERMATOLOGICAL
Alopecia Thinning detectable by [CONTACT_8712] (or by [CONTACT_227429])Thinning or patchy hair loss 
detectable by [CONTACT_227430] –rash Localized macular rash Diffuse macular, maculopapular, or 
morbilliform rash OR Target lesionsDiffuse macular, maculopapular, or 
morbilliform ra sh with vesicles or 
limited number of bullae OR 
Superficial ulcerations of mucous 
membrane limited to one siteExtensive or generalized bullous 
lesions OR Stevens -Johnson 
syndrome OR Ulceration of mucous 
membrane involving two or more 
distinct mucosal site s OR Toxic 
epi[INVESTIGATOR_194] (TEN)
Hyperpi[INVESTIGATOR_10810] (itching –no skin lesions)
(See also Injection Site Reactions: 
Pruritis a ssociated with injection)Itching causing no or minimal 
interference with usual social & 
functional activitiesItching causing greater than 
minimal interference with usual 
social & functional activitiesItching causing inability to perform 
usual social & f unctional activitiesNA
CARDIOVASCULAR
Cardiac arrhythmia (general)
(By [CONTACT_10871])Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -urgent 
medical intervention indicatedSymptomatic, non -life-threatening 
AND Non -urgent medical intervention 
indicatedLife-threatening arrhythmia OR Urgent 
intervention indicated
Cardiac -ischemia/infarction NA NA Symptomatic ischemia (stable 
angina) OR Testing consistent with 
ischemiaUnstable angina OR Acute myocardial 
infarction
Hemorrhage (sign ificant acute 
blood loss)NA Symptomatic AND No transfusion 
indicatedSymptomatic AND Transfusion of 2 
units packed RBCs (for children 10 
cc/kg) indicatedLife-threatening hypotension OR 
Transfusion of > 2 units packed RBCs 
(for children >10 cc/kg) ind icated
Hypertension
Adult > 17 years
(with repeat testing at same 
visit)140 –159 mmHg systolic
OR
90 –99 mmHg diastolic160 –179 mmHg systolic
OR
100 – 109 mmHg diastolic180 mmHg systolic
OR
110 mmHg diastolicLife-threatening consequence s (e.g., 
malignant hypertension) OR 
Hospi[INVESTIGATOR_374] (other than 
emergency room visit) 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
176CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Pediatric 17 Years
(with repeat testing at same 
visit)NA 91st –94thpercentile adjusted for 
age, height, and gender (systolic 
and/or diastolic)95thpercentile adjusted for age, 
height, and gender (systolic and/or 
diastolic)Life-threatening consequences (e.g., 
malignant hypertension) OR 
Hospi[INVESTIGATOR_374] (other than 
emergency room visit)
Hypotension NA Symptomatic, corrected with oral 
fluid repla cementSymptomatic, IV fluids indicated Shock requiring use of vasopressors or 
mechanical assistance to maintain 
blood pressure
Pericardial effusion Asymptomatic, small effusion 
requiring no interventionAsymptomatic, moderate or larger 
effusion requiring no interventionEffusion with non -life threatening 
physiologic consequences OR 
Effusion with non -urgent intervention 
indicatedLife-threatening consequences (e.g., 
tamponade) OR Urgent intervention 
indicated
Prolonged PR interval
Adult > 16 years PR interval
0.21 – 0.25 secPR interval
> 0.25 secType II 2nddegree AV block OR 
Ventricular pause > 3.0 secComplete AV block
Pediatric 16 Years 1stdegree AV block (PR > normal 
for age and rate)Type I 2nddegree AV block Type II 2nddegree AV block Com plete AV block
Prolonged QTc
Adult > 16 years Asymptomatic, QTc interval 
0.45-0.47 sec OR Increase interval 
<0.03 sec above baselineAsymptomatic, QTc interval 
0.48-0.49 sec OR Increase in 
interval 0.03 –0.05 sec above 
baselineAsymptomatic, QTc inter val 0.50 
sec OR Increase in interval 0.06 
sec above baselineLife-threatening consequences, e.g., 
Torsade de pointes or other associated 
serious ventricular dysrhythmia
Pediatric 16 years Asymptomatic, QTc interval 
0.450 –0.464 secAsymptomatic, QTc interval 
0.465 -0.479 secAsymptomatic, QTc
interval 0.480 secLife-threatening consequences, e.g., 
Torsade de pointes or other associated 
serious ventricular dysrhythmia
Thrombosis/embolism NA Deep vein thrombosis AND No 
intervention indicated (e.g., 
anticoagulation, lysis filter, invasive 
procedure)Deep vein thrombosis AND 
Intervention indicated (e.g., 
anticoagulation, lysis filter, invasive 
procedure)Embolic event (e.g., pulmonary 
embolism, life -threatening thrombus)
Vasovagal epi[INVESTIGATOR_1865] (associated 
with a procedure of any kind)Present without loss of 
consciousnessPresent with transient loss of 
consciousnessNA NA
Ventricular dysfunction 
(congestive heart failure)NA Asymptomatic diagnostic finding 
AND intervention indicatedNew onset with symptoms OR 
Worsening symptomatic congestive 
heart failureLife-threatening congestive heart 
failure 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
177CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
GASTROINTESTINAL
Anorexia Loss of appetite without decreased 
oral intakeLoss of appetite associated with 
decreased oral intake without 
significant weight lossLoss of appetite associated with 
significant weight lossLife-threatening consequences OR 
Aggressive intervention indicated [e.g., 
tube feeding or   total parenteral 
nutrition (TPN)]
Comment: Please note that, while the grading scale provided for Unintentio nal Weight Loss may be used as a guideline when grading anorexia, this is not a requirement and should 
not be used as a substitute for clinical judgment.
Ascites Asymptomatic Symptomatic AND Intervention 
indicated (e.g., diuretics or 
therapeutic paracente sis)Symptomatic despi[INVESTIGATOR_227345]-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or operative 
intervention indicatedLife-threatening consequences (e.g., 
sepsis or perforation)
Constipation NA Persistent constipation requiring 
regular use of dietary modifications, 
laxatives, or enemasObstipation with manual evacuation 
indicatedLife-threatening consequences (e.g., 
obstruction)
Diarrhea
Adult and
Pediatric 1 yearTransient or intermittent epi[INVESTIGATOR_227346] 
3 stools over baseline per 24 -hour 
periodPersistent epi[INVESTIGATOR_227347] 4 –6 
stools over baseline per 24 -hour 
periodBloody diarrhea OR Increase of 7 
stools per 24 -hour period OR IV fluid 
replacement indicatedLife-threatening consequences (e.g., 
hypotensive shock)
Pediatric < 1 year Liquid stools (more unformed than 
usual) but usual number of stoolsLiquid stools with increased number 
of stools OR Mild dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in severe 
dehydration with aggressive 
rehydration indicated OR Hypotensive 
shock
Dysphagia -
OdynophagiaSymptomatic but able to eat usual 
dietSymptoms causing altered dietary 
intake without medical intervention 
indicatedSymptoms causing severely altered 
dietary intake with medical 
intervention indicatedLife-threatening reduction in oral intake 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
178CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Mucositis/stomatitis ( clinical 
exam )
Indicate site (e.g., larynx, oral)
See Genitourinary for 
Vulvovaginitis 
See also Dysphagia -Odynophagia 
and ProctitisErythema of the mucosa Patchy pseudomembranes or 
ulcerationsConfluent pseudomembranes or 
ulcerations OR Mucosal bleeding 
with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding OR 
Life-threatening consequences (e.g., 
aspi[INVESTIGATOR_1516], choking)
Nausea Transient (< 24 hours) or 
intermittent nausea with no or 
minimal interference with oral 
intakePersistent nausea resulting in 
decreased oral intake for 24 –48 
hoursPersistent nausea re sulting in 
minimal oral intake for > 48 hours OR 
Aggressive rehydration indicated 
(e.g., IV fluids)Life-threatening consequences (e.g., 
hypotensive shock)
Pancreatitis NA Symptomatic AND Hospi[INVESTIGATOR_227348] (other than 
emergency room visit)Symptomatic AND Hospi[INVESTIGATOR_373] (other than emergency 
room visit)Life-threatening consequences (e.g., 
circulatory failure, hemorrhage, sepsis)
Proctitis (functional -symptomatic)
Also see Mucositis/stomatitis for 
clinical examRectal discomfort AN D No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicatedSymptoms causing inability to 
perform usual social & functional 
activities OR Operative intervention 
indicatedLife-threatening consequences (e.g., 
perforation)
Vomiting Transient or intermittent vomiting 
with no or minimal interference 
with oral intakeFrequent epi[INVESTIGATOR_227349] 
(e.g., IV fluids)Life-threatening consequences (e.g., 
hypotensive shock) 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
179CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
NEUROLOGIC
Alteration in personality -behavior 
or in mood (e.g., agitation, 
anxiety, depression, mania, 
psychosis)Alteration causin g no or minimal 
interference with usual social & 
functional activitiesAlteration causing greater than 
minimal interference with usual 
social & functional activitiesAlteration causing inability to perform 
usual social & functional activitiesBehavior pote ntially harmful to self or 
others (e.g., suicidal and homicidal 
ideation or attempt, acute psychosis) 
OR Causing inability to perform basic 
self-care functions
Altered Mental Status
For Dementia, see Cognitive and 
behavioral/attentional disturbance 
(including dementia and attention 
deficit disorder)Changes causing no or minimal 
interference with usual social & 
functional activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social & 
functional activitiesConfusion, m emory impairment, 
lethargy, or somnolence causing 
inability to perform usual social & 
functional activitiesDelirium OR obtundation, OR coma
Ataxia Asymptomatic ataxia detectable on 
exam OR Minimal ataxia causing 
no or minimal interference with 
usual  social & functional activitiesSymptomatic ataxia causing greater 
than minimal interference with usual 
social & functional activitiesSymptomatic ataxia causing inability 
to perform usual social & functional 
activitiesDisabling ataxia causing inability to 
perform basic self -care functions
Cognitive and 
behavioral/attentional disturbance 
(including dementia and attention 
deficit disorder)Disability causing no or minimal 
interference with usual social & 
functional activities OR 
Specialized resources not 
indicatedDisability causing greater than 
minimal interference with usual 
social & functional activities OR 
Specialized resources on part -time 
basis indicatedDisability causing inability to perform 
usual social & functional activities OR 
Specialized resources on a full -time 
basis indicatedDisability causing inability to perform 
basic self -care functions OR 
Institutionalization indicated
CNS ischemia (acute) NA NA Transient ischemic attack Cerebral vascular accident (CVA, 
stroke) with neurological deficit
Developmental delay
–Pediatric 16 YearsMild developmental delay, either 
motor or cognitive, as determined 
by [CONTACT_7425] a 
developmental screening tool 
appropriate for the settingModerate developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7425] a 
developmental screening tool 
appropriate for the settingSevere developmental delay, either 
motor or cognitive, as determined by 
[CONTACT_7425] a developmental 
screening tool appropriate for the 
settingDevelopmental regression, eithe r 
motor or cognitive, as determined by 
[CONTACT_7425] a developmental 
screening tool appropriate for the 
setting
Headache Symptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater than 
minimal interfer ence with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activitiesSymptoms causing inability to perform 
basic self -care functions OR 
Hospi[INVESTIGATOR_374] (other than 
emergency room visit) OR Head ache 
with significant impairment of alertness 
or other neurologic function 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
180CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Insomnia NA Difficulty sleepi[INVESTIGATOR_227350] & functional activitiesDifficulty sleepi[INVESTIGATOR_114750] & functional 
activitiesDisabling insomnia causing inability to 
perform basic self -care functions
Neuromuscular weakness 
(including myopathy & 
neuropathy)Asymptomatic with decreased 
strength on exam OR Minimal 
muscle weakness causing no or 
minimal interfer ence with usual 
social & functional activitiesMuscle weakness causing greater 
than minimal interference with usual 
social & functional activitiesMuscle weakness causing inability to 
perform usual social & functional 
activitiesDisabling muscle weakness c ausing 
inability to perform basic self -care 
functions OR Respi[INVESTIGATOR_339193] (including 
paresthesia and painful 
neuropathy)Asymptomatic with sensory 
alteration on exam or minimal 
paresthesia causing n o or minimal 
interference with usual social & 
functional activitiesSensory alteration or paresthesia 
causing greater than minimal 
interference with usual social & 
functional activitiesSensory alteration or paresthesia 
causing inability to perform usual 
social & functional activitiesDisabling sensory alteration or 
paresthesia causing inability to perform 
basic self -care functions
Seizure: ( new onset )
–Adult 18 years
See also Seizure: (known pre -
existing seizure disorder)NA 1 seizure 2 –4 seizures Seizures of any kind which are 
prolonged, repetitive (e.g., status 
epi[INVESTIGATOR_7397]), or difficult to control (e.g., 
refractory epi[INVESTIGATOR_002])
Seizure: ( known pre -existing 
seizure disorder )
–Adult 18 years
For worsening of existing epi[INVESTIGATOR_339194].NA Increased frequency of pre -existing 
seizures (non -repetitive) without 
change in seizure character OR 
Infrequent break -through seizures 
while on stable medication in a 
previously controlled seizure 
disorderChange in seizure character from 
baseline either in duration or quality 
(e.g., severity or focality)Seizures of any kind which are 
prolonged, repetitive (e.g., status 
epi[INVESTIGATOR_7397]), or difficult to control (e.g., 
refractory epi [INVESTIGATOR_002])
Seizure
–Pediatric < 18 yearsSeizure, generalized onset with or 
without secondary generalization, 
lasting < 5 minutes with < [ADDRESS_419436] ictal stateSeizure, generalized onset with or 
without secondary generalization, 
lasting 5 –20 minutes wit h <[ADDRESS_419437] ictal stateSeizure, generalized onset with or 
without secondary generalization, 
lasting >20 minutesSeizure, generalized onset with or 
without Secondary generalization, 
requiring intubation and sedation
Syncope (not associated with a 
procedure)NA Present NA NA 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
181CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Vertigo Vertigo causing no or minimal 
interference with usual social & 
functional activitiesVertigo causing greater than 
minimal interference with usual 
social & functional activitiesVertigo causing inability to perform 
usual so cial & functional activitiesDisabling vertigo causing inability to 
perform basic self -care Functions
RESPI[INVESTIGATOR_111092] (acute) FEV1 or peak flow reduced to 
70-80%FEV1 or peak flow 50 –69% FEV1 or peak flow 25 –49% Cyanosis OR FEV1 or peak flow < 
25% OR Intubation
Dyspnea or respi[INVESTIGATOR_111093] 14 years Dyspnea on exertion with no or 
minimal interference with usual 
social & functional activitiesDyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activitiesDyspnea at rest causing inability to 
perform usual social & functional 
activitiesRespi[INVESTIGATOR_227353] < 14 years Wheezing OR minimal increase in 
respi[INVESTIGATOR_339195] 90 –
95%Dyspnea at rest causing inability to 
perform usual social & functional 
activities OR Pulse oximetry < 90%Respi[INVESTIGATOR_339196] & 
functional activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability to perform 
usual social & functional activitiesDisabling joint pain causing inability to 
perform basic self -care Functions
Arthritis
See also ArthralgiaStiffness or joint swelling causing 
no or minimal interference with 
usual social & functional activitiesStiffness or joint swelling causing 
greater t han minimal interference 
with usual social & functional 
activitiesStiffness or joint swelling causing 
inability to perform usual social & 
functional activitiesDisabling joint stiffness or swelling 
causing inability to perform basic self -
care functions
Bone Mineral Loss
Adult 21 years BMD t -score -2.5 to -1.0 BMD t -score < -2.5 Pathological fracture (including loss 
of vertebral height)Pathologic fracture causing life -
threatening Consequences
Pediatric < 21 years BMD z -score -2.5 to -1.0 BMD z -score < -2.5 Pathological fracture (including loss 
of vertebral height)Pathologic fracture causing life -
threatening Consequences
Myalgia ( non-injection site ) Muscle pain causing no or 
minimal interference with usual 
social & functional activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing inability to 
perform usual social & functional 
activitiesDisabling muscle pain causing inability 
to perform basic self -care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR Operative 
intervention indicatedDisabling bone pain with radiographic 
findings causing inability to perform 
basic self -care functions 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
182CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
GENITOURINARY
Cervicitis ( symptoms )
(For use in studies evaluating 
topi[INVESTIGATOR_144491])
For other cervicitis see Infection: 
Infection (any other than HIV 
infection)Symptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activitiesSymptoms causing inability to perform 
basic self -care functions
Cervicitis (clinical exam )
(For use in studies evaluating 
topi[INVESTIGATOR_144491])
For other cervicitis see Infection: 
Infection (any other than HIV 
infection)Minimal cervical abnormalities on 
examination (erythema,
Mucopurulent discharge, or 
friability) OR Epi[INVESTIGATOR_24603] l disruption < 
25% of total surfaceModerate cervical abnormalities on 
examination (erythema, 
mucopurulent discharge, or 
friability) OR Epi[INVESTIGATOR_111101] 
25 –49% total surfaceSevere cervical abnormalities on 
examination (erythema, 
mucopurulent discharge, or friability) 
OR Epi[INVESTIGATOR_111100] 50 –75% 
total surfaceEpi[INVESTIGATOR_111100] > 75% total 
surface
Inter-menstrual bleeding (IMB) Spotting observed by [CONTACT_227431]-menstrual bleeding not greater 
in duration or amount than usual 
menstrual cycleInter-menstrual bleeding greater in 
duration or amount than usual 
menstrual cycleHemorrhage with life -threatening 
hypotension OR Operative intervention 
indicated
Urinary tract o bstruction (e.g., 
stone)NA Signs or symptoms of urinary tract 
obstruction without hydronephrosis 
or renal dysfunctionSigns or symptoms of urinary tract 
obstruction with hydronephrosis or 
renal dysfunctionObstruction causing life -threatening 
consequences
Vulvovaginitis ( symptoms )
(Use in studies evaluating topi[INVESTIGATOR_111097]) 
For other vulvovaginitis see 
Infection: Infection (any other than 
HIV infection)Symptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activitiesSymptoms causing inability to perform 
basic self -care functions 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
183CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Vulvovaginitis ( clinical exam )
(Use in studies evaluating topi[INVESTIGATOR_111097])
For other vulvovaginitis see 
Infection: Infection (any other than 
HIV infection)Minimal vaginal abnormalities on 
examination OR Epi[INVESTIGATOR_111098] <25% of total surfaceModerate vaginal abnormalities on
examination OR Epi[INVESTIGATOR_111099] 25 -49% total surfaceSevere vaginal abnormalities on 
examination OR Epi[INVESTIGATOR_111100] 
50 -75% total surfaceVaginal perforation OR Epi[INVESTIGATOR_111098] > 75% total surface
OCULAR/VISUAL
Uveitis Asymptomati c but detectable on 
examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR Operative 
intervention indicatedDisabling visual loss in affected eye(s)
Visual changes (from baseline) Visual changes causing no or 
minim al interference with usual 
social & functional activitiesVisual changes causing greater 
than minimal interference with usual 
social & functional activitiesVisual changes causing inability to 
perform usual social & functional 
activitiesDisabling visual l oss in affected eye(s)
ENDOCRINE/METABOLIC
Abnormal fat accumulation (e.g., 
back of neck, breasts, abdomen)Detectable by [CONTACT_111186] (or 
by [CONTACT_227432])Detectable on physical exam by 
[CONTACT_339301][INVESTIGATOR_10820]-threatening consequences (e.g., 
ketoacidosis, hyperosmolar non -ketotic 
coma)
Gynecomastia Detectable by [CONTACT_114836] (for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_339302] & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social & functional 
activities OR Uncontrolled despi[INVESTIGATOR_111102]-threatening consequences (e.g., 
thyroid storm) 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
184CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
socia l & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & functional 
activities OR Uncontrolled despi[INVESTIGATOR_111102]-threatening consequences (e.g., 
myxedema coma)
Lipoatrophy (e .g., fat loss from the 
face, extremities, buttocks)Detectable by [CONTACT_111186] (or 
by [CONTACT_227432])Detectable on physical exam by 
[CONTACT_227435]
1. Basic Se lf-care Functions –Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
2. Basic Self -care Functions –Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally appro priate eating implement).
3. Usual Social & Functional Activities –Adult: Adaptive tasks and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, use of transportation, pursuing a h obby, etc.
4. Usual Social & Functional Activities –Young Children: Activities that are age and culturally appropriate (e.g., social interactions, play activities, learning tasks, etc.). 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
[ADDRESS_419438] Internati onal Units are listed in italics
Absolute CD4+ count
–Adult and Pediatric
> 13 years
(HIV NEGATIVE ONLY)300 –400/mm3
300 – 400/µL200 –299/mm3
200 – 299/µL100 –199/mm3
100 – 199/µL< 100/mm3
< 100/µL
Absolute lymphocyte
count
–Adult and Pediatric
> 13 years
(HIV NEGATIVE ONLY)600 –650/mm3
0.600 x 109–
0.650 x 109/L500 –599/mm3
0.500 x 109–
0.599 x 109/L350 –499/mm3
0.350 x 109–
0.499 x 109/L< 350/mm3
<0.350 x 109/L
Comment:   Values in children 13 years are not given for the two parame ters above because the absolute counts are variable.
Absolute neutrophil count (ANC)
Adult and Pediatric,
> 7 days1,000 –1,300/mm3
1.000 x 109 –
1.300 x 109/L750 –999/mm3
0.750 x 109 –
0.999 x 109/L500 –749/mm3
0.500 x 109 –
0.749 x 109/L< 500/mm3
< 0.500 x 109/L
Infant*†, 2 –7 days 1,250 –1,500/mm3
1.250 x 109 –
1.500 x 109/L1,000 –1,249/mm3
1.000 x 109 –
1.249 x 109/L750 –999/mm3
0.750 x 109–
0.999 x 109/L< 750/mm3
< 0.750 x 109/L
Infant*†, 1 day 4,000 –5,000/mm3
4.000 x 109–
5.000 x 109/L3,000 –3,999/mm3
3.000 x 109–
3.999 x109/L1,500 –2,999/mm3
1.500 x 109–
2.999 x 109/L< 1,500/mm3
< 1.500 x 109/L
Fibrinogen, decreased 100 –200 mg/dL
1.00 – 2.00 g/L
OR
0.75 – 0.99 x LLN75 –99 mg/dL
0.75 – 0.99 g/L
OR
0.50 – 0.74 x LL N50 –74 mg/dL
0.50 – 0.74 g/L
OR
0.25 – 0.[ADDRESS_419439]< 50 mg/dL
< 0.50 g/L
OR
< 0.[ADDRESS_419440]
OR
Associated with gross bleeding 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
186CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Hemoglobin (Hgb)
Adult and Pediatric
57 days
(HIV POSITIVE ONLY)8.5 –10.0 g/dL
5.24 – 6.23 mmol/L7.5 –8.4 g/dL
4.62 – 5.23 mmol/L6.50 –7.4 g/dL
4.03 – 4.61 mmol/L< 6.5 g/dL
< 4.03 mmol/L
Adult and Pediatric
57 days
(HIV NEGATIVE ONLY)10.0 –10.9 g/dL
6.18 – 6.79 mmol/L
OR
Any decrease
2.5 – 3.4 g/dL
1.58 – 2.13 mmol/L9.0 –9.9 g/dL
5.55 – 6.17 mmol/L
OR
Any decrease
3.5 – 4.4 g/dL
2.14 – 2.78 mmol/L7.0 –8.9 g/dL
4.34 – 5.54 mmol/L
OR
Any decrease
4.5 g/dL
2.79 mmol/L< 7.0 g/dL
< 4.34 mmol/L
Infant*†, 36 –56 days
(HIV POSITIVE OR 
NEGATIVE)8.5 –9.4 g/dL
5.24 – 5.86 mmol/L7.0 –8.4 g/dL
4.31 – 5.23 mmol/L6.0 –6.9 g/dL
3.72 – 4.30 mmol/L< 6.00 g/dL
< 3.72 mmol/L
Infant*†, 22 –35 days
(HIV POSITIVE OR 
NEGATIVE )9.5 –10.5 g/dL
5.87 – 6.54 mmol/L8.0 –9.4 g/dL
4.93 – 5.86 mmol/L7.0 –7.9 g/dL
4.34 – 4.92 mmol/L< 7.00 g/dL
< 4.34 mmol/L
Infant*†, 21 days
(HIV POSITIVE OR 
NEGATIVE )12.0 –13.0 g/dL
7.42 – 8.09 mmol/L10.0 –11.9 g/dL
6.18 – 7.41 mmol/L9.0 –9.9 g/dL
5.59 – 6.17 mmol/L< 9.0 g/dL
< 5.59 mmol/L
International Normalized
Ratio of prothrombin time
(INR)1.1 –1.[ADDRESS_419441] 1.6 –2.[ADDRESS_419442] 2.1 –3.[ADDRESS_419443] > 3.[ADDRESS_419444]
Methemoglobin 5.0 –10.0% 10.1 –15.0% 15.1 –20.0% > 20.0%
Prothrombin Time (PT) 1.1 –1.[ADDRESS_419445] 1.26 –1.[ADDRESS_419446] 1.51 –3.[ADDRESS_419447] > 3.[ADDRESS_419448]
Partial Thromboplastin
Time (PTT)1.1 –1.[ADDRESS_419449] 1.67 –2.[ADDRESS_419450] 2.34 –3.[ADDRESS_419451] > 3.[ADDRESS_419452]
Platelets, decreased 100,000 –
124,999/mm3
100.000 x 109–
124.999 x 109/L50,000 –
99,999/mm3
50.000 x 109–
99.999 x 109/L25,000 –
49,999/mm3
25.000 x 109–
49.999 x 109/L< 25,000/mm3
< 25.000 x 109/L
WBC, decreased 2,000 –2,500/m m3
2.000 x 109–
2.500 x 109/L1,500 –1,999/mm3
1.500 x 109–
1.999 x 109/L1,000 –1,499/mm3
1.000 x 109–
1.499 x 109/L< 1,000/mm3
< 1.000 x 109/L 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
[ADDRESS_419453] International Units are listed in italics
Acidosis NA pH < normal, but  7.3 pH < 7.3 without life -threatening 
consequencespH < 7.3 with life -threatening 
consequences
Albumin, serum, low 3.0 g/dL –< LLN
30 g/L – < LLN2.0 –2.9 g/dL
20 –29 g/L< 2.0 g/dL
< 20 g/LNA
Alkaline Phosphatase 1.25 –2.[ADDRESS_419454]† 2.6 –5.[ADDRESS_419455]† 5.1 –10.[ADDRESS_419456]† > 10.[ADDRESS_419457]†
Alkalosis NA pH > normal, but  7.5 pH > 7.5 without life -threatening 
consequencespH > 7.5 with life -threatening 
consequences
ALT (SGPT) 1.25 –2.[ADDRESS_419458] 2.6 –5.[ADDRESS_419459] 5.1 –10.[ADDRESS_419460] > 10.[ADDRESS_419461] (SGOT) 1.25 –2.[ADDRESS_419462] 2.6 –5.[ADDRESS_419463] 5.1 –10.[ADDRESS_419464] > 10.[ADDRESS_419465]
Bicarbonate, serum, low 16.0 mEq/L –< LLN
16.0 mmol/L –< LLN11.0 –15.9 mEq/L
11.0 – 15.9 mmol/L8.0 –10.9 mEq/L
8.0 – 10.9 mmol/L< 8.0 mEq/L
< 8.0 mmol/L
Bilirubin (Total)
Adult and Pediatric >14 
days1.1 –1.[ADDRESS_419466] 1.6 –2.[ADDRESS_419467] 2.6 –5.[ADDRESS_419468] > 5.[ADDRESS_419469]
Infant*†, 14 days (non-
hemolytic)NA 20.0 –25.0 mg/dL
342 – 428 µmol/L25.1 –30.0 mg/dL
429 – 513 µmol/L> 30.0 mg/dL
>513.0 µmol/L
Infant*†, 14 days
(hemolytic)NA NA 20.0 –25.0 mg/dL
342 – 428 µmol/L> 25.0 mg/dL
> 428 µmol/L
Calcium, serum, high (corrected for albumin)
Adult and Pediatric  7 
days10.6 –11.5 mg/dL
2.65 – 2.88 mmol/L11.6 –12.5 mg/dL
2.89 – 3.13 mmol/L12.6 –13.5 mg/dL
3.14 – 3.38 mmol/L> 13.5 mg/dL
> 3.38 mmol /L
Infant*†, < 7 days 11.5 –12.4 mg/dL
2.88 – 3.10 mmol/L12.5 –12.9 mg/dL
3.11 – 3.23 mmol/L13.0 –13.5 mg/dL
3.245 – 3.38 mmol/L> 13.5 mg/dL
> 3.38 mmol/L
Calcium, serum, low 
Adult and Pediatric  7 
days7.8 –8.4 mg/dL
1.95 – 2.10 mmol/L7.0 –7.7 mg/dL
1.75 – 1.94 mmol/L6.1 –6.9 mg/dL
1.53 – 1.74 mmol/L< 6.1 mg/dL
< 1.53 mmol/L
Infant*†, < 7 days 6.5 –7.5 mg/dL
1.63 – 1.88 mmol/L6.0 –6.4 mg/dL
1.50 – 1.62 mmol/L5.50 –5.90 mg/dL
1.38 – 1.51 mmol/L< 5.50 mg/dL
< 1.38 mmol/L
Cardiac t roponin I (cTnI) NA NA NA Levels consistent with myocardial 
infarction or unstable angina as defined 
by [CONTACT_3455] 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
188CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Cardiac troponin T (cTnT) NA NA NA 0.20 ng/mL
OR
Levels consistent with myocardial 
infarction or unstable angina as defined 
by [CONTACT_941] m anufacturer
Cholesterol (fasting)
Adult 18 years 200 –239 mg/dL
5.18 – 6.19 mmol/L240 –300 mg/dL
6.20 – 7.77 mmol/L> 300 mg/dL
> 7.77 mmol/LNA
Pediatric < 18 years 170 –199 mg/dL
4.40 – 5.15 mmol/L200 –300 mg/dL
5.16 – 7.77 mmol/L> 300 mg/d L
> 7.77 mmol/LNA
Creatine Kinase 3.0 –5.[ADDRESS_419470]† 6.0 –9.[ADDRESS_419471]† 10.0 –19.[ADDRESS_419472]†20.[ADDRESS_419473]†
Creatinine 1.1 –1.[ADDRESS_419474]† 1.4 –1.[ADDRESS_419475]† 1.9 –3.[ADDRESS_419476]†3.[ADDRESS_419477]†
Glucose, serum, high
Nonfasting 116 –160 mg/dL
6.44 – 8.88 mmol/L161 –250 mg/dL
8.89 – 13.88 mmol/L251 –500 mg/dL
13.89 – 27.75 mmol/L> 500 mg/dL
> 27.75 mmol/L
Fasting 110 –125 mg/dL
6.11 – 6.94 mmol/L126 –250 mg/dL
6.95 – 13.88 mmol/L251 –500 mg/dL
13.89 – 27.75 mmol/L> 500 mg/dL
> 27.75 mmol/L
Glucose, serum, l ow
Adult and Pediatric  1 
month55 –64 mg/dL
3.05 – 3.55 mmol/L40 –54 mg/dL
2.22 – 3.06 mmol/L30 –39 mg/dL
1.67 – 2.23 mmol/L< 30 mg/dL
< 1.67 mmol/L
Infant*†, < 1 month 50 –54 mg/dL
2.78 – 3.00 mmol/L40 –49 mg/dL
2.22 – 2.77 mmol/L30 –39 m g/dL
1.67 – 2.21 mmol/L< 30 mg/dL
< 1.67 mmol/L
Lactate ULN -< 2.[ADDRESS_419478] without 
acidosis2.[ADDRESS_419479] without
acidosisIncreased lactate with pH < 7.3 
without life -threatening 
consequencesIncreased lactate with pH <7.3 with life -
threatening consequence s
LDL cholesterol (fasting)
Adult 18 years 130 –159 mg/dL
3.37 – 4.12 mmol/L160 –190 mg/dL
4.13 – 4.90 mmol/L190 mg/dL
4.91 mmol/LNA
Pediatric > 2 -< 18 years 110 –129 mg/dL
2.85 – 3.34 mmol/L130 –189 mg/dL
3.35 – 4.90 mmol/L190 mg/dL
4.91 mmol/LNA
Lipase 1.1 –1.[ADDRESS_419480] 1.6 –3.[ADDRESS_419481] 3.1 –5.[ADDRESS_419482] > 5.[ADDRESS_419483] 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
189CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Magnesium, serum, low 1.2 –1.4 mEq/L
0.60 – 0.70 mmol/L0.9 –1.1 mEq/L
0.45 – 0.59 mmol/L0.6 –0.8 mEq/L
0.30 – 0.44 mmol/L< 0.60 mEq/L
< 0.30 mmol/L
Pancreatic a mylase 1.1 –1.[ADDRESS_419484] 1.6 –2.[ADDRESS_419485] 2.1 –5.[ADDRESS_419486] > 5.[ADDRESS_419487]
Phosphate, serum, low
Adult and Pediatric > 14 
years2.5 mg/dL –< LLN
0.81 mmol/L –< LLN2.0 –2.4 mg/dL
0.65 – 0.80 mmol/L1.0 –1.9 mg/dL
0.32 – 0.64 mmol/L< 1.00 mg/dL
< 0.32 mmol/ L
Pediatric 1 year –14 years 3.0 –3.5 mg/dL
0.97 – 1.13 mmol/L2.5 –2.9 mg/dL
0.81 – 0.96 mmol/L1.5 –2.4 mg/dL
0.48 – 0.80 mmol/L< 1.50 mg/dL
< 0.48 mmol/L
Pediatric < 1 year 3.5 –4.5 mg/dL
1.13 – 1.45 mmol/L2.5 –3.4 mg/dL
0.81 – 1.12 mmol/L1.5 –2.4 mg/dL
0.48 – 0.80 mmol/L< 1.50 mg/dL
< 0.48 mmol/L
Potassium, serum, high 5.6 –6.0 mEq/L
5.6 – 6.0 mmol/L6.1 –6.5 mEq/L
6.1 – 6.5 mmol/L6.6 –7.0 mEq/L
6.6 – 7.0 mmol/L> 7.0 mEq/L
> 7.0 mmol/L
Potassium, serum, low 3.0 –3.4 mEq/L
3.0 – 3.4 mmol/L2.5 –2.9 mEq/L
2.5 – 2.9 mmol/L2.0 –2.4 mEq/L
2.0 – 2.4 mmol/L< 2.0 mEq/L
< 2.0 mmol/L
Sodium, serum, high 146 –150 mEq/L
146 – 150 mmol/L151 –154 mEq/L
151 – 154 mmol/L155 –159 mEq/L
155 – 159 mmol/L160 mEq/L
160 mmol/L
Sodium, se rum, low 130 –135 mEq/L
130 – 135 mmol/L125 –129 mEq/L
125 – 129 mmol/L121 –124 mEq/L
121 – 124 mmol/L120 mEq/L
120 mmol/L
Triglycerides (fasting) NA 500 –750 mg/dL
5.65 – 8.48 mmol/L751 –1,200 mg/dL
8.49 – 13.56 mmol/L> 1,200 mg/dL
> 13.56 mmol/L
Uric acid 7.5 –10.0 mg/dL
0.45 – 0.59 mmol/L10.1 –12.0 mg/dL
0.60 – 0.71 mmol/L12.1 –15.0 mg/dL
0.72 – 0.89 mmol/L> 15.0 mg/dL
> 0.89 mmol/L
URINALYSIS Standard International Units are listed in italics
Hematuria (microscopic) 6 –10 RBC/H PF > 10 RBC/HPF Gross, with or without clots OR with 
RBC castsTransfusion indicated
Proteinuria, random
Collection1 + 2 –3 + 4 + NA 
 
 2018N380094_00
2013N168152_09 CONFIDENT IAL
200056
190CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Proteinuria, 24 hour collection
Adult and Pediatric  10 
years200 –999 mg/24 h
0.200 – 0.999 g/d1,000 –1,999 mg/ 24 h
1.000 – 1.999 g/d2,000 –3,500 mg/24 h
2.000 – 3.500 g/d> 3,500 mg/24 h
> 3.500 g/d
Pediatric > 3 mo -< 10 
years201 –499 mg/m2/24 h
0.201 – 0.499 g/d500 –799 mg/m2/24 h
0.500 – 0.799 g/d800 –1,000 mg/m2/24 h
0.800 – 1.000 g/d> 1,000 mg/ m2/24 h
> 1.000 g/d
Values are for term infants.  Preterm infants should be assessed using local normal ranges.
† Use age and sex appropriate values (e.g., bilirubin). 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
[ZIP_CODE].3. Appendix 3: Pharmacogenetic Research
Pharmacogenetics –Background
Pharmacogenetics ( PGx) is the study  of variability in drug response due to hereditary  
factors in populations.  There is increasing evidence that an individual's genetic 
background (i.e., genot ype) may  impact the pharmacokinetics (absorption, distribution, 
metabolism, elimin ation), pharmacod ynamics (relationship between concentrations and 
pharmacologic effects or the time course of pharmacologic effects) and/or clinical 
outcome (in terms of efficacy  and/or safety  and tolerability ).  Some reported examples of 
PGx associations with safety/adverse events include:
Drug Disease Gene Variant Outcome
Abacavir HIV 
[Hetherington , 
2002; 
Mallal ,2002; 
Mallal ,2008]HLA-B* 57:01 
(Human 
Leukocyte 
Antigen B)Carriage of the HLA-B*57:01 variant has been 
shown to increase a patient's risk for 
experiencing hypersensitivity to abacavir.  
Prospective HLA-B*57:01 screening and 
exclusion of HLA-B*57:[ADDRESS_419488] labeling in the [LOCATION_002] 
and Europe now recommend (US) or require 
(EU) prospective HLA-B*57:01 screening prior 
to initiati on of abacavir to reduce the incidence 
of abacavir hypersensitivity.  HLA-B*57:[ADDRESS_419489] clinical risk management strategies for 
abacavir hypersensitivity.
Carbamaze
pi[INVESTIGATOR_339197], Bipolar 
disorders & 
Analgesia 
[Chung ,2010; 
Ferrell , 2008]HLA-B*15:[ADDRESS_419490] Asian ancestry who carry HLA-B*15:[ADDRESS_419491] updated the 
carbamazepi[INVESTIGATOR_339198]-B*15:02 prior to initiating 
treatment with carbamazepi[INVESTIGATOR_050]. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
192Drug Disease Gene Variant Outcome
Irinotecan Cancer 
[Innocenti , 2004; 
Liu, 2008; 
Schulz , 2009]UGT1A1*28 Variations in the UGT1A1 gene can influence 
a patient’s ability to break down irinotecan, 
which can lead to increased blood levels of the 
drug and a higher risk of side effects. A dose 
of irinotecan that is safe for one patient with a 
particular UGT1A1 gene variation might be too 
high for another patient without this variation, 
raising the risk of certain side -effects that 
include neutropenia following initiation of 
Irinotecan treatment.  The irinotecan drug 
label indicates that individuals who have two 
copi[INVESTIGATOR_23932]1A1* 28variant are at 
increased risk of neutropenia.  A genetic blood 
test is available that can detect variations in 
the gene.    
A key  component to successful PGx research is the collection of samples during the 
conduct of clinical studies.
Collection of whole blood samples, even when no a priori hypothesis has been identified, 
may enable PGx anal ysis to be conducted if at any time it appears that there is a potential 
unexpected or unexplained variation in response to [COMPANY_004]1265744.
Pharmacogenetic Research O bjectives
The objective of the PGx research (if there is a potential unexpected or unexplained 
variation) is to investigate a relationship between genetic factors and response to 
[COMPANY_004]1265744.  If at an y time it appears there is potential variability  in resp onse in this 
clinical study  or in a series of clinical studies with [COMPANY_004]1265744 the following objectives 
may be investigated – the relationship between genetic variants and study  treatment with 
respect to:
Pharmacokinetics and/or pharmacod ynamics of study  treatment
Safety  and/or tolerability 
Efficacy
Study Population
Any subject who is enrolled in the clinical study , can participate in PGx research.  Any  
subject who has received an allogeneic bone marrow transplant must be excluded from 
the PGx research.
Subject participation in the PGx research is voluntary  and refusal to participate will not 
indicate withdrawal from the clinical study  or result in any  penalty  or loss of benefits to 
which the subject would otherwise be entitled. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
193Study Assessments and Proced ures
Blood samples can be taken for Deox yribonucleic acid (DNA) extraction and used in 
PGx assessments.
If taking blood samples: in addition to any  blood samples taken for the clinical study , a 
whole blood sample (~6ml) will be collected for the PGx resear ch using a tube containing 
EDTA.  It is recommended that the blood sample be taken at the first opportunity  after a 
subject has been randomised and provided informed consent for PGx research, but may  
be taken at an y time while the subject is participating in the clinical study .
The PGx sample is labelled (or “coded”) with a study  specific number that can be 
traced or linked back to the subject b y the investigator or site staff.  Coded samples 
do not carry  personal identifiers (such as name [CONTACT_24004] y number).  The 
blood sample is taken on a single occasion unless a duplicate sample is required due 
to inability  to utilise the original sample.   
The DNA extracted from the blood sample may  be subjected to sample quality  control 
analysis.  This anal ysis will involve the genot ypi[INVESTIGATOR_23933] y of individual samples.  If inconsistencies are noted in the analysis, then those 
samples may  be destroy ed.
The need to conduct PGx anal ysis may  be identified after a study  (or a set of studies) of 
[COMPANY_004]1265744 has been completed and the clinical study  data reviewed.  In some cases, 
the samples may  not be studied. e.g., no questions are raised about how people respond to 
[COMPANY_004]1265744.
Samples will be stored securel y and may be kept f or up to [ADDRESS_419492] 
completes the study  or [COMPANY_004] may  destro y the samples sooner.  [COMPANY_004] or those working 
with [COMPANY_004] (for example, other researchers) will use samples collected from the study  for 
the purpose stated in this protocol and in the informed consent form.  
Subjects can request their sample to be destro yed at any  time.
Subject Withdrawal from Study
If a subject who has consented to participate in PGx research withdraws from the clinical 
study  for any  reason other than being lost to f ollow -up, the subject will be given a choice 
of one of the following options concerning the PGx sample, if alread y collected:
Continue to participate in the PGx research with the PGx sample retained for 
analysis 
Withdraw from the PGx research and destro y the PGx sample 
If a subject withdraws consent for PGx research or requests sample destruction for an y 
reason, the investigator must complete the appropriate documentation to request sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records . The investigator should forward the Pharmacogenetic Sample  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419493] s, drug metabolizing e nzymes, drug transporters or which may  
underpin adverse events, disease risk or drug response. These candidate genes may  
include a common set of ADME (Absorption, Distribution, Metabolism and 
Excretion) genes that are studied to determine the relationship between gene variants 
or treatment response and/or tolerance. 
In addition, continuing research may  identify  other enzy mes, transporters, proteins or 
receptors that may  be involved in response to [COMPANY_004]1265744.  The genes that may  code for 
these proteins may  also be studied.
2.Genome -wide scans involving a large number of poly morphic markers (e.g., single 
nucleotide poly morphisms) at defined locations in the genome, often correlated with 
a candidate gene, may  be studied to determine the relationship between gene tic 
variants and treatment response or tolerance. This approach is often employ ed when 
a definitive candidate gene(s) does not exist and/or the potential genetic effects are 
not well understood. 
If applicable and PGx research is conducted, appropriate sta tistical anal ysis methods will 
be used to evaluate pharmacogenetic data in the context of the other clinical data. Results 
of PGx investigations will be reported either as part of the main clinical study  report or as 
a separate report. Endpoints of interes t from all comparisons will be descriptively  and/or 
graphicall y summarised as appropriate to the data.  A detailed description of the anal ysis 
to be performed will be documented in the study  reporting and anal ysis plan (RAP) or in 
a separate pharmacogeneti cs RAP, as appropriate.  
Informed Consent
Subjects who do not wish to participate in the PGx research may  still participate in the 
clinical study .  PGx informed consent must be obtained prior to an y blood being taken for 
PGx research. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419494]’s PGx Data
[COMPANY_004] may  summarise the PGx research results in the clinical study  report, or separatel y, 
or may  publish the results in scientific journals. 
[COMPANY_004] does not inform the investigator, subject, or any one else (e.g. , family  members, 
study  investigators, primary  care ph ysicians, insurers, or emplo yers) of individual 
genot ypi[INVESTIGATOR_23934]’s medical care at the 
time of the study , unless required b y law. This is due to the fa ct that the information 
generated from PGx studies is generall y preliminary in nature, and therefore the 
significance and scientific validity  of the results are undetermined.
References
Chung WH, Hung SL , Chen YT. Genetic predisposition of life -threatening antiepi[INVESTIGATOR_23935] -
induced skin reactions.  Expert Opin. Drug Saf. 2010; 9: 15-21.
Ferrell PB, McLeod HL.  Carbamazepi[INVESTIGATOR_050], HLA -B*1502 and risk of Stevens -Johnson 
syndrome and toxic epi[INVESTIGATOR_23936]: US FDA recommendations.  
Pharmacogenomics. 2008; 9: 1543 -1546.
Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, 
Davies K, Handley  A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond L M, Roses 
AD. Genetic variations in HLA- B region and h ypersensitivity  reactions to abacavir. 
Lancet. 2002; 359:[ADDRESS_419495] the risk of severe neutropenia of irin otecan. J 
Clin Oncol 2004; 22: 1382 -1388.
Liu CY, Chen PM, Chiou TJ, L iu JH, Lin JK, L in TC, Chen WS, Jiang JK, Wang HS, 
Wang WS.  UGT1A1*28 poly morphism predicts irinotecan- induced severe toxicities 
without affecting treatment outcome and survival in patients with metastatic colorectal 
carcinoma.  Cancer. 2008; 112: 1932 -1940.
Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Say er D, Castley  A, Mamotte 
C, Maxwell D, James I .  Association between presence of HLA -B*5701, HLA -DR7, and 
HLA -DQ3 and hy persensitivity  to HIV -1 reverse -transcriptase inhibitor abacavir.  
Lancet. 2002; 359:727 -732.
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel -Guedes E, 
Rugina S, Kozy rev O, Cid JF, Hay  P, Nolan D, Hughes S, Hughes A, Ry an S, Fitch N, 
Thorborn D, Benbow A; PREDI CT-1 Study  Team.  HLA -B*5701 screening for 
hypersensitivity  to abacavir. N Engl J Med. 2008; 358; 568 -579
Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, Giessen C, 
Stemmler HJ. UGT1A1 gene pol ymorphism: I mpact on toxicity  and efficacy  of 
irinotecan -based regimens in metastatic colorectal cancer.  World J. Gastroenterol. 2009; 
15: 5058-5066. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
[ZIP_CODE].4. Appendix 4: Liver Safety  Drug Restart or Rechallenge 
Guidelines
VSLC GUIDELINES FOR DRUG RESTA RT OR RECH ALLENGE A FTER STOP
FOR LIVER CRITERIA
1.Drug rechallenge may  be considered for a subject exhibiting compelling benefit 
for a critical medicine following drug- induced liver injury , if favorable benefit: 
risk and no alternative medicine available ( Table 9,Figure 17)
2.In Phase III, drug restart may be considered for liver events with a clear 
underly ing cause (e.g. biliary , pancreatic events, hy potension, acute viral 
hepatitis), if not associated with drug- induced liver injury , alcoholic hepatitis or 
hypersensitivity , and drug not associated with HLA marker of liver injury , when 
liver chemistries improve to within 1.5xbaseline and AL T<3xUL N)(Table 10,
Figure 18).
Background: Following drug- induced liver injury, drug rechallenge is associated with 
a 13% mortality across all drugs in prospective studies .  Clinical outcomes vary  by 
[CONTACT_9934], with nearl y 50% fatality  with halothane re -administered in one month of initial 
injury [Andrade , 2009].  However, some drugs seldom result in recurrent liver injury  or 
fatality .
Risk factors for a fatal drug rechallenge outcome include:
hypersensitivity  with initial liver injury  (e.g. fever, rash, eosinophilia) [Andrade
2009]
jaundice or bilirubin 2xULN with initial liver injury
 
prior serious adverse event or fatality  has earlier been observed with drug 
rechallenge [Papay , 2009; Hunt , 2010]
evidence of drug- related preclinical liability  (e.g. reactive metabolites; 
mitochondrial impairment) [ Hunt , 2010]  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
197VSLC Decision Process for Drug Rechallenge A pproval or 
Disapproval (See Figure 17)
Principal I nvestigator (PI) requests consideration of drug rechallenge for a 
subject receiving compelling benefit from a critical or life -saving drug, who 
exhibits liver chemistry elevation meeting subject stoppi[INVESTIGATOR_3418], with no 
alternative tr eatment
By [CONTACT_339303]ïve subjects will only  be considered for rechallenge if 
they were infected with a multi -resistant virus.
Medical Monitor and Global Clinical Safety  and Pharmacovigilance (GCSP) 
Physician to review the subject’s rechallenge risk factors (consultation with the 
Hepatotoxicity  Panel is available) and complete checklist ( Table 9).
The Medical Monitor and GCSP Phy sician are accountable to review and agree 
on:
–compelling benefit of the inv estigational product (IP) for this subject and no 
alternative therap y 
–must present source data defining the patient’s current resistance profile with 
documented evidence of extensive drug resistance and previous drug history 
–Relative benefit -risk of drug rechallenge, with consideration of the following 
high risk factors:
Initial liver injury  event included: fever, rash, eosinophilia, or 
bilirubin 2xUL N (or direct bilirubin >35% of total, if available)
subject currently exhibits severe liver injury  defined by: [CONTACT_42386] 3xUL N, 
bilirubin 2xUL N (direct bilirubin >35% of total, if available), or INR1.5
SAE or fatality  has earlier been observed with IP rechallenge
IP associated with known preclinical hepatic liability / injury
Relevant phy sicians must review and ag ree on request for drug rechallenge:  
Safety  Team Leader, VP, or Senior Safet y Physician ([COMPANY_004])
Medicines Development Leader and Project Ph ysician Leader ([COMPANY_004] )
Request is taken to full VSL C for final decision  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
198Figure 17 VSLC process for drug rechallenge approval or disapproval
The local operating company  (LO C) ViiV medical director (and [COMPANY_004] where applicable)
should be informed that study  drug rechallenge is under consideration and of the final 
decision, whether or not to proceed.
Table [ADDRESS_419496] for drug rechallenge for critical medicine (Follo wing drug -
induced liver injury , drug rechallenge is associated with 13% 
mortality  across all drugs in prospective studies)
Yes No
Compelling benefit of the invest igational product (IP) for this subject andno 
alternative therapy .  Provide brief explanation:
Relative benefit -risk favorable for drug rechallenge , after considering the 
following high risk factors :
Initial liver injury event included: 
ofever, ras h, eosinophilia, or hypersensitivity
oor bilirubin 2xULN (direct bilirubin >35% of total)
oSubject currently exhibits ALT 3xULN, bilirubin 2xULN (direct 
bilirubin >35% of total, if available), orINR1.5
oSAE or fatality has earlier been observed w ith IP rechallenge
If yes, please provide brief explanation :
oIP associated with known preclinical hepatic liability/ injury
oSource data defining the patients current resistance profile
oPrevious drug history 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
199Drug Restart
Phase II “drug restart” can be approved by  [CONTACT_339304], defined non -drug -
induced liver injury if no evidence of:
•immunoallergic injury  /HLA association with injury
•DILI
•alcoholic hepatitis
Study  drug held while labs and evaluation is completed to assess diagnosis.
VSLC Decision Process for Drug Restart A pproval or Disapproval 
(Figure 18 ): 
PI [INVESTIGATOR_339199] -initiation for a subject stable or improving 
on IP, who exhibits liver chemistry  elevation meeting subject stoppi[INVESTIGATOR_33084], 
which is transient, non -drug-related, and liver chemistries improve to within 
1.5x baseline and AL T<3xULN. 
[COMPANY_004] Medical Monitor and Clinical Safety  Physician to review the subject’s
diagnosis, restart risk factors and complete checklist ( Table 10).
–must present source data defining the patient’s current resistance profile with 
documented evidence of extensive drug resistance and previous drug history.
The LOC ViiV medical director (and [COMPANY_004] where applicable) should be 
informed that study  drug restart is under consideration and of the final decision, 
whether or not to proceed.
Table [ADDRESS_419497] for Phase II drug restart after well -explained liver injury  
(e.g. biliary, pancreatic, hy pote nsive events, congestive heart 
failure , acute viral hepatitis), improving to liver chem istry  5x 
baseline & A LT<3xULN
Yes No
Is subject stable or improving on the investigational product (IP)?
Do not restart if the following risk factors at initial l iver injury :
fever, rash, eosinophilia, or hypersensitivity 
drug-induced liver injury 
alcoholic hepatitis (AST>ALT, typi[INVESTIGATOR_897] <10xULN)
IP has an HLA genetic marker associated with liver injury (e.g. lapatinib, 
abacavir, amoxicillin/clavulanat e)
Source data defining the patients current resistance profile
Previous drug history 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
200Relevant phy sicians must review and agree on request for drug restart:  
Safety  Team Leader, VP, or Senior Safet y Physician
Medicines Development Leader and Pro ject Phy sician Leader ([COMPANY_004]).
Hepatotoxicity  Panel consultation is available.
Justification for drug restart outlining the benefit and risk for this subject must 
be recorded b y GCSP Physician and sent to the VSL C Secretary .
VSL C must approve drug re -initiat ion and dosing regimen
Figure 18 VSLC process for drug restart approval or disapproval
1. Andrade , 2009; 2. Papay, 2009; 3. Hunt, 2010 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
201Medical monito r, GCSP Phy sician and PI [INVESTIGATOR_339200] ( GCSP )
Physician A ctions
Medical Monitor must notify  PI [INVESTIGATOR_339201]’s rechallenge (or restart) decision and 
recommended dosing regimen in writing and Medical Monitor must record note 
in study  files.
The Safet y Review Team must record rechallenge (or restart) outcomes and the 
GCSP Phy sician must send these to the VSL C
All severe reactions ( rechallenge associated wit h bilirubin>2xUL N or jaundice, 
or INR 1.5), SAEs or fatalities with drug rechallenge (or restart) must be 
immediately  reported to Line Management, VSLC Chair, VP Global Medical 
Strategy (ViiV) and EU Qualified Person for Pharmacovigilance. 
Principal Inves tigator A ctions :
The PI  [INVESTIGATOR_135436]/EC approval of drug rechallenge or restart, as required. 
If drug re -initiation VSLC -approved, the patient must provide informed consent 
with a clear description of possible benefits and risks of drug administration 
including recurrent, more severe liver injury  or possible death.
–Targeted drug rechallenge or drug restart consent form must be used.
The patient’s informed consent must be recorded in the study  chart, and the drug 
administered at agreed dose, as communica ted b y Medical Monitor.
Liver chemistries must be followed twice weekl y for ‘rechallenge’ cases and 
once weekl y for ‘restart’ cases for one month or for as long as clinicall y 
indicated following drug re -initiation.  If subject exhibits protocol -defined liv er 
chemistry  elevations, IP should be discontinued as protocol specified.
VSLC and the IRB/EC must be informed of the patient’s outcome following drug 
rechallenge or restart.
Rechallenge/restart safety  outcomes :
0 = no liver chemistry  elevation
1 = recurre nt liver chemistry  elevation not meeting subject stoppi[INVESTIGATOR_3418]
2 = recurrent liver chemistry  elevation meeting subject stoppi[INVESTIGATOR_3418]
3 = serious adverse event
4 = fatalit y 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
202REFERENCES:
Andrade RJ, Robles M, Lucena MI.  Rechallenge in drug -induced li ver injury : the 
attractive hazard.  Expert Opin Drug Saf. 2009;8:709-714.
Hunt, CM.  Mitochondrial and immunoallergic injury  increase risk of positive drug 
rechallenge after drug -induced liver injury : A s ystematic review.  Hepatol. 2010;52:2216-
2222.
Papay JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS, Hunt CM.  Drug -induced liver 
injury  following positive drug rechallenge.  Regul Tox Pharm. 2009;54:84 -90. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
[ZIP_CODE].5. Appendix 5: Country  Specific Requirements
No country -specific requirements exist.  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
[ZIP_CODE].6. Appendix 6: Changes to the Protocol
Amendment 1
Amendment 1 was finalized 28 October 2013 and applie dto all countries, however, was 
never implemented due to a design change requiring a second amendment .  
Amendment 1 was prepared to address the following changes:  univ ersal changes to 
naming conventions for the long acting formulation of [COMPANY_004]1265744, simplify ing the 
protocol summary to allow better understanding of the protocol, clarify ing the study  
schematic to increase understanding, clarification the purpose of and an alyses to be 
performed b y the IDMC to reflect current plans, clarification of the intent of the Day  [ADDRESS_419498] ing injectable formulation.  I n addition, throughout the 
document, the term parenteral was removed therefore an y abbreviations of  long acting 
parenteral “LAP” were revised to long acting “LA”.  Reference to a “parenteral” regimen 
was revised to an “IM” re gimen. 
Any reference to “control regimen” or “control arm” was revised to “oral regimen” or 
“oral arm”.  An y reference to a “monthl y” regimen was revised to an “every 4 weeks” 
regimen.
The “chronology ” on the first page of the Amendment clarifies the rati onale for multiple 
“Document Generator Numbers” or DNG numbers.  For example, this is Amendment 1, 
but the DNG number assigned to the final version of Amendment 1 is 2013N168152_03.
Abbreviations
Addition of several abbreviations:  
HIVTSQc HIV Treatment S atisfaction Questionnaire change version
HIVTSQs HIV Treatment Satisfaction Questionnaire status version
HIVMQ HIV medication questionnaire
LA Long acting
Trademarks
Added “Truvada” as a Trademark not owned b y ViiV Healthcare. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
205Protocol Summary
This sec tion was revised to include only  key pi[INVESTIGATOR_339202] a glance.  Removed background, study  rationale and 
secondary  study  objectives and added notable eligibility  criteria, key  study  assessments , 
permitted study  treatment substitutions and the definition of virologic failure.
References to Investigator’s Brochures
Throughout the document, any  reference to the Investigator’s Brochure for either 
[COMPANY_004]1265744 or TMC278 were updated to the newest versi on dates 2013 and 2012 
respectivel y.
Study  Rationale, Induction Period, 4thsentence, Section 1.8
Revised to (changes struck through and underlined):
Virologic suppression in the L AI116482 study  was rapid, with 837% of [COMPANY_004]744 30 mg
treated subjects achievi ng an HIV -1 RNA <50 c/mL  by [CONTACT_10585] [ADDRESS_419499] 16 weeks on the 24 week induction 
arm, prior to randomization into the Maintenance Period.
Study  Rationale, Maintenance Period, 1stsentence, Section 1.8 -clarification
Revised to (changes struck through and underlined):
Subjects must achieve an undetectable HIV -1 RNA (<50 c/mL) at Week ( -4) in order to 
be eligibl e to enter the Maintenance Period. Subjects with an undetectable HIV- 1 RNA 
(50 c/mL) at the Week ( -4) visit are eligible to enter the Maintenance Period.
Study  Rationale, Extension Period, 2ndand last sentence, Section 1.8 -clarification
Revised to (c hanges struck through and underlined):
These subjects will also have their regimen modified at Week [ADDRESS_419500] achieve with an undetectable HIV- 1 RNA (<50 c/mL ) at the
Week [ADDRESS_419501] paragraph, Section 1.9.1 -clarification
The 3rdparagraph was bulleted for better readability.
Revised to (changes struck through and underlined): 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
206The preferred maximum IM injection volume of 2 mL using a 200 mg/mL  [COMPANY_004]744 L A 
nanosuspension formulation would limits the maximum a single injection to 400 mg IM.
Study  Objectives, Section 2 -addition
Revised to (changes struck through and underlined):
To eva luate the change in treatment satisfaction 
for subjects in the long -acting and oral regimens 
through Week 96 of the Maintenance Period.
To evaluate the treatment satisfaction for 
subjects on the long -acting injectable regimen 
with those on the oral regimen through Week 96 
of the Maintenance Period.Change from Baseline in treatment satisfaction 
for the LAP and oral regimens at Maintenance 
Weeks 24, 48 and 96.
Summarize treatment satisfaction using the HIV 
Treatment Satisfaction Questionnaire Status 
(HIVTSQ( s)) over time. 
To evaluate the change in treatment satisfaction 
for subjects in both the long -acting injectable 
and oral regimens through Week 24 of the 
Maintenance Period.Measure change in treatment satisfaction using 
the HIV Treatment Satisfaction Que stionnaire 
Change (HIVTSQ(c)) over time.
To evaluate medication adherence over time. Summarize subject reported medication 
adherence using the HIV Medication 
Questionnaire (HIVMQ) over time. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
207Study  Schematic, Section 3.1 -clarification
Revised from
Oral Induction Period
•HIV-1 
infected
ART -naïve 
•CD4 ≥200 
cells/m m3
•HIV-1 RNA
•≥1000 c/mLOral Control
(n ≈ 25)LAP Regim en
(n ≈ 50)
Oral Control
(n ≈ 25)LAP Regim en
(n ≈ 50)Randomization
2:1
2
1
2
1Randomi zation
1:1
[COMPANY_004]7 44 30 mg + ABC/3TC
(n ≈ 90)
[COMPANY_004]744 30 mg + ABC/3TC
(n ≈ 90)Add 
RPV 25 mg  
Once Daily
Week -24 Week -20 Week -16 Week -12 Week -8 Week -4 Day 11
1Add 
RPV 25 mg  
Once Daily
Extension Period Maintenance  Period
[COMPANY_004]744  LAP 400 mg IM
+ 
TMC278  LA 600 mg IM
Every 4 Weeks†
Oral [COMPANY_004]744 30 mg + ABC/3TC
(n ≈ 50)Maintenance LAP Doses Every 4 Weeks
†Subj ects  who withdraw 
from LAP will be followed on 
study via Long Term Follow 
Up Period with ~quarterly 
visits for 52 weeksOral RPV 25 mg Once  
Daily for 2 weeks;  then 
[COMPANY_004]744 LAP 800 mg IM
LD + TMC278 LA 600 mg 
IM†then
[COMPANY_004]744 LAP 400 mg IM + 
TMC278 LA 600 mg IM
Every 4 Weeks† [COMPANY_004]7 44 LAP 800 mg (2 x 400 mg) IM Loading Dose (LD)  + 
TMC 278 LA 600 mg IM on Day 1  then
[COMPANY_004]7 44 LAP 400 mg IM + TM C278 LA 600 mg IM every 4 Weeks†
(N≈ 100)Continued 
From  
Induct ion 
Period
Schema
Last Induc tion Regimen Dose 
on Day 1 in Clinic 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
208To
Induction Period
•HIV-1 
infected
ART -naïve 
•CD4 ≥200 
cells/m m3
•HIV-1 RNA
•≥1000 c/mLContinue Oral 
Regim enBegin IM 
Regim en
Continue Oral 
Regim enBegin IM 
Regim enRandomization
2:1
2
1
2
1Randomization
1:1
[COMPANY_004]744 30 mg + ABC/3TC 
Orally Once Daily
(n ≈ 90)
[COMPANY_004]744 30 mg + ABC/3T C 
Orally Once Daily
(n ≈ 90)Add 
RPV 25 mg  
Orally Once 
Daily
Week -24 Week -20 Week -16 Week -12 Week -8 Week -4 Day 11
1Add 
RPV 25 mg  
Orally Once 
Daily
Extension Period Maintena nce Period
[COMPANY_004]744  LA 400 mg IM
+ 
TMC278  LA 600 mg IM
Every 4 Weeks†
[COMPANY_004]7 44 30 mg + ABC/3TC  Orally Once DailyIM Doses Every 4 Weeks
†Subjects  who withdraw 
after receiving any IM dose 
will be followed on study via 
Long -Term Follow Up Period 
with ~quarterly visits for 52 
weeks[COMPANY_004]7 44 LA 800 mg IM
Loading Dose + TMC278 
LA 600 mg IM†
then 
[COMPANY_004]7 44 LA 400 mg IM + 
TMC278 LA 600 mg IM
Every 4 Weeks† [COMPANY_004]7 44 LA 800 mg IM Loading Dos e  + 
TMC 278 LA 600 mg IM on Day 1 
then
[COMPANY_004]744 LA 400 mg IM + TMC278 LA 600 mg IM every 4 Weeks†Continued 
From  
Induct ion 
Period
Schem a
Last Induc tion Re gime n Dose 
on Day 1 in ClinicIM 
regimen
Oral 
regimenAdd 
RPV 25 
mg 
Orally 
Once 
Daily for 
2wks 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
209Induction Period, 2ndparagraph, Section 3.2.2 -clarification
Revised to (changes struck through and underlined):
Subjects first day  on study  treatment will be either Weeks ( -24) or Weeks ( -16) 
depending on the outcome of randomization.  Furth er weeks of treatment throughout the 
Induction Period will be counted up to Day  01 (Day  1 initiates the Maintenance Period).
Eligibility  for Maintenance, 1stparagraph, Section 3.2.3 -clarification
Revised to (changes struck through and underlined):
Subje cts must achieve with an undetectable HIV -1 RNA (<50 c/mL) at the Week ( -4) 
visit in order to be are eligible to enter the Maintenance Period. A single repeat to 
determine eligibility  may be allowed ONLY after consultation with the medical monitor.  
Subje cts with HI V-1 RNA 400c/mL  at Week ( -4) are not eligible to enter the 
Maintenance Period and will not be allowed a repeat to determine eligibility.
Maintenance Period, 2ndparagraph and last sentence, Section 3.2.4 -clarification
Revised to (changes str uck through and underlined):
On the first day  of the Maintenance Period (Day  1),subjects will receive their last dose of 
[COMPANY_004]744 ABC/3TC RPV Induction Period regimen in the clinic andinitiate either IM 
injections or be dispensed the oral regimen depending on the outcome of randomization 
arm.  Add-on RPV treatment will be discontinued for all subjects after the first day  of 
Maintenance Day 1.  
See the Time and Events Schedule Section 6.[ADDRESS_419502] sentence, Section [IP_ADDRESS] -clarification
Revised to (changes struck through and underlined):
If eligible, subjects will be taking [COMPANY_004]744 + ABC/3TC + RPV for the next 2 weeks from 
Week 98 to Week 100 of the Extension Period.  
Independent Data Monitor ing Committee, Section 3.2.8 –IDMC specifics will no w 
be in the IDMC charter
Revised to (changes struck through and underlined):
An Independent Data Monitoring Committee (IDMC) will evaluate the efficacy , 
tolerability , and safet y of [COMPANY_004]1265744 and TMC278 before all eligible subjects have 
transitioned from the Induction Period to the Maintenance Period.  This IDMC review 
may be conducted after approximately  [ADDRESS_419503] reached Week 8 of the 
Maintenance Period, depending on IDMC agreement.  The intent o f this analy sis is to 
identify  any early  safet y or tolerability  signals from the long acting regimen. Full details  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
210of the anal yses, estimated timing and the decision criteria that will be used to determine 
regimen performance will be pre- specified in the IDMC Charter. An Independent Data 
Monitoring Committee (IDMC) will evaluate the efficacy , tolerability , and safet y of 
[COMPANY_004]744 and TMC278 after [ADDRESS_419504] sentence, Section 3.2.9 –Revised planned 
analy ses and allowed for additional analy ses as needed.
Revised to (changes struck through and underlined):
Additional analy ses will be conducted at Day  1, Week 24, Week 48 and Week 96.  
Planned anal yses will be conducted at Week 48 and Week 96. Additional analy ses, for 
example at Day  1, may  be conducted to support internal decision making, scientific 
presenta tions or regulatory  document preparation, as needed.
Number of Subjects, Section 4.1 –not needed
Removed the following sentences:
Approximately  150 subjects are planned to enter the Maintenance Period.  The 
anticipated overall study  withdrawal rate is app roximately  30%.  
Inclusion Criteria and A dditional Eligibility  Criteria, Section 4.2 and Section 4.4 –
removed dates to allow for various updates that may  occur over the life of the 
study
Removed reference to dated product labels and Investigator’s Brochu res.
Exclusion Criteria, criteria #22, Section 4.3 -clarification
Revised to (changes struck through and underlined):
Subjects who are HLA-B*5701 positive and unable to use an alternative NRTI  backbone 
(subjects who are HLA -B*5701 positive may  be enrolled if they  use an alternative NRTI 
backbone that does not contain abacavir. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
211Withdra wal Criteria, Section 4.5 –allow for additional data collection
Added:
All subjects who discontinue prematurel y from the study, irrespective of arm, will be 
asked for additio nal information to establish the reason for withdrawal.
And
Subjects who cannot or do not wish to continue on to the L ong-Term Follow Up 
Period (see Section 3.2.6).
TMC278 Tablet, Section 5.1.2 -clarification
Revised to (changes struck through and underli ned):
RPV [ Edurant Product I nformation , 2012) is provided by  [CONTACT_12945] & 
Development, a division of Janssen Pharmaceuticals as 25 mg tablets that are off -white, 
round, biconvex, film -coated and debossed on one side with “TMC” and the other side 
with “25”. RPV is manufactured by  [CONTACT_48873] - Cilag S.p.A, Latina, Italy. RPV will be 
provided as globall ycommercial marketed product , including US and the European 
Union, and overlabeled, packaged in bottles of 30 tablets.  RPV tablets are to be stored at 
25°C and protected from light.
[COMPANY_004]1265744 Injectable Suspension, Section 5.1.4 –additional information
Revised to (changes struck through and underlined):
[COMPANY_004]744 L A is manufactured by  [CONTACT_339259] a sterile white to slightly  
colored suspension conta ining 200 mg/mL of [COMPANY_004]744 as free acid for administration by  
[CONTACT_33813] (IM) injection.  The product is packaged in a 3 mL USP Ty pe I glass vial 
with a 13 mm gray  stopper and aluminium seal. Each vial is for single use containing a 
nominal fill of 1.5 m L or2.0 mL , and does not require dilution prior to administration.  
[COMPANY_004]744 L A injectable suspension is to be stored at up to 30°C, do not freeze.
[COMPANY_004]744 L A is composed of [COMPANY_004]1265744 free acid, poly sorbate 20, pol yethylene gl ycol 
3350, mannitol, and water for injection.
TMC278 Injectable Suspension, Section 5.1.5 –additional information
Revised to (changes struck through and underlined):
TMC278 L A, also named JNJ-16150108 -AAA 300 mg/mL  Extended Release Suspension 
for Injection (G001), is provided by  [CONTACT_339305] n Research & Development, a division of 
Janssen Pharmaceuticals as a sterile white suspension containing 300 mg/mL of TMC278 
as free base for administration by  [CONTACT_33813] (IM) injection.  The product is packaged 
in a 2 mL USP Ty pe I glass vial with a 13 mm grey  stopper and aluminium seal. Each 
vial is for single use containing a nominal fill of 2.0 mL , and does not require dilution  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
212prior to administration but requires refrigeration.  TMC278 L A injectable suspension is to 
be stored 2- 8°C, do not freeze, p rotected from light and kept in the outer package.
TMC278 L A is composed of TMC278 free base, poloxamer 338, sodium dihy drogen 
phosphate monohy drate, citric acid monohy drate, glucose monoh ydrate, sodium 
hydroxide, water for injection.
Dosage and Administra tion, Induction Period, Section 5.1.6 -clarification
Clarified to require onl y RPV to be taken with a meal.
Dosing Considerations for [COMPANY_004]744 LA  + TMC278 LA , Section 5.1.7 –additional 
information
Added:
If possible, injections should be spaced approximate ly 2cm from one another and from 
the site of an y previous injection and or an y injection site reaction.
Treatment Compliance, Section 5.5 –allow for additional data collection
Added:
Subject awareness and knowledge of these dosing instructions will be as sessed by  
[CONTACT_339306] 6.13.  
Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014], 4thsentence, Section 5.9.2 -
clarification
Revised to (changes struck through and underlined):
Acetaminophen is cannot beused in patients with acute viral hepatitis.
Time and Events Schedule, Section 6 –clarification, simplification, additional 
information
In general, the following changes were made:
Specified in top left of each table which period the table applies to (i.e. 
Procedu res for 24 Week Induction)
Added that rescreened subjects would be assigned a new subject number
Changed “Medical” exam to “Phy sical” exam
Added timings for ECG completion
Changed requirement for vital signs to be assessed after [ADDRESS_419505] to 
“about ” [ADDRESS_419506] 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
213Clarified “Health Outcomes Questionnaire” to actual questionnaires being 
completed:  HIVSTQs, HIVSTQc, HIVMQ.  Included timings of completion.
Removed some unnecessary  assessments:  some fasting labs, some ECGs, some 
chemistry  and hemat ology  assessments
Added Follow Up visit to all
Split the Maintenance Time and Events (T&E) table in to 2 tables:  1 for the IM 
regimen ([COMPANY_004]744 LA+TMC278 L A) and 1 for the oral regimen 
([COMPANY_004]744+ABC/3TC)
Added the following to both the Maintenance and Extensi on T&E:
Dosing is expected to occur within 21 -35 day s from the previous dose while keepi[INVESTIGATOR_339203]  1 of the Maintenance Period.  All 
decisions regarding dose interruption/ resumption must be discussed with the 
medi cal monitor in advance.
Moved Week 98 to the Maintenance T&E, oral regimen
Simplified telephone visits for subjects on the oral regimen
Clarified the Extension T&E to be more clear and readable
Changed pregnancy  testing in Long -Term Follow Up to be serum i nstead of 
urine
Baseline A ssessments, Medical History , Section 6.7.2 –allow for additional data 
collection
Changed “recent” illicit drug use to “history ” of illicit drug use.
Added: 
intravenous drug use history
Safety  Assessments, Clinical Evaluations, S ection 6.9.1 –allow for additional data 
collection
Added:
Exercise habits will be assessed for subjects on the [COMPANY_004]744 L ATMC278 LA regimen. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
214Laboratory  Assessments, Section 6.9.2 –not collected
Removed:
If additional non -protocol specified laboratory  asse ssments are performed at the 
institution’s local laboratory  and result in a change in patient management or are 
considered clinically  significant by  [CONTACT_093] (e.g., SAE or AE or dose 
modification) the results must be recorded in the subject’s CRF. 
Health Outcomes, Section 6.13 –clarification, additional information
Revised to (changes struck through and underlined):
Health outcomes assessments will be conducted in all countries where translations of the 
instruments are available.  Assessments are recommended to be administered at the 
beginning of the visit.
The HIV Treatment Satisfaction Questionnaire (HIVTSQ) Woodcock [ Woodcock , 2001 
and Woodcock , 2006] was developed to evaluate treatments for HIV and patient 
satisfaction. The higher the score, the greater the improvement in treatment satisfaction as 
compared to the past few weeks. A smaller score represents a decline in treatment 
satisfaction compared to the past few weeks.  The HIVTSQ items are summed up to 
produce a treatment satisfaction score (0 to 60) and an individual satisfaction rating for 
each item (0 to 6) and two subscales: general satisfaction/clinical and lifesty le/ease 
subscales.
This study  will be using the HIVTSQ(s) (status version) and the revised HIVTSQ(c) 
(change version). T hishese measure sis specifically  designed to will assess change in 
treatment satisfaction over time (in the same subjects) and compare current satisfaction 
with previous satisfaction treatment satisfaction, from an earlier time point. 
The HIV Medication Questionnaire (HIVMQ) was developed to assess subject reported 
medication adherence.
The HIVTSQ items are summed up to produce a treatment satisfaction score (0 to 60) 
and an individual satisfaction rating for each item (0 to 6) and two subscales: general 
satisfa ction/clinical and lifesty le/ease subscales. These scores will be summarized and 
compared between the treatment groups in an exploratory  anal ysis at Week ( -12),Week 
(-4), Day  1, Week 24, Week 48, and Week 96, or withdrawal by [CONTACT_1570].
In addition, subject tolerability  data will be collected at Week (- 12), Week ( -4), Day  1, 
Week 24, Week 48, and Week 96.  Details of the data collection methods will be detailed 
in the SPM.
Moreover, data will be collected evaluating subject adherence to stud y treatme nt at Week 
(-12), Week ( -4), Day  1, Week 24, Week 48 and Week 96. Details of the data collection 
methods will be detailed in the SPM .
The HIVTSQ(s) will be administered at the following time points:  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
215Induction: Week -20 in the 24 Week Induction Period and Week - 12 in the 16 
Week I nduction Period and Week (-4) (pre-dose) in both I nduction Periods
Maintenance:  pre -dose at Day  [ADDRESS_419507] -dose at Week 4, Week 8, Week 24, 
Week 48, Week 96 & Withdrawal
The HIVTSQ(c) will be administered at the following time poi nts:  
Maintenance:  Week 24 and at Withdrawal for subjects withdrawn between Week 
4 and Week 24
HIVMQ will be administered at the following time points:
Induction: Week (-4)
Maintenance:  Week 8, Week 24, Week 48, Week 96 & Withdrawal
oIM Regimen:  Complet e post -injection
oOral Regimen:  Preferably completed at the beginning of the visit, but may 
be completed at an y time during the visit
Qualitative interviews with [ADDRESS_419508]’s 
experience on the injection regimen. This would be conducted under a separate IRB/IEC 
approved consent. Participation in the interviews would be voluntary .
Interim and Final A nalysis, Section 8.3.4 –allow for IDMC details to be listed in the 
charter instead of the protocol and clarification
Revised to (changes struck through and underlined):
The ITT- E population will be primary  efficacy  population and the safet y population will 
be the primary  safet y population for all anal yses.  All available data will be included in 
all interim analy ses, in cluding data bey ond the designated time point except for the Day  [ADDRESS_419509] be used to fully  characterise the long -term 
safet y and efficacy profile of [COMPANY_004]744.  As no h ypothesis is being tested for rejection 
during the constant monitoring of virologic response, no adjustment for multiplicity  will 
be performed.
Futility  Interim Monitoring, 3rdand 4thsentence, Section [IP_ADDRESS] -clarification
Revised to (changes struck through and underlined):
If the number of failures meets or exceeds the thresholds specified in the table below 
(Table 6), this will be considered strong evidence of an inadequate response and will 
trigger a comprehensive IDMC data review and possible discontinuation of that treatment 
arm.  If an inadequate response is seen in the shorter induction length arm and it is 
determined that that arm should be discontinued, then subjects on that treatment arm still 
in the I nduction Period canwill be switched to the longer induction length.
IDMC Interim A nalysis, Section [IP_ADDRESS] –allowfor IDMC details to be listed in the 
IDMC charter instead of the protocol, clarification
Revised to (changes struck through and underlined):
The purpose of these analy ses is for the Independent Data Monitoring Committee to 
evaluate the efficacy , safety  and tolerability  of [COMPANY_004]744 at earl y time points in the study .  
The IDMC will review at least one anal ysis, an analy sis of all data available at the time 
45 subjects reach Week 8 of the Maintenance Period. This analy sis will be used to 
remove an y sub optimal induction length from the study  before all subjects transition into 
the Maintenance Period.  As subjects enter the Maintenance Period of the study  the 
protocol defined virologic failure rate will be continually  monitored. If the number of 
failures meets or exceeds the thresholds specified in Table 4 , this will be considered 
strong evidence of an inadequate response and will trigger a comprehensive data review 
by [CONTACT_339307] 24.  The IDMC 
charter will contain detailed safet y summaries and efficacy  anal yses that will be provided
The purpose of these analy ses is for the Independent Data Monitoring Committee 
(IDMC) to evaluate the efficacy , safety  and tolerability  of [COMPANY_004]744 at earl y time points in 
the study .  The IDMC will review at least one analysis before all eligible subjects have 
transitioned from the Induction Period to the Maintenance Period.  Full details of the  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
217analyses, estimated timing and the decision criteria that will be used to determine 
regimen performance will be pre -specified in the IDMC Charter, with IDMC agreement.  
As subjects enter the Maintenance Period of the study , the protocol defined virologic 
failure rate will be continually  monitored. If the number of failures meets or exceeds the 
pre-specified thresholds specified in the IDMC Charter, this will be considered strong 
evidence of an inadequate response and will trigger a comprehensive data review b y the 
IDMC.  The IDMC charter will contain details of this continual monitoring of the 
protocol defined virologic failure rates, the specifics around what will trigger a data 
review, and the safety  summaries and efficacy  analy ses that will be provided should a 
data review be required.
Day 1 Interim A nalysis, Section [IP_ADDRESS] -clarification
Revised to (changes struck through and underlined):
A Day  1 interim analy sis may  be conducted to support regulatory  submissions and/or 
scientific conference presentations once the last randomized subject has completed the 
Day 1 study  visit and the database ha s been cleaned and released for anal ysis. The results 
of this analy sis will be used to evaluate efficacy , safet y and tolerability of [COMPANY_004]744 30 mg 
once dail y plus ABC/3TC once daily in the Induction Period.  Only  data from the 
Induction Period would be summarized in this analysis.   The Day  [ADDRESS_419510] has completed the Day  1 study  visit and 
the database has been cleaned and released for analy sis. The results of this analy sis will 
be used to evaluate e fficacy , safet y and tolerability of [COMPANY_004]744 30 mg once daily  plus 
ABC/3TC once dail y in the Induction Period.
Health Outcomes, Section [IP_ADDRESS] -clarification
Revised to (changes struck through and underlined):
Data from the eC -SSRS, HIVTSQ(s), HIVTSQ(c), a nd HIVMQ will be summarised by  
[CONTACT_765].  Total satisfaction scores and lifesty le/ease sub -scores will be summarised at each 
time point by  [CONTACT_339295], SD, median, min and max.
Data from the C -SSRS will be summarised by  [CONTACT_765].
In an effort to reduce ‘potentially  avoidable’ study discontinuations (for example, lost to 
follow up, subject withdrawal, non -compliance, protocol violation) and to improve data 
quality , patient characteristics will be studied to focus retention efforts on subgroups o f 
subjects more likely  to withdraw prematurel y from the study.
Each HIVTSQ item is scored 0 -6 where a higher score indicates greater satisfaction with 
treatment. The HIVTSQ items are summed up to produce a treatment satisfaction total 
score (0 to 60) and a lifesty le/ease sub -score (0 to 30). 
The number and proportion of subjects with each response (0 -6) to each of the 10 items 
in the HIVTSQ will be summarised at Week (- 12), Week ( -4), Day  1, Week 24, Week 48 
and Week 96 by [CONTACT_1570]. Total satisfacti on scores and lifesty le/ease sub -scores  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
218will be summarised at Week ( -12), Week ( -4), Day  1, Week 24, Week 48 and Week 96
by [CONTACT_339295], SD, median, min and max. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
219Amendment 2
Amendment 2applies to all countries.  
Amendment 2 was prepare d to introduce a major a design change.  The Induction Period 
was consolidated into a single 20 Week arm.  A n additional I M dosing arm was added:  
[COMPANY_004]744 L A 600 mg I M + TMC278 L A 900 mg IM every  8 weeks (Q8W).  As such, 
much of the protocol was amended to consolidate the Induction Period and to add a 3rd
dosing arm.  
Major changes include complete replacement of the protocol summary , the dose rationale 
was revised to support the Q8W I M dosing regimen, objectives and endpoints were 
updated including changin g the primary  endpoint from Week [ADDRESS_419511] requirements for the Q8W arm, the study  design and 
schematic updated, increased sample size to 265 subjects , all Time and Event Tables 
were replaced, PK sampli ng strategy  and data analy sis and statistical considerations 
updated.
Additionally , the liver stoppi[INVESTIGATOR_339204] / rechallenge 
information was revised and added, respectively.
Finally , the requirement to have hepatic impairment measured b y Child -Pugh 
assessments was removed.  Hepatic impairment will be assessed b y multiple other means 
(labs and ph ysical assessments).
General
Clarifications of naming conventions of [COMPANY_004]1265744 and TMC278 (both formulations) 
were made throughout to document to be in line with the defined terms in Section 1.2.  In 
addition, the I nduction Period was revised throughout the document to be [ADDRESS_419512] t wo IM dosing 
regimens are being eva luated [every  4 weeks (Q4W) and every  8 weeks (Q8W) ] and o ne 
oral dosing is being evaluated (oral).  This change was made throughout the document.
Week [ADDRESS_419513] information.
Various clarifications thr oughout. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
220Abbreviations
Addition of several abbreviations:  
BMI Body Mass Index
eC-SSRS Electronic Columbia Suicidality  Severity  Rating Scale
PDVF Protocol Defined Virologic Failure
PopPK Population Pharmacokinetics
Q4W Every  [ADDRESS_419514] sections were 
revised with the exception of key study  assessments, permitted study  treatment 
substitutions and the definition of virologic failure.
References to Investigator’s Brochures and Product Information
Throughout the document, any  reference to the Investigator’s Brochure or product 
information for TMC278 was updated to the newest version dates 2013 and June 2013 
(Edurant) respectively .
Section 1.4 [COMPANY_004]1265744 –Long A cting Injectable ([COMPANY_004]744 LA )
Original text:
A long acting (LA) injectable formulation of [COMPANY_004]1265744 ([COMPANY_004]744 LA) is also in 
development and has been dosed in over 98 HIV -1 uninf ected subjects at doses between 
100-800 mg with an adverse event (AE) profile similar to oral dosing of [COMPANY_004]744.  The 
LA injectable formulation has been dosed intramuscularl y (IM) and subcutaneously (SC), 
and has been generall y well -tolerated.  Painless nod ules were more common following 
SC injections than I M injections.  Intramuscular injection site reactions have been 
predominantly  mild or Grade 1 (85%), self- limited, and have not led to study  
discontinuation in any  subject to date. No treatment emergent serious AEs have been 
reported.  [Preliminary  data from ongoing study  LAI115428 GlaxoSmithKline Document 
Number 2011N112455_03 and GlaxoSmithKline Document Number RM2010/[ZIP_CODE]/04 : 
LAI114433]. 
All of the above characteristics make [COMPANY_004]744 an attractive comp ound for continued HIV 
drug development .
Revised text:
[COMPANY_004]744 L A, a long acting injectable formulation of [COMPANY_004]1265744 , has been dosed in 
136healthy subjects.  Subjects have received single or repeat doses of [COMPANY_004]744 LA at 
doses between 100 to 800 mg , either intramuscularly  (IM) or subcutaneously  (SC) and  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
221either alone or in combination with TMC 278 L A(completed study  LAI114433 [single 
dose LA, n=58], ongoing study  LAI115428 [repeat dose L A, n=40], and ongoing study  
LAI116815 [single dose LA, n=38]). Theadver se event (AE) profile has been similar 
tothose of [COMPANY_004]744 (oral) .  To date, no studies in HIV -[ADDRESS_419515] been 
conducted with [COMPANY_004]744 LA.  
[COMPANY_004]744 L A (has been generall y well -tolerated as either an IM or SC dose .    
Intramuscular injection site reactions (ISRs) have been predominantl y mild or Grade 1 
(85%), self -limited, and have not led to study  discontinuation in any  subject to date. 
Erythema, nodules, induration, and warmth at the injection site were most commonly
reported in healthy  subjects. Painless nodules were more common following SC 
injections than I M injections.   No treatment emergent serious AEs have been reported.  
[Preliminary  data from ongoing study  LAI115428 GlaxoSmithKline Document Number 
2011N112455_03 and GlaxoSmithKline Docume nt Number RM2010/[ZIP_CODE]/04: 
LAI114433]. 
All of the above characteristics make [COMPANY_004]1265 744 an attractive compound for continued 
HIV drug development .
Section 1.5 TMC278 -Oral (RPV)
Revised to (changes struck through and underlined).
RPV, the oral formulatio n of TMC278 ( rilpi[INVESTIGATOR_12979], RPV Edurant), is a diarylpy rimidine 
derivative , isand a potent non -nucleoside reverse transcriptase inhibitor (NNRTI) with in 
vitro activity  against wild ty pe HIV -[ADDRESS_419516] NNRTI -resistant mutants.  RPV , and is 
currentl y approve d as a 25 mg oral tablet formulation infor use in antiretroviral (ARV) 
treatment -naïve patients in the multiple countries such as the US, EU andCanada for use 
in antiretroviral (ARV) treatment- naïve patients and other countries as per the approved 
label in each country  / region. 
Section 1.6 TMC278 –Long A cting Injectable (TMC278 LA )
Revised to (changes struck through and underlined).
Rilpi[INVESTIGATOR_339205]278 can is alsobeformulated as a long acting injectable (TMC278 L A) 
with PK that could support sIM dosi ng every  4 or 8or more weeks. 
And
In C158 (N= 2019) , TMC278 L A injectable suspension in the current formulation after 
single IM injection of 300 mg or of 600 mg, or after multiple dosing regimens of 3 
successive IM doses was generall y safe and well tole rated.  
Added:
In LA I115428, TMC278 LA was administered as successive monthly  IM injections as 
1200/900 mg or 1200/[ADDRESS_419517] been reported.  [Preliminary  data from ongoing 
study  LAI115428 GlaxoSmithKline Document Number 2011N112455_03 ].
Section 1.7 -Study  LAI116482
Original text:
LAI116482 is an ongoing Phase IIb dose -ranging study  ([COMPANY_004]744 10 mg, 30 mg, 60 mg) 
evaluating the utility  of a two- drug, two- class combination ([COMPANY_004]744 + RPV) when both 
are given as a once dail y oral regimen following induction of virologic suppression using 
[COMPANY_004]744 plus 2 investigator selected NRTIs.  To date, th e study  has enrolled 244 
subjects, 181 of whom received one of three oral dose regimens of [COMPANY_004]744 (10 mg, 30 
mg or 60 mg) plus 2 NRTI s. A Week 24 planned interim analy sis is complete and 
demonstrated similar antiviral activity  across the three dosing arms of [COMPANY_004]744 in 
combination with 2 NRTIs, which compared favourably  to the control regimen of EFV 
600 mg once dail y plus 2 NRTI s.  Rates of protocol defined virologic failure through 
Week 24 were low across all study  arms (one subject receiving each dose of G SK744 and 
three subjects receiving EFV) without emergence of new genot ypic or phenoty pic 
resistance in an y of these subjects. 
Sixty -one percent of subjects were treated with investigator selected Truvada 
(tenofovir/emtricitibine, TDF/FTC) and 39% of the s ubjects were treated with 
EPZICOM/KIVEXA (abacavir/lamivudine, ABC/3TC) at randomization.  Similar 
virologic response rates (HIV -1 RNA < 50c/mL) through 24 weeks were seen in subjects 
taking [COMPANY_004]744 + ABC/3TC (87%) and in subjects taking [COMPANY_004]744 + TDF/FTC (8 7%). 
The most common treatment -emergent AEs reported for subjects on one of the [COMPANY_004]744 
doses, were nausea, headache, and diarrhea.  One subject receiving [COMPANY_004]744 60 mg had a 
Grade 3 headache.  All other AEs were Grade 1 or 2 with the majority  of them being
Grade 1.  Four subjects on [COMPANY_004]744 verses eight on EFV withdrew due to an AE, one 
receiving 30 mg (panic attack) and three receiving 60 mg (hepatitis, blood lactate 
dehy drogenase increased, and musculoskeletal pain).  The majorit y of [COMPANY_004]744 related 
AEs wer e Grade 1 and few of those AEs led to withdrawal through Week 24 (n=4 (2%)).  
There have been no drug related SAEs to date.  
Two of the subjects that withdrew due to AE met liver stoppi[INVESTIGATOR_339206]>10x UL N at approximately  Week 4 and Week 8 aft er initiating study drug.  Both 
had pre -existing steatohepatitis and were dosed with [COMPANY_004]744 60 mg + ABC/3TC.  Both 
subjects remained as ymptomatic, had normal serum bilirubin levels and had resolution of 
the ALT values after drug discontinuation.  These [ADDRESS_419518] abnormality  
were similar between [COMPANY_004]744 and EFV dosed subjects through Week 24: AL T:  15% 
and 19% respectivel y; AST:  18% and 15% respectively . 
Based u pon the results through Week 24 of the LAI116482 study , and in accordance with 
the pre -specified dose selection criteria, a 30 mg oral dose of [COMPANY_004]744 has been selected 
to be used in combination with ABC/3TC for induction of virologic suppression in study  
200056. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419519] of study  200056 by  [CONTACT_339308]744 when used as part of a HAART regimen.  Additionally , 
it is anticipated that L AI116482 will provide proof of principle for [COMPANY_004]744 L A + 
TMC278 L A as a maintenance regimen, through a demonstration of oral efficacy  of 
[COMPANY_004]744 + RPV as maintenance therap y.  
All subjects in the ongoing LAI116482 study  have entered into the Maintenance Phase.  
Eligible subjects enter Maintenance at Week 24 wh ere they  begin the [COMPANY_004]744 + RPV 
regimen.  All subjects will have completed [ADDRESS_419520] of the current study .  These 
data will be made available to I nvestigators.
Revised text:
LAI116482 is an ongoing Phase IIb dose -ranging study  ([COMPANY_004]744 10 mg, 30 mg, 60 mg) 
evaluating the utility  of a two- drug, two- class combination ([COMPANY_004]744 + RPV) when both 
are given as a once dail y oral regimen following induction of virologic suppression using 
[COMPANY_004]744 plus 2 investigator selected NRTIs. Eligible subjects enter Maintenance at 
Week 24 where they  began the [COMPANY_004]744 + RPV regimen.  
To date, the stud y has enrolled 244 subjects, 181 of whom received one of three oral dose 
regimens of [COMPANY_004]744 (10 mg, 30 mg or 60 mg) plus 2 NRTI s. A planned Week 48 (24 
weeks on Induction and 24 weeks on two -drug Maintenance) analy sis is complete and 
demonstrated similar antiviral activity  across the three dosing arms of [COMPANY_004]744 in 
combination with RPV , which compared favorably to the control regimen of EFV 600 
mg once daily plus 2 NRTI s.  
Rates of protocol defined virologic failure (PDVF) through Week 48 were low across all 
study arms . Three subjects receiving [COMPANY_004]744 (one at each dose) and three subjects 
receiving EFV were characterized as PDVFs during Induction.  During Maintenance, two 
subjects receiving [COMPANY_004]744 (10 mg and 30 mg) and one subject receiving EFV were 
characterized as PDVF.   
During Maintenance, t reatment emergent INI (Q148R) and NNRTI (E138Q) resistan ce
mutations were identified in one of the subjects on [COMPANY_004]744 (10 mg) .   The subject 
experienced suspected virologic failure (SVF) at Week 48, which was subsequently  
confirmed.  There was no change in RPV susceptibility , and a 3.[ADDRESS_419521] is pending.  By  [CONTACT_10585] 16 or at time of I P discontinuation if before Week 16, 
63% of subjects were treated with Truvada (tenofovir/emtricitibine, TDF/FTC) as their 
background dual NRTI and 3 7% of the subjects were treated with EPZICOM/KI VEXA 
(abacavir/lamivudine, ABC/3TC).  Similar virologic response rates (HIV -1 RNA < 
50c/mL ) through 24 weeks were seen in subjects taking [COMPANY_004]744 + ABC/3TC (87%) and 
in subjects taking [COMPANY_004]744 + TDF/FTC (8 6%). Rates continued to be similar through  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
224Week 48, 79% for subjects taking [COMPANY_004]744 + ABC/3TC and 84% in subjects taking 
[COMPANY_004]744 + TDF/FTC .
The most c ommon treatment -emergent AEs reported for subjects on an y of the [COMPANY_004]744 
doses, were nausea, headache, and diarrhea.  One subject receiving [COMPANY_004]744 [ADDRESS_419522] occurred on stud y day 343.  All other AEs were Grade 1 or 
2 with the majority  of them being Grade 1.  Six subjects on [COMPANY_004]744 verses eight on EFV 
withdrew due t o an AE, one receiving 10mg (ECG abnormal and palpi[INVESTIGATOR_814]), one 
receiving 30 mg (panic attack) and four receiving 60 mg (hepatitis, transaminases 
increased, anxiety  disorder and musculoskeletal pain).  The majorit y of [COMPANY_004]744 related 
AEs were Grade 1 and f ew of those AEs led to withdrawal through Week 48 (n=4 (2%)).  
There have been no [COMPANY_004]744 drug related SAEs to date.  
Two of the subjects that withdrew due to AE met liver stoppi[INVESTIGATOR_339206]>10x UL N at approximately  Week 4 and Week 8 after initiating study drug.  Both 
had pre -existing steatohepatitis and were dosed with [COMPANY_004]744 60 mg + ABC/3TC.  Both 
subjects remained as ymptomatic, had normal serum bilirubin levels and had resolution of 
the ALT values after drug discontinuation.  These [ADDRESS_419523] abnormality  
were similar between [COMPANY_004]744 and EFV dosed subjects through Week 48: AL T:  17% 
and 21% respectivel y; AST:  20% and 18% respectively .
These data from LAI116482 support the conduct of study  200056 by  [CONTACT_339309]744 when used initially  as part of a HAART regimen to induce 
virologic suppression.  In addition, this data confirmed antiviral activity  of [COMPANY_004]744 + 
RPV as a two-drug oral Maintenance regimen and provide s proof of principle for 
[COMPANY_004]744 L A + TMC278 LA as a maintenance regimen.  
Based upon the results through Week 48of the LAI116482 study , and in accordance with 
the pre -specified dose selection criteria at Week 24 , a30 mg oral dose of [COMPANY_004]744 has 
been selected to be used in combination with ABC/3TC for induction of virologic 
suppression in study  200056.
All ongoing subjects in the LAI116482 stud y have entered into Maintenance where they  
have completed [ADDRESS_419524] evaluation of the virologic efficacy  of 
the oral two drug regimen of [COMPANY_004]7 44 and RPV, prior to initiating the long acting 
injectable regimen .  These data will be made available to Investigators .
Section 1.8 –Study  Rationale
Revised to (changes struck through and underlined).
The overall objective of this study  is to select an i ntramuscular dosing regimen of 
[COMPANY_004]744 L A plus TMC278 L A based on a comparison of the Week 32 antiviral activity ,  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
225tolerability , and safety of two I M dosing regimens, relative to [COMPANY_004]744 30 mg plus 
ABC/3TC orally  once daily The overall objective of this study is to evaluate the efficacy , 
tolerability , and safet y of [COMPANY_004]744 L A plus TMC278 L A when both are administered as 
once -monthly  IM injections, following once dail y [COMPANY_004]744 + ABC/3TC FDC , in HI V-1 
infected antiretroviral -naïve subjects.  
Induction Period
The objective of the Induction Period is to induce virologic suppression prior to the 
initiation of the [COMPANY_004]744 LA + TMC278 LA regimen.  In addition, the Induction Period 
will evaluate the safety, tolerability and efficacy of [COMPANY_004]744 in combination with 
ABC/3TC in HIV -1-infected, ART -naive adults. The Induction Period consists of an 
evaluation of [COMPANY_004]744 30 mg once dail y plus ABC/3TC through 2016weeks or [ADDRESS_419525] remains virologicall y suppressed (HIV -1 RNA <50 c/mL) 
prior to initiating [COMPANY_004]744 L A + TMC278 LA treatment, impacts virologic response 
during the Maintenance Period.  Virologic suppression in the L AI116482 study  was 
rapid, with 83% of [COMPANY_004]744 30 mg treated subjects achieving an HIV -1 RNA <50 c/mL 
by [CONTACT_10585] [ADDRESS_419526] 16 weeks on the 24 week induction arm, prior to randomization into the 
Maintenance Period.  A review of the virology data from LAI116482 suggests that few 
subjects required greater than 16 weeks of therap y to achieve virologic suppression 
(HIV -1 RNA <50 c/mL), including subjects who ent ered the stud y with HIV -1 
RNA >100,000 c/mL.  
Subjects will be randomized at study  entry  to either the 16 or 24 week Induction Period 
and a difference in virologic response rates, between the two arms, is not anticipated. 
Initial randomization will be str atified b y screening HIV -1 RNA (<100,000 or 
≥100,000 c/mL ). 
Unless subjects meet a study  withdrawal criterion, their regimen will be modified during 
Induction at Week ( -4) by  [CONTACT_339235] 25 mg orally  once dail y.  RPV is being added 
to the ART regimen for all subjects at Week (- 4) to establish safet y and tolerability of 
RPV in individual subjects prior to initiating treatment with [COMPANY_004]744 L A + TMC278 L A 
during the Maintenance Period.  Subjects who do not or cannot tolerate [COMPANY_004]744 or RPV 
during this period should not enter the Maintenance Period. At the majorit y of time 
points, the incidence of (treatment related) AEs in the Phase III RPV studies were 
comparable between the RPV and control group and highest during the first [ADDRESS_419527] rash events was 10.5 days.  No grade 4 rash 
events were reported.  In addition, this RPV add on will serve as a pharmacokinetic lead 
in, achieving stead y state levels of RPV, prior to the administration of TMC278 L A 
[Rashbaum , 2011a and Rashbaum , 2011b].
Maintenance Period
Original text: 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
226Subjects with an undetectable HIV -1 RNA (<50 c/mL ) at the Week ( -4) visit are eligible 
to enter the Maintenance Period. 
The objective of the Maintenance Period of this study  is to assess the ability  of a long -
acting two -drug ART regimen, consi sting of intramuscularly  injected [COMPANY_004]744 L A 
400mg (following a loading dose of 800 mg) plus TMC278 L A 600 mg every  4 weeks, 
to maintain virologic suppression for 96 weeks with the primary  endpoint at Maintenance 
Period Week 24.  Subjects eligible to enter the Maintenance Period will enter a second 
randomization at Day  1 onto either the IM regimen or will remain on [COMPANY_004]744 (30 mg) + 
ABC/3TC (oral regimen).  All subjects will discontinue the I nduction regimen (including 
the add-on of RPV) after a final dose i n the clinic on Day  1.  Data from the Maintenance 
Period will be used to evaluate the ability  of this long -acting two -drug ART regimen to 
maintain virologic suppression through Week [ADDRESS_419528] accommodate the required injection volumes 
of both drugs and the better tolerability  of TMC278 L A IM, relative to SC.  
The selection of [COMPANY_004]744 30 mg + ABC/3TC as an oral comparator regimen in this study , 
will allow for a direct comparison of subjects who either i) continue their existing 
regimen or ii) simplify  their regimen to a once monthly  long -acting regimen.  The chosen 
comparator will also allow for a direct comparison of oral dail y pi[INVESTIGATOR_339153]. every 4 
week IM administration, a s it relates to efficacy , tolerability , safet y, and acceptability.  
Normalizing the comparator populations through a second randomization at Day  1, will 
also serve to strengthen this comparison.
Long -term maintenance of HIV virologic suppression will be as sessed.  
Revised text:
All subjects with an undetectable HIV -1 RNA (<50 c/mL ) at the Week ( -4) visit are 
eligible to enter the Maintenance Period. 
The objective of the Maintenance Period of this study  is to assess the ability  of a two -
drug regimen of [COMPANY_004] 744 L A and TMC278 LA to maintain virologic suppression for 96 
weeks with the primary  endpoint occurring after 32 weeks.  Two injectable IM dosing 
regimens (Q8W and Q4W) and one oral control dosing regimen will be evaluated.  
Subjects eligible to enter the Maintenance Period will be randomized 2:2:1 at Day 1 to 
one of the dosing regimens described below:
[COMPANY_004]744 L A 600 mg + TMC278 L A 900 mg IM every  8 Weeks (Q8W)
o+ Loading Dose of [COMPANY_004]744 800 mg at Day  1 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
227o+ Loading Dose of [COMPANY_004]744 600 mg at Week 4
[COMPANY_004]744 L A 400 mg + TMC278 L A 600 mg IM every  4 Weeks (Q4W)
o+ Loading Dose of [COMPANY_004]744 800 mg at Day  1
[COMPANY_004]744 30 mg + ABC/3TC once dail y
Randomization will be stratified b y HIV -1 RNA <50 c/mL  before Week (- 8)(yes or no).
All subjects on either IM regimen will discontinue the Induction regimen (including the 
add-on of RPV) after a final dose in the clinic on Day  1.  Subjects on the oral regimen 
will discontinue the add- on of RPV after a final dose in the clinic on Day  1.  
While both drugs, [COMPANY_004]744 L A and TMC [ADDRESS_419529] 
accommodate the required injection volumes of both drugs and to ensure good 
tolerability .  
The selection of [COMPANY_004]744 30 mg + ABC/3TC as an or al comparator regimen in this study , 
will allow for a direct comparison of subjects who either i) continue their existing 
regimen or ii) simplify  their regimen to one of the IM regimens.  The chosen comparator 
will also allow for a direct comparison of ora l daily  pi[INVESTIGATOR_339153]. Q4W and Q8W I M 
administration, as it relates to efficacy , tolerability, safet y, and acceptability.  
Normalizing the comparator populations by [CONTACT_339310]  
1, will also serve to strengthen this comparison.
Long -term maintenance of HIV virologic suppression will be assessed.  
Extension Period
Original text:
The Extension Period of this study will allow for a collection of longer term efficacy  and 
safet y and tolerability data from subjects receiving [COMPANY_004]744 LA and TMC278 L A.
Unless subjects meet a study  withdrawal criterion, subjects on the oral regimen may  elect 
to continue on the Extension Period via switching to the [COMPANY_004]744 L A + TMC278 L A 
regimen.  These subjects will also have their regimen modified at We ek 96 by  [CONTACT_339311] 25 mg orall y once daily for 2 weeks.  This short RPV add on will allow eligible 
subjects to achieve steady  state levels of RPV, prior to the administration of the [COMPANY_004]744 
LA + TMC278 LA regimen.  These switch subjects with an undetectabl e HIV -1 RNA 
(<50 c/mL) at the Week 96 visit will be eligible to enter the Extension Period .
Revised text:
The Extension Period of this study will allow for a collection of longer term efficacy  and 
safet y and tolerability data from subjects receiving [COMPANY_004]744 LA and TMC278 L A.  Only   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
228one IM dosing regimen, either Q4W or Q8W, will be taken into the Extension Period of 
the study  [based on criteria described in the Reporting and Analy sis Plan (RAP)].
Unless subjects meet a study  withdrawal criterion, subjects on t he oral regimen may  elect 
to continue on the Extension Period by  [CONTACT_339312]744 LA + TMC278 
LA dosing regimen.  If eligible, their regimen will be modified prior to entering 
Extension by  [CONTACT_339313] 25 mg orally  once daily  for 2 weeks.  This short RPV add on 
will allow eligible subjects to achieve stead y state levels of RPV, prior to the 
administration of the [COMPANY_004]744 LA + TMC278 LA.  
Long -Term Follow -Up Period
Original text:
Subjects who have received at least one dose of [COMPANY_004]744 L A and/or T MC278 L A are 
anticipated to be at high risk for development of virologic resistance if ART is 
interrupted. The time period during which subjects may  be at greatest risk for developi[INVESTIGATOR_339207]. This 
time period will vary  by [CONTACT_339239], 
inhibitory  concentration and half -life.  After a single [ADDRESS_419530] a single dose of [COMPANY_004]744 LA and/or 
TMC278 L A an d who discontinue the [COMPANY_004]744 LA + TMC278 LA regimen for any  
reason must remain on suppressive HAART for at least [ADDRESS_419531] dose of 
[COMPANY_004]744 L A and/or TMC278 L A in order to prevent selective pressure on HIV and the 
potential for selection of res istant mutants.  I n this study , this will be accomplished by  a 
Long -Term Follow -Up Period.
Revised text:
Subjects who have received at least one dose of [COMPANY_004]744 L A and/or TMC278 L A are 
anticipated to be at high risk for development of virologic resistance i f ART is 
interrupted. The time period during which subjects may  be at greatest risk for developi[INVESTIGATOR_339208]. This 
time period will vary  by [CONTACT_339239], 
inhibitory  concentration and half -life.   Plasma concentrations of both drugs may  be 
measurable for approximately  [ADDRESS_419532] ion 1.9 –Dose Rationale
Original text:
[COMPANY_004]1265744 –Oral and Long Acting Injectable
The oral dosing period intended for induction of virologic suppression will also serve as a 
lead-in period required to confirm tolerability  in each subject prior to initia ting the 
prolonged exposure following [COMPANY_004]744 LA injection, which has been observed to be up 
to 52 weeks following a single injection in some subjects [GlaxoSmithKline Document 
Number RM2010/[ZIP_CODE]/04 : LAI114433].  [COMPANY_004]744 10 mg, 30 mg and 60 mg once dail y 
incombination with 2 NRTI s achieved undetectable HIV RNA at Week 24 in 85 to 88% 
of HIV infected subjects [GlaxoSmithKline Document Number 2012N134026_02:  
LAI116482] .  Plasma exposures following these oral doses are shown in Table 1.  Given 
the equivalent efficacy  across all doses at Week 24 and the more frequent AL T elevations 
observed following 60 mg once dail y, [COMPANY_004]744 30 mg once dail y is the clinical dose that 
has been selected for the Induction Period.
During the IM dosing period intended to maintain vi rologic suppression, [COMPANY_004]744 L A 
800 mg IM (split into two 2 mL, 400 mg IM injections) will be administered as a loading 
dose on the same day  as the final oral dose to maintain [COMPANY_004]744 plasma concentrations 
above the protein adjusted 90% inhibitory  concentrat ion (PA -IC90) while prolonged 
absorption from the depot site begins.  [COMPANY_004]744 LA 400 mg IM every  4 weeks starting 28 
days following the loading dose was selected to approximate the plasma [COMPANY_004]744 
concentrations of the selected oral dose of 30 mg once -daily at steady  state.  Following an 
800 mg IM loading dose and three subsequent 400 mg IM maintenance doses 
administered every  4 weeks in healthy  subjects (LAI115428), the geometric mean 
[COMPANY_004]744 Cτ was 3.2 μg/mL , 19-fold above the PA -IC90, whereas oral 30 mg once daily 
(LAI116482) achieved a geometric mean plasma C0 of 4.2μg/mL ,~25-fold above the PA -
IC90.  Geometric mean plasma area under the curve (AUC )(0-τ) following the fourth 
monthly  dose (third monthly  400 mg IM dose) in healthy  subjects was 2362μg ∙h/mL  
(LAI 115428), below the AUC (0 -∞) of 2652
μg∙h/mL  observed in health y subjects 
receiving a single dose of 400 mg IM in another study  (LAI114433), suggesting that 
accumulation may  be ongoing and steady  state concentrations may  be higher than 
observed after four m onthly  doses.  
Plasma exposures after administration of [COMPANY_004]744 L A IM every  4 weeks:
are expected to be similar those observed in healthy  subjects (geometric mean 
maximum plasma drug concentration [Cmax ]4.37 μg/mL  and AUC(0- τ) 
2652μg ∙h/mL  (LAI115428), 
are not expected to exceed those following oral 30 mg once dail y (geometric 
mean Cmax, steady  state (ss) 4.20 μg/mL and 28*AUC (0- τ), ss 3752μg ∙h/mL ) 
studied in L AI116482,  
are expected to remain well- below exposures observed in the 60 mg level 
(geometric m ean Cmax, ss 13.1  g/mL and 28*AUC, (0- τ) ss 6384 μg ∙h/mL) in 
LAI116482 (See Table 1 ). 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
230Despi[INVESTIGATOR_040] a geometric mean C lower than 30 mg orally  once dail y, Cvalues observed 
following 800 mg/400 mg IM in healthy  subjects were ~2.4 -fold higher than following 
10mg orally  once dail y in HIV infected subjects, which was equally  efficacious to 30 mg 
orally  once dail y at 24 Weeks.  Mean observed [COMPANY_004]744 concentration -time profile 
following [COMPANY_004]744 LA administration in healthy  subjects with superposition of steady -
state oral dosing is compared to simulated 10 mg and 30 mg orally  every  day regimens 
based on LAI116482 data in Figure 1 . 
The preferred IM injection volume of 2 mL using a 200 mg/mL [COMPANY_004]744 LA 
nanosuspension formulation would limit a single injection to 400 mg IM. As dose 
splitting increases the number of injections, possibly  reducing patient tolerability , single 
injection maintenance doses are preferred.  In addition, a maximum SC injection volume 
of 1mL  using the 200 mg/mL  nanosuspension would require a 4 -injection loading dose 
and 2 -injection maintenance doses, limiting the acceptability  of delivery  by [CONTACT_339314].
Table 1 Summary  of [COMPANY_004]1265744 PK Parameters following oral 
administration in HIV infected subjects and [COMPANY_004]744 LA  
administration in healthy  subjects
Route
Study
Population[COMPANY_004]1265744 Regimen[COMPANY_004]1265744 PK Parameter
C  or C0
(g/mL)1Cmax
(g/mL)2AUC(0 -)
(gh/mL)3IQ
(C0:IC90 
ratio)4
Oral
LAI116482
HIV10 mg orally every day1.35
[45%]2.77
[33%]45.7
[32%]8.13
30 mg o rally every day4.20
[40%]7.49
[28%]134
[32%]25.3
60 mg orally every day7.93
[39%]13.1
[44%]228
[57%]47.8
IM
LAI115428 
HVs800 mg IM Loading Dose/ 
400 mg IM q4wk x33.22
[28%]4.37
[33%]2362
[27%]19.4
Data presented as Geometric mean [ CVb%], HV = Healthy Volunteers
1. C0:  n= 57 (10 mg orally), 53 (30 mg orally), 55 (60 mg orally), 9 (800 mg/400 mg IM), 
2. Cmax:  n= 14 (10 mg orally), 12 (30 mg orally), 11 (60 mg orally), 9 (800 mg/400 mg IM)
3. AUC(0 -):  n= 14 (10 mg orally), 12 (30 mg ora lly), 11 (60 mg orally), 9 (800 mg/400 mg IM)
4. PA-IC90 determined in vitro 0.166 g/mL. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
231Figure 1 Mean (SD) [COMPANY_004]1265744 Concentration -Time Profiles follo wing 800 
mg/400 mg IM LA  Administration and with Superposition of Final 30 
mg oral Steady  State Dose at D ay 0 compared to simulated 30 mg 
and 10 mg orally  once daily
TMC278 – Oral and Long Acting Injectable
All subjects will receive 4 weeks of RPV 25 mg daily , from Week ( -4) through Day  [ADDRESS_419533] prior to IM dosing with TMC27 8 LA.  RPV will thus 
be co -administered with the [COMPANY_004]744 + ABC/3TC regimen. Data from study  LAI116182 
[GlaxoSmithKline Document Number 2012N134026_02:  L AI116482 ] have 
demonstrated that there is no clinically  relevant drug -drug interaction following repeat 
oral administration of [COMPANY_004]744 with RPV. With this RPV add- on, subjects will also have 
steady -state RPV plasma concentrations prior to starting TMC278 LA dosing.
During the Maintenance Period, subjects will receive I M injections of TMC278 L A 
600mg every  4 weeks. The selection of the TMC278 L A dosing regimen is based on 
achieving RPV plasma concentrations comparable to those observed with RPV 25 mg 
every  day in HIV -infected patients. 
Figure 2 shows the model predicted RPV plasma concentrations with this TMC 278 L A 
dosing regimen. The graph shows the mean profile (red curve) with the 90% prediction 
interval (shaded area). The curve shows a full PK profile for the first 2 injections and for 
the 11thinjection, while for the injections in between only the trough plasma 
concentration (Ctrough) is shown. Figure 2 also indicates the mean PK parameters for 
RPV 25 mg every  day in HIV -infected patients (Phase III): Ctrough of 80 ng/mL, and  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
232Cavg (i.e., average RPV plasma concentration within a 24 hour dosing interval) o f 
100ng/mL.
For the simulations, a pharmacokinetic model was used based on all available data from 
studies with the current TMC278 L A formulation (TMC278 -C158, SSAT040, 
LAI115428) and the population PK model of RPV. With this model, the TMC278 L A 
dosing r egimen (i.e., 4 weeks RPV 25 mg every  day followed by  [CONTACT_339241]  
4 weeks of TMC278 LA 600 mg) was simulated for [ADDRESS_419534] between day  168 (i.e. after injection 5) and day 336 (i.e., after 
injection 11) was determined, and from these median values, the mean across subjects 
was calculated [GlaxoSmithKline Document Number 2011N112455_03: LAI115428].
As such, the mean stead y-state Ctrough with this TMC278 L A dosing regimen is 
predicted to be around 95 ng /mL. This is above the mean RPV Ctrough (80 ng/mL) and 
close to the mean Cavg (100 ng/mL) for RPV 25 mg every  day. Furthermore, as shown in 
Figure 2 , the mean RPV plasma concentrations are already  above the mean Ctrough for 
RPV as of the 1stinjection with TMC278 L A 600 mg. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
233Figure 2 Predicted Mean (90% prediction interval) RPV Plasma 
Concentration -Time Profile for IM injections every 4 w eeks of 
TMC278 LA  600 mg (immediately  follo wing 4 weeks RPV 25 mg 
every  day)
(green dotted line represents mean Ctrough fo r RPV 25 mg every 
day; blue dotted line represents mean Cavg for RPV 25 mg every 
day)
Revised text:
[COMPANY_004]744 
[COMPANY_004]744 10 mg, 30 mg and 60 mg oral once dail y achieved similar efficacy at Week 24 
of Induction when coadministered with 2 NRTI s and at Week 48 of Maintenance (24 
weeks on Maintenance) when coadministered with RPV 25 mg once daily  (Table 1).  
Rates of virologic suppression through Week 48 (Maintenance) on the two drug regimen 
remained similar to that attained through Week 24 (Induction) on three dru g ART.  
The oral dosing period intended for induction of virologic suppression also serves as a 
lead-in period required to confirm tolerability  in each subject prior to initiating the 
prolonged exposure following [COMPANY_004]744 LA injection, which has been observ ed to be up 
to 52 weeks following a single injection in some subjects GlaxoSmithKline Document 
Number RM2010/[ZIP_CODE]/04 : LAI114433].  Although all doses provided similar induction  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
234and maintenance of viral suppression, [COMPANY_004]744 30 mg once dail y was selected as the oral 
dose to be used in combination with ABC/3TC for induction of virologic suppression in 
this study .  [COMPANY_004]744 30mg achieves higher plasma exposures than the 10mg oral dose, 
providing higher toxicity coverage prior to initiating IM dosing.  
Based upon the results through Week 48 of the LAI116482 study , and in accordance with 
the pre -specified dose selection criteria at Week 24, a 30 mg oral dose of [COMPANY_004]744 has 
been selected to be used in combination with ABC/3TC for induction of virologic 
suppression in this study .
[COMPANY_004]744 LA
[COMPANY_004]744 10 mg, 30 mg and 60 mg orally  once daily  achieved similar efficacy  at Week 24 
of Induction when coadministered with 2 NRTI s and at Week 48 of Maintenance (24 
weeks on Maintenance) when coadministered with RPV 25 mg once daily  (Table 1).  
Rates of virologic suppression through Week 48 (Maintenance) on the two drug regimen 
remained similar to that attained through Week 24 (Induction) on three drug ART.  The 
similar efficacy  in all three treatment arms in LAI116482 suggests that m aintaining target 
Cfollowing IM administration of [COMPANY_004]744 LA with TMC278 LA at approximately  the 
level of the 10 mg oral dose (geometric mean 1.35 g/mL , 8.1- fold above PA -IC90) 
should also maintain suppression of HIV infection.  Once safet y and tolerabil
ity are 
confirmed with oral dosing, maintaining target C following IM administration of 
[COMPANY_004]744 L A with TMC278 L A at approximately  the level of the 10 mg oral dose 
(geometric mean 1.35 g/mL , 8.1-fold above PA -IC90) should be sufficient to maintain 
suppres sion of HIV infection.  Maintaining a target at approximately  the level of the [ADDRESS_419535] been established during Induction.  
Using population pharmacokinetic (PK) mo delling and simulations, [COMPANY_004]1265744 C 
values for several IM dosing regimens were calculated and two regimens were selected 
based upon:
ability  to reach target concentration earl y in treatment,
ability  to maintain mean C above that obtained with oral [COMPANY_004]7 44 10 mg once 
daily  during treatment ([COMPANY_004]744 trough concentrations 1.35g/mL), and
minimizing the total number of injections per visit. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
235Table 1 Proportion of Subjects with Plasma HIV -1 RNA <50 c/mL at Key Visits 
-Snapshot (MSDF) Analysis (ITT -E Populati on)
Visit[COMPANY_004]744
10 mg
N=60
n (%)[COMPANY_004]744
30 mg
N=60
n (%)[COMPANY_004]744
60 mg
N=61
n (%)[COMPANY_004]744 
Subtotal
N=181
n (%)EFV 
600 mg
N=62
n (%)
Week 16 –Induction 54 (90) 50 (83) 53 (87) 157 (87) 46 (74)
Week 24 –Induction 52 (87) 51 (85) 53 (87) 156 (86) 46 (7 4)
Week 48 - Maintenance 48 (80) 48 (80) 53 (87) 149 (82) 44 (71)
[COMPANY_004]744 LA Q8W
Subjects randomized to [COMPANY_004]744 L A Q8W will receive a [COMPANY_004]744 800 mg IM Loading 
Dose on Day  1 (within 2 hours of final oral dosing), a [ADDRESS_419536] 800 mg IM loading dose and second 600 mg IM loading dose were selected so 
that  80% of subjects will be above 1.35 g/mL throughout treatment.  Mean (90% CI) 
simulated [COMPANY_004]744 C values versus time across dos es for [COMPANY_004]744 LA Q8W are 
presented graphicall y in Figure 1.  
Figure 1 Simulated Mean (90% CI) [COMPANY_004]744 Trough Concentrations versus 
Time for [COMPANY_004]744 LA Q8W
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
236At Week 56 (approximately  one y ear of dosing), [COMPANY_004]744 L A Q8W is predicted to 
achieve [COMPANY_004]744 trough concentrations  1.35g/mL  (target) in 84% of subjects.  
Although the lower bound of the 90% CI falls below 1.35 g/mL, C for all subjects 
remains above 4PA -IC90(0.166 g/mL).  At Week 56, geometric mean [COMPANY_004]744 C for 
[COMPANY_004]744 L A Q8W is predicted to be 2.02 g/mL, 1.5 -fold above target and 12.2 -fold 
above PA -IC90(Table 2).  
A one week delay  in dosing at steady  state the Q8W regimen is predicted to result in a 
geometric mean C that is 9% lower than for dosing that is administered on schedule 
while remaini ng above the 1.35 g/mL target associated with the 10mg oral dose.  
[COMPANY_004]744 LA Q4W
Subjects randomized to the Q4W dosing arm will first receive [COMPANY_004]744 800 mg IM as a 
loading dose on Day  1 (within 2 hours of final oral dosing) and then, starting at Week 4, 
will receive [COMPANY_004]744 400 mg IM Q4W. 
The 800 mg loading dose was selected so that 80% of subjects will be above 
1.35 µg/mL  throughout treatment, including the end of the first dosing interval.  Mean 
(90% CI) simulated [COMPANY_004]744 C values versus time across Q4 W doses for [COMPANY_004]744 L A 
are presented graphically in Figure 2 .
Figure 2 Simulated Mean (90% CI) [COMPANY_004]744 Trough Concentrations versus 
Time for [COMPANY_004]744 LA Q4W
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
237At Week 56 (approximately  one y ear of dosing), [COMPANY_004]744 L A Q4W is predicted to 
achieve [COMPANY_004]744 trough co ncentrations  1.35g/mL  (target) in 99.6% of subjects.  
Geometric mean [COMPANY_004]744 C for [COMPANY_004]744 LA Q4W at Week 56 is predicted to be 
3.35g/mL , 2.5- fold above target, 20.2 -fold above the PA -IC90(0.166 g/mL), and 
similar to the observed mean C after 16 wee ks of this regimen in healthy  subjects ( Table 
2).
A one week delay  in dosing at steady  state for the Q4W regimen is predicted to result in a 
geometric mean C that is 8% lower than for dosing that is administered on schedule 
while remaining above the 1.35 g/mL target associated with the 10 mg oral dose.
Table 2 Summary of [COMPANY_004]744 PK Parameters following oral administration in 
HIV infected subjects, [COMPANY_004]744 LA administration in healthy subjects, 
and following Simulations
Route
Study
Population[COMPANY_004]1265744 Regim en[COMPANY_004]1265744 PK Parameter
C  or C0
(g/mL)aCmax
(g/mL)bAUC(0 -)
(gh/mL)cIQ
(C0:IC 90
ratio)d
Oral
LAI116482
HIV10 mg orally every day1.35
[45% ]2.77
[33%]45.7
[32%]8.13
30 mg orally every day4.20
[40%]7.49
[28%]134
[32%]25.3
60 mg orally every day7.93
[39%]13.1
[44%]195
[48%]47.8
IM
LAI115428 
HVs800 mg IM LD
400 mg IM Q4W x33.22
[28%]4.37
[33%]2362
[27%]19.4
IM 
PopPK 
simulation
HIVLA Regimen #1 (200056):
800mg IM LD
400mg IM Q4W from W43.35
[35%]ND ND 20.2
IM
PopPK 
simulation
HIVLA Regimen #2 (200056):
800mg IM LD 1
600mg IM LD 2 (Week 4)
600mg IM Q8W from W82.02
[52%]ND ND 12.2
Data presented as Geometric mean [CVb %], HIV = HIV infected subjects, HV = Healthy Volunteers, ND=Not 
determined, LD = Loading Dose
a. C0: n=57 (10 mg orally), 53 (30 mg orally), 55 (60 mg orally), 9 (800 mg/400 mg IM), 
b. Cmax:  n=14 (10 mg orally), 12 (30 mg orally), 11 (60 mg orally), 9 (800 mg/400 mg IM)
c. AUC(0 -):  n=14 (10 mg orally), 12 (30 mg orally), 11 (60 mg orally), 9 (800 mg/400 mg IM)
d. PA-IC90determined in vitro 0.166 g/mL.
RPV
All subjects will receive 4 weeks of RPV 25 mg once dail y, co -administered with 
[COMPANY_004]744+ABC/3TC, from Week (- 4) through Day  [ADDRESS_419537] prior to possible IM dosing with TMC278 LA.  Subjects switching from the oral 
regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
238once dail y, from Week 102 through Week 104.  Data from stud y LAI116182 
[GlaxoSmithKline Document Number 2012N134026_02:  L AI116482 ] have 
demonstrated that there is no clinically  relevant drug -drug interaction following repeat 
oral administration of [COMPANY_004]744 with RPV.  With this oral RPV add -on, subjects will also 
have stead y-state RPV plasma concentrations prior to starting TMC278 LA dosi ng.
TMC278 LA
During the Maintenance Period, subjects will receive either IM injections of TMC278 L A 
600mg every  4 weeks (Q4W) or TMC278 L A 900 mg every  8 weeks (Q8W).  The 
selection of the TMC278 L A dosing regimens is based on achieving RPV plasma 
concen trations in the range of those observed with oral RPV 25 mg once daily  in HIV -
infected patients (mean (SD) C trough of 80 (36) ng/mL  in pooled Phase III studies (RPV + 
2 NRTI s); and 77 (34) ng/mL  in the Maintenance Phase of LAI116482 (RPV + 
[COMPANY_004]744), as well as constructing a regimen that is most practical for patients, i.e. by  
[CONTACT_339315]/clinic visits while maintaining an acceptable injection 
volume.
Figure 3 and Figure 4 show the model -predicted RPV plasma concentrations over a 
dosing int erval at stead y-state with the respective Q4W and Q8W TMC278 L A dosing 
regimens.  The graphs show the mean profile (red curve) with the 90% prediction interval 
(shaded area).  Also indicated are the mean C trough for oral RPV 25 mg once daily  in HIV -
infecte d patients (Phase III, 80 ng/mL) and the protein -binding adjusted IC 90for RPV 
(12ng/mL), as well as a scatter of the individual C trough values (plotted both at the 
beginning and at the end of the TMC278 LA dosing interval) in HIV -infected patients 
(Phase III).
For the simulations, a pharmacokinetic model was used based on all available data from 
studies with the current TMC278 L A formulation (TMC278 -C158, SSAT040, 
LAI115428) and the population PK model of RPV. With this model, the TMC278 L A 
dosing regimen (i.e., 4 weeks RPV 25 mg every  day followed by  [CONTACT_339241]  
4 weeks of TMC278 LA 600 mg) was simulated for [ADDRESS_419538] between day  168 (i.e. after injection 5) and day 336 (i.e., after 
injection 11) wa s determined, and from these median values, the mean across subjects 
was calculated [GlaxoSmithKline Document Number 2011N112455_03: LAI115428]. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
239Figure 3 Model -Predicted Mean (90% prediction interval) TMC278 Plasma 
Concentration -Time Profile at steady -state after Q4W IM injections of 
TMC278 LA 600 mg (immediately following 4 weeks oral RPV 25 mg 
once daily)
Red line represents the predicted mean steady state C trough concentration.
Blue dotted line represents mean C trough for oral RPV 25 mg once daily ; 
Green dotted line represents protein -binding adjusted IC90 for RPV; 
Black open circles represent individual C trough values with oral RPV 25 mg once daily 
Figure 4 Model -Predicted Mean (90% prediction interval) TMC278 Plasma 
Concentration -Time Profile at steady-state after Q8W IM injections of 
TMC278 LA 900 mg (immediately following 4 weeks oral RPV 25 mg 
once daily)
Red line represents the predicted mean steady state C trough concentration.
Blue dotted line represents mean C trough for or al RPV 25 mg once daily; 
Green dotted line represents protein -binding adjusted IC90 for RPV; 
Black open circles represent individual C trough values with or al RPV 25 mg once daily 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
240TMC278 LA Q8W
For the Q8W TMC278 LA dosing regimen, the mean steady- state C trough is predic ted to 
be around 65 ng/mL, as of the 1stinjection. Though this is below the mean RPV C trough
with oral RPV 25 mg once dail y, the range of model -predicted C trough is similar to the 
range of C trough with oral RPV 25 mg once daily  in the RPV Phase III studie s (Figure 4) 
and in LAI116482 (Maintenance). The RPV plasma concentrations are also higher during 
the larger part of the TMC278 L A dosing interval. Furthermore, all patients are 
virologicall y suppressed before switching to the TMC278 L A regimen. In LAI116482, 
there were 59/160 HIV -infected patients with a RPV C trough (based on population PK 
modeling) below 65 ng/mL  These 59 patients all maintained virologic suppression.
TMC278 LA Q4W
As such, t he mean stead y-state C trough with theQ4W TMC278 L A dosing regime n is 
predicted to be around 115 ng/mL. This is above the mean RPV C trough (80 ng/mL) and 
the mean Cavg (100 ng/mL ) for RPV 25 mg once daily  (Phase III). Furthermore, the 
mean RPV plasma concentrations are alread y above the mean C trough for RPV as of the 1st
injection with TMC278 LA 600 mg.
Section [IP_ADDRESS] TMC278 Benefit Risk
Revised to (changes struck through and underlined).
Rash
Some observations of grade [ADDRESS_419539] been reported in clinical 
studies executed to date (the majority  are Grade 1 or 2 ).
Section [IP_ADDRESS] Efficacy Risk
Original text:
This study employ s an induction / maintenance approach to the treatment of HIV -[ADDRESS_419540] been selected to achieve exposures 
similar to the oral formulations.  Pharmacokinetics will be closely  monitored throughout 
the study .
Revised text: 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
241This study employ s an inducti on / maintenance approach to the treatment of HIV -[ADDRESS_419541] been selected to achieve exposures that 
are expected to maintain virologic efficacy  on the basis of available data with the oral 
formulations.  Neither [COMPANY_004]744 L A or TMC278 LA, at an y dose, has been used in HIV -1 
infected subjects.  Plasma samples will be collected throughout the Maintenance Period 
for determination of [COMPANY_004]744 and TMC278 concentration and possible pharmacokinetic 
correlation with virologic response. 
Section 1.10.2 Benefit A ssessment
Revised to (changes struck through and underlined ).
Efficacy  of the two- drug regimen, as oral agents, will be has been demonstrated through 
Week 48 of the ongoing LAI116482 study prior to the initiation of this study .
Section 2 -Objectives and Endpoints
Original text:
Objective Endpoint
Primary
To eval uate the efficacy, tolerability, and safety 
of a regimen of [COMPANY_004]744 LA 400 mg IM plus 
TMC278 LA 600 mg IM every 4 weeks, relative 
to [COMPANY_004]744 30 mg plus ABC/3TC orally once 
daily, through Week 24 of the Maintenance 
Period.The proportion of subjects with HIV -1 RNA 
<50c/mL at Maintenance Week 24 based on 
intent to treat -exposed (ITT- E) population using 
the Missing, Switch, or Discontinuation = Failure 
(MSDF) algorithm.
Incidence and severity of AEs and laboratory 
abnormalities over time.
Secondary
To evalu ate the antiviral activity, tolerability, and 
safety of [COMPANY_004]744 30 mg plus ABC/3TC orally 
once daily through the Induction and 
Maintenance Periods.Proportion of subjects with plasma HIV -1 RNA 
<200 c/mL and <50 c/mL over time.
Absolute values and change f rom Baseline in 
plasma HIV -1 RNA.
Absolute values and changes from Baseline in 
CD4+ cell counts. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
242Objective Endpoint
Incidence of disease progression (HIV -
associated conditions, acquired 
immunodeficiency syndrome [AIDS] and death).
Incidence and severity of AEs and labo ratory 
abnormalities over time.
Absolute values and changes in laboratory 
parameters over time.
To evaluate the impact of the duration of 
virologic suppression with [COMPANY_004]744 30 mg plus 
ABC/3TC orally once daily during the 16 and 24 
week Induction Period, on the ability of a 
regimen of [COMPANY_004]744 LA 400 mg IM plus 
TMC278 LA 600 mg IM every 4 weeks to 
maintain virologic suppression through Week 96 
of the Maintenance Period. Proportion of subjects with plasma HIV -1 RNA 
<200 c/mL and <50 c/mL over time.
Absolut e values and change from Baseline in 
plasma HIV -1 RNA.
Absolute values and changes from Baseline in 
CD4+ cell counts.
Incidence of disease progression (HIV -
associated conditions, acquired 
immunodeficiency syndrome [AIDS] and death).
To evaluate the ef ficacy, tolerability, and safety 
of a regimen of [COMPANY_004]744 LA 400 mg IM plus 
TMC278 LA 600 mg IM every 4 weeks, relative 
to [COMPANY_004]744 30 mg plus ABC/3TC orally once 
daily, through Week 96 of the Maintenance 
Period.Proportion of subjects with plasma HIV -1 RNA 
<200 c/mL and <50 c/mL over time.
Absolute values and change from Baseline in 
plasma HIV -1 RNA.
Absolute values and changes from Baseline in 
CD4+ cell counts.
Incidence of disease progression (HIV -
associated conditions, acquired 
immunodeficiency syndro me [AIDS] and death.
Incidence and severity of AEs and laboratory 
abnormalities over time.
Absolute values and changes in laboratory 
parameters over time.
To evaluate achievement of steady state for 
[COMPANY_004]744 LA and TMC278 LA regimens.Determination of a chievement of steady state 
following [COMPANY_004]744 LA and TMC278 LA 
administration.
To characterize the PK profile (Ctrough) of Plasma [COMPANY_004]744 and rilpi[INVESTIGATOR_339209]  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
243Objective Endpoint
[COMPANY_004]1265744 and rilpi[INVESTIGATOR_339210] -response relationships (e.g., the 
relationship between [COMPANY_004]744 and TMC278 
plasma exp osure and virologic response or 
occurrence of adverse events [AEs] through 
Week [ADDRESS_419542] of various demographic 
Baseline characteristics and adherence on 
virologic response of [COMPANY_004]744 and TMC278 
over time.Proportion of subjects with plasma HIV -1 RNA 
<50c/mL over time.
To evaluate the treatment satisfaction for 
subjects on the long -acting injectable regimen 
with those on the oral regimen through Week 96 
of the Maintenance Period.Summarize treatment satisfaction using the HIV 
Treatment Satisfaction Questionnaire Status 
(HIVTSQ(s)) over time. 
To evaluate the change in treatment satisfaction 
for subjects in both the long -acting injectable 
and oral regimens t hrough Week 24 of the 
Maintenance Period.Measure change in treatment satisfaction using 
the HIV Treatment Satisfaction Questionnaire 
Change (HIVTSQ(c)) over time.
To evaluate medication adherence over time. Summarize subject reported medication 
adherence using the HIV Medication 
Questionnaire (HIVMQ) over time.
Revised text:
Objective Endpoint
Primary
To select an intramuscular dosing regimen of 
[COMPANY_004]744 LA plus TMC278 LA based on a 
comparison of the Week 32 antiviral activity, 
tolerability, and safety of two IM dosing 
regimens, relative to [COMPANY_004]744 30 mg plus 
ABC/3TC orally once daily .The proportion of subjects with HIV -1 RNA 
<50c/mL at Maintenance Week 32based on 
intent to treat -maintenance exposed (ITT -ME) 
population using the Missing, Switch, or 
Discontinuation = Failure (MSDF) algorithm.
Proportion of subjects with protocol defined 
virologic failures over time 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
244Objective Endpoint
Incidence and severity of AEs and laboratory 
abnormalities over time.
Secondary
To evaluate the antiviral activity, tolerability, and 
safety of [COMPANY_004]744 30 mg plus ABC/3TC orally 
once daily through the Induction and 
Maintenance Periods.Proportion of subjects with plasma HIV -1 RNA 
<200 c/mL and <50 c/mL over time.
Absolute values and change from Baseline in 
plasma HIV -1 RNA.
Absolute values a nd changes from Baseline in 
CD4+ cell counts.
Incidence of disease progression (HIV -
associated conditions, acquired 
immunodeficiency syndrome [AIDS] and death).
Incidence and severity of AEs and laboratory 
abnormalities over time.
Absolute values and chang es in laboratory 
parameters over time.
To evaluate the efficacy, tolerability, and safety 
of [COMPANY_004]744 LA 400 mg IM plus TMC278 LA 600 
mg IM every 4 weeks and [COMPANY_004]744 LA 600 mg 
IM plus TMC278 LA 900 mg every 8 weeks , 
relative to [COMPANY_004]744 30 mg plus ABC/3TC oral ly 
once daily, through Week 96 of the 
Maintenance Period.Proportion of subjects with plasma HIV -1 RNA 
<200 c/mL and <50 c/mL over time.
Proportion of subjects with protocol defined 
virologic failures over time
Absolute values and change from Baseline in
plasma HIV -1 RNA.
Absolute values and changes from Baseline in 
CD4+ cell counts.
Incidence of disease progression (HIV -
associated conditions, acquired 
immunodeficiency syndrome [AIDS] and death.
Incidence and severity of AEs and laboratory 
abnormali ties over time.
Absolute values and changes in laboratory 
parameters over time.
To characterize [COMPANY_004] 744LA and TMC278 LA Plasma PK parameters for [COMPANY_004]744 LA and  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
245Objective Endpoint
PK and to explore PK-PD relationships.  TMC278 LA (Ctrough and concentrations post 
dose [~Cma x]) during the Maintenance Period.  
Plasma [COMPANY_004]744 and RPV trough 
concentrations will be used to determine when
steady state is achieved for each [COMPANY_004]744 LA 
and TMC278 LA regimen.
Relationship between plasma PK parameters 
and plasma HIV -1 RNA, CD4+ cell co unts 
and/or occurrence of adverse events [AEs] 
through Week [ADDRESS_419543] of various demographic 
Baseline characteristics and adherence on 
virologic response of [COMPANY_004] 1265 744 and 
TMC278 over time.Proportion of subjects with plasma HIV -1 RNA 
<50c/mL over time.
To evaluate the treatment satisfaction for 
subjects on the long -acting injectable regimen s
with those on the oral regimen through Week 96 
of the Maintenance Period.Summarize treatment satisfaction using the HIV 
Treatment Satis faction Questionnaire Status 
(HIVTSQ(s)) over time. 
To evaluate the change in treatment satisfaction 
for subjects in both the long -acting injectable 
and oral regimens through Week 32of the 
Maintenance Period.Measure change in treatment satisfaction usi ng 
the HIV Treatment Satisfaction Questionnaire 
Change (HIVTSQ(c)) over time.
To evaluate medication adherence over time. Summarize subject reported medication 
adherence using the HIV Medication 
Questionnaire (HIVMQ) over time. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
246Section 3.1 -Study  Desig n Schematic
Original text:
Induction Period
Induction Period
•HIV -1 
infected
ART -naïve 
•CD4 ≥200 
cells/mm3
•HIV -1 RNA
•≥1000 c/mLContinue Oral 
Regim enBegin IM 
Regim en
Continue Oral 
Regim enBegin IM 
Regim enRandomization
2:1
2
1
2
1Randomization
1:1
[COMPANY_004]744 30 mg + ABC/3TC 
Orally Once Daily
(n ≈ 90)
[COMPANY_004]744 30 mg + ABC/3TC 
Orally Once Daily
(n ≈ 90)Add 
RPV 25 mg  
Orally Once 
Daily
Week -24 Week -20 Week -16 Week -12 Week -8 Week -4 Day 11
1Add 
RPV 25 mg  
Orally Once 
Daily
Maintenance and Extension Period
Extension Period Maintena nce Period
[COMPANY_004]744  LA 400 mg IM
+ 
TMC278  LA 600 mg IM
Every 4 Weeks†
[COMPANY_004]7 44 30 mg + ABC/3TC  Orally Once DailyIM Doses Every 4 Weeks
†Subjects  who withdraw 
after receiving any IM dose 
will be followed on study via 
Long -Term Follow Up Period 
with ~quarterly visits for 52 
weeks[COMPANY_004]7 44 LA 800 mg IM
Loading Dose + TMC278 
LA 600 mg IM†
then 
[COMPANY_004]7 44 LA 400 mg IM + 
TMC278 LA 600 mg IM
Every 4 Weeks† [COMPANY_004]7 44 LA 800 mg IM Loading Dos e  + 
TMC 278 LA 600 mg IM on Day 1 
then
[COMPANY_004]744 LA 400 mg IM + TMC278 LA 600 mg IM every 4 Weeks†Continued 
From  
Induct ion 
Period
Schem a
Last Induc tion Re gime n Dose 
on Day 1 in ClinicIM 
regimen
Oral 
regimenAdd 
RPV 25 
mg 
Orally 
Once 
Daily for 
2wks 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
247Revised text:
Induction Period
Maintenance and Extension Period
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
248Section 3.2 -Study  Design
Revised to (changes struck through and underlined).
Protocol waivers or exempt ions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the study  design requirements, including those 
specified in the Time and Events Table, are essential and required for stud y conduct. 
Study  [ADDRESS_419544] of a Screening Period, Induction Period, Maintenance Period, 
Extension Period and a Long- term Follow -up Period (withdrawn subjects only ). 
A subject is considered to have completed the study  if they  complete the Induction and 
Maintenance Period through Week 96.
Supplementary  study  conduct information not mandated to be present in this protocol is 
provided in the accompany ing Study  Procedures Manual (SPM).  The SPM will provide 
the site personnel with administrative and detailed technical information that does not 
impact subject safet y. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
249Section 3.2.2 -Induction Period
Original text:
Following the Screening Period, eligible subjects will be randomized 1:1 to either 16 or 
24 weeks of induction of virologic suppression utilizing an oral regim en of [COMPANY_004]744 
30 mg once dail y plus ABC/3TC 600/300 mg once daily.  Randomization will be 
stratified by  [CONTACT_140204] -1 RNA (<100,000 c/mL or  100,000 c/mL).  
Subjects first day  on study  treatment will be either Weeks ( -24) or Weeks ( -16) 
depending on the outcome of randomization.  Further weeks of treatment throughout the 
Induction Period will be counted up to Day  1 (Day  1 initiates the Maintenance Period).
Example:  First day  on study  Week ( -16)
Next visit Week ( -12)
Next visit Week ( -8), etc
Subject s will initiate treatment on their first day  on study  and will be seen every  4 weeks 
for study  treatment dispensing and safet y and efficacy assessments (see Time and Events 
Section 6.1 or Section 6.2).
Revised text:
Following the Screening Period, eligible subjects will be enrolled into the study  and 
begin a 20 week I nduction Period utilizing an oral regimen of [COMPANY_004]744 30 mg once dail y 
plus ABC/3TC 600/[ADDRESS_419545] day  on study  treatment.  Fu rther 
weeks of treatment throughout the Induction Period will be counted up to Day  1 (Day  1 
initiates the Maintenance Period).
Example:  First day  on study  Week ( -20)
Next visit Week ( -16)
Next visit Week ( -12), etc
Subjects will initiate treatment at Baseline (Week -20) and will be seen every  4 weeks for 
study  treatment dispensing and safet y and efficacy assessments (see Time and Events 
Section 6.1 ).  
Section 3.2.3 -Eligibility for the Maintenance Period
Revised to (changes struck through and underli ned).
All subjects with an undetectable HIV -1 RNA (<50 c/mL ) at the Week ( -4) visit are 
eligible to enter the Maintenance Period. 
And: 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419546] from the study  prior to 
Week (-4) to avoid initiating RP V in a subject who is unlikely  to be eligible for the 
Maintenance Period.
In addition to the viral load criteria above, if in the opi[INVESTIGATOR_689], a subject 
experiences a significant safet y event while taking either [COMPANY_004]744 or RPV, Maintenance 
eligibility  will be determined ONLY in consultation with the medical monitor.  Any rash 
that is possibly related to study drug, and is present between Week ( -4) and Day 1, 
must be discussed with the Medical Monitor prior to initiation of [COMPANY_004]744 LA or 
TMC278 LA  (See Section [IP_ADDRESS]).
Subjects ineligible for the Maintenance Period will be withdrawn.  
And:
Sites may  be reimbursed for up to a one month supply  of antiretroviral medication to 
facilitate transition to non -study  ART for subjects that do not qual ify for the Maintenance 
Period due to incomplete virologic suppression.
Section 3.2.4 -Maintenance Period
Original text:
At Day  1, the Maintenance Period begins.  Eligible subjects will be randomized a second 
time 2:1 to receive either an IM regimen of GS K744 L A 400 mg + TMC278 L A 600 mg  
every  4 weeks or to continue on the oral Induction Period regimen of [COMPANY_004]744 30 mg + 
ABC/3TC for 96 weeks.  This second randomization will be stratified by  [CONTACT_1766]’ 
previous randomized length of induction and b y their scr eening HIV -1 RNA (<100,000 
c/mL  or 100,000 c/mL).
On the first day  of the Maintenance Period (Day  1), subjects will receive their last dose of 
[COMPANY_004]744+ABC/3TC+RPV in the clinic andinitiate either IM injections or be dispensed 
the oral regimen depending on the randomization arm.  Add -on RPV treatment will be 
discontinued for all subjects after Day  1.  
Those subjects randomized to begin treatment with [COMPANY_004]744 L A + TMC278 L A will first 
receive a loading dose of [COMPANY_004]744 L A 800 mg (delivered as two 400 mg IM inj ections) 
as well as TMC278 LA 600 mg IM.  Thereafter, subjects will receive [COMPANY_004]744 L A 400 
mg IM + TMC278 L A 600 mg IM every  4 weeks for 96 weeks.
Those subjects randomized to continue treatment with [COMPANY_004]744 + ABC/3TC will be 
dispensed this regimen as per th e Time and Events Schedule Section 6.2.
All subjects are then seen approximately  every  4 weeks for dosing / dispensing and 
safet y, efficacy and PK assessments for 24 weeks.  
Thereafter, subjects on the [COMPANY_004]744 LA + TMC278 LA arm will continue to be seen 
every 4 weeks for dosing, safet y, efficacy and PK assessments through Week 96.  
Subjects on the [COMPANY_004]744+ABC/3TC arm will be seen in the clinic at Weeks 32, 40, 48,  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
[ZIP_CODE], 72, 84 and 96 for dosing, safet y, efficacy  and / or PK assessments.  These subjects 
will al so be assessed for safet y via phone interview at Weeks 28, 36, 44, 52, 56, 64, 68, 
76, 80, 88 and 92.  
See the Time and Events Schedule Section 6.2and Section 6.3for more information .
Revised text:
At Day  1, the Maintenance Period begins.  Eligible subj ects will be randomized 2: 2:1 to 
receive an IM regimen of [COMPANY_004]744 L A 400 mg + TMC278 L A 600 mg every  4 weeks for 
96 weeks, an IM regimen of [COMPANY_004]744 LA 600 mg + TMC278 L A 900 mg every  8 weeks 
for 96 weeks, or to continue on the oral Induction Period regimen o f [COMPANY_004]744 30 mg + 
ABC/3TC once dail y for 96 weeks (or 104 weeks if continuing on to the Extension 
Period) .  Subject r andomization will be stratified by  [CONTACT_1766]’ HIV-1 RNA prior to Week 
(-8)(<50 c/mL, y es or no) .
On the first day  of the Maintenance Period (Day  1), subjects will receive their last dose of
the Induction regimen ( [COMPANY_004]744+ABC/3TC+RPV ) in the clinic andinitiate either IM 
injections or be dispensed the oral regimen depending on the randomization arm.  Add -on 
RPV treatment will be discontinued for all subjects after Day  1.  
Dosing for each arm is as follows (all injections are single injections unless otherwise 
noted):
IM injections every  8 weeks (Q8W)
oDay 1 only  –[COMPANY_004]744 LA 800 mg ( loading dose delivered as two 400 mg 
IM in jections) + TMC278 L A 900 mg IM
oWeek 4 only  -[COMPANY_004]744 LA 600 mg IM (second loading dose, no 
TMC278)
oWeek 8 - [COMPANY_004]744 LA 600 mg IM + TMC278 LA 900 mg IM every  8 
weeks for 96 weeks
IM injections every  4 weeks (Q4W)
oDay 1 only  -[COMPANY_004]744 LA 800 mg ( loading dose delivered as two 400 mg 
IM injections) + TMC278 L A 600 mg IM
oWeek 4 -[COMPANY_004]744 LA 400 mg IM + TMC278 LA 600 mg IM every  4 
weeks for 96 weeks
Oral Control Arm
o[COMPANY_004]744 30 mg + ABC/3TC once dail y for 96 weeks (or 104 weeks if 
continuing on to the Extension Period) 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419547]’s visit schedule is a very important 
component to the study.  IM dosing is expected to occur during the week in which 
the subject’s projected visit falls (as according to the Day 1 visit).  A (+ or -) [ADDRESS_419548]’s projected visit falls (as according to the 
Baseline visit).  
All subjects are seen approximately  every  4 weeks for safety , efficacy  and PK 
assessme nts through Week 32 .  After Week 32 , subjects will continue to be seen as per 
the Time and Events Schedule (see Section 6) for dosing, safet y, efficacy and PK 
assessments through Week 96 (or Week [ADDRESS_419549] is continuing on to 
the Exte nsion Period).  
Some visits that are not aligned with dosing will be conducted b y telephone interview.  
This allows for safety  assessments to be conducted at all visits, but limits clinic visits for 
non-dosing visits.  Telephone safet y assessments will include interviewing the subject for 
adverse events, concomitant medications, HIV associated conditions and any other issues 
including injection site reactions or oral compliance issues.  Telephone visits will be 
clearl y noted in the Time and Events Schedule .  
See the Time and Events Schedule Section 6.2 and Section 6.3for more information.   See 
Section [IP_ADDRESS] for additional information regarding special requirements from Week 96 
to Week 104 for subjects on the oral arm entering the Extension Period
If one of the IM dosing regimens (Q4W or Q8W) is discontinued as a result of an IDMC 
review or an y subsequent anal ysis, those subjects who have not met any  clinical 
management criteria for discontinuation and who were randomized to the discontinued 
dosing regime n may  be given the option to discontinue permanentl y from the study or to 
continue on the remaining IM dosing regimen at the next scheduled visit. 
Section 3.2.5 -Extension Period
Original text:
Entering From the [COMPANY_004]744 LA + TMC278 LA Arm
All subjects who successfully  complete 96 weeks of [COMPANY_004]744 LA + TMC278 L A 
treatment in the Maintenance Period will continue to have access to both [COMPANY_004]744 L A 
400mg IM and TMC278 L A [ADDRESS_419550] meets a protocol -defined reason for discontinuation or until 
development of either [COMPANY_004]744 L A or TMC278 LA is terminated.  At Week 96, these 
subjects will continue to receive [COMPANY_004]744 LA 400 mg IM and TMC278 L A 600 mg IM 
every  4 weeks for the remainder of study  participation.  Safety  and efficacy assessments 
will be conducted every  4 weeks until Week 112.  These assessments will then be 
quarterl y for the remainder of the stud y (do sing and AE assessments remain every  4 
weeks).  See the Time and Events Schedule Section 6.5 for more information. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
253Entering From the [COMPANY_004]744 + ABC/3TC Arm
All subjects who successfully  complete 96 weeks of [COMPANY_004]744 + ABC/3TC treatment in 
the Maintenance Perio d will have the option to either continue study  participation by  
[CONTACT_339316]744 LA + TMC278 LA in the Extension Period, or to discontinue from 
the study . 
Subjects not choosing to switch to the long acting regimen will complete their study  
participat ion.
Subjects who choose to continue on to the Extension Period will need to be assessed for 
eligibility  to begin the [COMPANY_004]744 L A + TMC278 LA regimen.  Subjects must have an 
undetectable HIV -1 RNA (<50 c/mL) at the Week 96 visit in order to be eligible to en ter 
the Extension Period.  Subjects with an HIV -1 RNA  50 c/mL  may  be allowed to enter 
the Extension Period at the discretion of the medical monitor or may  be withdrawn.
Subjects eligible to enter the Extension Period will add a short course (2 weeks) of RPV 
25 mg orally  once dail y to their [COMPANY_004]744 + ABC/3TC regimen at Week [ADDRESS_419551] 2 weeks of the Extension Period, subjects will remain on their oral Maintenance 
Period regimen until eligibility  is confirmed.  If eligible, subjects will be taking [COMPANY_004]744 
+ ABC/3TC + RPV from Week [ADDRESS_419552] dose of [COMPANY_004]744 + ABC/3TC + RPV in the 
clinic andwill receive a loading dose of [COMPANY_004]744 LA 800 mg (delivered as two 400 mg 
IM injections) as well as TMC278 L A 600 mg IM.  At Week 104, subjects will receive 
[COMPANY_004]744 L A 400 mg I M + TMC278 L A [ADDRESS_419553] meets a protocol -defined reason for discontinuation or until 
development of either G SK744 L A or TMC278 LA is terminated. Safet y and efficacy 
assessments will be conducted every  4 weeks until Week 112.  These assessments will 
then be quarterl y for the remainder of the stud y (dosing and AE assessments remain 
every  4 weeks).  See the Time and Events Schedule Section 6.3 and Section 6.5for more 
information .
Revised text:
A single IM dosing regimen will be selected as according to the RAP to be evaluated in 
the Extension period.
Entering From the [COMPANY_004]744 LA + TMC278 LA Arm
All subjects who succ essfully  complete 96 weeks of [COMPANY_004]744 LA + TMC278 L A 
treatment in the Maintenance Period will continue to have access to both [COMPANY_004]744 L A
and TMC278 L A in the Extension Period until study  treatment is eitherlocally  approved 
and commercially available, the subject no longer derives clinical benefit, the subject 
meets a protocol -defined reason for discontinuation or until development of either 
[COMPANY_004]744 L A or TMC278 L A is terminated.   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
254Subjects will be switched to the selected dose at Week 96 and will continue to r eceive the 
selected IM dosing regimen for the remainder of study  participation.  Safet y and efficacy 
assessments will be conducted every  16 weeks after the initial switch.   Dosing visits will 
occur according to the selected dosing regimen.  See the Time an d Events Schedule 
Section 6.5and Section 6.6 for more information.
Entering From the [COMPANY_004]744 + ABC/3TC Arm
All subjects who successfully  complete 96 weeks of [COMPANY_004]744 + ABC/3TC treatment in 
the Maintenance Period will have the option to either continue study participation by  
[CONTACT_339316]744 LA + TMC278 LA in the Extension Period, or to complete their 
study  participation at Week 96 (no withdraw visit needed) .
Subjects who choose to continue on to the Extension Period will need to be assessed for 
eligibilit y to begin the selected [COMPANY_004]744 LA + TMC278 L A regimen.  Subjects will 
continue on their Maintenance regimen ([COMPANY_004]744 + ABC/3TC) while eligibility  is being 
confirmed.  The Week [ADDRESS_419554] a visit at approximately  (depending on availability  of results) Week 
102 to assess eligibility .  All subjects with an undetectable HIV -1 RNA (<50 c/mL ) result 
from the Week 100visit are eligible to enter the Extension Period.   Note: Subjects with 
an HI V-1 RNA 50 c/mL result from the Week 100visit may  be allowed to enter the 
Extension Period only at the discretion of the medical monitor or withdrawn.
Subjects eligible to enter the Extension Period will add a short course (2 weeks) of RPV 
25 mg orally  once dail y to their [COMPANY_004]744 + ABC/3TC regimen at Week 102before 
initiating dosing with the long acting regimen at Week [ADDRESS_419555] dose of [COMPANY_004]744 + ABC/3TC + RPV in the 
clinic andwill begin IM dosing with the selected the IM regimen.  These subjects will 
receive loading doses as per the requirement of the selected regimen (see Section 5.1.6 
for dosing regimens).
Subjec ts will continue study  treatment until [COMPANY_004]744 L A and TMC278 LA areeither 
locally  approved and commercially  available, the subject no longer derives clinical 
benefit, the subject meets a protocol -defined reason for discontinuation or until 
development of e ither [COMPANY_004]744 L A or TMC278 LA is terminated. Safet y and efficacy 
assessments will be conducted every  16 weeks after the initial switch .    Dosing will 
occur according to the selected regimen. See the Time and Events Schedule Section 6.5
and Section 6.6formore information.
Subjects not eligible to enter the Extension Period will end their study  participation 
(Week [ADDRESS_419556] study  visit, no withdraw visit needed).  Sites may  be 
reimbursed for up to a one month supply  of antiretroviral medication to facilitate 
transition to non- study  ART for subjects that do not qualify  for the Extension Period.
Section 3.2.8 -Independent Data Monitoring Committee
Revised to (changes struck through and underlined). 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
255In addition, futility  guidance (e.g., a Bay esian posterior probability  approach when 50% 
of subjects have completed Week 24 of the Maintenance Period) is included to monitor 
the performance of all treatment arms in order to prevent subjects from continuing on a 
dosing regimen if existing data indicates that subjects are at unacceptable risk of 
inadequate maintenance of virologic suppression. Full details of the analy ses, estimated 
timing and the decision criteria that will be used to determine regimen performance will 
be pre -specified in the IDMC Charter .If one of the IM dosing regimens (Q4W or Q8W) is 
discontinued as a result of an IDMC review or an y subsequent anal ysis, those subjects 
who have not met an y clinical management criteria for discontinuation and who were 
randomized to the discontinued dosing regimen may  be given the option to discontinue 
permanentl y from the study or to continue on the remaining IM dosing regimen at the 
next scheduled visit. 
As subjects enter the Maintenance Period of the study , if the number of failures meets or 
exceeds the pre -specified thresholds specified in the IDMC Charter, this will be 
considered strong evidence of an inadequate response and will trigger a comprehensive 
data review b y the IDMC.  The IDMC charter will contain details of this continual 
monitoring of the protocol defined virologic failure rates, the specifics around what will 
trigger a data review, and the safet y summaries and efficacy  anal yses that will be 
provided should a data review be required.
Full details of the analyses, estimated timing and the decision criteria that will be used to 
determine regimen performance will be pre-specified in the IDMC Charter.
Section 3.2.9 -Primary A nalysis
Revised to (changes struck through and underlined).
The primary  anal ysis will be conducted when all subjects ha ve completed their 
Maintenance Period Week [ADDRESS_419557] information not mandated to be present in this protocol is 
provided in the a ccompany ing Study  Procedures Manual (SPM).  The SPM will provide 
the site personnel with administrative and detailed technical information that does not 
impact subject safet y.
Section 3.3 –Discussion of Design
Original text: 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
256Study  200056 is a Phase IIb as sessment of a regimen consisting of the long -acting 
injectable forms of [COMPANY_004]744 and TMC278 to maintain virologic suppression in 
previously  untreated HIV -infected subjects without evidence of transmitted resistance
who achieve virologic suppression on [COMPANY_004]744 plus ABC/3TC.  The ongoing stud y 
LAI116482 provides support for this unique approach of a two -class, two -drug regimen. 
Results from planned analy ses of LAI116482 support the choice of [ADDRESS_419558] evaluation of [COMPANY_004]744 L A or TMC278 L A in HIV -infected subjects.  The 
results to date sup port [COMPANY_004]744 L A and TMC278 LA for continued clinical development.  
Injection site reactions (ISR) of both agents have been generall y mild, self -limited, and 
well-tolerated in single and multiple dose studies.  
The early  results of LAI116482 support the use of oral [COMPANY_004]744 plus NRTIs as a 
reference regimen to the investigational two -drug long -acting regimen. At Week 24, the 
response rates (HIV -1 RNA <50 c/mL; ITT, MSDF) for the three doses of [COMPANY_004]744 in the 
LAI116482 study were 88%, 85% and 87% for the 10 mg, 30 mg, and 60 mg arms, 
respectivel y.  These rates compare favourably to the control regimen of EFV plus NRTI s 
in this study  where 74% of subjects achieved HIV- 1 RNA <50 c/mL at Week 24. The 
response rates seen at Week 24 are also consistent with a similarl y sized study of 
dolutegravir vs. EFV (ING112276), where each was administered to ART -naive subjects 
in combination with NRTI s.  In the study  ING112276, the Week 24 response rates (HIV-
1 RNA <50 c/mL) for dolutegravir and efavirenz were 94% and 82%, respectivel y 
[GlaxoSmithKline Document Number 2011N117114_01].
The background NRTIs (ABC/3TC) are accepted agents for initiation of antiretroviral 
therap y in treatment guidelines [ EACS , 2012; DHHS, 2013] and as such are considered 
appropriate for this trial.  RP V is approved as Edurant for use in combination ART at an 
oral dose of 25 mg, once daily  with a meal in treatment naive patients [ Edurant Product 
Information, 2012].
This trial is designed to allow for both an evaluation of the antiviral efficacy of two 
discrete induction periods of [COMPANY_004]744 in combination with a background of NRTI s as 
well as the evaluation of a long -acting two -drug regimen for the maintenance of 
previously  achieved virologic suppression for 96 weeks while using control regimen of 
oral [COMPANY_004]74 4 plus NRTIs.  The primary  endpoint, proportion of subjects with plasma 
HIV-1 RNA < 50 c/mL at Week 24, is a well established surrogate endpoint for 
prognosis of HIV -1 infection and disease progression [ CDER , 2002]. The Week 48 time 
point will permit an ev aluation of the ability  of this investigational two -drug long -acting 
combination to maintain virologic suppression. L onger term durability  of virologic  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
257suppression of this long -acting two -drug regimen will also be evaluated through a formal 
Week 96 anal ysis.
Revised text:
Long acting [COMPANY_004]744 has been investigated in [ADDRESS_419559] evaluation of [COMPANY_004]744 LA or TMC278 L A 
in HIV -infected subjects.  The results to date support [COMPANY_004]744 L A and T MC278 L A for 
continued clinical development.  I njection site reactions (I SR) of both agents have been 
generall y mild, self -limited, and well -tolerated in single and multiple dose studies.  
The results of LAI116482 support the use of oral [COMPANY_004]744 plus NRTI sas a reference 
regimen to the investigational two -drug long -acting regimen. At the primary  endpoint of 
Week 48, the response rates (HIV -1 RNA <50 c/mL; ITT, MSDF , Table 1) for the three 
doses of [COMPANY_004]744 in the LAI116482 study  were 8 0%, 80% and 87% for the 10 mg, 30 
mg, and 60 mg arms, respectivel y.  These rates compare favorabl y to the control regimen 
of EFV plus NRTIs in this study  where 71% of subjects achieved HIV -1 RNA <50 c/mL 
at Week 48. 
These data indicate continued viral suppression after 24 weeks of the two drug [COMPANY_004]744 
and RPV regimen.
The ITT- Maintenance Exposed (ITT -ME) Population consists of all randomized subjects 
who received at l east one dose of investigational product during the Maintenance P hase 
of the study .  Of the subjects who entered t he Maintenance Phase of the study , the 
majority  remained suppressed through Week 48 (24 weeks of two drug therapy ) (Table 
3).
Table 3 Proportion of Subjects with Plasma HIV -1 RNA <50 c/mL at Key Visits 
-Snapshot (MSDF) Analysis (ITT -ME Population)
Visit[COMPANY_004]744
10 mg
N=52
n (%)[COMPANY_004]744
30 mg
N=53
n (%)[COMPANY_004]744
60 mg
N=55
n (%)[COMPANY_004]744 
Subtotal
N=160
n (%)EFV 
600 mg
N=47
n (%)
Week 16 -Induction 50 (96) 49 (92) 52 (95) 151 (94) 43 (91)
Week 24 -Induction 50 (96) 50 (94) 53 (96) 153 (96) 45 (96)
Week 48 -Maintenance 48 (92) 48 (91) 53 (96) 149 (93) 44 (94)
The background NRTIs (ABC/3TC) are accepted agents for initiation of antiretroviral 
therap y in treatment guidelines [ EACS , 2012; DHHS , 2013] and as such are considered 
appropriate for this trial.  R PV is approved as Edurant for use in combination ART at an 
oral dose of 25 mg, once daily  with a meal in treatment naive patients [ Edurant Product 
Information, 2013].
This trial is designed to evaluate two distinct periods.  First, to evaluate the ability  of 
[COMPANY_004]744 + background NRTI s to induce virologic suppression during the Induction 
Period.  Second, during the Maintenance Period, two different dosing strategies of a long -
acting, two -drug, two- class regimen will be evaluated on their ability  to maintain  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
258virologic efficacy  for 96 weeks compared to a control regimen of oral [COMPANY_004]744 + 
ABC/3TC.  
The primary  endpoint, proportion of subjects with plasma HIV- 1 RNA < 50 c/mL , is a 
well established surrogate endpoint for prognosis of HIV -1 infection and disease 
progression [ CDER , 2002]. The primary endpoint for this study  is proportion of subjects 
with plasma HIV -1 RNA < 50 c/mL  at Week [ADDRESS_419560] an IM dosing 
regimen (Q8W or Q4W).  Week 32 has been selected to allow a comparable evaluation 
among the dosing regimens.  Q8W begins dosing at Week 8, following a loading dose at 
Day 1 and Week 4.  Therefore choosing Week 32 as an endpoint allows for a 24 week 
evaluation of the Q8W arm at steady  state.  
The Week 48 analysis will permit an evaluation of the ability  of the investigational two -
drug long -acting combination sto maintain virologic suppression over time, and will 
serve as the dose confirmation of the dosing regimen selected at Week 32.Longer term 
durability  of virologic suppression for theselong-acting two -drug regimens will also be 
evaluated through a formal Week 96 anal ysis.
Section 4.1 -Number of Subjects
Original text:
Sufficient subjects will be screened (approximately 260) in order to ensure that a total of 
approximately  180 subjects will be randomized at the beginning of the Induction Period, 
(approximately  90 to each treatment arm).  
Revised text:
Sufficient subjects will be screened (approximately 350) in order to ensure that a total of 
approximately  265subjects areenrolled at the beginning of the Induction Period and to 
ensure approximately  225 subjects are randomized into the Maintenance Period .  
Section 4.2 –Inclusion Criteria
Revised to (changes struck through and underlined).
Criteria 2b.
2. A female subject is eligible to e nter and participate in the study  if she:
b. is of child -bearing potential with a negative pregnancy  test at both Screening and 
first day  of the Induction Period [either Week (- 16) or Week ( -24)] and agrees to use 
one of the following methods of contracep tion to avoid pregnancy  [ADDRESS_419561] 52 weeks after 
discontinuation of [COMPANY_004]744 L A and TMC278 LA 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
259Section 4.3 –Exclusion Criteria
Revised to (changes struck through and underlined).
Subjects with known moderate to severe hepatic impairment. Subjects with known 
hepatic impairment must be assessed using the Child -Pugh classification and must be 
excluded if found to be C lass B or C classification [ Pugh , 1973].
Added:
Notwithstanding these minimum inclusion and exclusion criteria, investigators must also 
follow country  specific guidelines where they  exist when making decisions about 
subjects who are eligible for study  participation.
Section 4.5 -Withdra wal Criteria
Revised to (changes underlined).
Added:
Subjects permanentl y discontinuing study treatments prior to Week 96 are considered to 
be withdrawn from the study  treatments and also from the study .Similarly , subjects
permanentl y discontinuing participation from the Extension and L ong-Term Follow -Up 
Period prior to commercially  available drug supply  are considered to be withdrawn from 
the study  treatments and also from the study .
And:
Subjects must be withdrawn from the stud y for any of the following reasons:
Subjects who do not wish to continue on the remaining dosing regimen if one 
dosing regimen is discontinued further to an IDMC decision (see Section 3.2.8).
Liver toxicity  where Stoppi[INVESTIGATOR_339211] 6.10.3 are met 
and no compelling alternative cause is identified.
Renal toxicity  as specified in Section [IP_ADDRESS] and Section [IP_ADDRESS] is met and 
no compelling alternate cause is identified. 
Section 5.1.1 -[COMPANY_004]1265744 –Tablet ([COMPANY_004]744)
Revised to ( changes underlined).
[COMPANY_004]744 is manufactured by  [CONTACT_339317] 30 mg tablets for oral administration, packaged in high densit y 
polyethylene (HDPE) bottles with desiccant and child -resistant closure that include an 
induction seal. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
260Section 5.1.4 -[COMPANY_004]1265744 –Injectable Suspension ([COMPANY_004]744 LA )
Revised to (changes struck through and underlined).
[COMPANY_004]744 L A is manufactured by  [CONTACT_339259] a sterile white to slightly  
colored suspension c ontaining 200 mg/mL of [COMPANY_004]744 as free acid for administration by  
[CONTACT_33813] (IM) injection.  The product is packaged in a 3 mL USP Ty pe I glass vial 
with a 13 mm gray  stopper and aluminium seal. Each vial is for single use containing a 
nominal withdrawa ble fill volume of 1.5 mL  or2.0 mL ,and does not require dilution 
prior to administration.  [COMPANY_004]744 L A injectable suspension is to be stored at up to 30°C, 
do not freeze .
Section 5.1.6 -Dosage and A dministration
Original text:
Following is a table of dosi ng and administration for all treatment arms:
Background NRTI combination and 
Investigational ProductDose and Dose Interval
Induction Period –RPV to be taken with a meal
16 week Induction Arm
ABC/3TC 1 X 600 mg / 300 mg tablet once daily from 
Week ( -16) through Day 1 of Maintenance (Day 1 taken in 
clinic)
[COMPANY_004]744 1 X 30 mg tablet once daily from Week ( -16) through Day 
1 of Maintenance (Day 1 taken in clinic)
RPV 1 X 25 mg tablet once daily from Week ( -4) through Day 1 
of Maintenance (Day 1 taken in c linic)
24 week Induction Arm
ABC/3TC 1 X 600 mg /300 mg tablet once daily from 
Week ( -24) through Day 1 of Maintenance (Day 1 taken in 
clinic)
[COMPANY_004]744 1 X 30 mg tablet once daily from Week ( -24) through Day 
1 of Maintenance (Day 1 taken in clinic)
RPV 1 X 25 mg tablet once daily from Week ( -4) through Day 1 
of Maintenance (Day 1 taken in clinic)
Maintenance Period –no food requirements
[COMPANY_004]744 LA + TMC278 LA Dosing Arm
[COMPANY_004]744 LA 2 X 2 mL Injections (4 mL [800 mg] total) intramuscularly 
(IM) as load ing dose (Day 1 only) followed by 1 X 2 mL 
injection (400 mg) IM every 4 weeks for 96 weeks
TMC278 LA 1 X 2 mL Injection (600 mg) intramuscularly every 4 
weeks for 96 weeks
Oral Control Arm
ABC/3TC 1 X 600 mg / 300 mg tablet once daily for 96 weeks
[COMPANY_004]744 1 X 30 mg tablet once daily for 96 weeks
Extension Period
[COMPANY_004]744 LA + TMC278 LA Dosing Arm –no food requirements
[COMPANY_004]744 LA 1 X 2 mL injection (400 mg) IM every 4 weeks* 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
261Background NRTI combination and 
Investigational ProductDose and Dose Interval
TMC278 LA 1 X 2 mL Injection (600 mg) IM every 4 weeks*
following Oral Contr ol Arm –RPV to be taken with a meal
RPV 1 X 25 mg tablet once daily from Week 98 through Week 
100 
[COMPANY_004]744 LA 2 X 2 mL Injection (4 mL [800 mg] total) as loading dose 
(Week 100 only) followed by 1 X 2mL injection (400 mg) 
IM every 4 weeks*
TMC278 LA 1 X2mL injection (600 mg) IM every 4 weeks (starting at 
Week 100)*
*until it is either locally approved and commercially available, the subject no longer derives clinical benefit, 
the subject meets a protocol -defined reason for discontinuation or until dev elopment of [COMPANY_004]744 or 
TMC278 is terminated
Revised text:
Following is a table of dosing and administration for all treatment arms:
Induction Period (Week -20 through Day 1)
Week -20 to Week (-4)
(2 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg ta blet once daily 
Take 1 X [COMPANY_004]744 30 mg tablet once daily
Week ( -4) to Day 1
(3 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X [COMPANY_004]744 30 mg tablet once daily
Take 1 X RPV 25 mg tablet once daily
Take with a meal
Take Day 1 doses in the clinic
Maintenance Period (Day 1 to Week 96*)
[COMPANY_004]744 LA 600 mg + TMC278 LA 900 mg IM every 8 Weeks (Q8W)
Day 1 –loading dose
(3 injections once)Receive last dose of Induction regimen
Receive [COMPANY_004]744 LA 800 mg given as 2 X 2 mL IM injecti ons 
Receive TMC278 LA 900 mg given as 1 X 3 mL IM injection 
Week 4 – 2ndloading dose
(1 injection once)Receive [COMPANY_004]744 LA 600 mg given as 1 X 3 mL IM injections 
(No TMC278 LA) 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
262Week 8 to Week 88
(2 injections every 8 weeks)Receive [COMPANY_004]744 LA 600 mg given as 1 X 3 mL IM injection 
Receive TMC278 LA 900 mg given as 1 X 3 mL IM injection
[COMPANY_004]744 LA 400 mg + TMC278 LA 600 mg IM every 4 Weeks (Q4W)
Day 1 –loading dose
(3 injections once)Receive last dose of Induction regimen
Receive [COMPANY_004]744 LA 800 mg given as 2 X 2 mL IM injections 
Receive TMC278 LA 600 mg given as 1 X 2 mL IM injection 
Week 4 to Week 92
(2 injections every 4 weeks)Receive [COMPANY_004]744 LA 400 mg given as 1 X 2 mL IM injection
Receive TMC278 LA 600 mg given as 1 X 2 mL IM injection
[COMPANY_004] 744 30 mg + ABC/3TC once daily
Day 1Receive last dose of Induction regimen
Day 2 to Week 96
(2 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X [COMPANY_004]744 30 mg tablet once daily
If continuing to Extension Period:
Week 96 t o Week 102
(2 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X [COMPANY_004]744 30 mg tablet once daily
If eligible to enter Extension Period:
Week 102 to Week 104
(3 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X [COMPANY_004]744 30 mg tablet once daily
Take 1 X RPV 25 mg tablet once daily
Take with a meal
Extension Period (Week 96plus+) 
If [COMPANY_004]744 LA 600 mg + TMC278 LA 900 mg IM every 8 Weeks is selected:
Week 96 plus+
(2 injections every 8 weeks)Rece ive [COMPANY_004]744 LA 600 mg given as 1 X 3 mL IM injection 
Receive TMC278 LA 900 mg given as 1 X 3 mL IM injection 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
263If switching from Oral Arm:
Week 104 –loading dose
(3 injections once)Receive last dose of Maintenance regimen
Receive [COMPANY_004]744 LA 800 mg given as 2 X 2 mL IM injections 
Receive TMC278 LA 900 mg given as 1 X 3 mL IM injection
Week 108 – 2ndloading dose
(1 injection once)Receive [COMPANY_004]744 LA 600 mg given as 1 X 3 mL IM injections 
(No TMC278 LA)
Week 112 plus+
(2 injections every 8 weeks)Rece ive [COMPANY_004]744 LA 600 mg given as 1 X 3 mL IM injection 
Receive TMC278 LA 900 mg given as 1 X 3 mL IM injection
If [COMPANY_004]744 LA 400 mg + TMC278 LA 600 mg IM every 4 Weeks is selected:
Week 96 plus+
(2 injections every 4 weeks)Receive [COMPANY_004]744 LA 400 mg give n as 1 X 2 mL IM injection 
Receive TMC278 LA 600 mg given as 1 X 2 mL IM injection
If switching from Oral Arm:
Week 104 –loading dose
(3 injections once)Receive last dose of Maintenance regimen
Receive [COMPANY_004]744 LA 800 mg given as 2 X 2 mL IM injection s 
Receive TMC278 LA 600 mg given as 1 X 2 mL IM injection 
Week 108 plus+
(2 injections every 4 weeks)Receive [COMPANY_004]744 LA 400 mg given as 1 X 2 mL IM injection 
Receive TMC278 LA 600 mg given as 1 X 2 mL IM injection
* Or through Week 104 if eligible t o enter the Extension Period.
+ until locally approved and commercially available, the subject no longer derives clinical benefit, the subject meets a 
protocol -defined reason for discontinuation or until development of [COMPANY_004]744 or TMC278 is terminated
Sect ion 5.1.7 -Dosing Considerations for [COMPANY_004]744 LA  + TMC278 LA
Revised to (changes struck through and underlined).
IM injections should be administered at a 90 degree angle into the gluteus medius muscle 
using a 1.5” 25 gauge needle for [COMPANY_004]744 LA and a 1.5” [ADDRESS_419562] subjects .  The needle should be long enough to reach the muscle mass and 
prevent stud y drug from seepi[INVESTIGATOR_159193], but not so long as to involve 
underly ing nerves, blood vessels, or bone. Longer needle lengths will be required for 
subjects with higher body mass indexes (BMIs, example > 30), to ensure that injections 
are administered intramuscularl y as opposed to subcutaneousl y.  BMI and needle length 
used will be collected in the eCRF. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419563] intolerance to the single 3 mL injection, the injection may  be 
administered as 2 separate 1.5 mL  injections with the assent of the medical monitor.  I f 
the injection is split, this will be noted in the eCRF and the intolerance captured as an 
AE.
Detailed Additional dosing instructio ns and considerations can be found in the SPM .
Section 5.2 –Treatment A ssignment
Original text:
There are 2 randomizations in the study ; both will be stratified by  [CONTACT_140204] -1 RNA 
(<100,000 or 100,000 c/mL ).  At the first randomization, study  eligibl e subjects will be 
randomized to their length of induction treatment (either 16 or 24 weeks) at a1:1 ratio.  
Following completion of their Induction Period, subjects eligible to enter the 
Maintenance Period will be randomized again to either the [COMPANY_004]744 LA + TMC278 L A 
arm or the oral control arm ([COMPANY_004]744 + ABC/3TC) at a ratio of 2:1.  This second 
randomization will be stratified by  [CONTACT_1766]’ previous randomized length of induction and 
by [CONTACT_339318]- 1 RNA.
Revised text:
Following completion of the I nduction Period, subjects eligible to enter the Maintenance 
Period will be randomized 2:2:1 to Q8W or Q4W of [COMPANY_004]744 LA + TMC278 L A or to 
the oral control arm ([COMPANY_004]744 + ABC/3TC).  Randomization will be stratified by  [CONTACT_10840]-1 
RNA result before Week (-8)(<50 c/mL yes or no).
Section 5.7 -Interruption of Study  Treatment and Visit/Dosing Windows
Revised to (changes struck through and underlined).
It is important to note that keepi[INVESTIGATOR_85883]’s visit schedule is a very important 
component to the study.  
Note :All decisions regarding dose interruption / resumption must be discussed with 
the medical monitor in advance.
Should study  treatment be interrupted, the following guidance must be used:
[COMPANY_004]744 and/or RPV Containing ArmsOral Dosing
Oral dosing is expected to occur during the week in which the subject’s projected 
visit falls (as according to the Baseline visit).  
And: 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
265[COMPANY_004]744 LA and / or TMC278 LA Containing ArmsIM Dosing
Plasma concentrations of both drugs may  be measurable for approximately  [ADDRESS_419564]’s projected visit 
falls (as according to the Day 1 visit).  An additional (+ or - ) 7 day window is 
allowable for IM dosing but not preferred.  
After a single 800 mg dos e of [COMPANY_004]744 LA, concentrations may  be measurable for up to 
52 weeks and after a single 600 mg dose of TMC278 L A, concentrations may  be 
measurable for up to 24 weeks.
Dosing frequency  during the Maintenance and Extension Periods is scheduled to occur 
approx imately  every 4 weeks (28 days) .  Dose timing with [COMPANY_004]744 LA + TMC278 L A 
is critical to assure therapeutic drug levels are maintained and therefore the following 
guidance is provided regarding allowable windows around dosing:
Dosing is expected to occur within 21 -35 days from the previous dose while 
simultaneously  keepi[INVESTIGATOR_339212] 1 of the Maintenance Period (or Week 100 of the Extension Period for oral 
control arm switch subjects).  
Over time, the subject who comes in late in the visit window should return for 
the next injection on the earl y side of the window to get back on track with the 
original projected visit schedule.  
Dosing may  occur without consultation from the medical monitor if performed 
within the this dosing 7 day window.  
Any request for the visit/ dosing to occur outside of the allowed window either 
≥36 day s or ≤[ADDRESS_419565] be discussed and agreed with 
the medical monitor prior to dosing.  In the event of a late dos e, a revised dosing 
schedule for subsequent dosing may be required and will be communicated to 
the site staff at the time of approval for continued dosing.  Temporary  switch to 
oral dosing of [COMPANY_004]744 and/or RPV may  be an option based on individual 
subject c ircumstance as described in Section 5.6.1 .  
See the SPM for scheduling guidance and further information and examples. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
266Section 6 –Time and Events tables
Original text:
Time and Events Table – 24 Week Induction Period
Procedures  for the 24 Week Inductio n Screening 
Period aBaseline / 
Week ( -
24) Wee
k 
(-20) Wee
k
(-16)Wee
k
(-12)Wee
k
(-8)Wee
k
(-4)WD pNotes 
Written Informed Consent Xa. Complete all Screening assessments within [ADDRESS_419566] 
management and / or care.
c. Measure height at Screening Period only.  Measure 
weight at Screening Period and WD only.
d. Measure vital signs after about [ADDRESS_419567] in a 
semi -supi[INVESTIGATOR_2547].
e. Perform ECG at Baseline in triplicate prior to dosing; 
preferably 2 – [ADDRESS_419568] full routine medical history plus; 
cardiovascular risk factors (assessments include 
smoking status and history, family history of cardiac 
events, recent [ 6months] illicit drug use), 
gastrointestinal disease, metabolic, psychiatric, renal 
and neurologic disorders.Demography X
Eligibility Verification X X X n
Randomization X
Physical Exam b X
Symptom Directed Physical Exam and 
Medical Assessment bX X X X X X Xand 
smoking 
status
Vital Signs (BP, HR), We ight, Height c, d X X X X
12-Lead ECG e Xpre-dose X X X
Medical History and CDC Classification fX
Medication History / Prior ART History X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
267Procedures  for the 24 Week Inductio n Screening 
Period aBaseline / 
Week ( -
24) Wee
k 
(-20) Wee
k
(-16)Wee
k
(-12)Wee
k
(-8)Wee
k
(-4)WD pNotes 
HIV Associated Conditions , AE and 
SAE Assessment, Concomitant Meds X g X X X X X X Xg. Collect SAEs at Screen only if associated to study 
participation.
h. Preferably completed at the beginning of the visit .
i. Collect for women of childbearing potential only.  A 
negative urine pregnancy test is required prior to 
beginning the Induction Period. S=Serum/U=Urine
j. Plasma for storage will be used: to determine 
genotypic eligibility at Screen, for possible future 
analyses, as back -up in case samples are lost or 
damaged in transit to the lab and for genotypic and 
phenotypic analyses in cases of virologic failure.
k. Overnight fast is preferred; however, a minimum of a 
[ADDRESS_419569] subjects to continue to take the Induction 
regimen (including RPV) through Day 1 of the 
Maintenance Period.  Subjects should be reminded 
to take the Day 1 dose in the clinic and return t he PK 
diary.  The PK diary will be completed for all subjects 
in case they are randomized to continue on the 
[COMPANY_004]744 + ABC/3TC arm.
n. Confirmation of eligibility to enter the Maintenance 
Period.  See Section 3.2.3.
o. Remind subjects of the potential ch ange in study Columbia Suicide Severity Rating Scale 
(eC-SSRS) hX X X X X X X X
HIVTSQ(s) h X X X
HIVMQ X 
Chemistry and Hematology X X X X X X X X
Pregnancy Testingi S U S S S S S S
HIV-1 RNA and sample for storage j X X X X X X X X
CD4+ and CD8+ X X X X X X
Urinalysis and urine 
microalbumin/creatinine ratioX X X
Fasting Lab Assessments:  Glucose, 
Cholesterol (Total, HDL and LDL) and 
Triglycerides kX X X
Hepatitis B (HBsAg) and Hepatitis C 
(anti-HCV Ab), HLA -B*5701X
PT/PTT/INR X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
268Procedures  for the 24 Week Inductio n Screening 
Period aBaseline / 
Week ( -
24) Wee
k 
(-20) Wee
k
(-16)Wee
k
(-12)Wee
k
(-8)Wee
k
(-4)WD pNotes 
PGx l Xtreatment and visit frequency which begins at 
Day 1.
p. Follow Up Visit:  Conduct approximately [ADDRESS_419570] on -
study visit.  This visit may be conducted by 
[CONTACT_756].PK Sample for Storage X
Study Treatment Dispensation X X X X X X Add 
RPV m
Study Treatment Accountability
(pi[INVESTIGATOR_10685])X X X X X X
RPV  and PK Diary Dispensation m X
Subject Visit R eminder Contact X X X X X X X o X
Subject Contact [CONTACT_339265] X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
269Time and Events Table – 16 Week Induction Period
Procedures for the 16 Week Induction Period Screenin
g Period aBaseline / 
Week ( -16) Wee
k (-
12) Week 
(-8)Week 
(-4)WD p Notes 
Written Informed Consent Xq. Complete all Screening assessments within [ADDRESS_419571] 
management and / or care.  
s. Measure height at Screening Period only.  Measure 
weight at Screening Period and WD only.
t. Measure vital signs after about [ADDRESS_419572] in a 
semi -supi[INVESTIGATOR_2547].
u. Perform ECG at Baseline in triplicate prior to dosing; 
preferably 2 –[ADDRESS_419573] full routine medical history plus; 
cardiovascular risk factors (assessments include 
smoking status and history, family history of cardiac 
events, recent [ 6months] illicit drug use), 
gastrointestinal disease, metabolic, psyc hiatric, renal 
and neurologic disorders.
w. Collect SAEs at Screen only if associated to study 
participation.
x. Preferably completed at the beginning of the visit.Demography X
Eligibility Verification X X X n
Randomization X
Physical Examb X
Symptom Directed Physical Exam and Medical 
Assessment bX X X X X and 
smoking 
status
Vital Signs (BP, HR), Weight, Height c, d X X X X
12-Lead ECG e X pre-dose X X X
Medical History and CDC HIV -1 Classification f X
Medication History including Prior ART History X
HIV Associated Conditions , AE and SAE 
Assessment, Concomitant Meds X g X X X X X
Columbia Suicide Severity Rating Scale (eC -
SSRS) hX X X X X X
HIVTSQ(s) h X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
270Procedures for the 16 Week Induction Period Screenin
g Period aBaseline / 
Week ( -16) Wee
k (-
12) Week 
(-8)Week 
(-4)WD p Notes 
HIVMQ Xy. Collect for women of childbearing potential only.  A 
negative urine pregnancy test is requi red prior to 
beginning the Induction Period. S=Serum/U=Urine
z. Plasma for storage will be used: to determine 
genotypic eligibility at Screen, for possible future 
analyses, as back -up in case samples are lost or 
damaged in transit to the lab and for genotypi c and 
phenotypic analyses in cases of virologic failure.
aa. Overnight fast is preferred; however, a minimum of a 
[ADDRESS_419574] subjects to continue to take the Induction 
regimen (including RPV) through Day 1 of the 
Maintenance Period.  Subjects should be reminded to 
take the Day 1 dose in the clinic and return the PK 
diary.  The PK diary will be completed for all subjects 
in case they are randomized to the oral regimen arm.
dd. Confirmation of eligibility to enter the Maintenance 
Period.  See Section 3.2.3.
ee. Remind subjects of the potential change in study 
treatment and visit frequency which begins at Day 1.
ff. Follow Up Visit:  Conduct approximately [ADDRESS_419575] on -
study visit. This visit may be conducted by [CONTACT_756].Chemistry and Hematolog y X X X X X X
Pregnancy Testing i S U S S S S
HIV-1 RNA and sample for storage j X X X X X X
CD4+ and CD8+ X X X X X
Urinalysis and urine microalbumin / creatinine ratio X X X
Fasting Lab Assessments:  Glucose, Cholesterol 
(Total, HDL and LD L) and Triglycerides kX X X
Hep B (HBsAg), Hep C (anti -HCV Ab), HLA -
B*5701X
PT/PTT/INR X X
PGx l X
PK Sample for Storage X
Study Treatment Dispensation X X X X Add RPV m
Study Treatment Accountability (pi[INVESTIGATOR_10685]) X X X X
RPV  and PK Diary Dispensation m X
Subject Visit Reminder Contact X X X X X o X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
271Procedures for the 16 Week Induction Period Screenin
g Period aBaseline / 
Week ( -16) Wee
k (-
12) Week 
(-8)Week 
(-4)WD p Notes 
Subject Contact [CONTACT_339265] X X X X X
Time and Events Table – Maintenance Period for IM Regimen ([COMPANY_004]744 LA+TMC278 LA)
Procedures
For Maintenance 
–IM regimenD1 W
1W
4W
8W
12W
16W
20W
24W
28W
29W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD 
m,n
Verify Eligibility X
Randomization X
Symptom 
Directed PE, ISR 
& Medical 
Assessment aX X X X X X X X X X X X X X X X X X X X X X X X X X X X 
and 
smoking 
status
Vital Signs
(BP, HR) bX X X X X X X X X X X X
Weight X X X X X
ECG c Xpre X X X X X X X X X X X
HIV Associated 
Conditions, AE 
and SAE 
Assessment, Con  
Meds X X X X X X X X X X X X X X X X X X X X X X X X X X X X
ISR Diary D E E E E E E E D E E E E E E E E E E E E E E E E E E E 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
272Procedures
For Maintenance 
–IM regimenD1 W
1W
4W
8W
12W
16W
20W
24W
28W
29W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD 
m,n
Dispensation and 
Review d
Exercise Habit 
Assessment eX X
eC-SSRSf X X X X X X X X X X X X X X X X X X X X X X X X X X X X
HIVTSQ(s) g Xpre X X X X X X
HIVTSQ(c)g X X
HIVMQ g X X X X X g
Chemistry and 
HematologyX X X X X X X X X X X X X X X X X X X
Pregnancy 
Testing hU U U U U U U U U U U U U U U U U U U U U U U U U U U S
HIV-1 RNA &
sample for 
storage iX X X X X X X X X X X X X X X X X X X X X X X X X X X X
CD4+/ CD8+ X X X X X X X X X X X
Urinalysis and 
urine 
microalbumin/
creatinine ratioX X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
273Procedures
For Maintenance 
–IM regimenD1 W
1W
4W
8W
12W
16W
20W
24W
28W
29W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD 
m,n
Fasting:  Glucose, 
Cholesterol (Total, 
HDL and LDL) 
and 
Triglycerides jX X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
274Procedures
For Maintenance 
–IM regimenD1 W
1W
4W
8W
12W
16W
20W
24W
28W
29W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD 
m,n
Procedures
For Maintenance 
–IM regimenD1 W
1W
4W
8W
12W
16W
20W
24W
28W
29W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD 
m,n
PT/PTT/INR X X X X X
PK Sample k X X X X X X X X X X X X X X X S S S S S S S S S S S S S
Study Trea tment 
Administration oX l X X X X X X X X X X X X X X X X X X X X X X X X
Visit Reminder 
ContactX X X X X X X X X X X X X X X X X X X X X X X X X X X X
Subject Contact 
[CONTACT_339266] X X X X X X X X X X X X X X X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
275D=Day     W=Week    Pre=Pre -dosing   PE = Physical Exam
a) Physical exams should be conducted as part of normal routine clinical care but data 
will not be collected in the eCRF. Medical assessments include any decisions the 
study staff must make for subject management and/or care of the subject.
b) Measure vital signs after about [ADDRESS_419576] in a semi -supi[INVESTIGATOR_2547].
c) 12-Lead ECG –Conduct pre -dose at Day 1.  At all other visits, the ECG may be 
done at any time during the visit.
d) D = Daily  E = Epi[INVESTIGATOR_49564].  Subjects will complete a daily diary of injection site 
reactions from Day 1 to Week 1 and again from Week 28 to Week 29 (daily).  At all 
other visits subjects will complete a diary only if the subject experiences a reaction 
(epi[INVESTIGATOR_49564]).  Subjects will be dispensed a ne w diary at each visit.  
e) Subject’s exercise habits will be assessed daily between Day 1 and Week 1 and 
again between Week 28 and Week 29.  Assessments will include type and duration 
of cardiovascular exercise and duration of any strength or other strenuous
exercises. This information will be collected via the daily ISR diary.
f) Preferably completed at the beginning of the visit. 
g) Conduct the HIVTSQ(s) at Day 1 pre -dosing; at all other visits conduct post -
dosing.  Conduct the HIVTSQ(c) at WD ONLY if the subje ct WD between Week [ADDRESS_419577] injection.
h) Women of childbearing potential only.  A ( -) urine pregnancy test is required prior to 
any injection and prior to reinitiating injections after > [ADDRESS_419578] will need to be WD.  U=Urine  S=Serumi) Plasma for storage samples collected for possible analyses, back -up in case 
samples are lost or damaged in transit to lab, for geno/phen o analyses and 
virologic failures.
j) Fast overnight; however, a minimum of a [ADDRESS_419579] is acceptable.
k) Take PK samples pre -dose except Week 1 and Week 29 which can be taken at 
any time during the visit.  Day 1 PK sample should be taken after review of PK 
diary and pre -dose of [COMPANY_004]744+ABC/3TC+RPV and another sample taken [ADDRESS_419580] injection.  S=Sample for storage
l) Subjects should take [COMPANY_004]744+ABC/3TC+RPV on Day 1 in the clinic prior to PK 
sampling.  Day 1 injections will include 2 x [COMPANY_004]744 LA 400 mg + 1 x TMC278 LA 
600 mg IM.  Thereafter injections are 1 x [COMPANY_004]744 LA 400 mg + 1 TMC278 LA 
600 mg IM.  
m) Subjects who WD must enter Long -Term Follow Up (see Section 3.2.6) instead 
of completing the WD visit.  If they cannot enter Long -Term Follow -Up complete
WD assessments.
n) Follow Up Visit:  Conduct approximately [ADDRESS_419581] on -
study visit.  This visit may be conducted by [CONTACT_756].
o) If possible, injections sh ould be spaced approximately 2 cm from one another 
and from the site of any previous injection and or any injection site reaction.  
Bring TMC278 LA to approximately room temperature prior to injecting; note time 
and location of injection (right or left) in eCRF.  Dosing is expected to occur 
within 21 -35 days from the previous dose while keepi[INVESTIGATOR_339213] 1 of the Maintenance Period.  All decisions 
regarding dose interruption/ resumption must be discussed with the 
medi cal monitor in advance. 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
276Time and Events Table – Maintenance Period for Oral Regimen ([COMPANY_004]744+ABC/3TC)
Procedures
For 
Maintenance -
oral regimen D1 W
4W
8W
12W
16W
20W
24W
28W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96W
98 nWD o
Verify Eligibility X X jX kX k
Randomization X
Symptom 
Directed PE and 
Medical 
Assessment aX X X X X X X X X X X X X X X X and 
smoking 
status
Vital Signs
(BP, HR) bX X X X X X X X X X X
Weight X X X X X
ECG c Xpre X X X X X X X X X X
HIV Associated 
Conditions, AE 
and SAE 
Assessment, 
Concomitant 
Meds X X X X X X X X X X X X X X X X X X X X X X X X X X X 
PK Di ary d D/R D/R D/R R R
eC-SSRSe X X X X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
277Procedures
For 
Maintenance -
oral regimen D1 W
4W
8W
12W
16W
20W
24W
28W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96W
98 nWD o
HIVTSQ(s) e Xpre X X X X X X
HIVTSQ(c)e X X e
HIVMQ e X X X X X
Chemistry and 
Hematol ogyX X X X X X X X X X X X X X X
Pregnancy 
Testing fS S S S S S S S S S S S S S S
HIV-1 RNA &
sample for 
storage gX X X X X X X X X X X X X X X
CD4+/ CD8+ X X X X X X X X X X X
Urinalysis and 
urine
microalbumin/
creatinine ratioX X X X X X
Fasting:  
Glucose, 
Cholesterol 
(Total, HDL and 
LDL) and 
Triglycerides hX X X X X X X
PT/PTT/INR X X X X X
PK Sample i X X X X X
Study 
Treatment 
Dispensation & X X X X X X X X X X X X X X X 
Add
RPV,  
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419582] for any AEs, changes to Con Meds, changes to their 
overall health and any other medical concerns. 
D=Day      W=Week    Pre=Pre -dosing  PE = Physical Exam
a. Physical exams should be conducted as part of normal routine clinical care but data 
will not be collected in the eCRF. Medical assessments include any decisions the 
study staff must make for subject managem ent and/or care of the subject.
b. .Measure vital signs after about [ADDRESS_419583] in a semi -supi[INVESTIGATOR_2547].
c. 12-Lead ECG –Conduct pre -dose at Day 1.  At all other visits, it is preferable to 
conduct 2 –4 hours after dosing.
d. D=Dispense   R=Review
e. Preferably completed at the beginning of the visit.  Conduct the HIVTSQ(s) at Day [ADDRESS_419584] the HIVTSQ(c) at WD ONLY if the subject WD between 
Week 4 and Week 24.
f. Women of childbearing potential only.  S=Serum
g. Plasma for storage samples are coll ected for possible future analyses, as back -up 
in case of lost or damaged in transit to the lab and for geno/pheno analyses for 
virologic failuresh. Plasma for storage samples are collected for possible future analyses, as back -
up in case of lost or damag ed in transit to the lab and for geno/pheno analyses 
for virologic failures
i. Fast overnight; however, a minimum of a [ADDRESS_419585] be <50 c/mL and 
results available at the time of the Week 98 visit.  See Section [IP_ADDRESS].
m. For subjects eligible to enter the Extension Period Add RPV to current 
treatment regimen.  Subjects will take their Maintenance treatment 
regimen+RPV until Week 100.
n. Remind subjects of the change in study treatment and visit frequency which 
begins at Week 100.
o. Only for those subjects electing to transition to [COMPANY_004]744 LA+TMC278 LA.
p. Follow Up Visit:  Conduct approximately [ADDRESS_419586] 
on-study visit.  This visit ma y be conducted by [CONTACT_756] 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
279Time and Events Table – Extension Period
Procedures for 
ExtensionW 
100W 
104W 
108W 
112W
116W 
120W
124W
128W
132W
136W 
[ADDRESS_419587] no longer derives clinical 
benefit or meets a protocol -defined reason for discontinuation or until development is terminated.WD k,l Notes
See footnote “a” for continuation of 
visit schedule after Week 148.
Symptom Directed 
Physical Exam, ISR 
and Medical 
Assessment bX X X X X X X X X X X X X Xa. Continue this pattern for visits for the 
remainder of the study.  For example, 
Week [ADDRESS_419588] a ( -) urine pregnancy test prior 
to any injection and prior to 
reinitiating injections after > 7 days of 
treatment interruption. U=Urine
g. Plasma for storage samples are 
collected for possible future analyses, 
as back- up in case of lost damaged in Vital Signs (BP, HR) cX X X X X X
Weight X X X X X X
HIV Associated 
Conditions, AE and 
SAE Assessments, 
Con MedsX X X X X X X X X X X X X X
12-Lead ECG d X X X X X
Columbia Suicide 
Severity Rating Scale 
(eC-SSRS) eX X X X X X X X
Chemistry and 
HematologyX X X X X X X X
Pregnancy Testing f U U U U U U U U U U U U U U
HIV-1 RNA and 
sample for storage gX X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
280Procedures for 
ExtensionW 
100W 
104W 
108W 
112W
116W 
120W
124W
128W
132W
136W 
140 aW 
144 aW 
148 a
Continue 
until either WD k,l Notes
See footnote “a” for continuation of 
visit schedule after Week 148.
CD4+ X X X X X Xtransit to the lab and for geno/pheno 
analyses for virologic failures.
h. Fast o vernight; minimum of a [ADDRESS_419589] is acceptable.
i. Dispense at each visit.  E = Epi[INVESTIGATOR_49564]
j. If possible, injections should be 
spaced approximately 2 cm from one 
another and from the site of any 
previous injection and or any injection 
site reaction.  Bring TMC2 78 LA to 
approximately room temperature prior 
to injecting; note time and location of 
injection (right or left) in eCRF.  
Dosing is expected to occur within 
21-35 days from the previous dose 
while keepi[INVESTIGATOR_339213] 1 of the 
Maintenance Period.  All decisions 
regarding dose interruption/ 
resumption must be discussed 
with the medical monitor in 
advance.
k. Or  Long -Term Follow Up
l. Follow Up Visit: ~[ADDRESS_419590] has 
ongoing AEs/lab abnorm alities at the 
last visit.Urinalysis and u rine 
microalbumin/
creatinine ratioX X X X X
Continue until either locally approved and commercially available, the 
subject no longer derives clinical benefit or meets a protocol -defined reason X
Fasting:  Glucose, 
Cholesterol (Total, 
HDL and LDL) and 
Triglycerides hX X X X X X
PT/PTT/INR X
ISR Diary 
Dispensation 
and Review iE E E E E E E E E E E E E E 
review
Study Treatment 
Administration jX X X X X X X X X X X X X
Subject Visit 
Reminder ContactX X X X X X X X X X X X X
Subject Contact [CONTACT_339270] X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
281Time and Events Table – Long -Term Follow Up Period
Procedures for Long -Term Follow Up Month [ADDRESS_419591] one dose o f [COMPANY_004]744 LA and / or 
TMC278 LA.
a) The start of the [ADDRESS_419592] [COMPANY_004]744 LA and/or TMC278 LA dose.
b) Women of childbearing potential only.  S = Serum
c) Fast overnight; however, a minimum of a [ADDRESS_419593] 
is acceptable.
d) Women of childbearing potential should continue to 
receive counselling on the need to use adequate 
contraception for the entirety of the Long -Term 
Follow -Up Period. 
e) Investigators must discuss choice of HAART 
regimen and timing of initiation with the medical 
monitor before initiating.  This regimen is not 
provided by [CONTACT_339319].HIV-1 RNA X X X X X X
CD4+ X X X X X X
Plasma for Storage X X X X X X
Chemistry and Hematology X X X X X X
Pregnancy Testing b S S S S S S
Urinalysis and urine microalbumin/
creatinine ratioX X X
Fasting:  Glucose, Cholesterol (Total, 
HDL and LDL) and Triglycerides cX X
PT/PTT/INR X X
Contraception Counselling d X X X X X X
HAART Dispensation e X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
282Revised text:
Time and Events Table –Induction Period
Procedures  for Induction Screening 
Period aBaseline / 
Week ( -
20) Week 
(-16) Week
(-12)Week
(-8)Week
(-4)WD Notes 
Written Informed Consent Xa. Complete all Screening assessments within [ADDRESS_419594] management and / or care. 
c. Height collected at Baseline only.
d. Measure vital signs after about [ADDRESS_419595] 
in a sem i-supi[INVESTIGATOR_2547].
e. Perform ECG at Baseline in triplicate prior to 
dosing; preferably 2 –[ADDRESS_419596] full routine medical history plus; 
cardiovascular risk factors (assessments include 
smoking status and history, famil y history of 
cardiac events), recent [ 6months] illicit drug 
use, intravenous drug use, gastrointestinal 
disease, metabolic, psychiatric, renal and 
neurologic disorders.
g. Collect SAEs at Screen only if associated to study 
participation.Demography X
Eligibility Verification X X X h
Physical Exam b X
Symptom Directed Physical Exam and 
Medical Assess ment bX X X X X Xand 
smoking 
status
Weight and Height c X X
Vital Signs (BP, HR )d X X X X
12-Lead ECG e X Xpre-dose x3 X X
Medical History f X
Medication History / Prior ART History X
CDC Classification X X
HIV Associated Conditions X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
283Procedures  for Induction Screening 
Period aBaseline / 
Week ( -
20) Week 
(-16) Week
(-12)Week
(-8)Week
(-4)WD Notes 
AE and S AE Assessment, Con Meds X g X X X X X Xh. Confirmation of eli gibility to enter the Maintenance 
Period.  See Section 3.2.3.
i. Preferably completed at the beginning of the visit.
j. Collect for women of childbearing potential only.  
A negative urine pregnancy test is required prior 
to beginning the Induction Period. 
S=Ser um/U=Urine
k. Plasma for storage will be used: to determine 
genotypic eligibility at Screen, for possible future 
analyses, as back -up in case samples are lost or 
damaged in transit to the lab and for genotypic 
and phenotypic analyses in cases of virologic 
failure.
l. Overnight fast is preferred; however, a minimum 
of a [ADDRESS_419597] PGx sample at Baseline.  May be 
collected later during the study if necessary.Columbia Suicide Severity Rating Scale 
(eC-SSRS) iX X X X X X X
HIVTSQ(s) i X X X
HIVMQ X 
Clinical Chemistry 
and HematologyX X X X X X X
Pregnan cy Testingj S U S S S S S
HIV-1 RNA and sample for storage k X X X X X X X
CD4+ and CD8+ X X X X X X
Urinalysis X X X
Fasting Lab Assessments:  Glucose, 
Cholesterol (Total, HDL and LDL) and 
Triglycerides lX X X
Hepatitis B (HBsAg) an d Hepatitis C 
(anti-HCV Ab), HLA -B*5701X
PT/PTT/INR X X
PGx m X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
284Procedures  for Induction Screening 
Period aBaseline / 
Week ( -
20) Week 
(-16) Week
(-12)Week
(-8)Week
(-4)WD Notes 
PK Sample 
(S)torageS
n. Instruct subjects to continue to take the Induction 
regimen (inc luding RPV) through Day 1 of the 
Maintenance Period.  Subjects should be 
reminded to take the Day 1 dose in the clinic for 
PK sampling and return the PK diary.  The PK 
diary will be completed by [CONTACT_339320] G SK744 + 
ABC/3TC arm.
o. Remind subjects of the potential change in study 
treatment and visit frequency beginning at Day 1.Study Treatment Dispensation X X X X X n
Add RPV 
Study Treatment Accountability
(pi[INVESTIGATOR_10685])X X X X X
PK Diary Dispensation Xn
Subject Visit Reminder Contact X X X X X X o X
Subject Contact [CONTACT_339265] X X X X X X
Follow Up Visit:  Conduct approximately [ADDRESS_419598] on -study visit.  This visit may be conducted by [CONTACT_756]. 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
285Time and Events Table –Maintenance Period for IM Regimen ([COMPANY_004]744 LA +TMC278 LA  Q8W)
Procedures
For Maintenance –
Q8W   regimenD1 W
1W
4W
8W
12W
16W
20W
24W 
25W
28W
32W
36W
40W 
41W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD
p, q
Verify Eligibility X
Randomization X
Symptom Directed 
PE, ISR & Medical 
Assessment aX X X X X X X X X X X X X X X X X X X X X X X 
and 
smoking 
status
Vital Signs
(BP, HR) bX X X X X X X X X X X X X X
Weight and BMI X X X X X
ECG c Xpre X X X X X X X X X X
HIV Associated 
Conditions, AE and 
SAE As sessment, 
Con  Meds X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
ISR Diary 
(D)aily/(E)pi[INVESTIGATOR_49564]) dD E E E E E E D E E E E D E E E E E E E E E E
Exercise Habit 
Assessment eX X X
eC-SSRSf X X X X X X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
286Procedures
For Maintenance –
Q8W   regimenD1 W
1W
4W
8W
12W
16W
20W
24W 
25W
28W
32W
36W
40W 
41W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD
p, q
HIVTSQ(s) g Xpre X X X X X
HIVTSQ(c)g X X
HIVMQ g X X X X X g
Clinical Chemistry 
and HematologyX X X X X X X X X X X X X X X X X X X X X
Pregnancy Test 
(U)rine/(S)erum hU U U U U U U U U U U U U U U U U U U S
HIV-1 RNA &
sample for storageiX X X X X X X X X X X X X X X X X X X X
CD4+/ CD8+ X X X X X X X X X X X
Urinalysis X X X X X X
Fasting:  Glucose,  
Cholesterol (Total, 
HDL and LDL) and 
Triglycerides jX X X X X X X
PT/PTT/INR X X X X X
PK Sample 
(S)torage kX X X X X X X X X X X X X X X X S S S S S S S
Study Treatm ent 
Administration mX l X X X X X X X X X X X X Xn 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
287Procedures
For Maintenance –
Q8W   regimenD1 W
1W
4W
8W
12W
16W
20W
24W 
25W
28W
32W
36W
40W 
41W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD
p, q
Visit Reminder 
ContactX X X X X X X X X X X X X X X X X X X X X X X X X X XoX X
Subject Contact 
[CONTACT_339266] X X X X X X X X X X X X X X X X X X X X X X X X X X X X
D=Day     W=Week    Pre=Pre -dosing   PE = Physical Exam  BMI=Body Mass Index
Gray shading indicates telephone safety assessments that will include interviewing the 
subject for adverse events, concomitant medications, HIV associated conditions and any 
other issues including injection site reactions.
a) Physical exams should be conducted as part of normal routine clinical care but data will not 
be collected in the eCRF. Medical assessments include any decisions the study staff must 
make for subject management and/or care of the subject.  See Section 6.10.1 for ISR 
assessment requirements.
b) Measure vital signs after about [ADDRESS_419599] in a semi -supi[INVESTIGATOR_2547].
c) 12-Lead ECG – Conduct pre -dose at Day 1.  At all other visits, the ECG may be done at any 
time during the visit.
d) Subjects will complete a (D)aily diary of injection site reactions from Day [ADDRESS_419600] experiences a reaction ((E)pi[INVESTIGATOR_49564]).  Su bjects will be 
dispensed a new diary at each visit. Diary data will be entered into the eCRF.
e) Subject’s exercise habits will be assessed daily from Day 1 to Week 1, from Week 24 to 
Week 25 and again from Week 40 to Week 41.  Assessments will include type a nd duration 
of cardiovascular exercise and duration of any strength or other strenuous exercises. This 
information will be collected via the daily ISR diary and entered into the eCRF.
f) Preferably completed at the beginning of the visit. 
g) Conduct the HIVTSQ( s) at Day 1 pre- dosing; at all other visits conduct post -dosing.  
Conduct the HIVTSQ(c, WD) at WD ONLY if the subject WD between Week [ADDRESS_419601] injection.
h) Women of childbearing potential only.  A ( -) urine pregnancy test is req uired prior to any 
injection and as required by [CONTACT_339267] a treatment interruption. A positive urine 
test should be confirmed with a stat serum test.  If positive, subject will need to be WD.
i) Plasma for storage samples collected for possible an alyses, back -up in case samples are 
lost or damaged in transit to lab, for geno/pheno analyses and virologic failures.
j) Fast overnight; however, a minimum of a [ADDRESS_419602] is acceptable.k) Take PK samples pre -dose except Weeks 1, 12, 20, 25, 28, 36, 41 and 44 which can 
be taken at any time during the visit.  Day 1 PK sample should be taken after review of 
PK diary and pre -dose of [COMPANY_004]744+ABC/3TC+RPV.  A second Day [ADDRESS_419603] injection.
l) Subjects should take [COMPANY_004]744+ABC/3T C+RPV on Day 1 in the clinic prior to PK 
sampling and injections should be administered within 2 hours of this where possible.  
m) Subjects will take final dose of Induction regimen in the clinic at Day 1 and begin 
injections.   Day 1 injections are 2 x [COMPANY_004]7 44 LA 400 mg IM + 1 x TMC278 LA 900 mg 
IM.    Week 4 injection is 1 x [COMPANY_004]744 LA 600 mg IM (no TMC278 LA).  At Week 8 and 
Q8W, injections are 1 x [COMPANY_004]744 LA 600 mg IM + 1 x TMC278 LA 900 mg IM.  If 
possible, injections should be spaced approximately 2 cm fro m one another and from 
the site of any previous injection and or any injection site reaction.  Bring TMC278 LA 
to approximately room temperature prior to injecting.  Time and location of injection 
(right or left) as well as needle length used will be colle cted in the eCRF.  IM dosing is 
expected to occur during the week in which the subject’s projected visit falls (as 
according to the Day 1 visit).  An additional (+ or -) 7 day window is allowable for 
IM dosing but not preferred.  All decisions regarding do se interruption/ 
resumption must be discussed with the medical monitor in advance.  
n) Subjects will receive the selected Extension dosing regimen (either Q8W or Q4W) at 
this visit.  If switching to Q4W, injections are 1 x [COMPANY_004]744 LA 400 mg IM + 1 x TMC278 
LA600 mg IM.  Subjects may immediately begin the new regimen at Week 96.
o) Remind subjects of the potential change in study treatment and visit frequency 
beginning at Week 96.
p) Subjects who WD must enter Long -Term Follow Up (see Section 3.2.6) instead of 
compl eting the WD visit.  If they cannot enter Long -Term Follow -Up complete WD and 
Follow Up assessments.
q) Follow Up Visit:  Conduct approximately [ADDRESS_419604] on -study visit.  This visit may be conducted by [CONTACT_648]. 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
288Time and Events Table –Maintenance Period for IM Regimen ([COMPANY_004]744 LA +TMC278 LA  Q4W)
Procedures
For Maintenance –
Q4W   regimenD1 W
1W
4W
8W
12W
16W
20W
24W 
25W
28W
32W
36W
40W 
41W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD
p, q
Verify Eligibility X
Randomization X
Symptom Directed 
PE, ISR & Medical 
Asses sment aX X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
and 
smoking 
status
Vital Signs
(BP, HR) bX X X X X X X X X X X X X X
Weight and BMI X X X X X
ECG c Xpre X X X X X X X X X X
HIV Associated 
Conditions, AE and 
SAE Assessment, 
Con  Meds X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
ISR Diary 
(D)aily/(E)pi[INVESTIGATOR_49564]) dD E E E E E E D E E E E D E E E E E E E E E E E E E E E E
Exercise Habit 
Assessment eX X X
eC-SSRSf X X X X X X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
289Procedures
For Maintenance –
Q4W   regimenD1 W
1W
4W
8W
12W
16W
20W
24W 
25W
28W
32W
36W
40W 
41W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD
p, q
HIVTSQ(s) g Xpre X X X X X
HIVTSQ(c)g X X
HIVMQ g X X X X X g
Clinical Chemistry 
and HematologyX X X X X X X X X X X X X X X X X X X X X
Pregnancy Test 
(U)rine/(S)erum hU U U U U U U U U U U U U U U U U U U U U U U U U S
HIV-1 RNA &
sample for storageiX X X X X X X X X X X X X X X X X X X X
CD4+/ CD8+ X X X X X X X X X X X
Urinalysis X X X X X X
Fasting:  Glucose,  
Cholesterol (Total, 
HDL and LDL) and 
Triglycerides jX X X X X X X
PT/PTT/INR X X X X X
PK Sample 
(S)torage kX X X X X X X X X X X X X X X X S S S S S S S
Study Treatment 
Administration mX l X X X X X X X X X X X X X X X X X X X X X X X Xn 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
290Procedures
For Maintenance –
Q4W   regimenD1 W
1W
4W
8W
12W
16W
20W
24W 
25W
28W
32W
36W
40W 
41W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD
p, q
Visit Reminder 
ContactX X X X X X X X X X X X X X X X X X X X X X X X X X XoX X
Subject Contact 
[CONTACT_339266] X X X X X X X X X X X X X X X X X X X X X X X X X X X X
D=Day     W=Week    Pre=Pre -dosing   PE = Physical Exam  BMI=Body Mass Index
a) Physical exams should be conducted as part of normal routine clinical care but data will not 
be collected in the eCRF. Medical assessme nts include any decisions the study staff must 
make for subject management and/or care of the subject.  See Section 6.10.1 for ISR 
assessment requirements.
b) Measure vital signs after about [ADDRESS_419605] in a semi -supi[INVESTIGATOR_2547].
c) 12-Lead ECG – Conduct p re-dose at Day 1.  At all other visits, the ECG may be done at any 
time during the visit.
d) Subjects will complete a (D)aily diary of injection site reactions from Day [ADDRESS_419606] experiences a reaction ((E)pi[INVESTIGATOR_49564]).  Subjects will be 
dispensed a new diary at each visit. Diary data will be entered into the eCRF.
e) Subject’s exercise habits will be assessed daily from Day 1 to Week 1, from Week 24 to 
Week 25 and again from Week 40 to Week 41.  Assessments will include type and duration 
of cardiovascular exercise and duration of any strength or other strenuous exercises. This 
information will be collected via the daily ISR diary and e ntered into the eCRF.
f) Preferably completed at the beginning of the visit. 
g) Conduct the HIVTSQ(s) at Day 1 pre -dosing; at all other visits conduct post -dosing.  
Conduct the HIVTSQ(c, WD) at WD ONLY if the subject WD between Week [ADDRESS_419607] injection.
h) Women of childbearing potential only.  A ( -) urine pregnancy test is required prior to any 
injection and as required by [CONTACT_339267] a treatment interruption. A positive urine 
test should be confirmed with a stat serum test. If positive, subject will need to be WD.
i) Plasma for storage samples collected for possible analyses, back- up in case samples are 
lost or damaged in transit to lab, for geno/pheno analyses and virologic failures.
j) Fast overnight; however, a minimum of a [ADDRESS_419608] is acceptable.k) Take PK samples pre -dose except Week 1, Week 25 and Week 41 which can be 
taken at any time during the visit.  Day 1 PK sample should be taken after review of PK 
diary and pre- dose of [COMPANY_004]744+ABC/3TC+RPV.  A second Day [ADDRESS_419609] injection.
l) Subjects should take [COMPANY_004]744+ABC/3TC+RPV on Day 1 in the clinic prior to PK 
sampling and injections should be administered within 2 hours of this where possible.  
m) Subjects will take final dose of Induction r egimen in the clinic at Day 1 and begin 
injections.   Day 1 injections are 2 x [COMPANY_004]744 LA 400 mg IM + 1 x TMC278 LA 600 mg 
IM.  At Week 4 and Q4W, injections are 1 x [COMPANY_004]744 LA 400 mg IM + 1 x TMC278 LA 
600 mg IM.  If possible, injections should be spaced ap proximately 2 cm from one 
another and from the site of any previous injection and or any injection site reaction.  
Bring TMC278 LA to approximately room temperature prior to injecting.   Time and 
location of injection (right or left) as well as needle leng th used will be collected in the 
eCRF.  IM dosing is expected to occur during the week in which the subject’s 
projected visit falls (as according to the Day 1 visit).  An additional (+ or - ) 7 day 
window is allowable for IM dosing but not preferred.  All decisions regarding 
dose interruption/ resumption must be discussed with the medical monitor in 
advance. 
n) Subjects will receive the selected Extension dosing regimen (either Q8W or Q4W) at 
this visit.  If switching to Q8W, no loading dose is necessary.  In jections are 1 x 
[COMPANY_004]744 LA 600 mg IM + 1 x TMC278 LA 900 mg IM.
o) Remind subjects of the potential change in study treatment and visit frequency 
beginning at Week 96.
p) Subjects who WD must enter Long -Term Follow Up (see Section 3.2.6) instead of 
completing th e WD visit.  If they cannot enter Long -Term Follow -Up complete WD and 
Follow Up assessments.
q) Follow Up Visit:  Conduct approximately [ADDRESS_419610] on -study visit.  This visit may be conducted by [CONTACT_648]. 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
291Time and Events Table –Maintenance Period for Oral Regimen ([COMPANY_004]744+A BC/3TC)
Procedures
For Maintenance 
–ORAL regimenD1 W
4W
8W
12W
16W
20W
24W
28W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96W 
100mW
102mW
104mWD q
Verify Eligibility X X l X 
l, n
Randomization X
Symptom 
Directed PE & 
Medical 
Assessment aX X X X X X X X X X X X X X X X X X X X X X X and 
smoking 
status
Vital Signs
(BP, HR) bX X X X X X X X X X X X X X X X
Weight and BMI cX X X X X X
ECG d X
preX X X X X X X X X X X X
preX
HIVAssociated 
Conditions, AE 
and SAE 
Assessment, Con  
Meds X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
PK Diary 
(D)ispensation 
and (R)eview eR D R D R
eC-SSRSf X X X X X X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
292Procedures
For Maintenance 
–ORAL regimenD1 W
4W
8W
12W
16W
20W
24W
28W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96W 
100mW
102mW
104mWD q
HIVTSQ (s) g X
preX X X X X
HIVTSQ(c)g X X
HIVMQ g X X X X X g
Clinical 
Chemistry and 
HematologyX X X X X X X X X X X X X X X X X X X X X X X
Pregnancy Test 
(S)erum/(U)rine hS S S S S S S S S S S S S S S S S S S S S U S
HIV-1 RNA &
sample for 
storage iX X X X X X X X X X X X X X X X X X X X n X X X
CD4+/ CD8+ X X X X X X X X X X X X X
Urinalysis X X X X X X X
Fasting:  
Glucose, Insulin, 
Cholesterol 
(Total, HDL and 
LDL) and 
Triglycerides jX X X X X X X X
PT/PTT/INR X X X X X X
PK Sample k X X X S S X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
293Procedures
For Maintenance 
–ORAL regimenD1 W
4W
8W
12W
16W
20W
24W
28W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96W 
100mW
102mW
104mWD q
Study Treatment 
Dispensation and 
Accountability oX X X X X X X X X X X X X X X X X X Xm X X
Add
RPVX
Add 
injection
Visit Reminder 
ContactX X X X X X X X X X X X X X X X X X X X X X X X
pXm,p X p X p X p X
Subject Contact 
[CONTACT_339266] X X X X X X X X X X X X X X X X X X X X X X X Xm X X X X
D=Day     W=Week    Pre=Pre -dosing  PE = Physical Exam   BMI=Body Mass Index
Gray shading indicates telephone safety assessments that will include interviewing the subject 
for adverse events, concomitant medications, HIV associated conditions and any other issues 
including compliance. 
a. Physical exams should be conducted as part of normal routine clinical care but data will 
not be collected in the eCRF. Medical assessments include any decisions the study staff 
must make for subject management and/or care of the subject.
b. Measure vital signs after about [ADDRESS_419611] in a semi -supi[INVESTIGATOR_2547].
c. BMI collected at Week 104 only.
d. 12- Lead ECG – Conduct pre -dose at Day [ADDRESS_419612] 2 –[ADDRESS_419613]’s last dose is not within window.  Visi t may need 
to be rescheduled.
f. Preferably completed at the beginning of the visit.  
g. Conduct the HIVTSQ(s) at Day [ADDRESS_419614] the HIVTSQ(c, WD) at WD ONLY if the subject WD between Week [ADDRESS_419615] the HIVMQ preferably at the beginning of the visit, but may be 
completed at any time during the visit.
h. Women of childbearing potential only. A ( -) urine pregnancy test is required prior to any 
injection and as required by [CONTACT_339321] r after a treatment interruption. A positive urine 
test should be confirmed with a stat serum test.  If positive, subject will need to be WD.i. Plasma for storage samples are collected for possible future analyses, as back -up in 
case of lost or damaged in t ransit to the lab and for geno/pheno analyses for virologic 
failures
j. Fast overnight; however, a minimum of a [ADDRESS_419616] dose of IP 
taken.  Subjects will take their do se of IP in the clinic at PK visits. S=Storage
l. Assess subject’s willingness to continue on to the Extension Period.  If not continuing 
into the Extension Period, this is the subject’s last study visit.
m. For subjects continuing into the Extension Period only .  
n. The Week [ADDRESS_419617] be <50 c/mL to be eligible to continue into the 
Extension Period.  See Section [IP_ADDRESS].    Subjects ineligible for Extension will end their 
study participation at Week 102 (no withdrawal visit needed).
o. Subjects will d iscontinue RPV at Day 1 and begin taking 1 x [COMPANY_004]744 + 1 x ABC/3TC 
tablet once daily. At Week 96 and Week 100, while awaiting eligibility for Extension, 
subjects will continue their [COMPANY_004]744+ABC/3TC regimen.  At Week 102, subjects eligible 
to enter the Extens ion Period will add once daily RPV to their [COMPANY_004]744+ABC/3TC 
regimen and continue to take [COMPANY_004]744+ABC/3TC +RPV once daily through Week 104.  
At Week 104, subjects will take final dose of [COMPANY_004]744+ABC/3TC+RPV in the clinic and 
begin the selected IM regimen (Q8W or Q4W).  See Section 5.1.6 for IM dosing 
administration as loading doses are required.  
p. Remind subjects of the change in study and assessments for eligibility into Extension.
q. Follow Up Visit:  Conduct approximately [ADDRESS_419618] on -study visit.  This visit 
may be conducted by [CONTACT_756]. 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
294Time and Events Table –Extension Period if Q8W is Selected
Procedures for 
Extension if 
Q8W is SelectedW 
104 aW 
108b
From Oral 
Arm OnlyW 
112W 
120W 
128W
136W 
144W
152W
160W
168W
176W 
184 cW 
192 cW 
200 cWD 
n, oNotes
Symptom 
Directed 
Physical Exam, 
ISR and 
Medical 
Assessment dX X X X X X X X X X X X X X XSee footnote “b” for continuation of visit s chedule 
after Week 200.  Continue until either locally 
approved and commercially available, the subject 
no longer derives clinical benefit or meets a 
protocol -defined reason for discontinuation or 
until development is terminated.
a. Subjects switching from t he oral regimen will 
complete Week 104 visit as per the Maintenance 
T&E Section 6.4.
b. Week [ADDRESS_419619] 
in a semi -supi[INVESTIGATOR_2547].
f. Can be done at any time during the visit.
g. A (-) urine pregnancy test is required prior to any 
injection and as required by [CONTACT_339322] a treatment interruption. A (+) urine test 
should be confirmed with a stat serum test.  If 
(+), subject will need to be WD.Vital Signs
(BP, HR)eX X X X X X X X
Weight & BMI X X X X X X X X
HIV Associated 
Conditions, AE 
and SAE 
Assessments, 
Con MedsX X X X X X X X X X X X X X X
12-Lead ECG f X X X X X X X X X
Clinical 
Chemistry and 
HematologyX X X X X X X X X
Pregnancy 
Testing
(U)rinegU U U U U U U U U U U U U U U 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
295Procedures for 
Extension if 
Q8W is SelectedW 
104 aW 
108b
From Oral 
Arm OnlyW 
112W 
120W 
128W
136W 
144W
152W
160W
168W
176W 
184 cW 
192 cW 
200 cWD 
n, oNotes
HIV-1 RNA and 
sample for 
storage hX X X X X X X Xh. Plasma for storage samples are collected for 
possible future analyses, back -up in cases of 
loss/damage in transit and geno/pheno analyses 
for virologic failures.
i. Fast overnight; minimum of a [ADDRESS_419620] 
experiences a reaction ((E)pi[INVESTIGATOR_49564]).  Subje cts 
will be dispensed a new diary at each visit. Diary 
data will be entered into the eCRF.
l. Q8W Injections are 1 x [COMPANY_004]744 LA 600 mg IM 
+ 1 x TMC278 LA 900 mg IM.  If possible, 
injections should be spaced approximately 2 cm 
from one another and from the sit e of any 
previous injection and or any injection site 
reaction.  Bring TMC278 LA to approximately 
room temperature prior to injecting.   Time and 
location of injection (right or left) as well as 
needle length used will be collected in the eCRF.  
IM dosing is expected to occur during the 
week in which the subject’s projected visit 
falls (as according to the Day 1 visit).  An 
additional (+ or - ) 7 day window is allowable 
for IM dosing but not preferred.  All decisions 
regarding dose interruption/ resumption 
must be discussed with the medical monitor 
in advance .
m. Subjects switching from the oral arm will 
receive their 2ndloading dose injection of 
1 x [COMPANY_004]744 LA 600 mg (no TMC278 LA).CD4+ X X X X X X X X
Urinalysis X X X X X X X X
Fasting:  
Glucose, 
Cholesterol 
(Total, HDL and 
LDL) and 
Triglycerides iX X X X X X X X
PT/PTT/INR X
PK Sample 
(S)torage jS S S S S S S S
ISR Diary 
Dispensation kE E E E E E E E E E E E E E E 
review
Study Treatment 
Administration lX a X m X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419621] ~[ADDRESS_419622] 
Detai l 
ConfirmationX X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
297Time and Events Table –Extension Period if Q4W is Selected
Procedures for 
Extension if Q4W is 
SelectedW 
100aW 
104aW 
108W 
112W
116W 
120W
124W 
128bW 
132bW 
136bW 
140bWD 
l, mNotes
Symptom Directed 
Physical Exam, ISR and 
Medical Assessment cX X X X X X X X X X X XSee footnote “b” for continuation of visit schedule after 
Week 140.  Continue until either locally approved and 
commercially available, the subject no longer derives 
clinical benefit or meets a protocol- defined reason for 
discontinuation or until development is terminated. 
a. Subjects switching from the oral regimen will complete 
Week 100 and 104 visits as per the Maintenance T&E 
Section 6.4.
b. Continue this pattern for visits fo r the remainder of the 
study.  For example, Week [ADDRESS_419623] in a semi -
supi[INVESTIGATOR_2547].
e. Can be done at any time during the visit.
f. A (-) urine pregnancy test is required prior to any injection 
and as required by [CONTACT_339267] a treatment 
interruption. A (+) urine test should be confirmed with a stat 
serum test.  If (+), subj ect will need to be WD.
g. Plasma for storage samples are collected for possible 
future analyses, back -up in cases of loss/damage in transit 
and geno/pheno analyses for virologic failures.Vital Signs (BP, HR)d X X X X X
Weight & BMI X X X X X
HIV Associated 
Conditi ons, AE and SAE 
Assessments, Con 
MedsX X X X X X X X X X X X
12-Lead ECG e X X X X X
Clinical Chemistry and 
HematologyX X X X X X
Pregnancy Testing
(U)rinefU U U U U U U U U U U U
HIV-1 RNA and sample 
for storage gX X X X X X
CD4+ X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419624] overnight; minimum of a [ADDRESS_419625] 
experiences a reaction ((E)pi[INVESTIGATOR_49564]).  Subjects will be 
dispensed a new diary at each visit. Diary data will be 
entered into the eCRF.
k. Q4W Injections are 1 x [COMPANY_004]744 LA 400 mg IM + 1 x 
TMC278 LA 600 mg IM.  If possible, injections should be 
spaced approximately 2 cm from one another and from the 
site of any previous injection and or any injection site 
reaction.  Bring TMC278 LA to approximately room 
temperature prior to injecting.   Time and location of 
injection (right or left) as well as needle length used will be 
collected in the eCRF.  IM dosing is expected to occur 
during the week in which the subject’s projected visit 
falls (as according to the Day 1 visit).  An additional
(+ or -) 7 day window is allowable for IM dosing but not 
preferred.  All decisions regarding dose interruption/ 
resumption must be discussed with the medical 
monitor in advance .
l. Or Long -Term Follow Up
m. Follow Up Visit -Conduct ~[ADDRESS_419626] on -study 
visit.  May be conducted by [CONTACT_756].Fasting:  Glucose, 
Cholesterol (Total, HDL 
and LDL) and 
Triglycerides hX X X X X
PT/PTT/INR X
PK Sample 
(S)torage  iS S S S S S
ISR Diary Dispensation jE E E E E E E E E E E E 
review
Study Treatment 
Administration kXa Xa X X X X X X X X X
Subject Visit Reminder 
ContactX X X X X X X X X X X
Subject Contact [CONTACT_339270] X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
299Time and Events Table –Long -Term Follow Up Period
Procedures for Long -Term Follow Up Month [ADDRESS_419627] one dose of [COMPANY_004]744 LA and / or 
TMC278 LA.
a) The start of the [ADDRESS_419628] [COMPANY_004]744 LA and/or TMC278 LA dose.
b) Women of childbearing potential only.  S = Serum
c) Fast o vernigh t; however, a minimum of a [ADDRESS_419629] 
is acceptable.
d) Women of childbearing potential should continue to 
receive counselling on the need to use adequate 
contraception for the entirety of the Long -Term 
Follow -Up Period. 
e) Investigators must discuss choice of HAART 
regimen and timing of initiation with the medical 
monitor before initiating.  This regimen is not 
provided by [CONTACT_339319].HIV-1 RNA X X X X X X
CD4+ X X X X X X
Plasma for Storage X X X X X X
PK Sample for Storage X X X X X X
Clinical Chemistry and Hematology X X X X X X
Pregnancy Testing b S S S S S S
Urinalysis X X X
Fasting:  Glucose, Cholesterol (Total, 
HDL and LDL) and TriglyceridesX X
PT/PTT/INR X X
Contraception Cou nselling d X X X X X X
HAART Dispensation e X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
300Section 6.8.1 –Screening
Revised to (changes struck through and underlined).
All clinical and laboratory assessments of eligibility  must be performed and reviewed 
within [ADDRESS_419630] 
number. Subjects who are enrolled into the trial and subsequently  withdrawn from the 
study  for any  reason may not be rescreen ed.
At Screening, samples for HIV -1 genot ypic and phenotypic resistance testing and plasma 
HIV-1 RNA measurement will be obtained.
Known moderate or severe hepatic impairment (Class B or C) is exclusionary.  Child -
Pugh classification will be assessed at th e Screening visit in subjects with a concern for 
hepatic impairment (see Section 11.2).
Section 6.8.2 –Baseline
Revised to (changes struck through and underlined).
Subjects will have “Baseline” assessments completed at either Week ( -24) or Week ( -16) 
depe nding on the length of the beginning of the Induction Period in which they  were 
randomized.
Any changes to the eligibility  parameters must be assessed and any  results required must 
be available and reviewed prior to randomization enrollment (e.g. urine preg nancy  test 
for women of child bearing potential).
HIV-[ADDRESS_419631] be available prior to the Baseline visit.
Section 6.9.3 -HIV A ssociated Conditions
Revised to (changes underlined).
HIV-associated conditions will be recorded as per Time and Events schedule (Section 6).  
HIV-associated conditions will be assessed according to the 1993 CDC Revised  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
301Classification Sy stem for HIV Infection in Adults (see Section 11.1).  Indicators of 
clinical disease progression are defined as:
CDC Category  A at enrollment Category  B event;
CDC Category  A at enrollment Category  C event;
CDC Category  B at enrollment Category  C event;
CDC Category  C at enrollment New Category  C Event;
CDC Categ ory A, B or C at enrollment  Death.
Section 6.10.1 -Clinical evaluations
Revised to (changes struck through and underlined).
The following clinical evaluations will be performed according to the Time and Events 
schedule (see Section 6):
Pregnancy  testing .  A negative urine pregnancy  test is required prior to initiation of 
IP, an y dose of [COMPANY_004]744 LA or TMC278 LA or prior to reinitiating therapy after an 
interruption of [COMPANY_004]744 LA or TMC278 LA > 7 day as required b y the medical 
monitor following a treatment interruption(s).
Injection Site Reactions (ISRs) will be assessed for the following clinically  as well as 
patient -reported by [CONTACT_14662] a subject diary :
Daily  fromDay 1 – 7, from Week 24 –Week 25 and again dail y from 
Week 2840 to Week 2941:  Pain, tenderness, pruritis, warmth, bruising, 
discoloration, infections, rash, ery thema, swelling, induration, and nodules 
(granulomas or cy sts). 
Section 6.10.2 –Laboratory  Assessments
Removed collection of  Phosphate (inorganic phosphorus) and changed reporting of 
Creatinine clearance and CD8+ cells from Week 24 to Week 32.
Section 6.10.3 -Liver Chemistry  Stoppi[INVESTIGATOR_339214] (changes struck through and underlined).
Liver chemistry  threshold stoppi[INVESTIGATOR_339215] y
and to evaluate liver event etiology  during administration of I P and the follow -upperiod. 
IP will be stopped if an y of the following liver chemistry  criteria are met:
ALT ≥3xULN and bilirubin ≥2xUL N (>35% direct bilirubin, bilirubin 
fractionation required) .
NOTE: serum bilirubin fractionation should be performed if testing is available. If testing 
is unavailable, record presence of detectable urinary  bilirubin on dipsti ck, indicating 
direct bilirubin elevations and suggesting liver injury .  If testing is unavailable and a  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419632] meets the criterion of total bilirubin 2xULN, then the event meets liver stoppi[INVESTIGATOR_31732].
ALT ≥8xULN.
ALT ≥3xULN (if Baseline ALT is < ULN) with sy mptoms or worsening of 
acute hepatitis or hy persensitivity  such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, or eosinophilia, OR;
ALT ≥3x Baseline ALT with sy mptoms or worsening of acute hepatitis or 
hypersens itivity  such as fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash, or eosinophilia;
ALT ≥3xULN with acute hepatitis sy mptoms or hy persensitivity  if Baseline 
ALT≤UL N OR ALT ≥3 fold increase from Baseline with acute hepatitis 
symptoms or hy persensitivity  if Baseline ALT>ULN.
ALT ≥5xULN and <8xULN that persists ≥2 weeks (with bilirubin <2 UL N & no 
signs or s ymptoms of acute hepatitis or hy persensitivity ).
ALT ≥5xULN but <8xULN and cannot be monitored weekly  for >2 weeks.
NOTE: if serum bilirubin fractionation is not immediatel y available, withdraw study drug 
for that subject if ALT 3xULN andbilirubin 2xULN. Serum bilirubin fractionation 
should be performed if testing is available. If testing is unavailable, sites should evalua te 
the presence of detectable urinary bilirubin on dipstick , which indicates direct 
bilirubin elevations and suggests liver injury .
Liver Chemistry Stoppi[INVESTIGATOR_2121], Subject Management
Subjects who develop ALT ≥5xULN must be followed weekly  until resolution or
stabilization (ALT <5xULN on 2 consecutive evaluations).
When any of the liver chemistry stoppi[INVESTIGATOR_339175], do the following:
Immediately  hold I P.  
Report the event to the medical monitor within 24 hours of learning its 
occurrence (Section 6.10.13 , Section 6.10.15 ).
Complete the liver event eCRF and SAE eCRF, where applicable, (see 
Section 6.10.13 ).
Complete the liver imaging and/or liver biopsy  eCRFs if these tests are 
performed.
Perform liver e vent follow up assessments (described below), and monitor the 
subject until liver chemistries resolve, stabilize, or return to Baseline values as
described below.
Make every  reasonable attempt to have subjects return to clinic within 24 hours 
forrepeat liver chemistries, liver event follow up assessments (see below), and 
close monitoring. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
303A specialist or hepatology consultation is recommended.
Monitor subjects twice weekl y until liver chemistries (ALT, AST, alkaline
phosphatase, bilirubin) resolve, stabili ze or return to within Baseline values.
Make every  attempt to carry  out the liver event follow up assessments described below:
Viral hepatitis serology  including:
oHepatitis A IgM antibody;
oHBsAg and Hepatitis B Core Antibody  (IgM);
oHepatitis C RNA;
oHepatit is E IgM antibody;
Cytomegalovirus IgM antibody ;
Epstein -Barr viral capsid antigen IgM antibod y (or if unavailable, obtain 
heterophile antibody  or monospot testing);
Syphilis screening;
Drugs of abuse screen including alcohol;
Serum acetaminophen test (APA P adduct test). The site must contact [CONTACT_339277]. Please refer to the Quest L aboratory  Manual.
Hepatitis E IgM antibody;
Blood sample for pharmacokinetic (PK) anal ysis, obtained within [ADDRESS_419633] the date/time of t he PK blood sample draw and the date/time 
of the last dose of investigational product prior to blood sample draw on the 
eCRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. I f the date/time of the last dose canno t be approximated OR a 
PK sample cannot be collected in the time period indicated above, do not obtain 
a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_23915].
Serum creatine phosphokinase (CPK) and lactate dehy drogenase (LDH);
Fractionat e bilirubin, if total bilirubin is greater than 1.5xUL N;
Obtain complete blood count with differential to assess eosinophilia;
Anti- nuclear antibody , anti -smooth muscle antibody , and Ty pe 1 anti -liver 
kidney microsomal antibodies;
Liver imaging (ultrasound , magnetic resonance, or computerized tomography ) to
evaluate liver disease;
Record the appearance or worsening of clinical symptoms of hepatitis, or
hypersensitivity , fatigue, decreased appetite, nausea, vomiting, abdominal pain,
jaundice, fever, or rash as relevant on the AE report form;
Record use of concomitant medications, acetaminophen, herbal remedies, other 
over the counter medications, or putative hepatotoxins, on the concomitant  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419634] unless an exemption has been approved b y the ViiV Safet y and 
Labeling Commit tee (VSLC).  The guideline for Rechallenge/Restart approved by  [CONTACT_339323] C, which is maintained as a separate document (See Section 11.4, Appendix 4), must 
be followed.
Drug Restart/Rechallenge Following Liver Events that are Possibly Related to IP
Approval b y the VSLC for drug restart can be considered where:
The subject is receiving compelling benefit, benefit of drug restart exceeds risk, 
and no effective alternative therap y is available.  Ethics Committee or 
Institutional Review Board approval of drug rest art/rechallenge must be 
obtained, as required.
If the restart/rechallenge is approved b y the VSLC in writing, the subject must 
be provided with a clear description of the possible benefits and risks of drug 
administration, including the possibility  of recu rrent, more severe liver injury  or 
death.
The subject must also provide signed informed consent specificall y for the IP 
restart/rechallenge.  Documentation of informed consent must be recorded in the 
study  chart.
Study  drug must be administered at the dose specified by  [CONTACT_339279] C.
Subjects approved b y the VSL C for rechallenge of I P must return to the clinic 
twice a week for liver chemistry  tests for a minimum of one month and 
thereafter for as long as clinically  indicated and then laboratory  monitoring may  
resum e as per protocol.
Drug Restart Following Transient Resolving Liver Events Not Related to IP
Approval b y the VSLC for drug restart can be considered where:
Liver chemistries have a clear underl ying cause (e.g., biliary  obstruction, 
hypotension and liver chemistries have improved to normal or are within 
1.5 x baseline and AL T <3xULN).  Ethics Committee or Institutional Review 
Board approval of drug restart/rechallenge must be obtained, as required.
If restart of drug is approved by  [CONTACT_339279] C in writing, the subject must be 
provided with a clear description of the possible benefits and risks of drug 
administration, including the possibility  of recurrent, more severe liver injury  or 
death.
The subject must also provide signed informed consent specificall y for the 
restart.  Documentation of informed consent must be recorded in the stud y chart. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
305Study  drug must be administered at the dose specified by  [CONTACT_339279] C.
Subjects approved b y the VSLC for restarting IP must return to the clinic once a week for 
liver chemist ry tests for a minimum of one month and thereafter for as long as clinically  
indicated and then laboratory  monitoring may  resume as per protocol.  If protocol defined 
stoppi[INVESTIGATOR_339216], study  drug must be stopped.
See Section 11.4, Appendix 4 for further details.
Section [IP_ADDRESS] -Treatment Interruption Due to an A dverse Event
Revised to (changes struck through and underlined).
No toxicity -related dose reductions of IP will be allowed. IP and background NRTI s 
should be restarted as soon as medicall y appropriate; in general, this should be no longer 
than 14 day s after discontinuation (unless Grade [ADDRESS_419635]). Decisions 
regarding sequential reintroduction of IP or temporary  interruption of one or more but not 
all drugs within the ART regimen should be made with the understanding that these 
changes may  result in incomplete viral suppression and selection of resistant virus.  Any  
interruption in therap y during the Maintenance Period, oral dosing, of greate r than [ADDRESS_419636] be contact[CONTACT_339324] y, if therap y was resumed without prior approval (Section 5.7).  IM 
dosing is expected to occur during the week in which the subject’s projected visit 
falls (as according to the Day 1 visit).  An additional (+ or - ) [ADDRESS_419637] be discussed with the medical monitor prior to reinitiating IM IP (see Section 
5.7.2 ).
Section 6.10.11 -Injection Site Reaction Monitoring
Revised to (changes struck through and underlined).
Subjects on either IM regimen will be monitored closely  both clinicall y and by [CONTACT_339325]:
Pain, tenderness, pruritis, warmth, infections, rash, ery thema, swelling, 
induration, and nodules (granulomas or cy sts).  
Digital photographs will be documented where possible on all subjects who have an 
injection site reaction that is areeither serious orGrade [ADDRESS_419638] an injection site reaction 
considered serious, Grade 3 or above, or if clinically  significant and persistent bey ond 30 
days and others if the Investigator or Medical Monitor feels it is medically  necessary . 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
306Section [IP_ADDRESS] -Pregnancy  Testing
Women of childbearing potential must have a negative pregnancy  test at Screening, the 
first I nduction Period visit and prior to administration of each [COMPANY_004]744 LA and / or 
TMC278 L A injection.   Pregnancy  testing will also be conducted as per the Time and 
Events Table (see Section 6) and at an ytime during the trial when pr egnancy is suspected. 
Additionally , the medical monitor may  request that a pregnancy  test should also be 
performed in the event of a treatment interruption greater than [ADDRESS_419639] 
result is required to reinitiate [COMPANY_004]744 LA and / or TMC278 L A.  
Section 6.11 –Pharmacokinetics
Original text:
Plasma samples for determination of [COMPANY_004]744 and TMC278 concentration will be 
collected throughout the study .  Samples for determination of RPV will be protected from 
light until analyzed .
PK Sample Collecti on
Blood samples for evaluation of [COMPANY_004]744 (2mL  each) and TMC278 (3mL each) plasma 
PK will be collected from all subjects randomized to receive [COMPANY_004]744 LA + TMC278 L A 
for determination of [COMPANY_004]744 and TMC278 concentrations as described in Table 4.  All 
PK samples will be collected prior to LA dosing, except at Weeks [ADDRESS_419640] be recorded 
on the CRF.  Subjects will take their dose of oral IP in the clinic at PK visits. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
307Table 4 [COMPANY_004]744 and TMC278 Plasma Pharmacokinetic Sample Schedule
Group Analyte Week Sample Times Relati ve to Dose
LA [COMPANY_004]744 Day 1 (prior to LA and last 
oral Induction dose), 
Weeks: 1, 4, 8, 12, 16, 20, 
24, 28, 29, 32, 36, 40, 44 
and 48Pre-Dose:  Day 1, Weeks 4, 8, 12, 16, 
20, 24, 28, 32, 36, 40, [ADDRESS_419641] Dose:  Day [ADDRESS_419642] Dose:  Weeks 1, 29
TMC278 Day1 (prior to LA and last 
oral Induction dose), 
Weeks: 1, 4, 8, 12, 16, 20, 
24, 28, 29, 32, 36, 40, 44 
and 48Pre-Dose:  Day 1, Weeks 4, 8, 12, 16, 
20, 24, 28, 32, 36, 40, [ADDRESS_419643] Dose:  Day [ADDRESS_419644] Dose:  Weeks 1, 29
Oral 
(Control Arm 
only)[COMPANY_004]744 Day 1, Weeks: 24, 48 and 
96Pre-Dose:  Day 1, Weeks 24, 48 and 96
Additional [COMPANY_004]744 and TMC278 PK samples for storage will be collected at Weeks 52, 
56, 60, 64, 68, 72, 76, 80, 84, 88, 92 and 96 for subjects on [COMPANY_004]744 LA +TMC278 L A 
and at Months 1, 3, 6, 9 and 12 for subjects in the Long -Term Follow Up Period.  These 
samples may  be analy zed in case of protocol -defined virologic failure or to investigate 
any PK related issues (such as missing dose, missing sample, suspected non-adherence 
etc.).
Revised text:
Plasma samples for determination of [COMPANY_004] 1265 744 and TMC278 concentration will be 
collected throughout the Maintenance Period of the study .  Additional samples will be 
collected for storage during the Extension and Long- Term Follow Up Period.  Samples 
for determination of RPV will be protected from light until analyzed .
PK Sample Collection
Blood samples for evaluation of [COMPANY_004]1265 744 (2mL  each) and TMC278 (3mL  each) 
plasma PK will be collected from all subjects randomized to receive [COMPANY_004]744 L A + 
TMC278 L A for determination of [COMPANY_004] [ADDRESS_419645] date 
and time of the PK sample should be recorded in eCRF .
For subjects randomized to [COMPANY_004]744, pre-dose blood samples for evaluation of 
[COMPANY_004] 1265 744 (2mL  each) and TMC278 (3mL each) will be collected as described in 
Table 4. These samples must be co llected within the window of [ADDRESS_419646] be recorded on the e CRF.  Subjects will take their 
dose of oral IP in the clinic at PK visits. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
309Table 13 [COMPANY_004]744 and TMC278 Plasma Pharmacokinetic Sample Schedule
Group Analyte Week Sample Times Relative to Dose
IM [COMPANY_004]744 Day 1 (prior t o LA and 
last oral Induction 
dose), Weeks: 1, 4, 8, 
12, 16, 20, 24, 25, 28,  
32, 36, 40, 41, 44 and 
48Pre-Dose (Q8W) :  Day 1, Weeks 4, 8, 
16, 24, 32, 40 and 48
Pre-Dose (Q4W) :  Day 1, Weeks 4, 8, 
12, 16, 20, 24, 28, 32, 36, 40, [ADDRESS_419647] Dose :  Day [ADDRESS_419648] Dose:  Week 1, Week 
[ADDRESS_419649] Dose (Q8W):  Weeks 
12, 20, 28, 36 and 44
TMC278 Day1 (prior to LA and 
last oral Induction 
dose), Weeks: 1, 4, 8, 
12, 16, 20, 24, 25, 28, 
32, 36, 40, 41, 44 and 
48Pre-Dose (Q8W ):  Day 1, Weeks 4, 8, 
16, 24, 32, 40 and 48
Pre-Dose (Q4W) :  Day 1, Weeks 4, 8, 
12, 16, 20, 24, 28, 32, 36, 40, [ADDRESS_419650] Dose:  Day [ADDRESS_419651] Dose:  Week 1, Week 
[ADDRESS_419652] Dose (Q8W):  Weeks 
12, 20, 28, 36 and 44
Oral 
(Contro l Arm 
only)[COMPANY_004]744 Day 1, Weeks: 32 and
48Pre-Dose:  Day 1, Weeks 32 and 48
Additional [COMPANY_004] 1265 744 and TMC278 PK samples for storage will be collected pre-dose 
at Weeks  56,64, 72, 80, and 96 for subjects on [COMPANY_004]744 L A+TMC278 LA as per the 
Time and Events Table (see Section 6.2 and Section 6.3) and in the Extension Period (see 
Section 6.5 and Section 6.6).   Samples for storage will be also be collected at Week 96 
and 104 for subjects on [COMPANY_004]744+ABC/3TC and at Months 1, 3, 6, 9 and 12 for subjects 
in the L ong-Term Follow Up Period.  These samples may  be analy zed in case of 
protocol -defined virologic failure or to investigate any  PK related issues (such as missing 
dose, missing sample, suspected non -adherence etc.) . 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
310Section 6.14 –Health Outcomes
Revised to (c hanges struck through and underlined).
The HIVTSQ( s)will be administered at the following time points: 
Induction: Week -20 (- 16)in the 24 Week Induction Period and Week - 12 in the 
16 Week I nduction Period and Week (-4) (pre-dose if possible ) in both I nduction 
Periods
Maintenance:  pre -dose at Day  1and post -dose at Week [ADDRESS_419653] -dose (where 
possible in oral dosing arm) Week 8, Week 3224, Week 48 andWeek 96 
Withdrawal
The HIVTSQ(c) will be administered at the following time points:  
Maintenance:  Wee k 32
The HIVTSQ(c, WD) will be administered at the following time points:   
Withdrawal for subjects withdrawn between Week 8 and Week 32
HIVMQ will be administered at the following time points:
Induction: Week (-4)
Maintenance:  Week 8, Week 24 32 , Week 48, Week 96 & Withdrawal
oIM Regimen:  Complete post- injection
oOral Regimen:  Preferably completed at the beginning of the visit, but may 
be completed at an y time during the visit
Section 8.1 –Hypotheses
Revised to (changes struck through and underlined).
The study  is designed to evaluate the efficacy  and safet y ofa two -drug regimen consisting 
of [COMPANY_004]744 LA + TMC278 L A when both are administered as intramuscular injections 
every  4 weeks [COMPANY_004]744 LA 400 mg IM plus TMC278 L A 600 mg IM every  4 weeks and 
[COMPANY_004]744 L A 600 mg I M plus TMC278 L A 900 mg IM every  8 weeks, relative to 
[COMPANY_004]744 30 mg once daily  plus ABC/3TC once daily , through Week 24 32 of the 
Maintenance Period.
Section 8.2 -Sample Size A ssumptions
Original text: 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419654] the comparability  of [COMPANY_004]744 L A plus TMC278 L A two -
drug regimen to [COMPANY_004]744 30 mg once dail y plus ABC/3TC. The primar y comparison of 
interest will be performed using a Bay esian probability  model. If the posterior probability  
that the difference is greater than -10% is large (i.e., 90%), then sufficient statistical 
evidence has been provided for the positive outcome. A r esponse rate of 85% in the 
[COMPANY_004]744 L A plus TMC278 L A two -drug regimen (compared with an [COMPANY_004]744 plus 
ABC/3TC response rate of 95%) would result in a rejection of the null h ypothesis with a 
probability  of approximately  0.068 (t ypeI error). The given sample s ize is unlikely  to 
select a random sample that would falsel y conclude that [COMPANY_004]744 LA plus TMC278 L A 
two-drug regimen is comparable with [COMPANY_004]744 plus ABC/3TC if the response rates are 
truly  85% versus 95%, respectively . If the [COMPANY_004]744 L A plus TMC278 LA two -drug 
regimen yields an response rate of greater than 92%, then there is a high probability  of 
rejecting the null h ypothesis and correctl y concluding that [COMPANY_004]744 LA plus TMC278 L A 
two-drug regimen is at least as good as [COMPANY_004]744 plus ABC/3TC.
Historical response rates of dolutegravir, an integrase compound similar to [COMPANY_004]744, 
were used as reference for the oral control arm.  Response rates for dolutegravir plus 
ABC/3TC ranged from 93% to 96% at Week 48 in studies SPRI NG-1, SPRI NG-2 and 
SINGLE among subjects who w ere suppressed (HIV -1 viral load <50 c/mL) at Week 24. 
The probability  of a positive outcome assuming the true response rate for [COMPANY_004]744 L A 
plus TMC278 L A two-drug regimen is presented in Table 5.
Table 5 Probability of Positive Outcome Assuming True Resp onse Rates of LA
True Response Rate for 
[COMPANY_004]744 LA plus TMC278 LA 
two-drug regimen80% 83% 85%a86% 89% 92% 95% 98%
Probability of Positive 
Outcomeb0.4% 2.5% 6.8% 11% 34% 71% 96% 100%
a. Type I error is <10% .
b. It is assumed that the response rate for [COMPANY_004]744 plus ABC/3TC is 95%. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
312Incorporation of prior beliefs and information about population parameters is a required 
part of an y Bayesian probability  model. The assumptions made will help provide a more 
reliable estimate when the prior beliefs are combined with the observed data than the data 
alone as long as the beliefs are reasonable. Therefore, the trial will utilize a Beta (44, 2.6) 
distribution with the median response rate being 95%, with 99thpercentile of 99% and 5th
percentile of 88%.
Furthermore, a non -informative prior belief is assumed for the response rate for [COMPANY_004]744 
LA plus TMC278 LA two -drug regimen. Therefore, the trial will conservatively  utilize a 
Beta (1, 1) distribution. These priors are display ed in Figure 5 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
313Figure 5 Plot of Prior Distributi on for Response Rate for [COMPANY_004]744 LA plus 
TMC278 LA two -drug regimen and [COMPANY_004]744 plus ABC/3TC
Revised text:
IMtreatment relative to Oral treatment
The sample size of 45subjects in the oral treatment arm and 90 subjects each in the IM
treatment arms were c hosen to ensure a high probability  that a long -acting two drug 
treatment with truly  poor response relative to [COMPANY_004]744 once dail y plus ABC/3TC once 
daily  will not be studied further, while allowing for formal considerations of other factors 
should efficacy  be similar between the treatment arms .  It is assumed that 85% subjects 
enrolled will be suppressed at Week (-16),approximately  [ADDRESS_419655] the comparability of [COMPANY_004]744 L A plus TMC278 L A two -
drug regimen to [COMPANY_004]744 30 mg once dail y plus ABC/3TC. The primary  comparison of 
interest will be performed using a Bay esian probability  model. If the posterior probability  
that the difference is greater than -10% is large ( i.e., 90%), then sufficient statistical 
evidence has been provided for the positive outcome. A response rate of 8 2% in the 
[COMPANY_004]744 L A plus TMC278 L A two -drug regimen (compared with an [COMPANY_004]744 plus 
ABC/3TC response rate of 9 2%) would result in a rejection of the null hy pothesis with a 
probability  of approximately  0.06 4(typeI error). The given sample size is unlikely  to  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419656] a random sample that would falsel y conclude that [COMPANY_004]744 LA plus TMC278 L A 
two-drug regimen is comparable with [COMPANY_004]744 plus ABC/3TC if the response rates are 
truly  82% versus 92%, respectively . If the [COMPANY_004]744 L A plus TMC278 LA two -drug 
regimen yields an response rate of greater than 92%, then there is a high probability  of 
rejecting the null h ypothesis and correctl y concluding that [COMPANY_004]744 LA plus TMC278 L A 
two-drug regimen is at least as good as [COMPANY_004]744 plus ABC/3TC.
Historical response rates of dolutegravir, an integrase compound similar to [COMPANY_004]744, 
were used as reference for the oral control arm.  Response rates for dolutegravir plus 
ABC/3T C ranged from 9 2% to 94% at Week 60 in studies SPRI NG-1, SPRI NG-2 and 
SINGLE among subjects who were suppressed (HIV- 1 viral load <50 c/mL) at Week 24. 
The probability  of a positive outcome assuming the true response rate for [COMPANY_004]744 L A 
plus TMC278 L A two-drug regimen is presented in Table 5.
Table 5 Probability of Positive Outcome Assuming True Response Rates of 
[COMPANY_004]744 LA plus TMC278 LA
True Response Rate for 
[COMPANY_004]744 LA plus TMC278 LA 
two-drug regimen (Q4W or 
Q8W)80% 82%a86% 90% 92% 94% 96%
Probability o f Positive 
Outcomeb2.8% 6.4% 26% 63% 82% 95% 99%
a. Type I error is <10% .
b. It is assumed that the response rate for [COMPANY_004]744 plus ABC/3TC is 92%.
Incorporation of prior beliefs and information about population parameters is a required 
part of an y Bayesian pr obability  model. The assumptions made will help provide a more 
reliable estimate when the prior beliefs are combined with the observed data than the data 
alone as long as the beliefs are reasonable. Therefore, the trial will utilize a Beta ( 23, 2) 
distribu tion with the me anresponse rate being 9 2%, with 97.5thpercentile of 99% and 
2.5thpercentile of 78%.
Furthermore, a non -informative prior belief is assumed for the response rate for [COMPANY_004]744 
LA plus TMC278 LA two -drug regimen. Therefore, the trial will co nservatively  utilize a 
Beta (1, 1) distribution. These priors are display ed in Figure 6 . 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
315Figure 6 Plot of Prior Distribution for Response Rate for [COMPANY_004]744 LA plus 
TMC278 LA two -drug regimen and [COMPANY_004]744 plus ABC/3TC
Section 8.2.2 –Sample Size Sensitivity
Removed:
If sample size of LA arm decrease to 50 subjects in the event that the two induction 
length arms cannot be combined, the likelihood of establishing comparability  is reduced. 
With the smaller sample size, if [COMPANY_004]744 L A plus TMC278 L A two- drug regime n yields 
a response rate of 95%, there would be an 81% probability  of rejecting the null 
hypothesis, as compared with a 96% probability  with the selected sample size. 
Section 8.3.1 -Analysis Populations
Original text:
The following populations will be as sessed:
Intent -to-Treat Exposed Population (ITT -E)
The ITT- E population consists of all randomized subjects who received at least one dose 
of IP. Subjects will be analy zed according to the randomized treatment regardless of what 
treatment was actuall y rece ived. Unless stated otherwise, the ITT- E population will be 
the primary  population for efficacy  anal yses.  
Intent -to-Treat Maintenance Exposed Population (ITT -ME)
The ITT-ME population consists of all randomized who received at least one dose of IP 
during the Maintenance Period of the study .  Subjects will be anal yzed according to the  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
316randomized treatment regardless of what treatment was actuall y received. The ITT -ME 
population will be the secondary  population for some efficacy anal yses.
Per Protocol Popul ation (PP)
This population will consist of subjects in the I TT-E population with the exception of 
major protocol violators (these will be defined in the RAP of this study ).  The PP 
population will be a secondary  population for efficacy  purposes. 
Per Protocol Maintenance Population (PP -M)
This population will consist of subjects in the I TT-ME population with the exception of 
major protocol violators (these will be defined in the RAP of this study ).  The PP -M 
population will be a secondary  population for eff icacy  purposes. 
PK Population
The PK Population will include all subjects who received [COMPANY_004]1265 744 and / or TMC278 
and undergo PK sampling during the stud y, and provide evaluable [COMPANY_004] 1265 744 and /or 
TMC278 plasma concentration data. Subjects in this populat ion will be included in the 
PK analy sis. 
Safety Population
The Safet y Population consists of all enrolled subjects who were exposed to 
investigational products with the exception of any subjects with documented evidence of 
not having consumed any  amount o f investigational product.  Subjects will be anal yzed 
according to the actual treatments received.  Subjects will not be excluded from this 
population as a result of changes to the background regimen.  The safet y population will 
be the primary  population f or safety  anal yses.  All safet y analyses will be produced using 
the safety population.
Maintenance Safety Population
The Maintenance Safety  Population consists of all randomized subjects who were 
exposed to investigational products during the Maintenance P eriod of the study  with the 
exception of any  subjects with documented evidence of not having consumed or been 
administered an y amount of investigational product during the Maintenance Period of the 
study .  Subjects will be analy zed according to the actual treatments received.  Subjects 
will not be excluded from this population as a result of changes to the background 
regimen.  The maintenance safet y population will be an additional population for safety 
analyses.
Revised text:
The following populations will be assessed:
Intent -to-Treat Exposed Population (ITT -E) 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419657] one dose of 
IP. Subjects will be analyzed according to the irrandomized treatment regardless of what 
treatment was actuall y received. Those that are not randomized will be summarized 
together under a ‘Not Randomized’ category . The ITT -E population will be the 
secondary population for some efficacy  anal yses.  
Intent -to-Treat Maintenance Exposed Population (ITT -ME)
The ITT- MEpopulation consists of all randomized who received at least one dose of IP 
during the Maintenance Period of the study .  Subjects will be anal yzed according to the 
randomized treatment regardless of what treatment was actuall y received. Unless stated 
other wise, t he ITT -ME population will be the primar y population for efficacy  analy ses.
Per Protocol Maintenance Population (PP -M)
This population will consist of subjects in the I TT-ME population with the exception of 
major protocol violators (these will be de fined in the RAP of this study ).  The PP -M 
population will be a secondary  population for efficacy  purposes. 
PK Population
The PK Population will include all subjects who received [COMPANY_004]1265 744 and / or TMC278 
and undergo PK sampling during the stud y, and pro vide evaluable [COMPANY_004] 1265 744 and /or 
TMC278 plasma concentration data. Subjects in this population will be included in the 
PK analy sis. 
Safety Population
The Safet y Population consists of all enrolled subjects who were exposed to 
investigational products wit h the exception of any subjects with documented evidence of 
not having consumed any  amount of investigational product.  Subjects will be anal yzed 
according to the actual treatments received.  Subjects will not be excluded from this 
population as a result o f changes to the background regimen.  The safet y population will 
be the primary  population for safety  anal yses.  All safet y analyses will be produced using 
the safety population.
Section 8.3.3 -Treatment Comparisons
Original text:
Primary Comparisons of I nterest
The primary  efficacy  analy sis will be performed at Week 24 based on the proportion of 
subjects in the ITT -E population with plasma HIV -1 RNA <50 c/mL using MSDF 
algorithm. The primary  comparison of interest will be performed using a Bay esian 
proba bility  model.  The probability  of (Response rate for LA arm Response rate for 
Oral arm -10%) will be calculated.
Other Comparisons of Interest 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419658] of the duration 
of suppression, based on 16 or 24 weeks of 30 mg [COMPANY_004]744 once daily in combination 
with ABC/3TC on the ability  of a regimen of 400 mg IM of [COMPANY_004]744 LA plus 600 mg IM 
of TMC278 L A every  4 weeks to maintain virologic suppression through Week 96.  
Measures of safety  and tolerability will be assessed as detailed in the RAP
Revised text:
Primary Comparisons of Interest
The primary  efficacy  analy sis will be performed at Week 32 based on the proportion of 
subjects in the ITT -ME population with plasma HIV -1 RNA <50 c/mL using MSDF 
algorit hm. The primary  comparison of interest will be the response rate of each IM 
dosing arm to the oral control arm performed using a Bay esian probability  model.  The 
probability  of (Response rate for IMarm Response rate for Oral arm -10%) will be 
calculated.
Other Comparisons of Interest
The probability  of Q8W comparable to Q4W will be provided using the Bay esian 
probability  model .
Section 8.3.4 -Interim and Final A nalysis
Original text:
The ITT- E population will be primary  efficacy  population and the safet y population will 
be the primary  safet y population for all anal yses.  All available data will be included in 
all interim analy ses, including data bey ond the designated time point except for the Day  [ADDRESS_419659] 4 weeks of the maintenance dose regimen on 
LA (Week 4). If the number of failures meets or exceeds the thresholds specified in the 
table below ( Table 6) this will be considered strong evidence o f an inadequate response 
and will trigger a comprehensive IDMC data review and possible discontinuation of that 
treatment arm.  If an inadequate response is seen in the shorter induction length arm and 
it is determined that that arm should be discontinued, then subjects on that treatment arm 
still in the I nduction Period can be switched to the longer induction length.
Table [ADDRESS_419660] four weeks of 
maintenance dose on LANumber of protocol -defined 
virologic failures after 
maintenance dose on LA
3-21 >=3
22-32 >=4
33-43 >=5
44-54 >=6
55-65 >=7
66-75 >=8
76-86 >=9
87-97 >=10
98-100 >=11
The thresholds described in this table are derived on the basis of the ratio of the 
likelihoods for the null hy pothesis (H 0) that there is a subgroup of subjects with 
inadequate maintenance of virologic suppression and the alternative h ypothesis (H 1) that 
the only  failures in the study  are due to poor compliance. For this anal ysis, H 0translates 
to a protocol defined virologic failure rate of 20% or higher (as defined in Section 4.6) 
and H 1translates to an expected 3% rate of protocol defined virologic failure s. Further 
details on this method are contained in Section 11.5. Each threshold represents strong 
evidence in favour of H 0over H 1[Roy all, 1997].
The scenarios described above are not exhaustive – it is possible that the overall failure 
rate does not meet the threshold but that a subgroup of subjects (e.g. with a given 
combination of mutations or fold resistance to [COMPANY_004]744 above an as yet unknown 
threshold) are consistently failing. [COMPANY_004] will monitor virologic response b y Baseline 
genot ype and may  halt one or more treatment arms if at an y time subjects are deemed to 
be at an unacceptable risk of an inadequate response on the basis of such monitoring, 
although the high number of possible genot ypic subgroups precludes pre -specification of 
precise thresholds for such action.
IDMC Interim Analyses
The purpose of these analy ses is for the Independent Data Monitoring Committee 
(IDMC) to evaluate the efficacy , safety  and tolerability  of [COMPANY_004]744 at earl y time points in  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419661] 
transitioned from the Induction Period to the Maintenance Period.  Full details of the 
analyses, estimated timing and the decision criteria that will be used to determine 
regimen performance will be pre- specified in t he IDMC Charter, with IDMC agreement.  
As subjects enter the Maintenance Period of the study , the protocol defined virologic 
failure rate will be continually  monitored. If the number of failures meets or exceeds the 
pre-specified thresholds specified in the IDMC Charter, this will be considered strong 
evidence of an inadequate response and will trigger a comprehensive data review b y the 
IDMC.  The IDMC charter will contain details of this continual monitoring of the 
protocol defined virologic failure rates , the specifics around what will trigger a data 
review, and the safety  summaries and efficacy  analy ses that will be provided should a 
data review be required.
Day 1 Interim Analysis
A Day  1 interim analy sis may  be conducted to support regulatory  submissions and/or 
scientific conference presentations once the last randomized subject has completed the 
Day 1 study  visit and the database has been cleaned and released for anal ysis. The results 
of this analy sis will be used to evaluate efficacy , safet y and tolera bility  of [COMPANY_004]744 30 mg 
once dail y plus ABC/3TC once daily in the Induction Period.  Only  data from the 
Induction Period would be summarized in this analysis.
Week [ADDRESS_419662] has 
completed the Week 24 study  visit and the database has been cleaned and released for 
analysis.  The results of this analy sis will be used to characterize safety , tolerability  and 
durability  of antiviral response of the long -acting regimen of [COMPANY_004] 744 LA + TMC278 
LA.
Week [ADDRESS_419663] has 
completed the Week 48 study  visit and the database has been cleaned and released for 
analysis.  The results of this analy sis wi ll be used to characterize the safet y, tolerability  
and durability  of antiviral response of the long - acting regimen of [COMPANY_004]744 LA + 
TMC278 L A.
Week [ADDRESS_419664] has 
complete d the Week 96 study  visit and the database has been cleaned and released for 
analysis.  The results of this analy sis will be used to fully  characterise the long term 
safet y and efficacy profile of the long -acting regimen of [COMPANY_004]744 LA + TMC278 L A.
Additiona l analy ses may  be performed as needed.  The primary  and interim anal yses may  
be used to support regulatory  submissions and/or scientific conference presentations
Revised text: 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419665] interim anal ysis the I DMC will evaluate the efficacy , safet y and tolerability of 
[COMPANY_004]744 to determine if the [COMPANY_004]744 regimen is suboptimal such that it should be 
discontinued before all subjects transition into the Maintenance Period of the study .  Full 
details of the anal yses, estimated timing and the decision criteria that will be used to 
determine regimen performance will be pre-specified in the IDMC Charter.
This interim analy sis schedule does not require an adjustment for multipli city since there 
is no possibility  of a false positive finding at any  of the interim anal yses conducted before 
Week 32, and since the Week 48 and 96 anal yses will be used to further characterise the 
long-term safet y and efficacy  profile of [COMPANY_004]744.  As no h ypothesis is being tested for 
rejection during the constant monitoring of virologic response, no adjustment for 
multiplicity  will be performed.
IDMC Interim Analyses
The purpose of these analy ses is for the Independent Data Monitoring Committee 
(IDMC) to e valuate the efficacy , safety  and tolerability  of [COMPANY_004]744 at earl y time points in 
the study .  The IDMC will review at least one analysis before all eligible subjects have 
transitioned from the Induction Period to the Maintenance Period.  Full details of the 
analyses, estimated timing and the decision criteria that will be used to determine 
regimen performance will be pre-specified in the IDMC Charter, with IDMC agreement.
All the IDMC reviews will be produced by a Statistics and Data Analysis Centre 
(SDAC).  
Futility Interim Monitoring
Continuous monitoring of the number of protocol defined virologic failures during the 
Maintenance Period and a futility  interim anal ysis when 50% subjects have completed 
Week [ADDRESS_419666] 4 weeks of either of the M aintenance Period 
IM dosingregimen s(Week 4). If the number of failures meets or exceeds the thresholds 
specified in the table below ( Table 6) this will be considered strong evidence of an 
inadequate response and will trigger a comprehensive IDMC data review and possible 
discontinuation of that treatment arm.  If an inadequate response is seen in anyarm and it 
is determined by [CONTACT_339291], then subjects on that 
treatment arm can be switched to the remaining IM arm . 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419667] four weeks of 
maintenance dose on IMNumber of protocol -defined 
virologic failures after 
maintenance dose on IM
3-21 >=3
22-32 >=4
33-43 >=5
44-54 >=6
55-65 >=7
66-75 >=8
76-86 >=9
87-97 >=10
98-100 >=11
The thresholds described in this table are derived on the basis of the ratio of the 
likelihoods for the null hy pothesis (H 0) that there is a subgroup of subjects with 
inadequate maintenance of virologic suppression and the alternative hypothesis (H 1) that 
the only  failures in the study  are due to poor compliance. For this anal ysis, H 0translates 
to a protocol defined virologic failure rate of 20% or higher (as defined in Section 4.6) 
and H 1translates to an expected 3% rate of protocol defined virologic failures.   For the 
first IDMC review, if the true rate of virologic failure is 20% as specified in H 0, the 
probability  to detect the inadequate virologic suppression is greater than 70%.  If the true 
rate of virologic failure is 3%, the probability  to see number of virology  failure exceed 
the threshold is less than<1%. Further details on this method are contained in the IDMC 
charter . Each threshold represents strong evidence in favour of H 0over H 1[Roy all, 
1997].
The scenarios describe d above are not exhaustive –it is possible that the overall failure 
rate does not meet the threshold but that a subgroup of subjects (e.g. with a given 
combination of mutations or fold resistance to [COMPANY_004]1265 744 above an as yet unknown 
threshold) are consis tently failing. [COMPANY_004] will monitor virologic response by  [CONTACT_339326], 
although the high n umber of possible genot ypic subgroups precludes pre -specification of 
precise thresholds for such action. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
323Futility Analysis after 50% of subjects complete Week 24
An interim anal ysis for the purpose of review b y the IDMC will be performed after 
approximatel y 50% of subjects complete Week 24.   A futility  rule based on Bayesian
posterior probability approach will be applied to assess the probability  that the IM
treatment arm demonstrates the comparability  with the oral control arm given the partial 
data set.  Posterior probabilities of success ( Prob(pIM> p oral-0.1 | data) )are provided in 
Table 7 for a subset of possible outcomes that could occur at the interim. Those outcomes 
associated with a posterior probability  of success <40 % may trigger a comprehensive 
IDMC data review and possible discontinuation of that treatment arm , although all data 
will be taken into consideration for making this decision.
Table 7 Posterior Probability of Successaat the Interim Analysis Under Various 
Scenarios
# Successes in I M arm (out of 45)
# 
Successes 
in Oral 
arm (out 
of 23)35
(78% )36 
(80% )37
(82% )38
(84% )39
(87% )40
(89% )41
(91% )42
(93% )
18(78% ) 0.564 0.678 0.753 0.850 0.913 0.955 0.979 0.993
19(83% ) 0.454 0.558 0.679 0.782 0.859 0.931 0.966 0.986
20(87% ) 0.346 0.465 0.574 0.694 0.805 0.890 0.942 0.974
21(91% ) 0.244 0.348 0.455 0.584 0.706 0.829 0.907 0.961
22(96% ) 0.146 0.231 0.335 0.461 0.604 0.736 0.845 0.926
23(100% ) 0.081 0.135 0.218 0.324 0.473 0.612 0.755 0.874
c. Posterior probability of succes s is defined as (prob (pIM> p oral-0.1 | data)) with informative prior Beta (23,2) for oral 
arm and non- informative prior Beta (1,1) for IM arm.
d. Highlighted cells represent outcomes with posterior probability <0.4 that may trigger a comprehensive IDMC data
review.
Theproposed the futility  anal ysis has 91% chance to stop the stud y at the interim anal ysis
if the true response rates are 92% and 72% for the oral arm and IM arm, respectivel y.  
The power to stop the study is 46% if the true response rates are 92% and 82% for the 
oral arm and IM arm, respectivel y. The chance of stoppi[INVESTIGATOR_339217] 2% if the 
true response rates are 92% for both the oral arm and I M arm.
Day 1 Interim Analysis
A Day  1 interim analy sis may  be conducted to support regula tory submissions and/or 
scientific conference presentations once the last randomized subject has completed the 
Day 1 study  visit and the database has been cleaned and released for anal ysis. The results 
of this analy sis will be used to evaluate efficacy , safety and tolerability of [COMPANY_004]744 30 mg 
once dail y plus ABC/3TC once daily in the Induction Period.  Only  data from the 
Induction Period would be summarized in this analysis. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419668] has 
completed the Week 32study  visit and the database has been cleaned and released for 
analysis.  The results of this analy sis will be used to characterize safety , tolerability  and 
durability  of antiviral response of both IM dosing regimens of [COMPANY_004]744 LA + TMC278 
LAand to select a regimen for further development should both I M dosing regimens be 
comparable to the oral control arm .
Week [ADDRESS_419669] randomized subjec t has 
completed the Week 48 study  visit and the database has been cleaned and released for 
analysis.  The results of this analy sis will be used to characterize the safet y, tolerability  
and durability  of antiviral response of both IM dosing regimens of [COMPANY_004]744 L A + 
TMC278 L Aand to confirm the selected regimen for further development should both 
IM dosing regimens be comparable to the oral control arm .
Week [ADDRESS_419670] has 
completed the Week 96 study  visit and the database has been cleaned and released for 
analysis.  The results of this analy sis will be used to fully  characterise the long term 
safet y and efficacy profile of both IM dosing regimen sof [COMPANY_004]744 LA + TMC278 L A.
Follow-up analy ses after the Week [ADDRESS_419671] 
switched to the chosen dose of [COMPANY_004]744 LAmay be conducted to more fully  characterize 
the long- term safety  and efficacy  profile of [COMPANY_004]744 LA.
Section 8.3.5 -Key Elements of A nalysis Plan
Revised to (changes struck through and underlined).
Efficacy Analyses
All efficacy  analy ses, except as stated otherwise, will be based on the ITT-M E 
population.
The primary  efficacy  analy sis will be based on the MSDF approach mentioned in 
Sectio n 8.3.[ADDRESS_419672] to the target 
visit date. Detailed explanations of the derivation of visit windows will be included in the 
RAP. Any  deviations from the planned anal yses described in this protoco l or the RAP 
will be detailed in the clinical study  report (CSR). 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
325And:
Original text:
For the anal ysis of [COMPANY_004]744 L A+TMC278 LA arm (LA arm) response rate relative to 
[COMPANY_004]744 + ABC/3TC (oral arm), let:
XLA= number of responder in LA arm, and 
Xoral= number of responder in oral arm
The binomial distribution is the assumed likelihood of the eRVR data, as follows:
XLA~ Binomial (100, p LA)  
Xoral~ Binomial (50, p oral)  
Since the true response rate is unknown, prior distributions are placed on these 
paramet ers of interest to reflect current beliefs and balanced with acceptable decision 
criteria performance. Conjugate beta densities are assumed. The information pertaining to 
the oral arm response rate is well understood and the prior that was chosen reflects the 
belief that the response rate is between 88% and 99% with 94% certainty . There is very  
few information about the response rate for LA arm, therefore, a non -informative prior 
assumed. 
PLA~ Beta (1, 1)
Poral~ Beta (44, 2.6)
The posterior probability that the response rate for L A arm demonstrates the 
comparability  of oral arm is as follows: 
p1= P (P LA> p oral-0.1 | data)
A posterior probabilit y of at least 90% (i.e., p 1>0.90) corresponds to “substantial 
evidence of positive outcome” and is chose n as the weight of evidence threshold. 
Sensitivity  analy ses may  be performed to assess the impact of the choice of informative 
prior for oral arm response rate though the anal ysis described above will remain primary  
for indication of efficacy  decision -making purposes. As an alternative to the informative 
prior, a Beta (1, 1) prior distribution for oral arm may be considered. Full details of the 
planned Bay esian anal yses will be provided in the RAP.
The proportion of subjects with plasma HIV -1 RNA <50 c/mL as determined by  [CONTACT_339294] b y treatment group and induction length over the 
entire time on study  by [CONTACT_147247] I TT-E population and the ITT -ME population. 
In addition, an OC anal ysis will be performed for supportive purposes . 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
326Revised text:
For the anal ysis of [COMPANY_004]744 L A+TMC278 LA arm s (IMarms) response rate relative to 
[COMPANY_004]744 + ABC/3TC (oral arm), let:
XLA= number of responder in IMarm, and 
Xoral= number of responder in oral arm
The binomial distribution is the assumed lik elihood of the response data, as follows:
XLA~ Binomial ( 90, pIM)  
Xoral~ Binomial ( 45, poral)  
Since the true response rate is unknown, prior distributions are placed on these 
parameters of interest to reflect current beliefs and balanced with accep table decision 
criteria performance. Conjugate beta densities are assumed. The information pertaining to 
the oral arm response rate is well understood and the prior that was chosen reflects the 
belief that the response rate is between 78% and 99% with 9 5% certainty . There is very  
few information about the response rate for IMarm, therefore, a non- informative prior 
assumed. 
PLA~ Beta (1, 1)
Poral~ Beta ( 23, 2)
The posterior probability that the response rate for IMarm demonstrates the 
comparability  oforal arm is as follows: 
p1= P (P IM> p oral-0.1 | data)
A posterior probabilit y of at least 90% (i.e., p 1>0.90) corresponds to “substantial 
evidence of positive outcome” and is chosen as the weight of evidence threshold. 
Sensitivity  analy ses may  be performed to assess the impact of the choice of informative 
prior for oral arm response rate though the anal ysis described above will remain primary  
for indication of efficacy  decision -making purposes. As an alternative to the informative 
prior, a Beta (1, 1) prior distribution for oral arm may  be considered. Full details of the 
planned Bay esian anal yses will be provided in the RAP.
The proportion of subjects with plasma HIV -1 RNA <50 c/mL as determined by  [CONTACT_339294] b y treatment gr oup over the entire time on study  by 
[CONTACT_147247] I TT-ME population and the ITT -E population. 
In addition, an OC anal ysis will be performed for supportive purposes.
For the probability  of comparability between two IM arms, a non -informative prior of 
Beta (1, 1) will be used for both I M treatment arms. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
327Section [IP_ADDRESS] - Safety  Analyses
Added:
Framingham Risk assessment will be calculated as detailed in the RAP and will be 
summarized by  [CONTACT_2939].
Section 11.2 –Appendix 2
Removed the Child -Pugh Appendi x.
Section 11.4 –Appendix 5
Removed the Statistical Method for Plasma HIV -1 RNA Monitoring .  This is now in the 
RAP.
Section 11 –New Appendix 
With the removal and addition of Appendices, this Appendix is now number 4.
Added the following information reg arding liver stoppi[INVESTIGATOR_339218] / 
rechallenging stud y drug:
VSLC GUIDELINES FOR DRUG RESTA RT OR RECH ALLENGE A FTER STOP 
FOR LIVER CRITERIA
3.Drug rechallenge may  be considered for a subject exhibiting compelling benefit 
for a critical medicine f ollowing drug -induced liver injury , if favorable benefit: 
risk and no alternative medicine available ( Table 8,Figure 7)
4.In Phase III, drug restart may be considered for liver events with a clear 
underly ing cause (e.g. biliary , pancreatic events, hy potension, acute viral 
hepatitis), if not associated with drug- induced liver injury , alcoholic hepatitis or 
hypersensitivity , and drug not associated with HLA marker of liver injury , when 
liver chemistries improve to within 1.5xbaseline and AL T<3xUL N)(Table 9,
Figure 8).
Background: Following drug- induced liver injury, drug rechallenge is associated with 
a 13% mortality across all drugs in prospective studies .  Clinical outcomes vary  by 
[CONTACT_9934], with nearl y 50% fatality  with halothane re -administered in one month of initial 
injury [Andrade , 2009].  However, some drugs seldom result in recurrent liver injury  or 
fatality .
Risk factors for a fatal drug rechallenge outcome include:
hypersensitivity  with initial liver injury  (e.g. fever, rash, eosinophilia) [ Andrade 
2009]
jaundice or bilirubin 2xULN with initial liver injury  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
328prior serious adverse event or fatality  has earlier been observed with drug 
rechallenge [Papay  , 2009; Hunt , 2010]
evidence of drug- related preclinical liability  (e.g. reactive metabolites; 
mitochon drial impairment) [ Hunt , 2010] 
VSLC Decision Process for Drug Rechallenge A pproval or 
Disapproval (See Figure 7)
Principal I nvestigator (PI) requests consideration of drug rechallenge for a 
subject receiving compelling benefit from a critical or life -saving drug, who 
exhibits liver chemistry elevation meeting subject stoppi[INVESTIGATOR_3418], with no 
alternative treatment
By [CONTACT_339303]ïve subjects will only  be considered for rechallenge if 
they were infected with a multi -resistant virus.
Medical Moni tor and Global Clinical Safety  and Pharmacovigilance (GCSP) 
Physician to review the subject’s rechallenge risk factors (consultation with the 
Hepatotoxicity  Panel is available) and complete checklist (Table 8).
The Medical Monitor and GCSP Phy sician are ac countable to review and agree 
on:
–compelling benefit of the investigational product (IP) for this subject and no 
alternative therap y 
–must present source data defining the patient’s current resistance profile with 
documented evidence of extensive drug resi stance and previous drug history  
–Relative benefit -risk of drug rechallenge, with consideration of the following 
high risk factors:
Initial liver injury  event included: fever, rash, eosinophilia, or 
bilirubin 2xUL N (or direct bilirubin >35% of total, if available)
subject currently exhibits severe liver injury  defined by : [CONTACT_42386] 3xUL N, 
bilirubin 2xUL N (direct bilirubin >35% of total, if available), or INR1.5
SAE or fatality  has earlier been observed with IP rechallenge
IP associated with known preclinical h epatic liability / injury
Relevant phy sicians must review and agree on request for drug rechallenge:  
Safety  Team Leader, VP, or Senior Safet y Physician ([COMPANY_004])
Medicines Development Leader and Project Ph ysician Leader ([COMPANY_004])
Request is taken to full VSL C for final decision  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
329Figure 7 VSLC process for drug rechallenge approval or disapproval
The local operating company  (LO C) ViiV medical director (and [COMPANY_004] where applicable)
should be informed that study  drug rechallenge is under consideration and of the final
decision, whether or not to proceed.
Table [ADDRESS_419673] for drug rechallenge for critical medicine  (Following drug -
induced liver injury, drug rechallenge is associated with 13% mortality 
across all drugs in prospective studies)
Yes No
Compelling benefit of the investigational product (IP) for this subject andno 
alternative therapy .  Provide brief explanation:
Relative benefit -risk favorable for drug rechallenge , after considering the 
following high risk factors :
Initial liver injury event included : 
ofever, rash, eosinophilia, or hypersensitivity
oor bilirubin 2xULN (direct bilirubin >35% of total)
oSubject currently exhibits ALT 3xULN, bilirubin 2xULN 
(direct bilirubin >35% of total, if available), orINR1.5
oSAE or fatality has earlier b een observed with IP rechallenge
If yes, please provide brief explanation :
oIP associated with known preclinical hepatic liability/ injury
oSource data defining the patients current resistance profile
oPrevious drug history 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
330Drug Restart
Phase II “drug restart” can be approved by  [CONTACT_339304], defined non -drug-
induced liver injury  if no evidence of:
•immunoallergic injury  /HLA association with injury
•DILI
•alcoholic hepatitis
Study  drug held while labs and evaluation is completed to assess diagnosis.
VSLC Decision Process for Drug Restart A pproval or Disapproval 
(Figure 8 ): 
PI [INVESTIGATOR_339199] -initiation for a subject stable or improving 
on IP, who exhibits liver chemistry  elevation meeting subject stoppi[INVESTIGATOR_3418], 
which is transient, non- drug-related, and liver chemistries improve to within 
1.5x baseline and AL T<3xULN. 
[COMPANY_004] Medical Monitor and Clinical Safety  Physician to review the subject’s 
diagnosis, restart risk factors and complete checklist (Table 9 ).
–must present source data defining the patient’s current resistance profile with 
documented evidence of extensive drug resistance and previous drug history.
The LOC ViiV medical director (and [COMPANY_004] where applicable) should be 
informed that study  drug restart is under cons ideration and of the final decision, 
whether or not to proceed.
Table [ADDRESS_419674] for Phase II drug restart after well- explained liver injury (e.g. 
biliary, pancreatic, hypotensive events, congestive heart failure, acute 
viral hepatitis), improving to live r chemistry 1.5x baseline & 
ALT<3xULN
Yes No
Is subject stable or improving on the investigational product (IP)?
Do not restart if the following risk factors at initial liver injury :
fever, rash, eosinophilia, or hypersensitivity 
drug-induced liver injury 
alcoholic hepatitis (AST>ALT, typi[INVESTIGATOR_897] <10xULN)
IP has an HLA genetic marker associated with liver injury (e.g. 
lapatinib, abacavir, amoxicillin/clavulanate)
Source data defining the patients current resistance profile
Previous drug history 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
331Relevant phy sicians must review and agree on request for drug restart:  
Safety  Team Leader, VP, or Senior Safet y Physician
Medicines Development Leader and Project Ph ysician Leader ([COMPANY_004]).
Hepatotoxicity  Panel consultation is available.
Justification for drug restart outlining the benefit and risk for this subject must 
be recorded b y GCSP Physician and sent to the VSL C Secretary .
VSL C must approve drug re -initiation and dosing regimen
Figure 8 VSLC process for drug restart approval or disap proval
1. Andrade 2009; 2. Papay , 2009; 3. Hunt, 2010
Medical monitor, GCSP Phy sician and PI [INVESTIGATOR_339219] (Global Clinical Safety and Pharmacovigilance) GCSP 
Physician A ctions
Medical Monitor must notify  PI [INVESTIGATOR_339201]’s rechallenge (or restart) decision and 
recommended dosing regimen in writing and Medical Monitor must record note 
in study  files. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
332The Safet y Review Team must record rechallenge (or restart) outcomes and the 
GCSP Phy sician must send these to the VSL C
All severe reactions ( rechallenge associated with bilirubin>2xUL N or jaundice, 
or INR 1.5), SAEs or fatalities with drug rechallenge (or restart) must be 
immediately  reported to Line Management, VSLC Chair, VP Global Medical 
Strateg y(ViiV) and EU Qualified Person for Pharmacovigilance. 
Principal Investigator A ctions :
The PI  [INVESTIGATOR_135436]/EC approval of drug rechallenge or restart, as required. 
If drug re -initiation VSLC -approved, the patient must provide informed consent 
with a clear description of possible benefits and risks of drug administration 
including recurrent, more severe liver injury  or possible death.
–Targeted drug rechallenge or drug restart consent form must be used.
The patient’s informed consent must be recorded in the study  chart, and the drug 
administered at agreed dose, as communicated b y Medical Monitor.
Liver chemistries must be followed twice weekl y for ‘rechallenge’ cases and 
once weekl y for ‘restart’ cases for one month or for as long as clinicall y 
indicated following drug re -initiation.  If subject exhibits protocol -defined liver 
chemistry  elevations, IP should be discontinued as protocol specified.
VSLC and the IRB/EC must be informed of the patient’s outcome following drug 
rechallenge or restart.
Rechallen ge/restart safety  outcomes :
0 = no liver chemistry  elevation
1 = recurrent liver chemistry  elevation not meeting subject stoppi[INVESTIGATOR_3418]
2 = recurrent liver chemistry  elevation meeting subject stoppi[INVESTIGATOR_3418]
3 = serious adverse event
4 = fatalit y
REFE RENCES:
Andrade RJ, Robles M, Lucena MI.  Rechallenge in drug -induced liver injury : the 
attractive hazard.  Expert Opin Drug Saf. 2009;8:709-714.
Hunt, CM.  Mitochondrial and immunoallergic injury  increase risk of positive drug 
rechallenge after drug -induc ed liver injury : A s ystematic review.  Hepatol. 2010;52:2216-
2222.
Papay  JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS, Hunt CM.  Drug -induced liver 
injury  following positive drug rechallenge.  Regul Tox Pharm. 2009;54:84 -90. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
333Amendment 3
Amendment 3 a pplies to all countries and all sites.  Primary modifications are as follows:  
Epzicom / Kivexa added as Investigational Product beginning at Day  1 of the 
Maintenance Period; clarification that alternative background therap y (if positive for 
HLA -B*5701) is not counted as the protocol permitted switch for NRTI; clarification 
regarding provision of alternative NRTI therap y; clarification that Exclusion for 
treatment of hepatitis C infection is exclusionary  at any  time during the study ; removed 
example of effe ctive barrier method from Inclusion criteria; change in visit window for 
subjects on the oral dosing arm; excursion temperatures added for Epzicom / Kivexa and 
Edurant; text added for Epzicom / Kivexa overdose; simplified text for results from 
primary  anal ysis; deleted option for subject informed consent by  [CONTACT_339327]; 
deleted duplicate text for “lack of efficacy ”; added RPV pre -dose pharmacokinetic (PK) 
sample at Day  1 to PK table; updated PK information for LAI116482 subject with 
integrase and N NRTI resistance; updated operating characteristic figure to include legend 
for 94% response; Time and Events Table clarifications: 1) added the collection of HIV 
risk factors at Screening ( or a later visit) ; 2)added collection of plasma for storage at 
time of confirmation of virologic failure; 3) subjects should have PK sample drawn prior
to dosing; 4) safety  assessments should be conducted every  16 weeks if every  8 weeks is 
chosen for the extension schedule; 5) simplified ECG assessments for oral Maintena nce 
arm; 6) created new row in Table to separate CD4+ and CD8+ cell counts; corrected 
typographical errors, updated and/or corrected list of abbreviations, Trademarks, and
references.
List of Abbreviations –Updated to remove abbreviations not used within the protocol, 
added abbreviation for FTC.
Trademark List – Updated to remove Trademarks not referenced within the protocol.
Protocol Summary and Section 1.2.:  List of Study Terms –updated to include 
Epzicom / Kivexa as I P starting at Day  1 –based on Reg ulatory  feedback from [LOCATION_009].
Original Text:
IP = Investigational product; both formulations of [COMPANY_004]1265744 and TMC278.  
Revised Text:
IP = Investigational product; both formulations of [COMPANY_004]1265744 and TMC278.  
Epi[INVESTIGATOR_339145] / Kivexa will also be considered I P beginning at Day  1 of the 
Maintenance Period.
Protocol Summary: Notable Inclusion Criteria –corrected t ypo for “ ”
Original Text:
Male or female subjects at least 18 y ears old that are HIV -1 positive (HIV -1 
RNA >1000 copi[INVESTIGATOR_014]/millilitre [c/mL ]) 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
334Revised Text:
Male or female subjects at least 18 y ears old that are HIV -1 positive (HIV -1 
RNA 1000 copi[INVESTIGATOR_014]/millilitre [c/mL ])
Protocol Summary:  Notable Exclusion Criteria – clarification that treatment for 
hepatitis C infection is not permitted at an y time during the stud y:
Original Text:
History  of ongoing or clinically  relevant hepatitis within the previous 6 months, 
including chronic hepatitis B virus (HBV) infection (HBsAg positive). 
Asymptomatic individuals with chronic hepatitis C virus (HCV) infection will not
be excluded, however Investigators must carefully assess if therap y specific for 
HCV infection is required; subjects who are anticipated to require such therapy 
during the randomized portion of the study must be excluded.
Revised Text:
History  of ongoing or clinically  relevant hepatitis within the previous 6 months, 
including chronic hepatitis B virus (HBV) infection (HBsAg positive). 
Asymptomatic individuals with chronic hepatitis C virus (HCV) infection will not 
be excluded, however Investigators must ca refully  assess if therapy  specific for 
HCV infection is required; subjects who are anticipated to require such therapy 
must be excluded.
Protocol Summary:  Study Design:  Maintenance Period AND Section 
3.2.4 . Maintenance Period –clarification of timing of dosing windows:  
Original Text:
A (+ or -) [ADDRESS_419675]’s projected visit falls (as 
according to the Baseline visit).
Revised Text:
A (+ or -) 7 day  window , from the projected visit date, is allowable for IM dosing b ut not 
preferred.
Visits for subjects on the oral dosing arm are expected to occur as projected according to 
the Baseline visit.  There is a (+ or -) 3 day  visit window, from th e projected visit date.  
However, the number of tablets dispensed should be considered when scheduling the next 
visit. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
335Protocol Summary:  Study Design:  Maintenance Period:  Entering from the 
[COMPANY_004]744 + ABC/3TC Arm – Typo Correction:
Original Text:
At Week [ADDRESS_419676] dose of [COMPANY_004]744 + ABC/3TC + RPV in the 
clinic andwill begin IM dosing with the selected the IM regimen.
Revised Text:
At Week [ADDRESS_419677] dose of [COMPANY_004]744 + ABC/3TC + RPV in the 
clinic andwill b egin IM dosing with the selected IM regimen.
Protocol Summary:  Study Design:  Long -term Follow -Up Period IM Regimens
AND Section 3.2.6. L ong-term Follow- Up Period – IM Regimens only - clarification 
on provision of alternative NRTI therap y:
Original Text: 
In order to assure that subjects have access to HAART during the Long -Term Follow -Up 
Period, the Sponsor will reimburse sites for HAART prescribed during this period.
Revised Text:
In order to assure that subjects have access to HAART during the Long -Term Follow- Up 
Period, [COMPANY_004] may  suppl y HAART regionall y or reimbursement will be provided during 
this period.
Protocol Summary:  Permitted Treatment Substitutions AND Section 5.6. Protocol 
Permitted Substitutions AND Setion 6.7. Time and Events Table –Long -Term 
Follow -Up – footnote e – clarification regarding provision of alternative NRTI  therapy .
Original Text:
This regimen will not be provided b y [COMPANY_004], but the Sponsor will reimburse sites for this 
cost.
Revised Text:
This regimen may  be supplied regionally  by[CONTACT_339255].
Protocol Summary:  Primary Analysis –clarification of how analysis will be used.
Original Text:
The results of this anal ysis will be used to characterize safet y, tolerability  and durability  
of antiviral response of both I M dosing regimens of [COMPANY_004]744 LA + TMC278 LA and to 
select a regimen for further development should both I M dosing regimens be comparable 
to the oral control arm. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
336Revised Text:
The results of this anal ysis will be used to characterize safet y, tolerabil ity and durability  
of antiviral response of both I M dosing regimens of [COMPANY_004]744 LA + TMC278 LA and to 
select a regimen for further development .
Section 1.4. [COMPANY_004]1265744 – Long Acting Injectable ([COMPANY_004]744 LA) –correction of ty po
Original Text:
[COMPANY_004]744 L A (has been generall ywell- tolerated as either an IM or SC dose .  
Intramuscular injection site reactions (ISRs) have been predominantl y mild or Grade 1 
(85%), self -limited, and have not led to study  discontinuation in any  subject to date.
Revised Text:
[COMPANY_004]744 L Ahas been generally well-tolerated as either an IM or SC dose .  Intramuscular 
injection site reactions (ISRs) have been predominantly  mild or Grade 1 (85%), self-
limited, and have not led to study  discontinuation in any  subject to date.
Section 1.5. TMC278 –Oral (RPV) – clarification provided regarding Week 48 
analysis, reference updated.
Original Text:  
The Week 48 efficacy  outcome for the pooled data from TMC278 -C209 and TMC278-
C215 (N=1360) showed that the proportion of subjects with HIV-1 RNA < 50 c/mL  was 
83% for RPV based regimen compared to 80% for the EFV based regimen. The overall 
virologic failure rate was 13% for the RPV compared to 9% for EFV. The proportion of 
patients who discontinued study  due to an adverse event or death was 2% for RPV and 
7% for EFV [ Edurant Product I nformation, 2013 ].
Revised Text:
The Week 48 efficacy  outcome for the pooled data from TMC278 -C209 and TMC278-
C215 (N=1368) showed that the proportion of subjects with HIV-1 RNA < 50 c/mL  was 
83% for RPV based regimen compared to 80% for the EFV based regimen (Snapshot 
algorithm) . The overall virologic failure rate was 13% for the RPV compared to 9% for 
EFV. The proportion of patients who discontinued study  due to an adverse event or death 
was 2% for RPV and 7% for EFV [ Cohen, 2012]. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
337Section 1.7. Study LAI116482 –updated PK information for Subject 
Original Text:
Week [ADDRESS_419678] is pending. 
Revised Text:
The Week [ADDRESS_419679] was consistent with Maintenance Phase 
Individual Average pre -dose values determined prior to the reported dates of calorie 
restriction.
Section [IP_ADDRESS]. TMC278, Section 3.3. Discussion of Design, Section 5.1.2. TMC278 
– Tablet (Rilpi[INVESTIGATOR_12979], RPV) - Updated Refer ence
Original Text:
[Edurant Product I nformation, 2013].
Revised Text:
[Edurant Product I nformation, 201 4].
Section 3.2.1. Screening Period –clarification of background switch and provision of 
alternative NRTI therap y.
Original Text:
Subjects who are HLA -B*5701 positive at the Screening visit are allowed to enter the 
study  on a dual -NRTI backbone that does not contain abacavir ; this would comprise the 
single allowed NRTI switch for this subject .  The cost of the selected dual -NRTI  
backbone will be reimbursed b y the Sponsor.
Revised Text:
Subjects who are HLA -B*570 1 positive at the Screening visit are allowed to enter the 
study  on a dual -NRTI backbone that does not contain abacavir.   The selected dual- NRTI 
backbone may be supplied regionally  by [CONTACT_339255].
Section 4.2. Inclusion Criteria –Criteria 2 –removed example of effective barrier 
method.
Original Text:
ALL subjects participating in the stud y must be counseled on safer sexual practices 
including the use of effective barrier methods (e.g. male condom/spermicide) to minimize 
risk of H IV transmission. 2018N380094_00
[COMPANY_003]
2013N168152_09 CONFIDENTIA L
200056
338Revised Text:
ALL subjects participating in the stud y must be counseled on safer sexual practices 
including the use of effective barrier methods to minimize risk of HI V transmission.
Section 4.3. Exclusion Criteria –Criteria 7 –clarifica tion that hepatitis C treatment 
would be exclusionary  at any  time during the study .
Original Text:
7.History  of ongoing or clinically  relevant hepatitis within the previous 6 months, 
including chronic hepatitis B virus (HBV) infection (HBsAg positive). 
Asymptomatic individuals with chronic hepatitis C virus (HCV) infection will not be 
excluded, however Investigators must carefull y assess if therap y specific for HCV 
infection is required; subjects who are anticipated to require such therap y during the 
randomiz ed portion of the study  must be excluded.
Revised Text:
7.History  of ongoing or clinically  relevant hepatitis within the previous 6 months, 
including chronic hepatitis B virus (HBV) infection (HBsAg positive). 
Asymptomatic individuals with chronic hepatitis C virus (HCV) infection will not be 
excluded, however Investigators must carefull y assess if therap y specific for HCV 
infection is required; subjects who are anticipated to require such therap y must be 
excluded.
Section [IP_ADDRESS]. Confirmed Virologic Sample –added plasma sample collection from 
the confirmation visit.
New Text Added:
A plasma sample from the confirmation visit will be obtained for storage.  This sample 
may be used for possible future analy ses, e.g. for genoty pic and phenot ypic anal yses of 
subjects who experience virologic failure.
Section 5.1. Investigational Product and Other Study Treatment – Changed Epzicom 
/ Kivexa to I P at Day  1 and clarification regarding other background therapy supplies.
Original Text:
In this stud y, investigational pr oduct (IP) refers to [COMPANY_004]744, [COMPANY_004]744 L A, RPV and 
TMC278 L A.  These will be supplied by  [CONTACT_339254], 
respectivel y.  
Other antiretrovirals administered in the study  as dual background NRTIs are not 
considered IP.  However, these will be supplied by [CONTACT_339328], in some cases,
reimbursement will be provided.
Revised Text:
In this stud y, investigational product (IP) refers to [COMPANY_004]744, [COMPANY_004]744 L A, RPV and 
TMC278 L A.  These will be supplied by  [CONTACT_339254],  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
339respectivel y.  Epzicom / Kivexa will also be considered IP from Day  1 of the 
Maintenance Period and will be provided by  [CONTACT_23983].   
Other antiretrovirals administered in the study  as dual background NRTIs (e.g. for 
subjects who are HLA -B*5701 positive or switch due to toxicity ) are not considered IP.  
These may besupplied regionall yby [CONTACT_339255].
Section 5.1.2. TMC278 – Tablet (Rilpi[INVESTIGATOR_12979], RPV) –Added Excurion temperatures.
Original Text:  
RPV tablets are to be stored at 25°C and protected from light.
Revised Text:
RPV tablets are to be stored at 25°C (excursions permitted to 15°-30°C [59°- 86°F]) and 
protected from light.
Section 5.1.3. Background NRTIs –Section title changed, Reference Information 
clarification, excursion temperatures added.
Original Text:
5.1.3. Background NRTIs
ABC/3TC [ Epzicom /Kivexa Product I nformation , 2012] is manufactured by  
[CONTACT_339329]/3TC fixed dose combination (FDC) oral 
tablet, which contains 600 mg of ABC (as abacavir sul fate) and 300 mg of 3TC. The 
tablets are orange, film -coated, modified capsule -shaped and debossed with GS FC2 on 
one side with no markings on the reverse side. ABC/3TC is packaged in bottles of 
30 tablets. ABC/3TC will be supplied by  [CONTACT_339258]. ABC/3TC tablets 
are to be stored at 25°C.
Revised Text:
5.1.3. Epzicom / Kivexa
ABC/3TC [ Epzicom Product I nformation , 2012] is manufactured by [CONTACT_339257]/3TC fixed dose combination (FDC) oral tablet, which 
contains 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC. The tablets are 
orange, film -coated, modified capsule -shaped and debossed with GS FC2 on one side 
with no markings on the reverse side. ABC/3TC is packaged in bottles of 30 tablets. 
ABC/3TC will be supplied by  [CONTACT_339258]. ABC/3TC tablets are to be 
stored at 25°C (excursions permitted to 15°-30°C [59° -86°F]). 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
340Section 5.7.1 Oral Dosing –Clarification of Visit Window.
Original Text:
Oral dosing is expected to occur during the week in w hich the subject’s projected 
visit falls (as according to the Baseline visit).  
Revised Text:
Visits for subjects on the oral dosing arm are expected to occur as projected 
according to the Baseline visit.  There is a (+ or -) 3 day visit window, from the 
projected visit date.  However, the number of tablets dispensed should be considered 
when scheduling the next visit.
Section 5.7.2. IM Dosing AND Section [IP_ADDRESS]. – dosing window clarification.
Original Text:  
An additional (+ or -) 7 day window is allow able for IM dosing but not preferred .  
Revised Text:
An additional (+ or -) 7 day window, from the projected visit date, is allowable for 
IM dosing but not preferred .  
Section 5.8. Discontinuation of Study Treatment – deleted name [CONTACT_339342].
Original Text:
Subjects unable to manage drug toxicity  or tolerate investigational product (IP, either 
formulations of [COMPANY_004]1265744 or TMC278) must have IP discontinued.
Revised Text:
Subjects unable to manage drug toxicity  or tolerate investigational product must have I P 
discontinued.
Section 5.9.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] – clarifications.
Original Text:
Chronic use of oral glucocorticoster oids must be avoided; however, short treatment 
courses (e.g., 1 0 day s or less) and topi[INVESTIGATOR_2855], inhaled or intranasal use of 
glucocortic oster oids will be allowed.
For information on concurrent therapi[INVESTIGATOR_339172] y in the regimen, please consult the local presc ribing information. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
341Revised Text:
Chronic use of oral glucocorticoids must be avoided; however, short treatment courses 
(e.g., 10 day s or less) and topi[INVESTIGATOR_2855], inhaled or intranasal use of glucocorticoids will be 
allowed.
Hepatitis C infection treatment will not be permitted during the study.
For information on concurrent therapi[INVESTIGATOR_339172] y in the regimen (e.g. Epzicom / Kivexa) , please consult the local 
prescribing information.
Section 5.10.1. L ong-Term Follow -Up Period –clarification regarding provision of 
alternative NRTI therap y.
Original Text:
The Sponsor will not provide this regimen but will reimburse sites for cost .
Revised Text:
[COMPANY_004] may  suppl y HAART regionall y or reimbursement will be pr ovided.
Section 5.11. Treatment of Study Treatment Overdose – overdose information 
provided for Epzicom / Kivexa.
New Text Added:  For subjects receiving Epzicom / Kivexa, any  tablet intake exceeding 
the protocol defined daily number of tablets (one tablet daily ) will be considered an 
overdose.
Section 6.1. Time and Events Table – Induction Period , Section 6.2. Time and 
Events Table –Maintenance Period for IM Regimen ([COMPANY_004]744 LA + TMC278 LA
Q8W), AND Section 6.3. Time and Events Table –Maintenance Period f or IM 
Regimen ([COMPANY_004]744 LA + TMC278 LA Q4W) – clarification provided.
Split CD8+ cell count into new row in table.
Section 6.1 Time and Events Table – Induction Period –Footnote a – clarification for 
subjects who begin the Induction Period (no longer randomized at Induction).
Footnote a: Original Text:
Subjects may  be randomized and begin the Induction Period as soon as all 
Scree ning assessments are complete.
Revised Text:
Subjects may  begin the Induction Period as soon as all Scree ning assessments are 
compl ete. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
342Demography:   Moved collection from Week ( -20) to Screening Period.
Footnote f:   Addition of HIV Risk Factors and clarification of when data is 
reported in InForm 
Original Text:
f. Collect full routine medical history  plus: cardiovascular risk factors
(assessments include smoking status and history , family  history  of cardiac 
events), recent [ 6 months] illicit drug use, intravenous drug use, gastrointestinal 
disease, metabolic, ps ychiatric, renal and neurologic disorders.
Revised Text:
f. Collect full routine medical history  plus (report at Baseline visit): HIV risk 
factors (may  be collected at a later stud y visit), cardiovascular risk factors 
(assessments include smoking status and history , family  history  of cardiac 
events), recent [ 6months] illicit drug use, intravenous drug use, gastrointestinal 
disease, metabolic, ps ychiatric, renal and neurologic disorders.
HIV -1 RNA and sample for storage:   “and genoty pe” added for clarification at 
Screening visit.
Section 6.2. Time and Events Table – Maintenance Period for IM Regimen ([COMPANY_004]744 
LA + TMC278 LA Q8W) – clarification.
PK Sample for Storage –changed to “X” at Withdrawal Visit.
Section 6.2. Time and Events Table – Maintenance Period for IM Regimen ([COMPANY_004]744 
LA + TMC278 LA Q8W) AND Section 6.3. Time and Events Table –Maintenance 
Period for IM Regimen ([COMPANY_004]744 LA + TMC278 LA Q4W) – clarification provided.
Footnotes l and m :
Original Text:
l) Subjects should take [COMPANY_004]744+ABC/3TC+RPV on Day  1 in the clinic 
prior to PK sampling and injections should be administered within 2 hours of this 
where possible.  
m) ............ IM dosing is expected to occur during the week in which the 
subject’s projected visit falls (as according to the Day 1 visit).  An additional 
(+ or -) 7 day window is allowable fo r IM dosing but no t preferred.......
Revised Text:
l) Subjects should take [COMPANY_004]744+ABC/3TC+RPV on Day  1 in the clinic 
after PK sampling and injections should be administered within 2 hours of this 
where possible.   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
343m) .......... IM dosing is expected to occur during the week in which the 
subject’s projected visit falls (as according to the Day 1 visit).  An additional 
(+ or -) 7 day window ,from date of projected visit ,is allowable for IM dosing 
but not preferred ........  
Section 6.4. Time and Events Table – Maintenance Peri od for Oral Regimen 
([COMPANY_004]744 + ABC/3TC) –simplified ECG schedule to be consistent with IM regimens.  
Removed ECGs at Week 56, Week 72, and Week 88.
Section 6.5. Time and Events Table – Extension Period if Q8W is Selected –
clarification for timings in foot note c.
Original Text:
c. Continue this pattern for visits for the remainder of the study.  For example, 
Week208 will be conducted just like Week [ADDRESS_419680] like Week 200.
Revised Text:
c. Continue this pattern for visits for the remainder o f the study .  For example, 
Week [ADDRESS_419681] like Week 192.
Section 6.5. Time and E vents Table – Extension Period if Q8W is Selected AND 
Section 6.6. Time and Events Table – Extension Period if Q4 W is Selected –
clarifications provided:
PK Sample for Storage:   Changed to “X” at Withdrawal Visit.
Footnote l (Section 6.5.) and Footnote k ( Section 6.6.) –Clarification regarding 
dosing window:
Original Text:
..........IM dosing is expected to occur during the week in which the subject’s 
projected visit falls (as according to the Day 1 visit).  An additional (+ or -) 7 
day window is allowable for IM dosing but not preferred.. ......  
Revised Text:
..........IM dosing is expected to occur during the week in which the subject’s 
projected visit falls (as according to the Day 1 visit).  An additional (+ or -) 7 
day window, from date of projected visit , is allowable for IM dosing but not 
preferred........
Section 6.7. Time and Events Table – Long -Term Follow Up Period – clarification 
provided.
PK Sample for Storage:   Changed to “S” at all visits during this period. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
344Section 6.8. Critical Screening a nd Baseline Assessments –clarification provided 
regarding legal representative –per French Regulatory  request.
Original Text:
Written informed consent must be obtained from each potentiall y eligible subject (or 
his/her legal representative) by [CONTACT_339330] y 
Screening procedures as outlined in this protocol.
Revised Text:
Written informed consent must be obtained from each potentiall y eligible subject by 
[CONTACT_339331].
Section 6.8.2. Baseline –clarification provided.
Original Text:  
In addition to a full routine medical history at Baseline , more detailed information will be 
collected for some disease processes such as:
Revised Text :
In addition to a full routine medical history , more detailed information will be collected 
for some disease processes such as:
Section 6.9.2. Lymphocyte Subsets, CD4+ and CD8+ - additional protocol reference 
added.
Original Text:
Lym phocy te subsets will be collected for assessment by  [CONTACT_4133]  (total 
lymphocy te counts, percentage and absolute CD4+ and CD8+ l ymphocy te counts, ratios) 
according to Time and Events schedule (Section 6).
Revised Text:
Lym phocy te subsets will be collected for assessment by [CONTACT_190961]  (total 
lymphocy te counts, percentage and absolute CD4+ and CD8+ l ymphocy te counts, ratios) 
according to Time and Events schedule (Section 6) and Laboratory Assessments 
(Section 6.10.2 ).
Section [IP_ADDRESS]. Definition of an AE – removed duplic ate text.
The signs and symptoms and/or clinical sequelae resulting from lack of efficacy  will be 
reported if they  fulfill the definition of an AE or SAE.  Also, “lack of efficacy ” or 
“failure of expected pharmacological action” also constitutes an AE or S AE. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
345Section [IP_ADDRESS]. Treatment Interruption Due to an Adverse Event –clarification 
provided.
Original Text:
IP and background NRTIs should be restarted as soon as medicall y appropriate; in 
general, this should be no longer than 14 day s after discontinuat ion (unless Grade [ADDRESS_419682]).
Revised Text:
IP and background NRTIs should be restarted as soon as medicall y appropriate; in 
general, for oral dosing , this should be no longer than 14 day s after discontinuation 
(unless Grade [ADDRESS_419683]).
Section [IP_ADDRESS].1. Essential Patient Information –clarification of brand name .
Original Text:
In order to avoid restarting abacavir, subjects who have experienced a 
hypersensitivity  reaction should be asked to return any  remaining EPZICOM tablets 
to the I nvestigator or site staff.
Subjects, who have stopped abacavir for an y reason, and particularly due to possible 
adverse reactions or illness, must be advised to contact [CONTACT_339332] -
threatening h ypotension and death.
Each subject should be reminded to read the Package Leaflet included in the 
EPZICOM pack. They  should be reminded of the importance of removing the Alert 
Card included in the pack, and k eepi[INVESTIGATOR_227319]. 
Revised Text:
In order to avoid restarting abacavir, subjects who have experienced a 
hypersensitivity  reaction should be asked to return any  remaining EPZICOM / 
KIVEXA tablets to the Investigator or site staff.
Subjects, who have stopped abacavir for an y reason, and particularly due to possible 
adverse reactions or illness, must be advised to contact [CONTACT_339333] / KIVEXA as more severe s ymptoms may  recur within hours and may  
include life -threaten ing hy potension and death.
Each subject should be reminded to read the Package Leaflet included in the 
EPZICOM / KIVEXA pack. They  should be reminded of the importance of 
removing the Alert Card included in the pack, and keepi[INVESTIGATOR_227319].  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
346Section 6.11.1. PK Sample Collection –clarification of TMC278 sample at Day  1.
Original Text:
For subjects randomized to [COMPANY_004]744, pre-dose blood samples for evaluation of 
[COMPANY_004] 1265 744 (2 mL each) and TMC278 (3 mLeach) will be collected as described in 
Table 4.
Revised Text:
For subjects randomized to oral[COMPANY_004]744, pre-dose blood samples for evaluation of 
[COMPANY_004] 1265 744 (2 mL each) and TMC278 (3 mL, Day 1 predose only ) will be collected as 
described in Table 4.
New Text Added:  New row in Table 4 showing pre -dose TMC278 collection at Day 1.
Section 8.2.2. Sample Size Sensitivity –Updated Figure 6 legend to include 94% 
response.
Original Figure:
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
347Revised Figure:
Section [IP_ADDRESS]. Intent- to-Treat Exposed Population (ITT -E)–corrected ty po.
Original Text:
The I TT-E population consists of all enroll ed subjects who receive dat least one dose of 
IP. 
Revised Text:
The ITT- E population consists of all enroll ed subjects who receive at least one dose of IP. 
Section [IP_ADDRESS]. Intent -to-Treat Maintenance Exposed Popul ation (ITT -ME)–
corrected t ypo.
Original Text:
The ITT-M E population consists of all randomized who receive dat least one dose of IP
during the Maintenance Period of the study . 
Revised Text:
The ITT- ME population consists of all randomized subjects who receive at least one dose 
of IP during the Maintenance Period of the study .   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
348Section [IP_ADDRESS]. PK Population –corrected t ypo.
Original Text:
The PK Population will include all subjects who receive d[COMPANY_004] 1265 744 and / or TMC278 
and undergo PK sampling during the study , and provide evaluable [COMPANY_004] 1265 744 and /or 
TMC278 plasma concentration data. 
Revised Text:
The PK Population will include all subjects who receive [COMPANY_004]1265 744 and / or TMC278 
and undergo PK sampling during the stud y, and provide evaluable [COMPANY_004] 1265744 and /or 
TMC278 plasma concentration data. 
Section 10. References –Updated.
Added New Reference:
Cohen C, Molina JM, Cahn P, et at.  Efficacy  and Safety  of Rilpi[INVESTIGATOR_12979] (TMC278) 
Versus Efavirenz at 48 Weeks in Treatment -Naïve HIV -1-Infected Patients:   
Pooled Results From the Phase 3 Double -Blind Randomized ECHO and THRI VE 
Trials.  JAIDS .  2012; 60 (1):33-42.
Updated Date:
Original Text:
Edurant Product Information (rilpi[INVESTIGATOR_12979]) June, 201 3.
Revised Text:
Edurant Product Information (rilpi[INVESTIGATOR_12979]) May, 2014.
Original Text:
Epzicom /Kivexa Product I nformation (abacavir/lamivudine) May , 2012.
Revised Text:
Epzicom Product I nformation (abacavir/lamivudine) May , 2012.
Removed duplicate reference:
GlaxoSmithKline Document Number 2011N112455_03:  L AI115428 A 
Randomized, Open Label Study  to Investigate the Safety , Tolerabilit y and 
Pharmacokinetics of Repeat Dose Administration of L ong-Acting [COMPANY_004]1265744 
and L ong-Acting TMC278 I ntramuscular and Subcutaneous Injections in Healthy  
Adult Subjects.  Effective Date:  04F eb2013. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419684] dose ECG at Week 32 and Week 48.  There is no observed safety  issue, 
however, preliminary  PK data pre ceeding IDMC review #[ADDRESS_419685] 
dose as there is documentation of some QTc prolongation at higher concentrations of 
TMC278 which theoretically  could occur on this study .  Although nothing has been 
observed to date on either study  LAI116482 or 200056.
At the time of the development of the Amendment, Week 96 data from LAI116482 was 
available and therefore included for informational purposes.
A more de tailed description of how injection site reactions has been included for clarit y.
Removed “preliminary ” or “ongoing” when describing studies that are now complete.
Finally , several miscellaneous clarifications were made throughout.
Authors
Original authors:
Author (s):    (phy sician lead and medical monitor);  
(project statistician),  (stud
y statistician);  
(pharmacologist);  (virologist);  (clinical scientist), 
 (pharmacokineticist);  (pharmacokineticist);  
 (medical development lead);  (operations)
Revised to:
Author (s):   (phy sician lead and medical monitor); 
(project statistician), (study  statistician); (pharmacologist); 
 (virologist);  (clinical scientist),  
(pharmacokineticist);  (medical development lead); 
(operations)
Sponsor Information
Changed the medical monitor’s affiliation from GlaxoSmithKline to ViiV Healthcare.  
The medical monitor’s contact [CONTACT_339334], including the email 
address.
Changes underlined and struckthrough: 2018N380094_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2013N168152_09 CONFIDENTIA L
[ADDRESS_419686] Information : 
 MD, MPH
ViiV Healthcare
GlaxoSmithKline
Research Triangle Park
Five Moore Drive, Research Triangle Park, NC [ZIP_CODE] ([LOCATION_003])
Mobile: 
Office Telephone: 
Fax: 
e-mail: 
Sponsor Serious Adverse Events (SAE) Contact [CONTACT_7171]:
 MD, MPH
ViiV Healthcare
GlaxoSmithKline
Research Triangle Park
Five Moore Drive, Research Triangle Park, NC [ZIP_CODE] ([LOCATION_003])
Mobile: 
Office Telephone: 
Fax: 
e-mail: 
Protocol Sy nopsis
Added:
At one-week post dose visits (Week 1, Week 25, and Week 41), there is no defined visit 
window, rather visits should occur approximately  [ADDRESS_419687] injection with a 
(+or -) 3 day  visit window, from the projected visit date.
Added:
Visits in L ong Term Follow Up are to occur as projected from the last injection w ith a 
(+or -) 3 day  visit window, from the projected visit date.
Added under Key  Study  Assessments (changes underlined):
PK assessments including [ADDRESS_419688] dose samples at Day  1, Week 32 and Week 
48 2018N380094_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2013N168152_09 CONFIDENTIA L
200056
351Section 1.4 [COMPANY_004]1265744 –Long A cting Injectable ([COMPANY_004]74 4 LA )
Revised to (changes struck through and underlined):
[COMPANY_004]744 L A, a long acting injectable formulation of [COMPANY_004]1265744 , has been dosed in 
136healthy subjects.  Subjects have received single or repeat doses of [COMPANY_004]744 LA at 
doses between 100 to 800 mg , either intramuscularly  (IM) or subcutaneously  (SC) and 
either alone or in combination with TMC 278 L A (completed study  LAI114433 [single 
dose LA, n=58], ongoing study  LAI115428 [repeat dose L A, n=40], and ongoing study  
LAI116815 [single dose LA, n=38]). Theadverse event (AE) profile has been similar to
those of [COMPANY_004]744 (oral).  To date, no studies in HIV -[ADDRESS_419689] been 
conducted with [COMPANY_004]744 LA.  
[COMPANY_004]744 L Ahas been generall ywell-tolerated as either an IM or SC dose .  Intramuscular 
injection si te reactions (ISRs) have been predominantly  mild or Grade 1 (85%), self-
limited, and have not led to study  discontinuation in any  subject to date. Erythema, 
nodules, induration, and warmth at the injection site were most commonl yreported in 
healthy  subje cts.  Painless nodules were more common following SC injections than I M 
injections.   No treatment emergent serious AEs have been reported in any  of the healthy  
volunteer studies involving [COMPANY_004]744 LA .  [Preliminary  data from ongoing study
LAI115428 GlaxoSmit hKline Document Number 2011N112455_03 and 
GlaxoSmithKline Document Number RM2010/[ZIP_CODE]/04 : LAI114433 ]. 
Section 1.7 Study  LAI116482
Revised to (changes struck through and underlined):
LAI116482 is an ongoing Phase IIb dose -ranging study  ([COMPANY_004]744 10 mg, 30 m g, 60 mg) 
evaluating the utility  of a two- drug, two- class combination ([COMPANY_004]744 + RPV) when both 
are given as a once dail y oral regimen following induction of virologic suppression using 
[COMPANY_004]744 plus 2 investigator selected NRTIs. Eligible subjects enter Mai ntenance at 
Week 24 where they  begin the [COMPANY_004]744 + RPV regimen.  
To date, the study has enrolled 244 subjects, 181 of whom received one of three oral dose 
regimens of [COMPANY_004]744 (10 mg, 30 mg or 60 mg) plus 2 NRTI s. A planned Week 48 96 
(24weeks on Induction and 2472 weeks on two- drug Maintenance) analy sis is complete 
and demonstrated similar antiviral activity  across the three dosing arms of [COMPANY_004]744 in 
combination with RPV , which compared favorably to the control regimen of 
EFV 600mg once daily  plus 2 NRTI s. 
Rates of protocol defined virologic failure (PDVF) through Week 48 96 were low across 
all study  arms . Three subjects receiving [COMPANY_004]744 (one at each dose) and three subjects 
receiving EFV were characterized as PDVFs during Induction.  During Maintenance, two 
three subjects receiving [COMPANY_004]744 (10 mg, n=2; and 30 mg, n=1) and one two subject s 
receiving EFV were characterized as PDVF.   
During Maintenance, t reatment emergent integrase inhibitor ( INI)(Q148R) and NNRTI 
(E138Q) resistance mutations were identifi ed in one of thesubject son [COMPANY_004]744 (10 mg) .
The subject experienced suspected virologic failure (SVF) at Week 48, which was  2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419690] on [COMPANY_004]744 (10 mg) developed treatment emergent NNRTI resistance 
NNRTI (K101K/E and E138E/A).  The subject experienced virologic failure at Week 72 
which was subsequently  confirmed.   There was no change to [COMPANY_004]744 susceptibility , and 
a 4.6 fold change in susceptibility  to TMC278.  The re was no treatment -emergent 
integrase resistance.
By [CONTACT_10585] 16 or at time of I P discontinuation if before Week 16, 63% of subjects were 
treated with Truvada (tenofovir/emtricitibine, TDF/FTC) as their background dual NRTI 
and 3 7% of the subjects were treate d with EPZICOM/KIVEXA™ (abacavir/lamivudine, 
ABC/3TC).  Similar virologic response rates (HIV -1 RNA < 50 c/mL) through 24 weeks 
were seen in subjects taking [COMPANY_004]744 + ABC/3TC (87%) and in subjects taking [COMPANY_004]744 
+ TDF/FTC (86%). Rates continued to be simila r through Week 48, 79% for subjects 
taking [COMPANY_004]744 + ABC/3TC and 84% in subjects taking [COMPANY_004]744 + TDF/FTC.
Following induction therapy , [COMPANY_004]744 + RPV (86%) maintained virologic suppression at 
a rate similar to EFV + NRTI s (83%) through [ADDRESS_419691] occurred on 
study  day 343.  All other AEs were Grade 1 or 2 with the majority  of them being Grade 
1.  The majority  of AEs were Grade 1 (29%) or Grade 2 (49%) severit y.  Six Seven
subjects on [COMPANY_004]744 versus eight nine on EFV withdrew due to an AE, one receiving 10
mg (ECG abnormal and palpi[INVESTIGATOR_814]), one tworeceiving 30 mg (panic attack , Burkitt’s 
lymphoma ) and four receiving 60 mg (hepatitis, transaminases increased, anxiety  
disorder and musculoskeletal pain).  The majority  of [COMPANY_004]744 related AEs were Grade 1 
and few of those AEs led to withdrawal through Week 48 96(n=4 [2%] ).  There have 
been no [COMPANY_004]744 drug related SAEs to date.  
Two of the subjects that withdrew due to AE met l iver stoppi[INVESTIGATOR_339151] ( ALT) >10x upper limit of normal ( ULN )at approximately  Week 4 and 
Week 8 after initiating study drug.  Both had pre -existing steatohepatitis and were dosed 
with [COMPANY_004]744 60 mg + ABC/3TC.  Both subjects remained as ymptomatic, had normal 
serum bilirubin levels and had resolution of the ALT values after drug discontinuation.  
These 2 subjects were accounted for the onl y Grade 3 -4 ALT abnormalities in this study 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
353to date.  Overall, the rates of an y graded ALT or aspartate aminotransferase ( AST )
abnormality  were similar between [COMPANY_004]744 and EFV dosed subjects through Week 48 96: 
ALT:  17 20% and 21% respectivel y; AST:  250% and 1821% respectivel y.
These data from LAI116482 support the conduct of study  200056 by  [CONTACT_339309]744 when used initially  as part of a HAART regimen to induce 
virologic suppression.  In addition, this data confirmed antiviral activity  of [COMPANY_004]744 + 
RPV as a two- drug oral Maintenance regimen and provide sproof of principle for 
[COMPANY_004]744 L A + TMC278 LA as a maintenance regimen.  
Based upon the results through Week 48 96of the LAI116482 study [Margolis, 2015], 
and in accordance with the pre -specified dose selection criteria at Week 2448, a 30 mg 
oral dose of [COMPANY_004]744 h as been selected to be used in combination with ABC/3TC for 
induction of virologic suppression in study  200056.
All ongoing subjects in the LAI116482 stud y have entered into Maintenance the Open 
Label Extension phase to continue to receive the two drug reg imen of [COMPANY_004]744 30 mg + 
RPV [ADDRESS_419692] 
evaluation of the virologic efficacy  of the oral tw o drug regimen of [COMPANY_004]744 and RPV, 
prior to initiating the long acting injectable regimen .  These data will be made available 
to Investigators.
Section 1.10.1 Risk A ssessment
Section [IP_ADDRESS] [COMPANY_004]744 and [COMPANY_004]744 LA
Added:
Inadvertent Intravenous Injection (Accidental Maladministration)
As with any  intramuscular injection, it is possible that [COMPANY_004]744 LA can be inadvertentl y 
administered intravenously  instead of intramuscularly  resulting in higher than expected 
concentrations of [COMPANY_004]744 L A.  This could be due to administrator error, improper 
injection technique and / or improper needle length used based on bod y type.    
Mitigation:  Training will be provided to all sites on proper injection technique.  
Laboratory  samples for safet y parameters and HIV -[ADDRESS_419693] dose PK samples will be obtained at a few earl y 
timepoints (Day  1, Week 32 and Week 48) for determination of [COMPANY_004]744 concentrati on 
and possible pharmacokinetic correlation with safety  parameters such as ECG changes 
and virologic response.  Should I M maladministration be suspected at an y time (e.g. 
suspected under or overdose or inadvertent IV dosing), a post dose ECG or any  other 
supportive testing may  be obtained at the discretion of the investigator, and the medical 
monitor notified.  Additionally , an unscheduled PK sample may  be drawn approximately  
[ADDRESS_419694] dosing for future evaluation of [COMPANY_004]744 and TMC278 concentrations. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
354Section [IP_ADDRESS] TMC278 LA
Added:
Inadvertent Intravenous Injection (Accidental Maladministration)
As with any  intramuscular injection, it is possible that TMC278 L A can be inadvertentl y 
administered intravenously  instead of intramuscularly  resulting in highe r than expected 
concentrations of TMC278 L A.  This could be due to administrator error, improper 
injection technique and / or improper needle length used based on bod y type.  
Mitigation:  Training will be provided to all sites on proper injection technique.  
Laboratory  samples for safet y parameters and HIV -[ADDRESS_419695] dose PK samples will be obtained at a few earl y 
timepoints (Day  1, Week 32 and Week 48) for determination of TMC278 concentration 
and possible pharmacokinetic correlation with safety  parameters such as ECG changes 
and virologic response.  Should I M maladministration be suspected at an y time (e.g. 
suspected under or overdose or inadvertent IV dosing), a post dose ECG or any  other 
supportive testing may  be obtained at the discretion of the investigator, and the medical 
monitor notified.  Additionally , an unscheduled PK sample may  be drawn approximately  
[ADDRESS_419696] dosing for future evaluation of [COMPANY_004]744 and TMC278 concentrations.
Section [IP_ADDRESS] Efficacy  Risk
Changed title of section to “ Risk of Treatment Failure ”
And added:
Due to administrationor error, it is possible that a subject could receive an inadequate 
dose of [COMPANY_004]744 LA or TMC278 L A.  Sub- therapeutic concentrations of eithe r [COMPANY_004]744 
LA or TMC278 LA could lead to virologic failure and possibly  the development of 
resistance.  HIV -[ADDRESS_419697] sentence updated to be through Week 96.  
Revised to (changes struckthrough and underlined):
Efficacy  of the two- drug regimen ,as oral agents ,has been demonstrated through 
Week 48 96of the ongoing LAI116482 study .  
Section 3.3 Discussion of Design
Added study  number to T able 3. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
355Revised to (changes underlined):
Table 10 LAI116482 Proportion of Subjects with Plasma HIV -1 RNA  <50 c/mL at 
Key Visits -Snapshot (MSDF) A nalysis (ITT -ME Population)
Visit[COMPANY_004]744
10 mg
N=52
n (%)[COMPANY_004]744
30 mg
N=53
n (%)[COMPANY_004]744
60 mg
N=55
n (%)[COMPANY_004] 744 
Subtotal
N=160
n (%)EFV 
600 mg
N=47
n (%)
Week 16 -Induction 50 (96) 49 (92) 52 (95) 151 (94) 43 (91)
Week 24 -Induction 50 (96) 50 (94) 53 (96) 153 (96) 45 (96)
Week 48 -Maintenance 48 (92) 48 (91) 53 (96) 149 (93) 44 (94)
Section 4.[ADDRESS_419698] awal Criteria
Clarified that the change from Baseline QT criteria is an increase in QTc > 60 msec.
Revised to (changes underlined):
The following QT criteria:
QTc >500 msec
Uncorrected QT >600 msec
Change from Baseline: Increase in QTc > 60 msec
Section 5. 1.7 Dosing Considerations for [COMPANY_004]744 LA  + TMC278 LA
Clarified need for varied needle lengths and added language regarding maladministration.
Revised to (changes struckthrough and underlined):
Variable needle lengths may need to be used to accommodate individual body  type.  For 
example , longer needle lengths willmay be required for subjects with higher body  mass 
indexes (BMIs, example > 30), to ensure that injections are administered intramuscularl y 
as opposed to subcutaneously .  BM I and needle length used will be collected in the 
eCRF.
Added:
Should I M maladministration be suspected at an y time (e.g. suspected under or overdose 
or inadvertent IV dosing), the investigator may  consider requesting the subject stay  onsite 
for up to [ADDRESS_419699] dosing for future 
evaluation of [COMPANY_004]744 and TMC27 8 concentrations.
Section 5.7.1 Oral Dosing
Revised section heading to “Oral Dosing Including Long Term Follow Up .” 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
356Added:
Visits for subjects in L ong Term Follow Up are expected to occur as projected according 
to the last injection.  There is a (+ or -) 3day visit window, from the projected visit date.
Section 5.7.[ADDRESS_419700] dose visits.
Revised to (changes underlined):
IM dosing is expected to occur during the week in which the subject’s projected visit falls 
(asaccording to the Day  1 visit).  An additional (+ or -) [ADDRESS_419701] dose visits 
(Week 1, Week 25, and Week 41), there is no defined visit window, rather visits should 
occur approximately  [ADDRESS_419702] injection.
Section 5.11 Treatment of Study  Treatment Overdose
Added:
Should I M maladministration be suspected at an y time (e.g. suspected under or overdose 
or inadvertent IV dosing), the investigator may  consider requesting the subject stay  onsite 
for up to [ADDRESS_419703] dosing for future 
evaluation of [COMPANY_004]744 and TMC278 concentrations.
Section 6.2 Time and Events Table –Maintenance Period for IM Regimen ([COMPANY_004]744 
LA + TMC278 LA  Q8W)
Added a footnote “c” to ECG line at Week 32 and 48.  Added a footnote “k” to PK line at 
Week 32 and 48.
Procedure
s
For 
Maintenan
ce –Q8W   
regimenD
1W
1W
4W
8W
1
2W
1
6W
2
0W
2
4W
2
5W
2
8W
3
2W
3
6W
4
0W
4
1W
4
4W
4
8W
5
2W
5
6W
6
0W
6
4W
6
8W
7
2W
7
6W
8
0W
8
4W
8
8W
9
2W
9
6W
D
p, q
ECG c X
pr
eX X X X X
cX
cX X X X
PK 
Sample 
(S)torage kX 
kX X X X X X X X X X
kX X X X X
kS S S S S S X
Revised footnote “c” to (changes underlined): 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
357c)  12-Lead ECG – Conduct pre -dose at Day  1.  At all other visits, the ECG may  be done 
at an y time during the visit. At Week [ADDRESS_419704] dose PK 
sampling.
Revised footnote “k” to (changes underlined):
k) Take PK samples pre -dose except Week s 1, 12, 20, 25, 28, 36, 41 and 44 which can be 
taken at an y time during the visit.  Day 1 PK sample should be taken after review of PK 
diary  and pre -dose of [COMPANY_004]744+ABC/3TC+RPV.  A second Day  1, Week [ADDRESS_419705] injection.
Section 6.3 Time and Events Table –Maintenance Period for IM Regimen ([COMPANY_004]744 
LA + TMC278 LA  Q4W)
Added a footnote “c” to ECG line at Week 32 and 48.  Added a footnote “k” to PK line at 
Week [ADDRESS_419706] cell.  Changes underlined.
Procedure
s
For 
Maintenan
ce –Q8W   
regimenD
1W
1W
4W
8W
1
2W
1
6W
2
0W
2
4W
2
5W
2
8W
3
2W
3
6W
4
0W
4
1W
4
4W
4
8W
5
2W
5
6W
6
0W
6
4W
6
8W
7
2W
7
6W
8
0W
8
4W
8
8W
9
2W
9
6W
D
p, q
ECG c X
pr
eX X X X X
cX
cX X X X
PK 
Sample 
(S)torage kX 
kX X X X X X X X X X
kX X X X X
kS S S S S S X
Revised footnote “c” to (changes underlined):
c)  12-Lead ECG – Conduct pre -dose at Day  1.  At all other visits, the ECG may  be done 
at an y time during t he visit. At Week [ADDRESS_419707] dose PK 
sampling.
Revised footnote “k” to (changes underlined):
k) Take PK samples pre -dose except Weeks 1, Week 25 and Week 41 which can be taken 
at an y time during the visit.  Day 1 PK sample should be taken after review of PK diary 
and pre -dose of [COMPANY_004]744+ABC/3TC+RPV.  A second Day  1, Week [ADDRESS_419708] injection.
Section 6.7 Time and Events Table –Long -Term Follow Up Period
Missing footnote “c”.  Added (underlined): 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
358Fasting:  Glucose, Cholesterol (Total, 
HDL and LDL) and TriglyceridescX X
Section 6.9.[ADDRESS_419709] sentenc e to (changes struckthrough and underlined):
Plasma for quantitative HIV- 1 RNA will be collected according to the Time and Events 
schedule (Section 6).  Methods to be used may  include but are not limited to the Abbott 
RealTime HIV -1 Assay  lower limit of de tection (LLOD) 40 c/mL.  In some cases (e.g., 
where the HIV -1 RNA is below the lower limit of detection for a given assay ) additional 
exploratory  methods may will be used to further characterize HIV -1 RNA levels.
Section 6.10.1 Clinical evaluations
Clarified injection site reaction evaluations.
Added:
The investigator should utilize subject diary  reports to assist with a clinical assessment 
(using Division of Acquired Immunodeficiency  Syndrome [DAIDS] grading scale).  A 
clinical assessment should be performe d both before and after an injection to identify  
resolving and new ISRs.  The clinical assessment and interpretation of any  ISR, including 
those reported b y the subject via diary, will be documented in the I SR AE eCRF.  Daily  
diary  data, or subject assessm ent, will be documented verbatim in the diary  eCRF.
Section 6.10.2 Laboratory  Assessments, Section [IP_ADDRESS] Liver Chemistry  
Stoppi[INVESTIGATOR_2121], Subject Management and Section 6.12 Viral Genotypi[INVESTIGATOR_339220] “Quest Diagnostics” to “central labo ratory ” throughout.
Section 6.10.2 Laboratory  Assessments
Removed reference to Cockgroft- Gault formula as Creatinine Clearance may  be derived 
by [CONTACT_339335].  Changes to footnote struck through.
b) Creatinine clearance will be estimated by  [CONTACT_339336] -Gault method [Cockcroft, 1976] and assessed at Screening, Baseline, Week 
(-12), Week ( -4), Day  1 and Weeks 4, 16, 32, 48 and 96.
Removed erroneous footnote “h”.
Section [IP_ADDRESS] Definition of an A E
Added as an event meeting the definition of AE: 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
359• All injection site reactions.
Section [IP_ADDRESS] QTc Prolongation
Clarified instances when IP should be discontinued.
Revised to (changes underlined):
Subjects with an average QTc interval > 500 msec or a >[ADDRESS_419710] I P discontinued .
Section [IP_ADDRESS] Injection Site Reactions (ISRs)
Clarified that I SRs will be managed through investigator assessment and subject diaries.  
Combined this section with original S ection 6.10.11 I njection Site Reaction Monitoring.
Revised to (changes struckthrough and underlined):
Injection site reactions will be managed through AE reporting and patient investigator 
assessment and subject diary  collection throughout t he study .  All Grade [ADDRESS_419711] an injection site reaction 
considered serious, Grade 3 or above, or if clinically  significant and persistent bey ond 30 
days and others if the Investigator or Medical Monitor feels it is medically  necessary .
Details regarding photo collection and an y other follow up will be given by [CONTACT_339285].
ISR discomfort can be managed s ymptomaticall y (e.g. cold/warm compress, 
acetaminophen, ibuprofen) if the reaction is interfering with the subject’s ability  to 
perform activities of daily living.  The required intervention should be documented on the 
appropriate eCRF page.   
Section 6.10.11 Injection Site Reaction Monitoring
Deleted this section and combined with S ection [IP_ADDRESS].
Subjects on either IM regimen will be monitored closely both clinicall y and by [CONTACT_339325]:
• Pain, tenderness, pruri tis, warmth, infections, rash, erythema, swelling, 
induration, and nodules (granulomas or cy sts).  
Digital photographs will be documented where possible on all subjects who have an 
injection site reaction that is either serious or Grade [ADDRESS_419712] dose sample for [COMPANY_004]1265744 and 
TMC278 at Week 32 and Week 48.
Group Analyte Week Sample Times Relative to Dose
IM [COMPANY_004]1265744 Day 1 (prior to LA and 
last oral Induction 
dose), Weeks: 1, 4, 8, 
12, 16, 20, 24, 25, 28,  
32, 36, 40, 41, 44 and 
48Pre-Dose (Q8W):  Day 1, Week s 4, 8, 
16, 24, 32, 40 and 48
Pre-Dose (Q4W):  Day 1, Weeks 4, 8, 
12, 16, 20, 24, 28, 32, 36, 40, [ADDRESS_419713] Dose:  Day [ADDRESS_419714] Dose:  Week 1, Week 
[ADDRESS_419715] Dose (Q8W):  Weeks 
12, 20, 28, 36 and 44
TMC278 Day1 (prior to LA and 
last oral Induction 
dose), Weeks: 1, 4, 8, 
12, 16, 20, 24, 25, 28, 
32, 36, 40, 41, 44 and 
48Pre-Dose (Q8W):  Day 1, Weeks 4, 8, 
16, 24, 32, 40 and 48
Pre-Dose (Q4W):  Day 1, Weeks 4, 8, 
12, 16, 20, 24, 28, 32, 36, 40, [ADDRESS_419716] Dose:  Day [ADDRESS_419717] Dose:  Week 1, Week 
[ADDRESS_419718] Dose (Q8W):  Weeks 
12, 20, 28, 36 and 44
Oral [COMPANY_004]1265744 Day 1, Weeks: 32 and 
48Pre-Dose:  Day 1, Weeks 32 and 48
TMC278 Day 1 Pre-Dose:  Day 1
Section 6.11.1 PK Sample Collection and Section 6.11.3 Bioanaly sis of 
[COMPANY_004]1265744 and TMC278
Removed reference to SPM.  All PK sampling details are in the central laboratory  
manual. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
361Section 8.2.2 Sample Size Sensitivity
Corrected spelling of “positi ve” in Figure 6.
Section [IP_ADDRESS] Per Protocol Maintenance Population
Clarified this as the Maintenance Exposed Population.  Changed section title to “Per 
Protocol Maintenance Exposed Population (PP- ME).”
Revised to (changes underlined):
The PP -ME populat ion will be a secondary population for efficacy  purposes.
Section [IP_ADDRESS] Primary Comparisons of Interest
Corrected response rate.
Revised to (changes struckthrough and underlined):
The probability  of (Response rate for IMarm Response rate for Oral ar m -10%) will 
be calculated. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
362Section [IP_ADDRESS] IDMC Interim A nalysis
Clairified that the first IDMC analy sis may  not occur before all subjects enter 
Maintenance.
Revised to (changes struckthrough and underlined):
The IDMC willintends to review at least one a nalysis before all eligible subjects have 
transitioned from the Induction Period to the Maintenance Period, or as soon as 
reasonabl y possible after subjects begin to enter the Maintenance Period .
Section [IP_ADDRESS] Safety  Analyses
Clarified that injection sit e reactions will be part of the AE summaries provided.
Revised to (changes underlined):
Exposure to study medication, measured by  [CONTACT_339337], will be 
summarized by  [CONTACT_2939].  The proportion of subjects reporting adverse events ( AEs) 
will be tabulated for each treatment arm.  The following summaries of AEs will be 
provided:
Incidence and severit y of All AEs including injection site reactions ;
References
Added:
Margolis, D, et al.  Cabotegravir and Rilpi[INVESTIGATOR_339188] -Drug Oral Main tenance 
Therap y: LATTE Week 96 Results.  22nd Conference on Retroviruses and Opportunistic 
Infections; February  23-26, 2015 Poster 554LB 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
363Amendment 5
General
Clarifications of naming conventions of cabotegravir and rilpi[INVESTIGATOR_12979] (both formulations) 
were made throughout to document to be in line with the defined terms in Section 1.2.  In 
addition, the Extension Period was revised throughout the document to allow subjects to 
remain on their randomized IM regimens (rather than switching to a single selected IM 
regimen as originall y planned), and to allow subjects randomized to the oral arm in the 
Maintenance Period to switch to one of the optimized Q8W/Q4W regimens, based on 
subject preference
Week [ADDRESS_419719] 
sections had minor revis ions.
Section 1.8 200056
Section added to Protocol.
The 200056 study  (LATTE -2) evaluated a 20 week indu ction of HIV -1 RNA suppression 
with a three drug oral antiretroviral regimen consisting of CAB + ABC / 3TC Fixed Dose 
Combination (FDC) followed b y randomization to a two -drug regimen consisting of 
intramuscular (IM) long -acting (LA) CAB LA + RPV L A compared to continuation of 
oral CAB + ABC / 3TC for the maintenance of HIV -1 RNA suppression.  A total of 309 
participants were enrolled and treated.
During the Induction Period there was a rapid and sustained decline in HIV -1 RNA, with 
91% of participants (282 /309) achieving HIV -1 RNA <50 c/mL through 20 weeks of 
therap y.  There was a single participant ( with known compliance issues) with confirmed 
virologic failure during the Induction Period.  Virologic testing revealed no treatment 
emergent phenot ypic or gen otypic resistance in this participant.
The primary  endpoint for 200056 was the Week 32 proportion of participants with HI V-1 
RNA <50 c/mL (Snapshot, I ntent -to-Treat Maintenance Exposed population [I TT-ME]). 
Following virologic suppression on three drug or al therap y in the Induction Period, 
286participants qualified to enter randomization at the Day  1 visit, and were 
subsequently  randomized 2:2:1 onto every  4 week intramuscular (IM) injections with 
CAB LA + RPV LA (Q4W), every  8 week IM injections with CAB LA + RPV L A 
(Q8W) or continuation of oral CAB + NRTIs, respectivel y.  At the time of randomization 
at Day  1, participants entering one of the IM arms discontinued all oral ART. Through 
32 weeks of two -drug maintenance therapy, 95% (Q8W) and 94% (Q4W) of participants 
on injectable dosing were virologic successes, compared to 91% of participants  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
364continuing three drug oral CAB + NRTIs, meeting pre- specified criteria for comparability  
between the dosing arms. Through 32 weeks of Maintenance therap y, there wa s one 
participant each on Q8W and oral dosing with confirmed virologic failure (CVF), without 
any evolution of viral resistance. The CVF on Q8W dosing occurred following an 
aberrant RPV injection, without measurable plasma RPV concentrations [ADDRESS_419720] 
dosing.  
Week 48 data was a secondary  endpoint for 200056, and permitted the evaluation of the 
two-drug long- acting combinations’ ability  to maintain the virologic suppression 
demonstrated at Week 32.  At Week 48, 92% (Q8W) and 91% (Q4W) of participants 
receiving injectable dosing had a sustained virologic response (HIV -1 RNA <50 c/mL) 
compared to 89% of participants continuing oral CAB + 2 NRTIs.  Although the 
proportion of participants with virologic success was similar for Q8W and Q4W dosing, 
the reason for Snapshot failure was different between the arms.  There were more 
Snapshot failures for virologic reasons on the Q8W arm (n=8, 7%) than in the Q4W arm 
(n=1, <1%), and more participants with no virologic data (discontinued due to AE or 
other reasons) on the Q4W arm (n=9, 8%) compared to the Q8W arm (n=1, <1%).  
Between Week 32 and Week 48, one additional participant (Q8W) had confirmed 
virologic failure.  This participant had a Baseline HIV -1 RNA of 444,489 c/mL .  At 
Week 48, the participant was a susp ected virologic failure with HIV- 1 RNA = 463 c/mL.  
Upon retest, ten day s later, the virologic failure was confirmed with HIV -1 RNA of 
205c/mL .  At the time of CVF, this participant had treatment emergent NNRTI  
resistance K103N, E138G, and K238T, with hig h level phenot ypic resistance to 
delaviridine (>MAX), efavirenz (48 fold change [FC]), nevirapi[INVESTIGATOR_050] (>Max), and 
rilpi[INVESTIGATOR_12979] (3.34 FC). The fold change to etravirine (1.91) was below the lower cutoff.
Week 48 integrase genotype had the treatment emergent in tegrase resistance mutation 
Q148R, with accompan ying resistance to raltegravir (29 FC), elvitegravir (138 FC), and 
cabotegravir (6.06 FC). The Week 48 sample was not resistant to dolutegravir (1.38 FC).
Overall ,AEs and clinical chemistries were similar t o those observed in prior studies with 
CAB, without discernible trends between Q8W, Q4W, and oral. Injections were well 
tolerated with two participants discontinuing due to injection tolerability  through 48 
weeks (both on Q8W dosing). The vast majorit y of injection site reactions were due to 
pain/discomfort with nearly  all injection site reactions classified as mild (82%) or 
moderate (17%), with <1% of reactions classified as severe. There was no discernible 
tolerability  difference between Q4W (2 mL) dos ing and Q8W (3 mL  dosing).  The most 
common non -ISR AEs during the Maintenance Phase were nasophary ngitis (24%), 
headache (16%), and diarrhea (13%) on IM arms and nasophary ngitis (30%), headache 
(11%), and diarrhea (5%) on oral CAB.  Through Week 48, SAEs during the 
Maintenance Period occurred in 7% of participants randomized to CAB LA + RPV L A 
and 5% of participants randomized to remain on oral treatment, none were drug related.  
Based on the data from the Week [ADDRESS_419721] in 
evaluating the potential of Q8W dosing, subjects entering the Extension Period from the 
oral CAB 30 mg + ABC/3TC arm in this study  will be given the option to swit ch to either 
an optimized Q8W or Q4W regimen.  Subjects originall y randomized to the IM regimen 
and entering the extension phase will remain on their randomized regimen. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
365Section 1.9 Study  Rationale
Extension Period revised to (changes struck through and u nderlined):
The Extension Period of this study will allow for a collection of longer term efficacy  and 
safet y and tolerability data from subjects receiving [COMPANY_004]744 CAB LA and TMC278 RPV
LA.  Only  one Both of the current IM dosing regimens, either Q4W or Q8W and Q4W , 
will be taken into the Extension Period of the study (based on criteria described in the 
Reporting and Anal ysis Plan [RAP]) similar efficacy  results across each arm (see Section 
1.8)..
Unless subjects meet a study  withdrawal criterion, subjects on the oral regimen may  elect 
to continue on the Extension Period by [CONTACT_339312]744 LA + TMC278 
LA dosing regimen.  If eligible, their regimen will be modified prior to entering 
Extension by  [CONTACT_339313] 25 mg orally  once daily  for 2 weeks.  This short RPV add on 
will allow eligible subjects to achieve stead y state levels of RPV, prior to the 
administration of the [COMPANY_004]744 LA + TMC278 LA. an optimized I M dosing regimen of 
their choice of CAB LA + RPV L A (either Q8W or Q4W).
Section 1.10 Dose Rat ionale
Added the following sections for CAB LA -Extension and RPV L A-Extension :
CAB LA – Extension Period
CAB concentrations following administration of CAB LA Q8W and Q4W during the 
Maintenance Period of LATTE -2 were lower than predicted b y the modelling a nd 
simulation in the original protocol,  Observed data for both CAB LA regimens in 
LATTE- 2 are presented in Figure 3.  The CAB LA population PK model has been 
updated to include data from Phase 2a/b studies, specificall y Study 201120 (CAB LA 
PrEP) and Stud y 200056.  The current model has increased from 93 subjects to 416 
subjects receiving CAB LA single or repeat IM injections.  The rationales for the new 
CAB LA IM dosing regimens are described below. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
366Figure 3 Observed Mean (SD) Concentration -Time Data foll owing CAB LA 
Q8W and Q4W and C following 30 mg PO QD through Week 48 (200056, LATTE -
2)
Week0 0 1 4 8 12 16 20 24 25 28 3232 36 40 41 44 48 48Plasma CAB ( g/mL)
0.1110
800mg IM LD, 600mg IM W 4, W 8 and Q8W
800mg IM LD, 400mg IM Q4W
30mg PO QD
PA-IC90 (0.166 g/mL)
10mg PO QD C  (LATTE, 1.35 g/mL)
Both predose and 2h post injection concentrations are shown at Time Zero, Week 32, and Week 48.
Extension Phase Rationale for CAB LA Q8W
After the Maintenance Period oral regimen, the first and second CAB LA 600 mg IM 
dose at study visit Week 100 (1stinjection day) and Week 104 (2ndinjection) of the 
Extension Period of this study  was selected so that 50% of subjects are anticipated to be 
above 1.35 g/mL, the geomet ric mean C following oral CAB 10 mg once daily , 
throughout treatment which was shown to be efficacious in the LATTE study .  The lower 
bound of the 90% prediction interval is approximately  0.166 g/mL, indicating that 95% 
of subjects on this regimen should remain above the PA -IC90throughout dosing (). 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
367Figure 4 Simulated* Median (90% Prediction Interval [PI]) CAB Plasma 
Concentrations versus Time for the Optimized CAB LA Q8W Regimen (600 mg IM 
Day 1, Week 4, Q8W thereafter)^
*Note: current simulations based on interim plasma concentration dataset
^Study Time and Events include a 4 week oral lead in.  Therefore, Day 1 = date of first injections (Week 100 study 
visit); Week 4 = second injections (Week 104 study visit)
Model based predicted stead y-state CAB concentrations were consistent with observed 
data in this study , where CAB LA [ADDRESS_419722] dose of 600 mg IM at Week 8 prior to initiating Q8W.  
The mean CAB plasma concentration at W eek 32 was 1.53 g/mL ( Figure 4).
At steady  state, a one week delay  in dosing of the Q8W regimen is predicted to result in a 
median stead y state C that is 15% lower than for dosing that is administered on 
schedule, with 92% remaining above thePA-IC90(Figure 5). 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419723] of 1-week Delay in Dosing at Steady State (Week 44) on 
Simulated* Median (90% PI) CAB Plasma Concentrations versus Time for the 
Optimized CAB LA 600 mg IM Q8W regimen (Day 1, Week 4, and Q8W 
thereafter^)
*Note: current simulations based on interim plasma concentration dataset
^Study Time and Events include a 4 week oral lead in.  Therefore, Day 1 = date of first injections (Week 100 study 
visit); Week 4 = second injections (Week 104 study visit)
Extension Phase Dose Rationale f or CAB LA Q4W
The simulation of the predicted median (90% prediction interval [PI ]) CAB 
concentration -time profile based on the population PK model is shown in Figure 6.  The 
lower bound of the PI [INVESTIGATOR_339155] 4x PA-IC90throughout dos ing.  
At steady  state, 98% of the population is predicted to achieve trough concentrations 
above 4x PA -IC90, and 88% is predicted to achieve trough concentrations above the 
geometric mean trough following the 10 mg oral dose in LATTE of 1.35 g/mL (8x PA -
IC90).   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
369Figure 6 Simulated* Median (90% Prediction Interval [PI]) CAB Plasma 
Concentrations versus Time for the Optimized CAB LA Q4W Regimen (600 mg IM 
Day 1, then 400 mg IM Q4W thereafter^)
* Note: current simulations based on interim plasma concentrati on dataset
^Study Time and Events include a 4 week oral le ad in.  Therefore, Day 1 = day of first injections (Week 100study visit); 
Week 4 = second injections (Week 104study visit)
Medium dashed line at 1.35 g/mL corre sponds to the geometric mean Ctroug h concentration following oral CAB 10 
mg once daily  (LATTE) and is equivalent to 8x PA -IC90
Dotted line at 0.664 g/mL corresponds to 4x PA -IC90
Long dashed line at 0.166 g/mL corresponds to the PA -IC90.
At steady  state, a one week delay  in dosing o f the Q4W regimen results in approximately  
15% reduction in median CAB trough. With this delay , 95% are predicted to remain 
above 4x PA -IC90, and79% are predicted to remain above the 10 mg oral target ( Figure 
7).  Simulations including delay s greater than one week have been explored (not shown), 
with <70% of subjects remaining above the [ADDRESS_419724] of 1- week Delay in Dosing at Steady State (Week 40 delayed to 
Week 41) on Simulated* Median (90% PI) CAB Plasma Concentrations versus 
Time for the Optimized CAB LA Q4W regimen (600 mg IM Day 1, then 400 mg IM 
Q4W thereafter^)
* Note: current simulations based on interim plasma concentration dataset
^Study Time and Events include a 4 week oral lead in.  Therefore, Day 1 = day of first injections (Week 100study visit); 
Week 4 = second injections (Week 104study visit)
Medium dashed line at 1.35 g/mL corresponds to the geometric mean C following oral CAB 10 mg once daily 
(LATTE) and is equivalent to 8x PA -IC90
Dotted line at 0.664 g/mL corresponds to 4x PA -IC90
Long dashed line at 0.166 g/mL corresponds to the PA -IC90.
RPV LA – Extension Period
Similar to CAB, RPV concentrations following RPV L A in LATTE -2 were lower than 
predicted by [CONTACT_339242].  Observed data for 
both RPV LA regimens in L ATTE -2 are presented in Figure 10.  The RPV L A 
population PK model has been updated to include data from LATTE-2. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
371Figure 10 Observed Mean ( SD) Concentration -Time Data following RPV LA 
Q8W and Q4W through Week 48 and Day 1 C following RPV 25 mg PO QD 
(LATTE -2)
Week0 0 1 4 8 12 16 20 24 25 28 32 32 36 40 41 44 4848Plasma RPV (ng/mL)
101001000
900m g IM Q8W
600m g IM Q4W
25mg PO QD
PA-IC90 (12ng/mL)
25mg PO QD  (LATTE, 70ng/mL)
Extension Phase Rationale for RPV LA Q8W
The new optimized RPV LA Q8W regimen for this study  was selected based on safet y 
and effica cy data from this study , 200056 (LATTE -2) and supported b y modelling and 
simulation of pharmacokinetic and response data obtained following administration RPV 
LA administration in healthy  subjects (Phase 1 studies C158 and LAI115428 
[GlaxoSmithKline Docume nt Number 2011N112455_03] ) and in HIV -infected subjects 
(Phase 2 study  LATTE -2), the majority  of the data coming from 200056 (LATTE- 2). 
The predicted median (90% PI) stead y-state Cfor the optimized RPV L A Q8W regimen 
is 54 ng/mL  (25– 109 ng/mL ) (Figure 11).  With this regimen, 100% of subjects remain 
above the RPV PA- IC90during the whole dose interval at steady -state.  These data are 
similar to the observed Week 32 median stead y-state C which was also 54 ng/mL and 
the mean C was 58 ng/mL  (Figure 10).  With the 2ndRPV L A dose at Week 104, the 
anticipated median RPV Cat Week 104 is 42 ng/mL  (versus 30 ng/mL  observed prior to 
second injection at Week 8 in L ATTE -2), with >98% of subjects above the RPV PA-
IC90. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
372Figure 11 Simulated* Median (90% PI) RPV P lasma Concentrations versus 
Time Profile for the Optimized RPV LA Q8W regimen (900 mg IM Day 1, Week 4, 
and Q8W thereafter^)
* Note: current simulations based on interim plasma concentration dataset
^Study Time and Events include a 4 week oral lead in.  Therefore, Day 1 = date of first injections (Week 100 study 
visit); Week 4 = second injections (Week 104 study visit)
At steady -state, a one week delay  in dosing for the Q8W regimen is predicted to result in 
a median stead y-state C that is approximately  13% lower (47 ng/mL) than for dosing 
that is administered on schedule, with >99% of subjects still remaining above the RPV 
PA-IC90(Figure 12).  This supports allowance of some flexibility  in the dosing regimen 
in this study , similar to what is currentl y practiced in this study . 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
373Figure 12 Simulated* Median (90% PI) RPV Plasma Concentrations versus 
Time Profile for Optimized RPV LA Q8W dosing regimen, impact of 1 -week visit 
window (injection at Week 45 instead of Week 44)^
* Note: current simulations based on interim plasma concentration dataset
^Study Time and Events include a 4 week oral lead in.  Therefore, Day 1 = date of first injections (Week 100 study 
visit); Week 4 = second injections (Week 104 study visit)
Extension Phase Rationale for RPV LA Q4W
The optimized RPV L A Q4W regimen for this study  was selected based on L ATTE -2 
safet y and efficacy data as described above and supported b y modeling and simulation of 
pharmacokinetic data obtained following administration of RPV L A in healthy  
participants (Ph ase 1 studies C158 and LAI115428 [GlaxoSmithKline Document Number 
2011N112455_03]) and in HIV -infected participants (Phase 2 study  LATTE -2), with the 
majority  of the data coming from 200056 (LATTE- 2). 
The predicted median (90% PI) stead y-state C for the proposed regimen is 86.8 ng/mL 
(45.6 – 168 ng/mL) (Figure 13).  With this regimen, >99% of participants remain above 
the 5thpercentile of steady state trough values following oral RPV 25mg(corresponding 
to 2x the PA -IC90).  With a loading dose of 900 mg RPV LA on Day  1, the anticipated  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
374median RPV C at Week 4 is 42 ng/mL , with >98% of participants above the RPV PA -
IC90.
Figure 13 Simulated* Median (90% PI) RPV Plasma Concentrations versus 
Time Profile for the Optimized RPV LA Q4W regimen (900 mg IM Day 1 , then 600 
mg IM Q4W thereafter^)
* Note: current simulations based on interim plasma concentration dataset
^Study Time and Events include a 4 week oral lead in.  Therefore, Day 1 = day of first injections (Week 100 study visit); 
Week 4 = second injectio ns (Week 104 study visit) 
Horizontal line at 72 ng/mL corresponds to median C following oral RPV 25mg once daily in LATTE -2 (oral lead -in) 
and is similar to median RPV C in other studies in HIV -infected patients (LATTE, ECHO/THRIVE)
At steady -state, a one week delay  in dosing for the Q4W regimen is predicted to result in 
a median stead y-state C that remains above the median trough for RPV 25 mg (Figure 
14).  This supports allowance of some flexibility  in the dosing regimen. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419725] of 1- week D elay in Dosing at Steady State (Week 40 delayed to 
Week 41) on Simulated* Median (90% PI) RPV Plasma Concentrations versus 
Time for Optimized RPV LA Q4W dosing regimen (900 mg IM Day 1 and then 600 
mg IM Q4W thereafter^)
*Note: current simulations based on interim plasma concentration dataset
^Study Time and Events include a 4 week oral lead in.  Therefore, Day 1 = day of first injections (Week 100 study visit); 
Week 4 = second injections (Week 104study visit)
Horizontal line at 72 ng/mL corresponds to m edian C following oral RPV 25 mg once daily in LATTE -2 (oral lead -in) 
and is similar to median RPV C in other studies in HIV -infected patients (LATTE, ECHO/THRIVE)
Section 1. 11 Benefit:  Risk A ssessment
Revised to (changes struck through and underlined):
Section 1.11.1 Risk AssessmentSection 
[IP_ADDRESS] [COMPANY_004]744 CAB and [COMPANY_004]744 CAB LA
Since [COMPANY_004]744 CAB is at an earl y stage of clinical development, and exposure in humans 
with or without HI V infection is limited, the clinical safet y profile in humans has yet to 
be fully  elucidated. The following risks have primarily  been identified during routine  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
376preclinical testing and/or in the clinical trial experience to date and are considered of 
potential relevance to clinical usage in the context of this protocol.   Additio nal 
information about the clinical experience to date and possible risks associated with 
treatment using CAB can be found in the Summary  of Data and Guidance for the 
Investigator section of the IB.
Elevated Liver Transaminases
Two out of [ADDRESS_419726] developed elevated liver enzymes, 
considered probabl y related to [COMPANY_004]744. Both subjects met protocol defined liver 
stoppi[INVESTIGATOR_339221]744 as a result of these elevations. 
Transaminases returned to pre -treatment levels after stoppi[INVESTIGATOR_339222]. In the 
two subjects, the peak ALT elevation was >10xULN and occurred approximately  4 
weeks and 8 weeks, respectivel y, after initiat ing daily  [COMPANY_004]744 60 mg+ ABC/3TC. In 
both cases the ALT and AST values were elevated while other liver tests remained 
normal (bilirubin, alkaline phosphatase, albumin).  Neither subject developed clinical 
symptoms of liver dy sfunction. No other subjects ha ve required discontinuation of 
[COMPANY_004]744 as a result of a transaminase elevation.  To date approximately  [ADDRESS_419727] with a transient Grade 2 ALT elevation following the 
three monthly  injections with [COMPANY_004]744 L A 400 mg that resolved while remaining on 
[COMPANY_004]744 L A.A small proportion of participants in the CAB program to date (total 
exposure approximately  1198 to 01 April 2016) have developed transaminitis (elevated 
liver transaminases characterised b y predominant AL T elevation).  In some of these 
participants’ transient transaminitis were explained by  [CONTACT_339244] C in fection and 
whilst a small number of others did not have alternative explanations, suggesting a mild 
form of DILI (drug induced liver injury ) without hepatic d ysfunction which resolved 
upon withdrawal of treatment with CAB. 
Of the five participants with p ossible or probable cases of DILI identified in Phase 2 
studies, four participants were receiving oral CAB and one participant developed 
probable DILI following CAB LA or Placebo LA administration.
Creatine Phosphokinase (CPK) elevations
Occurrences of as ymptomatic, transient instances of elevations of CPK levels have been 
observed in Phase I studies and an ongoing Phase IIb study studies with [COMPANY_004]744 CAB at 
dose levels of 10, 30 and 60 mg (LAI116482) and with CAB LA (200056) . These 
generall y appeared to be related to ph ysical activity , were not associated with clinical 
symptoms and returned to pre -treatment levels in all cases.  No subject has required a 
discontinuation of [COMPANY_004]744 CAB as a result of a CPK elevation. Rhabdomy olysis of 
uncertain cause has bee n included in labeling for a currentl y available integrase inhibitor 
(raltegravir) but has not been seen in an y subject receiving [COMPANY_004]744 CAB to date. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
377Injection Site Reactions 
The occurrence of ISRs was identified in rats and monkey s at all dose levels of [COMPANY_004]744
CAB LA and associated with both the I M and SC route of administration. In humans, 
experience to date has demonstrated I SRs occur in the majority  of exposed subjects but 
are generally  mild (Grade 1) or moderate (Grade 2) and include tenderness, ery thema, or 
nodule formation of several da ys duration. Reactions have been well tolerated and have 
not to date been associated with only rarel y led to subject withdrawal.
Development of Resistance
Residual concentrations of [COMPANY_004]744 CAB would remain in the sy stemic circulation of 
subjects who stopped participants for prolonged periods (up to 1 year) despi[INVESTIGATOR_339223] (e.g. for tolerability  issues or treatment failure) for prolonged periods (months) . 
Subjects Participants discontinuing a CAB LA regimen may be at risk for developi[INVESTIGATOR_339224]-1 resistance to [COMPANY_004]744 CAB many weeks after discontinuing injectable therap y.
Mitigation:  Alternative oral HAART regimens will be constructed for subjects stoppi[INVESTIGATOR_339163] y which prescribed within four weeks after participants stop CAB LA.  
This would be anticipated to result in rapid resuppression of HIV -[ADDRESS_419728] CAB LA 
injection.
Inadvertent Intravenous Injection (Accidental Maladministration)
As with any  intramuscular injection, it is possible that [COMPANY_004]744 CAB LA can be 
inadvertentl y administered intravenously instead of intramuscularl y resulting in higher 
than expected concentrations of [COMPANY_004]744 CAB LA.  This could be due to administrator 
error, improper injection technique and / or improper needle length used ba sed on body  
type.  The clinical consequences of overdose with CAB are currentl y unknown. HIV-1 
viral suppression may  not be effective following accidental maladministration.
Mitigation:  Training will be provided to all sites on proper injection technique.   Should 
IM maladministration be suspected at an y time (e.g. suspected under or overdose or 
inadvertent IV dosing), a PK sample, post dose ECG, vital signs or an y other supportive 
testing may  be obtained at the discretion of the investigator, and the Medic al Monitor 
notified.  Laboratory samples for safety parameters and HIV -[ADDRESS_419729] dose PK samples will be obtained at 
a few earl y timepoints (Day 1, Week 32 and Week 48) for determination of [COMPANY_004]744
CAB concentration and possible pharmacokinetic correlation with safet y parameters such 
as ECG changes and virologic response.   Should IM maladministration be suspected at 
any time (e.g. suspected under or overdose or inadvertent IV dosing), a post d ose ECG or 
any other supportive testing may  be obtained at the discretion of the investigator, and the 
medical monitor notified.  Additionally , an unscheduled PK sample may  be drawn 
approximately  [ADDRESS_419730] dosing for future evaluation of [COMPANY_004]744 CAB and TMC278
RPV concentrations. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
378Section [IP_ADDRESS] TMC278
[IP_ADDRESS]. RPV and RPV LA
For safet y and risk mitigation for TMC278 RPV refer to the RPV rilpi[INVESTIGATOR_339225] [ Edurant Product I nformation , 201 45].
[IP_ADDRESS] TMC278 L A
Since TMC278 L A is at a n earl y stage of clinical development, and exposure in humans 
with or without HI V infection is limited, Information about the clinical safety  profile in 
humans experience to date and possible risks associated with treatment using RPV LA 
can be found in the Summary  of Data and Guidance for the Investigator section of the IB.  
Beyond what has yet to be fully elucidated alread y been identified with oral RPV, no new 
systemic adverse reactions to RPV LA (same active moiety ) have been observed. The 
following ri sks have primarily  been identified during routine preclinical testing and/or in 
the clinical trial experience to date and are considered to be of potential specific clinical
relevance to clinical usage in the context of this protocol IM use:
Inadvertent I ntravenous Injection (Accidental Maladministration)
As with any  intramuscular injection, it is possible that TMC278 RPV LA can be 
inadvertentl y administered intravenously instead of intramuscularl y resulting in higher 
than expected concentrations of TMC278 RPV L A.  This could be due to administrator 
error, improper injection technique and / or improper needle length used based on body  
type.  The clinical consequences of overdose with RPV L A are currentl y unknown.  HIV -
1 viral suppression may  not be effective following accidental maladministration.
Mitigation:  Training will be provided to all sites on proper injection technique.  Should 
IM maladministration be suspected at an y time (e.g. suspected under or overdose or 
inadvertent IV dosing), a PK sample, pos t dose ECG monitoring and vital signs or an y 
other supportive testing may  be obtained at the discretion of the investigator, and the 
Medical Monitor notified.  Laboratory samples for safet y parameters and HIV -[ADDRESS_419731] dose PK samples will 
be obtained at a few early timepoints (Day 1, Week 32 and Week 48) for determination 
of TMC278 RPV concentration and possible pharmacokinetic correlation with safet y 
parameters such as ECG changes and virologic response.  Should I M maladministration 
be suspected at an y time (e.g. suspected under or overdose or inadvertent IV dosing), a 
post dose ECG or an y other supportive testing may be obtained at the discretion of the 
investigator, and the medical monitor notified.  Additionally, an unscheduled PK sample 
may be drawn approximately  [ADDRESS_419732] dosing for future evaluation of [COMPANY_004]744 CAB
and TMC278 RPV concentrations.
[IP_ADDRESS] . [IP_ADDRESS] Risk of Treatment Failure
This study employ s an induction / maintenance approach to the treatment of HIV-[ADDRESS_419733] demonstrated antiviral activity  in large clinic althe Phase 2b studies and the 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
379LAI116482 (oral two drug combination has demonstrated antiviral activity in study  
LAI116482, the risk of virologic failure in stud ytreatment) and 200056 is unknown. 
(through 48 weeks LA treatment ).   Viral loads will be cl osely  monitored throughout the 
study .
Doses of the [COMPANY_004]744 CAB LA and TMC278 RPV LA have been selected to achieve 
exposures that are expected to maintain virologic efficacy  on the basis of available data 
with the oral formulations.  Neither [COMPANY_004]744 CAB LA or TMC278 nor RPV LA, at an y 
dose, has been used in HIV- [ADDRESS_419734] could receive an inadequate dose 
of [COMPANY_004]744 CAB LA or TMC278 RPV LA.  Sub -therapeutic concentrations of either 
[COMPANY_004]744 CAB LA or TMC278 RPV LA could lead to virologic failure and poss ibly the 
development of resistance.  HIV -1 RNA viral loads will be closely  monitored throughout 
the injection period of the study .
Mitigation:  HIV -1 RNA will be closely  monitored throughout the study .  Plasma 
samples will be collected throughout the Maintenance Phase for determination of CAB 
and RPV concentration and possible pharmacokinetic correlation with virologic response.
Section 1.11.2. Other Clinically  Relevant Information
New Section added (underlined):
Additional details concerning safet y observa tions from clinical studies and for which a 
causal association has not been established or which are of minimal clinical significance 
may be found in the Investigator’s Brochure.  Please refer to Section 6: ‘Summary  of 
Data and Guidance for the Investigato r’
Adverse Events of Special Interest:
Seizure:
Four cases of possible or definitive seizures have occurred in the CAB program 
cumulatively  through [ADDRESS_419735] 
contributed to the event, and e ach case was determined by  [CONTACT_339246] y likel y related to CAB or RPV.  Overall, there is insufficient evidence that 
CAB exposure may  be causally  associated with seizure or with reduction of seizure 
threshold, due to the low frequency  of reports, the confounders present in the cases 
received to date and lack of an y pre -clinical signal or identified plausible mechanism.  
However, seizure and seizure- like events will be closely  monitored in clinical studies, 
including this study  (200056).  An y case of seizure or possible seizure must be reported 
to the Sponsor within 24 hours o f notification, as detailed in S ection 6.10.14 . 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
380Section 1.11.3  Benefit A ssessment
Added line to section (underlined):
...Efficacy  of the two- drug regimen ,as oral ag ents,has been demonstrated through 
Week 96of the ongoing LAI116482 study .  Efficacy  of the two -drug regimen, as LA 
agents, has been demonstrated through Week 48 of the ongoing 200056 study .
Section 2 Objectives and Endpoints
Added the Exploratory  Objectives and Endpoints to table (underlined) 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419736] an intramuscular dosing regimen of 
CAB LA plus RPV LA based on a comparison of 
the Week 32 antiviral activity, tolerability, and 
safety of two IM dosing regimens , relative to 
CAB30mg plus ABC/3TC orally once daily.The proportion of subjects with HIV -1 RNA 
<50c/mL at Maintenance Week 32based on 
intent to treat -maintenance exposed (ITT -ME) 
population using the Missing, Switch, or 
Discontinuation = Failure (MSDF) algorithm.
Proportion of subjects with protocol defined 
virologic failures over time
Incidence and severity of AEs and laboratory 
abnormalities over time.
Secondary
To evaluate the antiviral activity, tolerability, and 
safety of CAB 30mg plus ABC/3TC orally once 
daily through the Induction and Maintenance 
Periods.Proportion of subjects with plasma HIV -1 RNA 
<200 c/mL and <50 c/mL over time.
Absolute values and change from Baseline in 
plasma HIV -1 RNA.
Absolute values and changes from Baseline in 
CD4+ cell counts.
Incidence of disease progression (HIV -
associated conditions, acquired 
immunodeficiency syndrome [AIDS] and death).
Incidence and severity of AEs and laboratory 
abnormalities over time.
Absolute values and changes in laboratory 
parameters over time.
To eval uate the efficacy, tolerability, and safety 
of CAB LA 400 mg IM plus RPV LA 600 mg IM 
every 4 weeks and CAB LA 600 mg IM plus 
RPV LA 900 mg every 8 weeks , relative to CAB
30mg plus ABC/3TC orally once daily, through 
Week 96 of the Maintenance Period.Prop ortion of subjects with plasma HIV -1 RNA 
<200 c/mL and <50 c/mL over time.
Proportion of subjects with protocol defined 
virologic failures over time.
Absolute values and change from Baseline in 
plasma HIV -1 RNA.
Absolute values and changes from Baselin e in 
CD4+ cell counts.
Incidence of disease progression (HIV -
associated conditions, acquired 
immunodeficiency syndrome [AIDS] and death.
Incidence and severity of AEs and laboratory 
abnormalities over time. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
382Objective Endpoint
Absolute values and changes in laboratory 
parameters over time.
To characterize CAB LA and RPV LA PK and to 
explore PK-PD relationships.  Plasma PK parameters for CAB LA and RPV LA
(Ctrough and concentrations post dose [~Cmax]) 
during the Maintenance Period.  
Plasma CAB and RPV trough concentrat ions
will be used to determine when steady state is 
achieved for each CAB LA and RPV LA
regimen.
Relationship between plasma PK parameters 
and plasma HIV -1 RNA, CD4+ cell counts 
and/or occurrence of adverse events [AEs] 
through Week [ADDRESS_419737] of various demographic 
Baseline characteristics and adherence on 
virologic response of CAB and RPV over time.Proportion of subjects with plasma HIV -1 RNA 
<50c/mL over time.
To evaluate the treatment satisfaction for 
subjects on the long -acting inj ectable regimens
with those on the oral regimen through Week 96 
of the Maintenance Period.Summarize treatment satisfaction using the HIV 
Treatment Satisfaction Questionnaire Status 
(HIVTSQ(s)) over time. 
To evaluate the change in treatment satisfaction 
for subjects in both the long -acting injectable 
and oral regimens through Week 32of the 
Maintenance Period.Measure change in treatment satisfaction using 
the HIV Treatment Satisfaction Questionnaire 
Change (HIVTSQ(c)) over time.
To evaluate medication a dherence over time. Summarize subject reported medication 
adherence using the HIV Medication 
Questionnaire (HIVMQ) over time.
Exploratory
To evaluate the efficacy, tolerability, and safety 
of optimized IM dosing regimens CAB LA 400 
mg IM plus RPV LA 600 mg IM every 4 weeks 
and CAB LA 600 mg IM plus RPV LA 900 mg 
every 8 weeks at Weeks 128 and 152 for 
subjects switching from the oral regimen 
therapy at the end of the Maintenace Period.
To evaluate the long term efficacy, tolerability, 
and safety of IM dosi ng regimens CAB LA 400 Proportion of subjects with a ‘virologic failure’ 
endpoint as per FDA Snapshot algorithm at 
Week 128 and 152 ( Missing, Switch or 
Discontinuation = Failure, Extension Switch 
population)
Proportion of subjects with Plasma HIV -1 RNA 
<50 copi[INVESTIGATOR_014]/mL (c/mL) at Week 128 and 152 
using the FDA Snapshot algorithm (Ext ension 
Switch population) 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
383Objective Endpoint
mg IM plus RPV LA 600 mg IM every 4 weeks 
and CAB LA 600 mg IM plus RPV LA 900 mg 
every 8 weeks at Week 152 for subjects who 
continued randomized IM dosing in the 
Extension Period.Proportion of subjects with protocol defined 
virologic failures over time
Proportion of subjects with plasma HIV -1 RNA 
<200 c/mL and <50 c/mL over time.Absolute 
values and changes in CD4+ cell counts over 
time
Incidence of disease progression (HIV -
associated conditions, acquired 
immunodeficiency syndrome [AIDS] and death).
Incidence and severity of AEs and laboratory 
abnormalities over time.
Absolute values and changes in laboratory 
parameters over time.
Section 3.1 Study  Design Schematic
Updated the Extension Period of schematic:
Old: 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
384New:
Section 3.2.5 Extension Period
Redesign of the Extension Period (Old version, strikethrough; New version, underlined):
Old:
A single IM dosing regimen will be selected as according to the RAP to be evaluated in 
the Extension period.
Section [IP_ADDRESS] Entering From the [COMPANY_004]744 LA + TMC278 L A Arm
All subjects who successfully  complete 96 weeks of [COMPANY_004]744 LA + TMC278 L A 
treatment in the Maintenance Period will continue to have access to both [COMPANY_004]74 [ADDRESS_419738] 
meets a protocol -defined reason for discontinuation or until development of either 
[COMPANY_004]744 L A or TMC278 L A is terminated.  
Subjects will be switched to the selected dose at Week 96 and will continue to receive the 
selected IM dosing regimen for the remainder of study  participation.  Safet y and efficacy 
assessments will be conducte d every  16 weeks after the initial switch.  Dosing visits will  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
385occur according to the selected dosing regimen.  See the Time and Events Schedule 
Section 6.5and Section 6.6for more information.
Section [IP_ADDRESS] Entering From the [COMPANY_004]744 + ABC/3TC Arm
All su bjects who successfully  complete 96 weeks of [COMPANY_004]744 + ABC/3TC treatment in 
the Maintenance Period will have the option to either continue study  participation by  
[CONTACT_339316]744 LA + TMC278 LA in the Extension Period, or to complete their 
study  particip ation at Week 96 (no withdraw visit needed).
Subjects who choose to continue on to the Extension Period will need to be assessed for 
eligibility  to begin the selected [COMPANY_004]744 LA + TMC278 L A regimen.  Subjects will 
continue on their Maintenance regimen ([COMPANY_004]7 44 + ABC/3TC) while eligibility  is being 
confirmed.  The Week [ADDRESS_419739] a visit at approximately  (depending on availability  of results) 
Week 102 to assess eligibility .  All subjects wi th an undetectable HIV- 1 RNA 
(<50 c/mL) result from the Week 100 visit are eligible to enter the Extension Period.   
Note:  Subjects with an HIV -1 RNA  50 c/mL  result from the Week 100 visit may  be 
allowed to enter the Extension Period only  at the discret ion of the medical monitor or 
withdrawn.
Subjects eligible to enter the Extension Period will add a short course (2 weeks) of 
RPV 25 mg orall y once daily to their [COMPANY_004]744 + ABC/3TC regimen at Week [ADDRESS_419740] dose of [COMPANY_004]744 + ABC/3TC + RPV in the 
clinic andwill begin dosing with the selected IM regimen.  Thes e subjects will receive 
loading doses as per the requirement of the selected regimen (see Section 5.1.6 for dosing 
regimens).
Subjects will continue study  treatment until [COMPANY_004]744 L A and TMC278 LA are either 
locally  approved and commercially  available, the s ubject no longer derives clinical 
benefit, the subject meets a protocol -defined reason for discontinuation or until 
development of either [COMPANY_004]744 L A or TMC278 LA is terminated.  Safet y and efficacy 
assessments will be conducted every  16 weeks after the init ial switch.  Dosing will occur 
according to the selected regimen. See the Time and Events Schedule Section 6.5and 
Section 6.6for more information.
Subjects not eligible to enter the Extension Period will end their study  participation 
(Week [ADDRESS_419741] study  visit, no withdraw visit needed).  Sites may  be 
reimbursed for up to a one month supply  of antiretroviral medication to facilitate 
transition to non- study  ART for subjects that do not qualify  for the Extension Period.
New:
Both IM dosing regim ens (Q8W and Q4W) will continue evaluation in the Extension 
period.  Subjects who successfull y complete 96 weeks of CAB 30 mg + ABC/3TC 
treatment in the Maintenance Period will have the option of continuing study   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
386participation by [CONTACT_339230] (either 
Q8W or Q4W).
Section [IP_ADDRESS] Entering From the CAB LA + RPV LA Arm
All subjects who successfully  complete 96 weeks of CAB LA + RPV LA treatment in the 
Maintenance Period will continue with their current I M dosing r egimen of CAB LA and 
RPV L A in the Extension Period until:
study  treatment is locally approved and commercially  available, 
the subject no longer derives clinical benefit, 
the subject meets a protocol- defined reason for discontinuation  
the development of either CAB LA or RPV L A is terminated.  
Subjects will remain on their current regimen after Week 96 and will continue to receive 
their Maintenance Period I M dosing regimen for the remainder of study  participation.  
Safety  and efficacy  assessments will be conducted every  16 weeks. Dosing visits will 
occur according to the selected dosing regimen.  See the Time and Events Schedule 
Section 6.5and Section 6.6for more information.
Section [IP_ADDRESS] Eligibility  for the Extension Period for Subjects Entering From the CAB 
30mg + ABC/3TC Arm
All subjects with an undetectable HIV -1 RNA (<50 c/mL ) at the Week 96 visit are 
eligible to enter the Extension Period. A single repeat to determine eligibility  may  be 
allowed ONLY after consultation with the medical monit or.  Subjects with HIV -1 
RNA 400c/mL  at Week 96 are not eligible to enter the Extension Period and will not be 
allowed a repeat to determine eligibility .
Result of HIV -1 RNA at Week 96 Action
<50 c/mL Begin Extension Period
50 c/mL but <400 c/mL Singl e repeat allowed only after consultation 
and approval from medical monitor
Single repeat <50 c/mL Begin Extension Period
Single repeat 50 c/mL Cannot begin Extension Period and must be 
withdrawn from study; Complete withdrawal 
visit.  
400 c/mL Cannot begin Extension Period and must be 
withdrawn from study; Complete withdrawal 
visit. 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419742] is ineligible for the Extension Period, samples will be sent to a central 
laboratory  for resistance testing and results provided to the Inves tigator once available.
Sites may  be reimbursed for up to a one month supply  of antiretroviral medication to 
facilitate transition to non -study  ART for subjects that do not qualify  for the Extension 
Period.
Section [IP_ADDRESS] Entering From the CAB 30 mg + ABC /3TC Arm
All subjects who successfully  complete 96 weeks of CAB 30 mg+ ABC/3TC treatment 
in the Maintenance Period will have the option to continue study  participation by  
[CONTACT_339248] I M dosing regimen of their choice (either Q8W or Q4W) of 
CAB LA + RPV LA in the Extension Period.  Subjects not choosing to switch to an 
optimized long acting regimen will complete their study  participation at Week 96.
Subjects who choose to continue on to the Extension Period will be assessed for 
eligibility  tobegin their selected CAB LA + RPV LA regimen as described in Section 
[IP_ADDRESS] .   Subjects will continue on their oral Maintenance regimen (CAB 30 mg + 
ABC/3TC) until Week 100 while eligibility  is being confirmed.  
In order to qualify  to receive CAB LA + R PV LA injections at Week 100, the HIV-[ADDRESS_419743] be undetectable (<50 c/mL ; a single repeat 
HIV-[ADDRESS_419744] may  be allowed prior to Week 100 following consultation with the 
Medical Monitor). 
If the Optimized Q4W IM Dosing Reg imen is Selected by [CONTACT_339231] 100, participants will return to the clinic, take the last dose of their oral 
regimen (CAB 30 mg + ABC/3TC), and receive the first CAB LA (600 mg) + RPV LA 
(900 mg) injections (within 2 hours of the final oral dose of CAB + ABC/3TC).  The 
second and third injections ( CAB LA 400 mg + RPV L A 600 mg) will be administered at 
Week [ADDRESS_419745] injections occur within the 
window of Week 107 to Week 108, but no later than Week 108.  Subsequent injections 
(CAB LA 400 mg + RPV L A 600 mg) will occur every  4 weeks there after, from the 
projected visit date, with a (+ or -) 7 day  dosing window being allowed (but not 
preferred).  Following the Week [ADDRESS_419746] dose of their oral (CAB 
30 mg + ABC/3TC), and receive the first CAB LA (600 mg) + RPV LA (900 mg) 
injections (within 2 hours of the final oral dose of CAB + ABC/3TC).  The second 
loading injections will be administered at Week 104 ( CAB LA 600 mg + RPV L A 
900mg), with subsequent injections (CAB LA 600 mg + RPV L A 900 mg) occurring 
every  [ADDRESS_419747] case management.  After Week 112, a dosing window ( 7 day s) for injections is 
allowed, but not preferred.
Subjects will continue study  treatment until: 
study  treatment is locally approved and commercially  available, 
the subject no longer derives clinica l benefit, 
the subject meets a protocol- defined reason for discontinuation  
the development of either CAB LA or RPV L A is terminated..  
Safety  and efficacy  assessments will be conducted as per the Time and Events schedule 
(Section 6.5and Section 6.6for more information).  Dosing will occur according to the 
selected regimen. 
Subjects not eligible to enter the Extension Period will end their study  participation.  
Sites may  be reimbursed for up to a one month supply  of antiretroviral medication to 
facili tate transition to non -study  ART for subjects that do not qualify  for the Extension 
Period.
If one of the optimized IM dosing regimens (Q8W or Q4W) is discontinued as a result of 
an IDMC review or an y subsequent anal ysis, those subjects who have not met an y 
clinical management criteria for discontinuation and who selected a discontinued 
optimized I M dosing regimen may  be given the option to discontinue permanently  from 
the study  or to continue on the remaining IM dosing regimen at the next scheduled visit.
Section 3.2.[ADDRESS_419748] new IDMC monitoring for Extension Period
...If one of the IM dosing regimens (Q 48W or Q 84W) is discontinued as a result of an 
IDMC review or an y subsequent anal ysis, those subj ects who have not met any  clinical 
management criteria for discontinuation and who were randomized to the discontinued 
dosing regimen , or selected a discontinued optimized I M dosing regimen, may be given  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
389the option to discontinue permanentl y from the stud y or to continue on the remaining IM 
dosing regimen at the next scheduled visit. 
As subjects enter the Maintenance Period of the study , if the number of protocol defined 
virologic failures meets or exceeds the pre -specified thresholds specified in the IDM C 
Charter, this will be considered strong evidence of an inadequate response and will 
trigger a comprehensive data review b y the IDMC.  Similar thresholds will be used b y the 
IDMC to monitor the number of protocol defined virologic failures for subjects sw itching 
from oral CAB 30 mg + ABC/3TC to an optimized I M dosing regimen during the 
Extension Period.   The IDMC charter will contain details of this continual monitoring of 
the protocol defined virologic failure rates, the specifics around what will trigger a data 
review, and the safety  summaries and efficacy  analy ses that will be provided should a 
data review be required.
Full details of the analy ses, estimated timing and the decision criteria that will be used to 
determine regimen performance will be pre-specified in the IDMC Charter.
Section 3.3 Discussion of Design
Added the following wording (underlined):
The Extension Period will allow participants on the oral Maintenance Period regimen 
who successfull y complete Week 96 with an HIV -1 RNA viral load <50 c/mL  the 
opportunity  to choose an optimized I M dosing regimen (Q8W or Q4W).  This will permit 
an evaluation of the ability of the optimized investigational two -drug long acting 
combinations (see Section 5.1.6 ) to maintain virologic suppression over time.  This 
period will also allow participants currentl y on a IM Maintenance Period regimen who 
successfull y complete Week 96 with an HIV -1 RNA viral load <50 c/mL  the ability  to 
continue to receive their current IM dosing regimen and to generate additional long -term 
safet y and efficacy data for randomized IM dosing regimens.
A planned Week 128 analy sis will primarly evaluate the efficacy , tolerability , and safet y 
of the optimized I M dosing regimens through 28 weeks of optimized I M treatment in 
subjects switching from oral Maintenance therap y. Long term durability  of virologic 
suppression of the randomized long -acting two -drug regimens through Week 128 may  
also be evaluated.
A Week 152 anal ysis will permit an evaluation of the ability  of the randomized and 
optimized investigational two -drug long-acting combinations to showcase long- term 
durability  of virologic suppression.  Additional long -term safety  and efficacy  data for all 
IM dosing regimens will be generated.
Section 4.5 Withdra wal Criteria
Removed the follow ing Withdrawal Criteria (strikethrough):
Change from Baseline: Increase in QTc > 60 msec 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
390Section 5.1.6 Dosage and A dministration
Updated Extension Period Dosing 
Old:
Induction Period (Week -20 through Day 1)
Week -20 to Week (-4)
(2 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X [COMPANY_004]744 30 mg tablet once daily
Week ( -4) to Day 1
(3 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X [COMPANY_004]744 30 mg tablet once daily
Take 1 X RPV 25 mg tablet onc e daily
Take with a meal
Take Day 1 doses in the clinic
Maintenance Period (Day 1 toWeek 96*)
[COMPANY_004]744 LA 600 mg + TMC278 LA 900 mg IM every 8 Weeks (Q8W)
Day 1 –loading dose
(3 injections once)Receive last dose of Induction regimen
Receive [COMPANY_004]744 LA 800 mg given as 2 X 2 mL IM injections 
Receive TMC278 LA 900 mg given as 1 X 3 mL IM injection 
Week 4 – 2ndloading dose
(1 injection once)Receive [COMPANY_004]744 LA 600 mg given as 1 X 3 mL IM injections 
(No TMC278 LA)
Week 8 to Week 88
(2 injections every 8 weeks)Receive [COMPANY_004]744 LA 600 mg given as 1 X 3 mL IM injection 
Receive TMC278 LA 900 mg given as 1 X 3 mL IM injection
[COMPANY_004]744 LA 400 mg + TMC278 LA 600 mg IM every 4 Weeks (Q4W)
Day 1 –loading dose
(3 injections once)Receive last dose of Induction regimen
Receive [COMPANY_004]744 LA 800 mg given as 2 X 2 mL IM injections 
Receive TMC278 LA 600 mg given as 1 X 2 mL IM injection 
Week 4 to Week 92
(2 injections every 4 weeks)Receive [COMPANY_004]744 LA 400 mg given as 1 X 2 mL IM injection
Receive TMC278 LA 600 mg given as 1 X 2 mL IM injection 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
391[COMPANY_004]744 30 mg + ABC/3TC once daily
Day 1Receive last dose of Induction regimen
Day 2 to Week 96
(2 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X [COMPANY_004]744 30 mg tablet once daily
If continu ing to Extension Period:
Week 96 to Week 102
(2 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X [COMPANY_004]744 30 mg tablet once daily
If eligible to enter Extension Period:
Week 102 to Week 104
(3 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X [COMPANY_004]744 30 mg tablet once daily
Take 1 X RPV 25 mg tablet once daily
Take with a meal
Extension Period (Week 96plus+) 
If [COMPANY_004]744 LA 600 mg + TMC278 LA 900 mg IM every 8 Weeks is selected:
Week 96 plus+
(2 injections every 8 weeks)Receive [COMPANY_004]744 LA 600 mg given as 1 X 3 mL IM injection 
Receive TMC278 LA 900 mg given as 1 X 3 mL IM injection
If switching from Oral Arm:
Week 104 –loading dose
(3 injections once)Receive last dose of Maintenance regi men
Receive [COMPANY_004]744 LA 800 mg given as 2 X 2 mL IM injections 
Receive TMC278 LA 900 mg given as 1 X 3 mL IM injection
Extension Period (Week 96 plus+)
If [COMPANY_004]744 LA 600 mg + TMC278 LA 900 mg IM every 8 Weeks is selected:
Week 108 – 2ndloading dose
(1injection once)Receive [COMPANY_004]744 LA 600 mg given as 1 X 3 mL IM injections 
(No TMC278 LA)
Week 112 plus+Receive [COMPANY_004]744 LA 600 mg given as 1 X 3 mL IM injection  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
392(2 injections every 8 weeks)Receive TMC278 LA 900 mg given as 1 X 3 mL IM injection
If[COMPANY_004]744 LA 400 mg + TMC278 LA 600 mg IM every 4 Weeks is selected:
Week 96 plus+
(2 injections every 4 weeks)Receive [COMPANY_004]744 LA 400 mg given as 1 X 2 mL IM injection 
Receive TMC278 LA 600 mg given as 1 X 2 mL IM injection
If switching from Oral Arm:
Week 104 –loading dose
(3 injections once)Receive last dose of Maintenance regimen
Receive [COMPANY_004]744 LA 800 mg given as 2 X 2 mL IM injections 
Receive TMC278 LA 600 mg given as 1 X 2 mL IM injection 
Week 108 plus+
(2 injections every 4 weeks)Receive GS K744 LA 400 mg given as 1 X 2 mL IM injection 
Receive TMC278 LA 600 mg given as 1 X 2 mL IM injection
*Or through Week 104 if eligible to enter the Extension Period.
+until locally approved and commercially available, the subject no longer derives clini cal benefit, the subject meets a 
protocol -defined reason for discontinuation or until development of [COMPANY_004]744 or TMC278 is terminated
New (Modifications Underlined):
Induction Period (Week -20 through Day 1)
Week -20 to Week (-4)
(2 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X CAB 30 mg tablet once daily
Week ( -4) to Day 1
(3 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X CAB 30 mg tablet once daily
Take 1 X RPV 25 mg tablet once daily
Take with a meal
Take Day 1 doses in the clinic
Maintenance Period (Day 1 toWeek 96*)
CAB LA 600 mg + RPV LA 900 mg IM every 8 Weeks (Q8W)
Day 1 –loading dose
(3 injections once)Receive last dose of Induction regimen
Receive CAB LA 800 mg given as 2 X 2 mL IM injections  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
393Receive RPV LA 900 mg given as 1 X 3 mL IM injection 
Week 4 – 2ndloading dose
(1 injection once)Receive CAB LA 600 mg given as 1 X 3 mL IM injections 
(No RPV LA)
Week 8 to Week 88
(2 injections every 8 weeks)Receive CAB LA 6 00 mg given as 1 X 3 mL IM injection 
Receive RPV LA 900 mg given as 1 X 3 mL IM injection
CAB LA 400 mg + RPV LA 600 mg IM every 4 Weeks (Q4W)
Day 1 –loading dose
(3 injections once)Receive last dose of Induction regimen
Receive CAB LA 800 mg given as 2 X 2 mL IM injections 
Receive RPV LA 600 mg given as 1 X 2 mL IM injection 
Week 4 to Week 92
(2 injections every 4 weeks)Receive CAB LA 400 mg given as 1 X 2 mL IM injection
Receive RPV LA 600 mg given as 1 X 2 mL IM injection
CAB 30 mg + ABC/3T C once daily
Day 1Receive last dose of Induction regimen
Day 2 to Week 96
(2 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X CAB 30 mg tablet once daily
If continuing to Extension Period:
Week 96 to Week 100
(2 tablets once daily)Take 1 X ABC 600 mg / 3TC 300 mg tablet once daily 
Take 1 X CAB 30 mg tablet once daily
Extension Period (Week 96 +) 
If subject was randomized to the Q8W regimen during the Maintenance Period:
Week 96 plus+
(2 injections every 8 weeks)Receive CAB LA [ADDRESS_419749]:
Week 100 – 1stloading dose
(2 injections once)Receive last dose o f Maintenance regimen
Receive CAB LA 600 mg given as 1 X 3 mL IM injections 
Receive RPV LA 900 mg given as 1 X 3 mL IM injection
Week 104  – 2ndloading doseReceive CAB LA 600 mg given as 1 X 3 mL IM injections  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
394(2 injection once)Receive RPV LA 900 mg given as 1 X 3 mL IM injection
Week 112 plus+
(2 injections every 8 weeks)Receive CAB LA [ADDRESS_419750] was Randomized to the Q4W regimen during the Maintena nce Period: 
Week 96 plus+
(2 injections every 4 weeks)Receive CAB LA [ADDRESS_419751]:
Week 100 – 1stloading dose
(2 injections once)Receive last dose of Maintenance regimen
Receive CAB LA 600 mg given as 1 X 3 mL IM injections 
Receive RPV LA 900 mg given as 1 X 3 mL IM injection 
Week 104 – 2ndloading dose
(2 injections once)Receive CAB LA 400 mg given as 1 X 2 mL IM injection 
Receive RPV LA 600 mg given as 1 X 2 mL IM injection
Week 108 plus+
(2 injections every 4 weeks)Receive CAB LA 400 mg given as 1 X 2 mL IM injection 
Receive RPV LA 600 mg given as 1 X 2 mL IM injection
*Or throu gh Week 100 if eligible to enter the Extension Period.
+until locally approved and commercially available, the subject no longer derives clinical benefit, the subject meets a 
protocol -defined reason for discontinuation or until development of CAB or RPV is terminated
Section 5.9.2 Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_339226] (removed items, strikethrough; added items underlined):
Hepatitis C infection treatment will not be permitted therap y is allowed during the study , 
but int erferon -based HCV therapy  is prohibited throughout the entire study.  Options for 
treatment of hepatitis C must be discussed with the Medical Monitor prior to initiation of 
therap y.
Section 6.2 Time and Events Table –Maintenance Period for IM Regimen (CA BLA 
+ RPV LA  Q8W)
Removed footnote ‘o’ and modified footnote ‘n’
n)Subjects will continue to receive the selected Extension their Maintenance Period
dosing regimen in the Extension Period (either Q8W or Q4W ) at this visit.  If  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
395switching to Q4W, injections a re 1 x [COMPANY_004]744 L A 400 mg IM + 1 x TMC278 L A 600 
mg IM.  Subjects may  immediately  begin the new regimen at Week 96.
o)Remind subjects of the potential change in stud y treatment and visit frequency 
beginning at Week 96
Section 6.3 Time and Events Table –Maint enance Period for IM Regimen (CA B LA  
+ RPV LA  Q4W)
Removed footnote ‘o’ and modified footnote ‘n’
n)Subjects will continue to receive the selected Extension their Maintenance Period
dosing regimen in the Extension Period (either Q4W or Q4W ) at this visit.  If 
switching to Q4W, no loading dose is necessary  injections are 1 x [COMPANY_004]744 L A 600 
mg IM + 1 x TMC278 LA 900 mg IM.  
o)Remind subjects of the potential change in stud y treatment and visit frequency 
beginning at Week 96 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
396Section 6.4 Time and Events Table – Maintenance Period for Oral Regimen (CA B 30 mg + ABC/3TC)
Modified T&E table and footnotes. R emoved Weeks 100, 102 and 104 from table :
Old:
Procedures For 
Maintenance –
ORAL regimenD1 W
4W
8W
12W
16W
20W
24W
28W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96W 
100mW
102mW
104mWD q
Verify 
Eligibility X X l X l, 
n
Randomization X
Symptom 
Directed PE & 
Medical 
Assessment aX X X X X X X X X X X X X X X X X X X X X X X and 
smoking 
status
Vital Signs
(BP, HR) bX X X X X X X X X X X X X X X X
Weight and BMI X X X X X X
ECG d X
preX X X X X X X X X
preX
HIV 
Associated 
Conditions, AE 
and SAE 
Assessment, 
Con  Meds X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
PK Diary 
(D)ispensation 
and (R)eview eR D R D R
eC-SSRSf X X X X X X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
397Procedures For 
Maintenance –
ORAL regimenD1 W
4W
8W
12W
16W
20W
24W
28W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96W 
100mW
102mW
104mWD q
HIVTSQ(s) g X
preX X X X X
HIVTSQ(c)g X X
HIVMQ g X X X X X g
Clinical 
Chemistry and 
HematologyX X X X X X X X X X X X X X X X X X X X X X X
Pregnancy Test 
(S)erum/(U)rine hS S S S S S S S S S S S S S S S S S S S S U S
HIV-1 RNA &
sample for 
storage iX X X X X X X X X X X X X X X X X X X X nX X X
CD4+ X X X X X X X X X X X X X
CD8+ X X X X
Urinalysis X X X X X X X
Fasting:  
Glucose,
Insulin, 
Cholesterol 
(Total, HDL 
and LDL) and 
Triglycerides jX X X X X X X X
PT/PTT/INR X X X X X X
PK Sample k X X X S S X
Study 
Treatment 
Dispensation 
and 
Accountability oX X X X X X X X X X X X X X X X X X Xm X X
Add
RPVX
Add 
injection
Visit Reminder X X X X X X X X X X X X X X X X X X X X X X X XpXm,p X pX pX p X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
398Procedures For 
Maintenance –
ORAL regimenD1 W
4W
8W
12W
16W
20W
24W
28W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96W 
100mW
102mW
104mWD q
Contact
[CONTACT_339338] X X X X X X X X X X X X X X X X X X X X X X X Xm X X X X
D=Day    W=Week    Pre=Pre -dosing  PE = Physical Exam   BMI=Body Mass Index
Gray shading indicates telephone safety assessments that will include interviewing the 
subject for adverse events, concomitant medications, HIV associated conditions and any 
other issues including compliance. 
a. Physical exams should be conducted as part of normal routine clinical care but data 
will not be collected in the eCRF. Medical assessments include any decisions the 
study staff must make for subject management and/or care of the subje ct.
b. Measure vital signs after about [ADDRESS_419752] in a semi -supi[INVESTIGATOR_2547].
c. BMI collected at Week 104 only.
d. 12- Lead ECG –Conduct pre -dose at Day [ADDRESS_419753] 2 –[ADDRESS_419754]’s last dose is not within 
window.  Visit may need to be rescheduled.
f. Preferably completed at the beginning of the visit.  
g. Conduct the HIVTSQ(s) at Day [ADDRESS_419755] the HIVTSQ(c, WD) at WD ONLY if the subject WD between 
Week [ADDRESS_419756] the HIVMQ preferably at the beginning of the visit, 
but may be completed at any time during the visit.
h. Women of childbearing potential only. A ( -) urine pregnancy test is required prior to 
any injection and as required by [CONTACT_339339] r a treatment interruption. A 
positive urine test should be confirmed with a stat serum test.  If positive, subject will 
need to be WD.i. Plasma for storage samples are collected for possible future analyses, as back -up in 
case of lost or damaged in transit to the lab and for geno/pheno analyses for virologic 
failures
j. Fast overnight; however, a minimum of a [ADDRESS_419757] dose of IP 
taken.  Subjects will take their dose of IP in the clinic at PK visits. S=Storage
l. Assess subject’s willingness to continue on to the Extension Period.  If not continuing 
into the Extension Period, this is the subject’s last study visit.
m. For subjects continuing into the Extension Period only.  
n. The Week [ADDRESS_419758] be <50 c/mL to be eligible to continue into the 
Extension Period.  See Section [IP_ADDRESS] .    Subjects ineligible for Extension will end 
their study participation at Week 102 (no withdrawal visit needed).
o. Subjects will discont inue RPV at Day 1 and begin taking 1 x [COMPANY_004]744 + 1 x ABC/3TC 
tablet once daily. At Week 96 and Week 100, while awaiting eligibility for Extension, 
subjects will continue their [COMPANY_004]744+ABC/3TC regimen.  At Week 102, subjects 
eligible to enter the Extension Pe riod will add once daily RPV to their 
[COMPANY_004]744+ABC/3TC regimen and continue to take [COMPANY_004]744+ABC/3TC +RPV once 
daily through Week 104.  At Week 104, subjects will take final dose of 
[COMPANY_004]744+ABC/3TC+RPV in the clinic and begin the selected IM regimen (Q8W or 
Q4W ).  See Section 5.1.6 for IM dosing administration as loading doses are required.  
p. Remind subjects of the change in study and assessments for eligibility into 
Extension.
q. Follow Up Visit:  Conduct approximately [ADDRESS_419759] on -study visit.  
This visit may be conducted by [CONTACT_756]. 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
399New:
Procedures For 
Maintenance –
ORAL regimenD1 W
4W
8W
12W
16W
20W
24W
28W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD p
Verify Eligibility X X k
Randomization X
Symptom 
Directed PE & 
Medical 
Assessment aX X X X X X X X X X X X X X X X X X X X and smoking 
status
Vital Signs
(BP, HR) bX X X X X X X X X X X X X
Weight and BMI c X X X X X
ECG c X
preX X X X X X X X X
HIV Associated 
Conditions, AE 
and SAE 
Assessment, Con  
Meds X X X X X X X X X X X X X X X X X X X X X X X X X X
PK Diary 
(D)ispensation 
and (R)eview dR D R D R D
eC-SSRSe X X X X X X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
400Procedures For 
Maintenance –
ORAL regimenD1 W
4W
8W
12W
16W
20W
24W
28W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD p
HIVTSQ(s) f X
preX X X X X
HIVTSQ(c)f X X
HIVMQ f X X X X X f
Clinical Chemistry 
and HematologyX X X X X X X X X X X X X X X X X X X X
Pregnancy Test 
(S)erum/(U)rine gS S S S S S S S S S S S S S S S S S S S
HIV-1 RNA &
sample for 
storage hX X X X X X X X X X X X X X X X X X Xm X
CD4+ X X X X X X X X X X X
CD8+ X X X X
Urinalysis X X X X X X
Fasting:  Glucose, 
Insulin, 
Cholesterol 
(Total, HDL and 
LDL) and 
Triglycerides iX X X X X X X
PT/PTT/INR X X X X X
PK Sample j X X X S X
Study Treatment 
Dispensation and 
Accountability nX X X X X X X X X X X X X X X X X X Xq
Study Treatment 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
401Procedures For 
Maintenance –
ORAL regimenD1 W
4W
8W
12W
16W
20W
24W
28W
32W
36W
40W
44W
48W
52W
56W
60W
64W
68W
72W
76W
80W
84W
88W
92W
96WD p
Administration 
Visit Reminder 
ContactX X X X X X X X X X X X X X X X X X X X X X X Xo Xl,o X
Subject Contact 
[CONTACT_339266] X X X X X X X X X X X X X X X X X X X X X X X Xl X
D=Day     W=Week    Pre=Pre -dosing  PE = Physical Exam   BMI=Body Mass Index
Gray shading indicates telephone safety assessments that will include interviewing the subject for 
adverse events, concomitant medications, HIV associated conditions and any other issues 
including compliance. 
a. Physical exams should be conducted as part of normal routine clinical care but data wi ll not 
be collected in the eCRF. Medical assessments include any decisions the study staff must 
make for subject management and/or care of the subject.
b. Measure vital signs after about [ADDRESS_419760] in a semi -supi[INVESTIGATOR_2547].
c. 12-Lead ECG –Conduct pre -dose at Day 1.  At all other visits, it is preferable to conduct 2 –[ADDRESS_419761]’s last dose is not within window.  Visit may need to be 
rescheduled.
e. Preferably completed at the beginning of the visit.  
f. Conduct the HIVTSQ(s) at Day [ADDRESS_419762] the HIVTSQ(c, WD) at WD ONLY if the subject WD between Week [ADDRESS_419763] the HIVMQ preferably at the beginning of the visit, but may be completed 
at any time during the visit.
g. Women of childbearing potential only . A (-) urine pregnancy test is required prior to any 
injection and as required by [CONTACT_339267] a treatment interruption. A positive urine 
test should be confirmed with a stat serum test.  If positive, subject will need to be WD.h. Plasma for storag e samples are collected for possible future analyses, as 
back -up in case of lost or damaged in transit to the lab and for geno/pheno 
analyses for virologic failures
i. Fast overnight; however, a minimum of a [ADDRESS_419764] 
dose of IP taken.  Subjects will take their dose of IP in the clinic at PK visits. 
S=Storage
k. Assess subject’s willingness to continue on to the Extension Period.  If not 
continuing into the Extension Perio d, this is the subject’s last study visit.
l. For subjects continuing into the Extension Period only.  
m. The Week 96 HIV -1 RNA result (or single re -test prior to Week 100) must be 
<50 c/mL to be eligible to continue into the Extension Period.  See Section 
[IP_ADDRESS] .  Subjects ineligible for Extension will end their study participation at 
Week 96 (withdrawal visit needed).
n. Subjects will discontinue RPV at Day 1 and begin taking 1 x CAB 30 mg + 1 
x ABC/3TC tablet once daily. At Week 96, while awaiting eligibility f or 
Extension, subjects will continue their CAB 30 mg+ABC/3TC regimen.  
o. Remind subjects of the change in study and assessments for eligibility into 
Extension.
p. Follow Up Visit:  Conduct approximately [ADDRESS_419765] 
on-study visit.  This visit may be conducted by [CONTACT_756].
q. Assess Treatment Accountability only 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
402Section 6.5 Time and Events Table –Extension Period for IM Regimen (CA B LA + RPV LA -Q8W
Old:
Procedu res for 
Extension if 
Q8W is SelectedW 
104 aW 
108b
From Oral 
Arm OnlyW 
112W 
120W 
128W
136W 
144W
152W
160W
168W
176W 
184W 
192 cW 
200 cWD 
n, oNotes
Symptom 
Directed 
Physical Exam, 
ISR and 
Medical 
Assessment dX X X X X X X X X X X X X X XSee footnote “b” for continuation of visit schedule 
after Week 200.  Continue until either locally 
approved and commercially available, the subject 
no longer derives clinical benefit or meets a 
protocol -defined reason for discontinuation or 
until d evelopment is terminated.
a. Subjects switching from the oral regimen will 
complete Week 104 visit as per the Maintenance 
T&E Section 6.4.
b. Week [ADDRESS_419766] 
in a semi -supi[INVESTIGATOR_2547].
f. Can be done at any time during the visit.
g. A (-) urine pregnancy test is required prior to any 
injection and as required by [CONTACT_339322] a treatment interruption. A (+) urine test Vital Sign s
(BP, HR) eX X X X X X X X
Weight & BMI X X X X X X X X
HIV Associated 
Conditions, AE 
and SAE 
Assessments, 
Con MedsX X X X X X X X X X X X X X X
12-Lead ECG f X X X X X X X X X
Clinical 
Chemistry and 
HematologyX X X X X X X X X
Pregnancy 
TestingU U U U U U U U U U U U U U U 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
403Procedu res for 
Extension if 
Q8W is SelectedW 
104 aW 
108b
From Oral 
Arm OnlyW 
112W 
120W 
128W
136W 
144W
152W
160W
168W
176W 
184W 
192 cW 
200 cWD 
n, oNotes
(U)rineg should be confirmed with a stat serum test.  If 
(+), subject will need to be WD.
h. Plasma for storage samples are collected f or 
possible future analyses, back -up in cases of 
loss/damage in transit and geno/pheno analyses 
for virologic failures.
i. Fast overnight; minimum of a [ADDRESS_419767] 
experiences a reaction ((E)pi[INVESTIGATOR_49564]).  Subjects 
will be dispensed a new diary at each visit. Diary 
data will be entered into the eCRF.
l. Q8W Injections are 1 x [COMPANY_004]744 LA 600 mg IM 
+ 1 x TMC278 LA 900 mg IM.  If possible, 
injections should be spaced approximately 2 cm 
from one another and from the site of any 
previous injection and or any injection site 
reaction.  Bring TMC278 LA to approximately 
room temperature prior to injecting.   Time and 
location of injection (right or left) as well as 
needle length used will be collected in the eCRF.  
IM dosing is expected to occur during the 
week in which the subject’s projected visit 
falls (as according to the Day 1 visit).  An 
additional (+ or - ) 7 day window from date of 
projected visit is allowable for IM dosing but 
not preferred.  All decisions regarding dose 
interruption/ resumption must be discussed 
with the medical monitor in advance .
m. Subjects switching from the oral arm will 
receive their 2ndloading dose injection of 
1 x [COMPANY_004]744 LA 600 mg (no TMC278 L A).HIV-1 RNA and 
sample for 
storage hX X X X X X X X
CD4+ X X X X X X X X
Urinalysis X X X X X X X X
Fasting:  
Glucose, 
Cholesterol 
(Total, HDL and 
LDL) and 
Triglycerides iX X X X X X X X
PT/PTT/INR X
PK Sample 
(S)torage jS S S S S S S X
ISR Diary 
Dispensation kE E E E E E E E E E E E E E E 
review
Study Treatment 
Administration lX a X m X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419768] ~[ADDRESS_419769] 
Detail 
ConfirmationX X X X X X X X X X X X X X
New:
Added Visits W101 and W121 for subjects switching from oral to the Q8W I M regimen.  
Added labs and procedures for subjects s witching from oral to the Q8W IM regimen, denoted with footnote ‘n’.
Removed the following footnotes:
p. Subjects switching from the oral regimen will complete Week 104 visit as per the Maintenance T&E Section 6.4 .
q.Week 108 visit is only  for subjects switchin g from the oral arm.
r.Samples should be collected pre- dose.
m.Subjects switching from the oral arm will receive their 2ndloading dose injection of 
1 x [COMPANY_004]744 L A 600 mg (no TMC278 L A).
Added the following footnotes:
h.Take PK samples pre -dose except Week [ADDRESS_419770] injection 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
405k. At Week 100, oral Maintenance subjects eligible for extension dosing will take final dose o f CAB 30 mg+ABC/3TC in the clinic 
within 2 hours of  the optimized Q8W I M regimen.  See Section 5.1.6 for IM dosing administration as loading doses are required. 
(W100=1stloading dose; W104=2ndloading dose
n. Procedures and visits for subjects who switch fr om oral to the optimized Q8W I M dosing regimen.
o. First Extension Period visit for subjects continuing Q8W dosing from the Maintenance Period.
Procedures for 
Extension -
Q8W W 
100 
nW 
101 nW 
104 oW 
112W 
120W 
121 
nW 
128W
136W 
144W
152W
160W
168W
176W 
184W 
192 aW 
200 
aWD 
l, mNotes
Symptom 
Directed 
Physical Exam, 
ISR and 
Medical 
Assessment bX X X X X X X X X X X X X X X X XSee footnote “a” for continuation of visit 
schedule after Week 200.  Continue until 
either locally approved and commercially 
available, the subject no longer derives 
clinical benefit or meets a protocol- defined 
reason for discontinuation or until 
development is terminated.
a. Continue this pattern for visits for the 
remainder of the study.  For example, Week 
[ADDRESS_419771] in a semi -supi[INVESTIGATOR_2547].
d. Can be done at any time during the visit.
e. A (-) urine pregnancy test is required prior 
to any injection and as required by [CONTACT_339340]
(BP, HR) cX X X X X X X X X
Weight & BMI X X X X X X X X X
HIV Associated 
Conditions, AE 
and SAE 
Assessments, 
Con MedsX X X X X X X X X X X X X X X X X
12-Lead ECG dX X X X X X X X X
Clinical 
Chemistry and 
HematologyX X X X X n X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
406Procedures for 
Extension -
Q8W W 
100 
nW 
101 nW 
104 oW 
112W 
120W 
121 
nW 
128W
136W 
144W
152W
160W
168W
176W 
184W 
192 aW 
200 
aWD 
l, mNotes
Pregnancy 
Testing
(U)rineeU U U U U U U U U U U U U U U U Umonitor after a treatment interruption. A (+) 
urine test should be confirmed with a stat 
serum test.  If (+), subject will need to be 
WD.
f. Plasma for storage samples are collected 
for possible future analyses, back -up in 
cases of loss/damage in transit and 
geno/pheno analyses for virologic failures.
g. Fast overnight; however, a minimum of a [ADDRESS_419772] experiences a reaction ((E)pi[INVESTIGATOR_49564]).  
Subjects will be dispensed a new diary at 
each visit. Diary data will be entered into the 
eCRF.
j. Q8W Injections are 1 x CAB LA 600 mg 
IM + 1 x RPV LA 900 mg IM.  If possible, 
injections should be spaced approximately 
2 cm from one another and from the site of 
any previous injection and or any injection 
site reaction.  B ring RPV LA to 
approximately room temperature prior to 
injecting.   Time and location of injection 
(right or left) as well as needle length used 
will be collected in the eCRF.  IM dosing is 
expected to occur during the week in 
which the subject’s projected visit falls HIV-1 RNA and 
sample for 
storage fX X X X n X X X X X X
CD4+ X X X X n X X X X X X
Urinalysis X X X X n X X X X X X
Fasting 
Glucose, 
Cholestero l 
(Total, HDL 
and LDL) and 
Triglycerides gX X X X n X X X X X X
PT/PTT/INR X
PK Diary 
(D)ispensation 
and (R)eviewR n
PK Sample 
(S)torage hS S S S S n S S S S S S X
ISR Diary 
Dispensation iE E E E E E E E E E E E E E E 
review 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
407Procedures for 
Extension -
Q8W W 
100 
nW 
101 nW 
104 oW 
112W 
120W 
121 
nW 
128W
136W 
144W
152W
160W
168W
176W 
184W 
192 aW 
200 
aWD 
l, mNotes
Study 
Treatment 
Administration jX k X k X X X X X X X X X X X X(as according to the Day 1 visit).  An 
additional (+ or - ) 7 day window from 
date of projected visit is allowable for IM 
dosing but not preferred.  All decisions 
regarding dose interruption/ resumption 
must be discussed with the medical 
monit or in advance .
k. At Week 100, oral Maintenance subjects 
eligible for extension dosing will take final 
dose of CAB 30 mg+ABC/3TC in the clinic 
within 2 hours of  the optimized Q8W IM 
regimen.  See Section 5.1.6 for IM dosing 
administration as loading doses ar e 
required. (W100=1stloading dose; 
W104=2ndloading dose)
l. Or Long -Term Follow Up
m. Follow Up Visit -Conduct ~[ADDRESS_419773] Detail 
ConfirmationX X X X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
408Section 6.6 Time and Events Table –Extension Period for IM Regimen (CA B LA  + RPV LA  –Q4W)
Old:
Procedures for 
Extension if Q4W is 
SelectedW 
100
aW 
104
aW 
108W 
112W
116W 
120W
124W 
128
bW 
132
bW 
136
bW 
140
bWD 
l, mNotes
Symptom Directed 
Physical Exa m, ISR 
and Medical 
Assessment cX X X X X X X X X X X XSee footnote “b” for continuation of visit schedule after Week 140.  
Continue until either locally approved and commercially available, 
the subject no longer derives clinical benefit or meets a protoc ol-
defined reason for discontinuation or until development is 
terminated. 
a. Subjects switching from the oral regimen will complete Week 100 
and 104 visits as per the Maintenance T&E Section 6.4.
b. Continue this pattern for visits for the remainder of the study.  For 
example, Week [ADDRESS_419774] in a semi -supi[INVESTIGATOR_12251].
e. Can be done at any time during the visit.
f. A (-) urine pregnancy test is required prior to any injection and as 
required by [CONTACT_339267] a treatment interruption. A (+) 
urine test should be confirmed with a stat serum test.  If (+), 
subject will need to be WD.
g. Plasma for storage samples are collected for possible future 
analyses, back -up in cases of loss/damage in transit and Vital Signs (BP, HR)d X X X X X
Weight & BMI X X X X X
HIV Associated
Conditions, AE and 
SAE Assessments, 
Con MedsX X X X X X X X X X X X
12-Lead ECG e X X X X X
Clinical Chemistry and 
HematologyX X X X X X
Pregnancy Testing
(U)rinefU U U U U U U U U U U U
HIV-1 RNA and 
sample for storage gX X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
409Procedures for 
Extension if Q4W is 
SelectedW 
100
aW 
104
aW 
108W 
112W
116W 
120W
124W 
128
bW 
132
bW 
136
bW 
140
bWD 
l, mNotes
CD4+ X X X X X Xgeno/pheno analyses for virologic failures.
h. Fast overnight; minimum of a [ADDRESS_419775] experiences a 
reaction ((E)pi[INVESTIGATOR_49564]).  Subjects will be dispensed a new diary at 
each visit. Diary data will be entered into the eCRF.   
k.
l. Q4W Injections are 1 x [COMPANY_004]744 LA 400 mg IM + 1 x TMC278 
LA 600 mg I M.  If possible, injections should be spaced 
approximately 2 cm from one another and from the site of any 
previous injection and or any injection site reaction.  Bring 
TMC278 LA to approximately room temperature prior to injecting.   
Time and location of i njection (right or left) as well as needle 
length used will be collected in the eCRF.  IM dosing is 
expected to occur during the week in which the subject’s 
projected visit falls (as according to the Day 1 visit).  An 
additional
(+ or -) 7 day window from date of projected visit is allowable 
for IM dosing but not preferred.  All decisions regarding dose 
interruption/ resumption must be discussed with the medical 
monitor in advance .
m. Or Long -Term Follow Up
n. Follow Up Visit -Conduct ~[ADDRESS_419776] on -study visit.  May be 
conducted by [CONTACT_756].Urinalysis X X X X X
Fasting:  Glucose, 
Cholesterol (Total, 
HDL and LDL) and 
Triglycerides hX X X X X
PT/PTT/INR X
PK Sample 
(S)torage  iS S S S S X
ISR Diary 
Dispensation jE E E E E E E E E E E E 
review
Study Treatment 
Administration kXa Xa X X X X X X X X X
Subject Visit Reminder 
ContactX X X X X X X X X X X
Subject Contact [CONTACT_339270] X X X X X X X X X X
New:   
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
410Added Visits W101, W121 and W144 for su bjects switching from oral to the Q4W IM regimen.  
Added labs and procedures for subjects switching from oral to the Q4W IM regimen, denoted with footnote ‘m’.
Removed the following footnotes:
a.Subjects switching from the oral regimen will complete Week 10 0 and 104 visits as per the Maintenance T&E Section 6.4.
h. Samples should be collected pre- dose.
i.Subjects switching from the oral arm will receive their 2ndloading dose injection of 
1 x [COMPANY_004]744 L A 600 mg (no TMC278 L A).
Added the following footnotes:
h.Take PK samples pre -dose except Week [ADDRESS_419777] injection
n.At Week 100, oral Maintenance subjects eligible for ext ension dosing will take final dose of CAB 30 mg+ABC/3TC in the clinic 
within 2 hours of  the optimized Q 4W IM regimen.  See Section 5.1.6 for IM dosing administration as loading doses are required. 
m.Procedures and visits for subjects who switch from oral to the optimized Q4 W IM dosing regimen. 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
411Procedures for Extension -
Q4W W 100 W 101 
mW 
104 W 
108W 
112W
116W 
120W 
121 mW
124W 
128 W 
132 
aW 
136 aW 
140 aW 
144 aWD k, 
lNotes
Symptom Directed 
Physical Exam, ISR and 
Medical Assessment bX X X X X X X X X X X X X X XSee footnote “a” for 
continuation of visit 
schedule after Week 144.  
Continue until either locally 
approved and 
commercially available, the 
subject no longer derives 
clinical benefit or meets a 
protocol -defined reason for 
discontinuation or until 
development is terminated. 
a. Continue this pattern for 
visits for the remainder 
of the study.  For 
example, Week [ADDRESS_419778] Vital Signs (BP, HR)c X X m X m X X X X
Weight & BMI X X X X X X
HIV Associated 
Conditions, AE and SAE 
Assessments, Con MedsX X X X X X X X X X X X X X X
12-Lead ECG d X X m X m X X X X
Clinical Chemistry and 
HematologyX X X X X X m X m X X m X X X
Pregnancy Testing
(U)rineeU U U U U U U U U U U U U U U
HIV-1 RNA and sample 
for storage fX X X X X m X m Xm X X X
CD4+ X X X X X m X m Xm X X X
Urinalysis X X m X m X X m X m X m X X X
Fasting Glucose, 
Cholesterol (Total, HDL X X m Xm X X m X m X m X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
412Procedures for Extension -
Q4W W 100 W 101 
mW 
104 W 
108W 
112W
116W 
120W 
121 mW
124W 
128 W 
132 
aW 
136 aW 
140 aW 
144 aWD k, 
lNotes
and LDL) and 
Triglycerides gmanagement.
c. Measure vital signs after 
about [ADDRESS_419779] 
in a semi -supi[INVESTIGATOR_12251].
d. Can be done at any 
time during the visit.
e. A (-) urine pregnancy 
test is required prior to 
any injection and as 
required by [CONTACT_339268] a 
treatment in terruption. A 
(+) urine test should be 
confirmed with a stat 
serum test.  If (+), 
subject will need to be 
WD.
f. Plasma for storage 
samples are collected 
for possible future 
analyses, back -up in PT/PTT/INR X
PK Diary 
(D)ispensation and 
(R)eviewR m
PK Sample 
(S)torage  hS S S S S S m S m S S m S S X
ISR Diary Dispensationi E E E E E E E E E E E E E 
review
Study Treatment 
Administration jX n X X X X X X X X X X X
Subject Visit Reminder 
ContactX X X X X X X X X X X X X X 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419780] Detail 
ConfirmationX X X X X X X X X X X X X Xcases of loss/damage in 
transit and geno/pheno 
analyses for viro logic 
failures.
g. Fast overnight; 
however, a minimum of 
a [ADDRESS_419781] is 
acceptable.
h. Take PK samples pre -
dose except Week 101 
and Week 121 which 
can be taken at any 
time during the visit.  
Week 100 PK sample 
should be taken after 
review of PK diary and 
pre-dose of CAB 
30mg+ABC/3TC.  A 
second Week [ADDRESS_419782] 
experiences a reaction 
((E)pi[INVESTIGATOR_49564]).  Subjects 
will be dispensed a new 
diary at each visit. Diary 
data will be entered into 
the eCRF.
j. Q4W Injections are 1 x 
CAB LA 400 mg IM + 1 
x RPV LA 600 mg IM.   
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
414Procedures for Extension -
Q4W W 100 W 101 
mW 
104 W 
108W 
112W
116W 
120W 
121 mW
124W 
128 W 
132 
aW 
136 aW 
140 aW 
144 aWD k, 
lNotes
If possible, injections 
should be spaced 
approximately 2 cm 
from one another and 
from the site of any 
previous injection and or
any injection site 
reaction.  Bring RPV LA 
to approximately room 
temperature prior to 
injecting.   Time and 
location of injection 
(right or left) as well as 
needle length used will 
be collected in the 
eCRF.  IM dosing is 
expected to occur 
during the week in 
which the subject’s 
projected visit falls (as 
according to the Day 1 
visit).  An additional
(+ or -) 7 day window 
from date of projected 
visit is allowable for 
IM dosing but not 
preferred.  All 
decisions regarding 
dose interruption/ 
resumption must be
discussed with the 
medical monitor in 
advance .
k. Or Long -Term Follow  
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
[ADDRESS_419783] ~[ADDRESS_419784] on- study visit.   
May be conducted by 
[CONTACT_756].
m. Procedures and visits 
for subjects who switch 
from oral to the 
optimized Q4W IM 
dosing regimen.
n. At Week 100, oral 
Maintenance subjects 
eligible for extension 
dosing will take final 
dose of CAB 
30mg+ABC/3TC in the 
clinic within 2 hours of 
the optimized Q4W IM 
regimen.  See Section 
5.1.6 for IM dosing 
administration as 
loading doses are 
required. 
 
 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
416Section [IP_ADDRESS] Liver Stoppi[INVESTIGATOR_2121] -Rechallenge
Added clarify ing statements to this section (additions underlined):
Subjects who meet liver toxicity  stoppi[INVESTIGATOR_339176] b y the ViiV Safet y and 
Labeling Committee (VSLC).  The guideline for Rechallenge/Restart approved by  [CONTACT_339323] C, which is maintained as a separate document (See Section 11.4, Appendix 4), must 
be followed.
Drug Restart/Rechallenge Following Liver Events that are Possibly Related to IP
Approval b y the VSLC for drug restart or additional I M administration can be considered 
where:
The subj ect is receiving compelling benefit, benefit of drug restart exceeds risk, 
and no effective alternative therap y is available.  Ethics Committee or 
Institutional Review Board approval of drug restart/rechallenge must be 
obtained, as required.
If the restart /rechallenge is approved by [CONTACT_339278], the subject must 
be provided with a clear description of the possible benefits and risks of drug 
administration, including the possibility  of recurrent, more severe liver injury  or 
death.
The subject must al so provide signed informed consent specificall y for the IP 
restart/rechallenge.  Documentation of informed consent must be recorded in the 
study  chart.
Study  drug must be administered at the dose specified by  [CONTACT_339279] C.
Subjects approved b y the VSLC for rec hallenge of I P must return to the clinic 
twice a week for liver chemistry  tests for a minimum of one month and 
thereafter for as long as clinically  indicated and then laboratory  monitoring may  
resume as per protocol.
Drug Restart Following Transient Resolv ing Liver Events Not Related to IP
Approval b y the VSLC for drug restart or additional I M administration can be considered 
where:
Liver chemistries have a clear underl ying cause (e.g., biliary  obstruction, 
hypotension and liver chemistries have improved to normal or are within 
1.5 x baseline and AL T <3xULN).  Ethics Committee or Institutional Review 
Board approval of drug restart/rechallenge must be obtained, as required.
If restart of drug or continuation of LA dosing is approved by  [CONTACT_339341], th e subject must be provided with a clear description of the possible 
benefits and risks of drug administration, including the possibility  of recurrent, 
more severe liver injury  or death. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
417The subject must also provide signed informed consent specificall y for the 
restart.  Documentation of informed consent must be recorded in the stud y chart.
Study  drug must be administered at the dose specified by  [CONTACT_339279] C.
Subjects approved b y the VSLC for restarting or re-dosing IP must return to the clinic 
once a week for liver chemistry  tests for a minimum of one month and thereafter for as 
long as clinically  indicated and then laboratory  monitoring may  resume as per protocol.  
If protocol defined stoppi[INVESTIGATOR_339216], study  drug 
must be stopped.
See Section 11.4, Appendix 4 for further details.
Section [IP_ADDRESS] Seizures
New section added to protocol (underlined)
Seizures that occur on study  should be managed according to the local guidelines on 
emergency  seizure management which may  include treatment with benzodiazepi[INVESTIGATOR_1651], 
general supportive treatment, exclusion of metabolic and toxicological abnormalities 
using laboratory  tests, and septic workup and excluding underly ing structural 
abnormalities with neuroimaging.
Where seizures occur, t he Sponsor would like to better characterize these occurrences to 
enable s ystematic anal yses.
Investigators are requested to document and report seizure or possible seizure events 
promptly  (within 24 hours of learning of the event) to the Sponsor for evalu ation and 
onward reporting.  Data should be documented on the appropriate eCRF page.
Section 6.10.14 Prompt Reporting of Serious A dverse Events and Other Events to 
[COMPANY_004]
Updated table with the following row (Seizure or suspected seizure -underlined):
Initial Reports Follow -up Information on a Previous 
Report
Type of Event Time Frame Documents Time Frame Documents
All SAEs 24 hours “SAE” data 
collection tool24 hours Updated “SAE” 
data collection tool 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
418Initial Reports Follow -up Information on a Previous 
Report
Type of Event Time Frame Documents Time Frame Documents
Cardiovascular (CV) 
or death eventInitial and 
follow up 
reports to be 
completed 
within one 
week of when 
the 
cardiovascular 
event or death 
is reported “CV events” 
and/or “death” 
data collection 
tool(s) if 
applicableInitial and follow 
up reports to be 
completed within 
one week of when 
the cardiovascular 
event or death is 
reportedUpdated “CV 
events” and/or 
“death” data 
collection tool(s) if 
applicable
PRSAE 1 week PRSAE data 
collection tool1 weeks Updated PRSAE 
data collection tool
Suspected ABC 
HSR324 hours ABC HSR eCRF 1 Week Updated ABC HSR 
eCRF
Pregnancy 2 weeks “Pregnancy 
Notification Form”2 weeks “Pregnancy Follow -
up Form”
Seizure or suspected 
seizure24 hours eCRF 24 hours eCRF
Non-serious adverse 
events related to 
study treatment5 calendar 
days“Adverse 
Reaction” data 
collection tool2 wee ks Updated “Adverse 
Reaction” data 
collection tool
Liver chemistry abnormalities see Section 6.10.31,2:
ALT≥3xULN plus 
Bilirubin ≥2xULN 
(35% direct) 24 hours SAE data 
collection tool 
Liver Event eCRF 
and liver imaging 
and/or biopsy 
eCRFs if 
applicable 24 hours Updated SAE data 
collection tool 
Updated Liver 
Event eCRF 
ALT≥5xULN that 
persists ≥2 weeks 24hours Liver Event eCRF 24 hours Updated Liver 
Event eCRF 
ALT ≥8xULN 24 hours Liver Event eCRF 24 hours Updated Liver 
Event eCRF  2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
419Initial Reports Follow -up Information on a Previous 
Report
Type of Event Time Frame Documents Time Frame Documents
ALT ≥3xULN or ALT 
≥[ADDRESS_419785] safety.
2. Liver Event Documents (i.e., “Liver Event eCRF” and “Liver Imaging eCRF” and/or “Liver Bio psy eCRF”, as 
applicable) should be completed as soon as possible.
3. ABC HSR eCRF required only if event meets one of the ICH- E2A, 1994 definitions of seriousness (see 
Section [IP_ADDRESS].2 ).
Section 6.11 Pharmacokinetics
Updated paragraph ( changes struck thr ough and underlined)
Plasma samples for determination of [COMPANY_004]1265744 CAB and TMC278 RPV
concentration will be collected throughout the Maintenance Period and from Week 100 –
Week 128 in the Extension Period of the study for subjects switching from oral 
Maintenance period regimen to the optimized IM dosing regimen of their choice .  
Additional samples will be collected for storage during the Extension and Long -Term 
Follow Up Period.  Samples for determination of RPV will be protected from light until 
analyzed.
Section 6.11.1 PK Sample Collection
Updated table with Extension Period PK collection times (underlined) 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
420Group Analyte Week Sample Times Relative to Dose
IM [COMPANY_004]1265744
CABDay 1 (prior to LA and 
last oral Induction 
dose), Weeks: 1, 4, 8, 
12, 16, 20, 24, 25, 28,  
32, 36, 40, 41, 44 and
48
100* (prior to LA and 
last oral Maintenance 
dose), 104*, 108*, 112*, 
116*, 120*, 124* and 
128*Pre-Dose (Q8W):  Day 1, Weeks 4, 8, 
16, 24, 32, 40 ,48, 100*, 104*, 112*, 
120* and 128*
Pre-Dose (Q4W):  Day 1, Weeks 4, 8, 
12, 16, 20, 24, 28, 32, 36, 40, 44 ,48, 
100*, 104*, 108*, 112*, 116*, 120*, 
124* and 128*
[ADDRESS_419786] Dose:  Day 1 , Weeks 
32, 48, 100*aand 128*a
[ADDRESS_419787] Dose:  Week 1, Week s
25,41, 101*aand Week 121*a
[ADDRESS_419788] Dose (Q8W):  Weeks 
12, 20, 28, 36 a nd 44
TMC278 RPV Day1 (prior to LA and 
last oral Induction 
dose), Weeks: 1, 4, 8, 
12, 16, 20, 24, 25, 28, 
32, 36, 40, 41, 44 and
48
100* (prior to LA and 
last oral Maintenance 
dose), 104*, 108*, 112*, 
116*, 120*, 124* and 
128*Pre-Dose (Q8W):  Day 1, W eeks 4, 8, 
16, 24, 32, 40 ,48, 100*, 104*, 112*, 
120* and 128*
Pre-Dose (Q4W):  Day 1, Weeks 4, 8, 
12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 
100*, 104*, 108*, 112*, 116*, 120*, 
124* and 128*
[ADDRESS_419789] Dose:  Day 1 , Weeks 
32, 48, 100*aand 128*a
[ADDRESS_419790] Dose:  Week 1, Week s
25,41, 101*aand Week 121*a
[ADDRESS_419791] Dose (Q8W):  Weeks 
12, 20, 28, 36 and 44
Oral [COMPANY_004]1265744
CABDay 1, Weeks: 32 and 
48Pre-Dose:  Day 1, Weeks 32 and 48
TMC278 RPV Day 1 Pre-Dose:  Day 1
*Denotes PK sample times for su bjects in the Extension Period .  Samples will be placed in storage.
a. PK sample time for subjects switching from oral to an optimized IM dosing regimen only. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
421Section 6.11.2 Rationale of PK Sampling Strategy
Updated paragraph ( changes struck through and underlined)
Given that PK data has been collected following oral administration of [COMPANY_004]744 CAB 
and RPV (LAI116482), there will be no sampling during the Induction Period of the 
study .  Blood sampling for [COMPANY_004]1265744 CAB and TMC278 RPV concentrations will be 
performed during the Maintenance Period and Extension Periods of the study  to evaluate 
PK in HI V infected subjects.  The proposed PK visits and sampling scheme at each visit 
presented in Table 4is based on consideration of available PK data to support inter im and 
final PK and PK/Pharmacody namic (PD) anal ysis planned in this study .
Section [IP_ADDRESS] Extension Switch Population
Added new section to protocol (underlined)
The Extension Switch population will include all subjects randomized to the oral 30 mg + 
ABC/ 3TC arm who switch to and receive at least one dose of the optimized I M dosing 
regimen of their choice (either Q8W or Q4W) in the Extension Period.
The Extension Switch population will be used to evaluate safet y and efficacy of the 
optimized I M dosing regi mens during the Extension Period.
Section 8.3.4 Interim and Final A nalysis
Updated section name ( changes struck through and underlined)
Interim and Final Planned Analy sis
Section [IP_ADDRESS] IDMC Interim A nalyses
Updated paragraph ( changes struck through and u nderlined)
The purpose of these analy ses is for the Independent Data Monitoring Committee 
(IDMC )to evaluate the efficacy , safety  and tolerability  of [COMPANY_004]1265744 CAB at earl y 
time points in the study . and to monitor the occurrence of protocol defined virolo gic 
failure in subjects switching from oral CAB 30 mg +ABC/3TC to an optimized I M 
dosing regimens during the Extension Period.   
The IDMC intends to review at least one anal ysis before all eligible subjects have 
transitioned from the Induction Period to t he Maintenance Period , or as soon as 
reasonabl y possible after subjects begin to enter the Maintenance Period.   Full details of 
the anal yses, estimated timing and the decision criteria that will be used to determine 
regimen performance will be pre- specifie d in the IDMC Charter, with IDMC agreement.
All of the IDMC reviews will be produced b y a Statistics and Data Analysis Centre 
(SDAC).   2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
422Section [IP_ADDRESS] Futility  Interim Monitoring
Added the following line (underlined)
Continuous monitoring of the number of protocol defined virologic failures for subjects 
switching from oral CAB 30 mg + ABC/3TC to the optimized I M dosing regimen of their 
choice (Q8W or Q4W) will also be monitored during the Extension Period .
Updated language (changes struck through and under lined)
...If the true rate of virologic failure is 3%, the probability  to see that the number of 
virology  failure virologic failures observed will exceed the threshold is less than<1%.
Further details on this method are contained in the IDMC charter. Each threshold 
represents strong evidence in favour of H 0over H 1[Royall, 1997].
Added the following paragraph and table to section (underlined)
The number of protocol defined virologic failures will also be monitored in subjects 
switching from oral CAB 30 mg + ABC/3TC to the optimized I M dosing regimen of their 
choice (Q8W or Q4W) during the Extension Period.  For subjects that have at least 4 
weeks of treatment with an optimized I M dosing regimen, if the number of protocol 
defined virologic failures meets or exceeds the thresholds specified in the table below 
(Table 7) prior to all subjects completing Week 152, this will be considered strong 
evidence of an inadequate response and will trigger a comprehensive IDMC data review.  
If an inadequate response is see n in an y arm and it is determined b y IDMC that that arm 
should be discontinued, then subjects on that treatment arm can be switched to the 
remaining IM dosing regimens.
Table 7   Number of protocol -defined virologic failures for each Extension Period 
optimized I M dosing regimen that constitutes strong evidence of inadequate virologic 
response –Subjects switching from Maintenance oral CAB + ABC/3TC only
Number of subjects with at least four 
weeks of IM dosingNumber of protocol -defined virologic 
failures nee ded to trigger IDMC revie w 
3-21 >=3
22-32 >=4
33-43 >=5
44-54 >=6
Section [IP_ADDRESS] Week 96 A nalysis
Changed section name (changes struck through)
Week 96 Final Anal ysis 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
423Section [IP_ADDRESS] Week 128 Extension S witch A nalysis
Added new section to protocol (underlined)
The Week [ADDRESS_419792] has 
completed the Week 128 study  visit and the database has been cleaned and released for 
analysis.  The results of this analy sis will be used to characterize the efficac y, tolerability , 
and safet y of optimized IM dosing regimens for subjects switching from the oral regimen 
therap y at the end of the Maintenace Period.
Section [IP_ADDRESS] Week 152 A nalysis
Added new section to protocol ( changes struck through and underlined )
The Week [ADDRESS_419793] has 
completed the Week 152 study  visit and the database has been cleaned and released for 
analysis.  The results of this analy sis will be used to characterize the following: (a) the 
long-term safet y and efficacy  profile of both IM dosing regimens for subjects who 
continued randomized IM dosing in the Extension Period and (b) the safety , tolerability  
and durability  of antiviral response of the optimized IM dosing regimens for subjects 
switching from the oral regimen therap y at the end of the Maintenace Period.
Follow -up analy ses after the Week [ADDRESS_419794] 
switched to the chosen dose of [COMPANY_004]744 LA 152 analy sismay be conducted to more fully  
characterize the long -term safet y and efficacy  profile of [COMPANY_004]744 CAB LA + RPV L A 
dosing regimens .
Section [IP_ADDRESS] Efficacy A nalyses
The following changes were made to the section (changes struck through and underlined )
...Data collected from extra visits within a wind ow will be included in the derivation of 
the time to loss of protocol defined virologic response (TLOVR) failure , but summary  
tables using OC datasets will only  use the data captured closest to the target visit date.
...In addition, an OC analy sis willmaybe performed for supportive purposes.
References
Updated the Rilpi[INVESTIGATOR_339227]’s Brochure effective date from November 2013 to 
April 2016. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
424Amendment 7
Update dExploratory Objectives, Primary Analysis, Discussion of Design, Futility Interim 
Monito ring, and Week 160 Interim Analysis sections to support an interim analysis at Week 
160.Section 2 Objectives and Endpoints Exploratory
To evaluate the efficacy, tolerability, and safety 
of optimized IM dosing regimens CAB LA 400 
mg IM plus RPV LA 600 mg IM every 4 weeks
and CAB LA 600 mg IM plus RPV LA 900 mg 
every 8 weeks at Weeks 128 and 152 160for 
subjects switching from the oral regimen 
therapy at the end of the Maintenace Period.
To evaluate the long term efficacy, tolerability, 
and safety of IM dosin g regimens CAB LA 400 
mg IM plus RPV LA 600 mg IM every 4 weeks
and CAB LA 600 mg IM plus RPV LA 900 mg 
every 8 weeks at Week 152 160 for subjects 
who continued randomized IM dosing in the 
Extension Period.Proportion of subjects with a ‘virologic failure’
endpoint as per FDA Snapshot algorithm at 
Week 128and 152160(Missing, Switch or 
Discontinuation = Failure, Extension Switch 
population )
Proportion of subjects with Plasma HIV -1 RNA 
<50 copi[INVESTIGATOR_014]/mL (c/mL) at Week 128 and 160 
using the FDA Snapshot algorit hm (Extension 
Switch population )
Proportion of subjects with protocol defined 
virologic failures over time
Proportion of subjects with plasma HIV -1 RNA 
<200 c/mL and <50 c/mL over time.A bsolute 
values and changes in CD4+ cell counts over 
time
Incidence of disease progression (HIV-
associated conditions, acquired 
immunodeficiency syndrome [AIDS] and death).
Incidence and severity of AEs and laboratory 
abnormalities over time.
Absolute values and changes in laboratory 
parameters over time.
Section 3.2.[ADDRESS_419795] entered into the Extension Period may be conducted to more 
fully  characterize the long -term safety  and efficacy  profile of CAB and RPV .
Section 3.3 Discussion of Design
…A Week 152 160 analy sis will permit an evaluation of the ability  of the randomized 
and optimized investigational two- drug long -acting combinations to showcase long- term 
durability  of virologic suppression.  Additional long -term safety  and efficacy  data for all 
IM dosing regimens will be generated. 2018N380094_00
2013N168152_09 CONFIDENTIA L
200056
425Section [IP_ADDRESS] Futility  Interim Monitoring
…The number of protocol defined virologic failures will also be monitored in subject s 
switching from oral CAB 30 mg + ABC/3TC to the optimized I M dosing regimen of their 
choice (Q8W or Q4W) during the Extension Period.  For subjects that ha veat least 4 
weeks of treatment with an optimized I M dosing regimen, if the number of protocol 
defined virologic failures meets or exceeds the thresholds specified in the table below 
(Table 7) prior to all subjects completing Week 152160,this will be considered strong 
evidence of an inadequate response and will trigger a comprehensive IDMC data review .  
If an inadequate response is seen in any arm and it is determined by [CONTACT_339292], then subjects on that treatment arm can be switched to the 
remaining IM dosing regimens.
Section [IP_ADDRESS] Week 152160Analysis
The Week [ADDRESS_419796] has 
completed the Week 152 160 study  visit and the database has been cleaned and released 
for anal ysis.  The results of this analy sis will be used to characteri ze the following: (a) the 
long-term safet y and efficacy  profile of both IM dosing regimens for subjects who 
continued randomized IM dosing in the Extension Period and (b) t he safety , tolerability  
and durability  of antiviral response of the optimized IM dosing regimens for subjects 
switching from the oral regimen therap y at the end of the Maintenace Period .
Follow -up analy ses after the Week 152
160analysis may  be conducted to more fully  
characterize the long- term safet y and efficacy profile of CAB LA + RPV LA dosing 
regimens . 2018N380094_00